Dear Colleagues and Guests:

Welcome to the 154th Annual Meeting of the American Psychiatric Association, the first in the new century. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care into the future.

This year's Annual Meeting theme is "Mind Meets Brain: Integrating Psychiatry, Psychoanalysis, Neuroscience." Many sessions throughout the week will highlight an important aspect of the theme. Please make a special effort to attend the Monday afternoon Presidential Symposium, from 2:00 p.m.-5:00 p.m., entitled, "The Royal Road Revisited: Dreams in the 21st Century."

I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in New Orleans. At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world. I will present my Presidential Address, and I look forward to seeing you there.

Please also make sure to attend the Convocation on Monday night at 7:30 p.m., where we will honor all those being inducted as fellows and those receiving awards from the APA. A special treat will be the William C. Menninger Convocation Lecture, presented this year by Mr. Harrison H. Schmitt, former astronaut and former Senator from New Mexico. His lecture is entitled, "A Trip to the Moon and Beyond."

Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Philip R. Muskin and the members of the Scientific Program Committee, Dr. Edward F. Foulks and Mrs. Janice Foulks and the members of the Local Arrangements Committee, and to the APA staff who work on the Annual Meeting.


Sincerely,

Daniel B. Borenstein, M.D.
President
Dear APA Members and Guests:

Welcome to New Orleans, LA, and the 154th Annual Meeting of the American Psychiatric Association. This exciting city, with its vibrancy, cultural diversity, and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the Program Book, you will notice a number of sessions related to the theme “Mind Meets Brain: Integrating Psychiatry, Psychoanalysis, Neuroscience,” chosen by our President, Dr. Daniel B. Borenstein. Let me draw your attention to just a few of the many exciting sessions presented this week. Eric R. Kandel, M.D., one of the recipients of the 2000 Nobel Prize for Medicine, will present the Marmor Award Lecture on Monday at 9:00 a.m. Later that day, we will present the Presidential Symposium entitled, “The Royal Road Revisited: Dreams in the 21st Century.” Steven E. Hyman, M.D., Director of NIMH, will present the Adolf Meyer Award Lecture on Wednesday at 9:00 a.m. He will discuss how research will approach the mind/brain integration for psychiatric diagnosis as we prepare for DSM-V. Drs. Gerald M. Edelman, Michael Gershon, Edith F. London, Robert Sapolsky, Mark L. Solms, and Nicholas Tononi will be speaking throughout the week. A finale to the meeting will be a session not to be missed. On Thursday at 9:00 a.m., Ray Kurzweil, writer and inventor, will present a lecture that promises to collide present ideas with future technology. I encourage you to take advantage of the tremendous variety of topics and speakers over the next week.

The Local Arrangements Committee, under the excellent guidance of its Co-Chairpersons, Dr. Edward Foulks and Mrs. Janice Foulks, have developed a wide array of activities that will help you take advantage of New Orleans. You will notice that a number of activities are designed especially for families and children.

The Business Meeting will be held on Sunday, from 12:30 p.m. to 1:30 p.m.; all voting members are encouraged to attend. The Opening Session will be held on Sunday, from 5:00 p.m. to 6:30 p.m. Exhibits will be open 11:00 a.m. to 4:30 p.m. on Sunday, 10:00 a.m. to 6:00 p.m. on Monday and Tuesday, and 10:00 a.m. to 3:00 p.m. on Wednesday. The Convocation will begin Monday, May 7, at 7:30 p.m.

The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. This session has become an excellent way to start off the Annual Meeting’s research programs, in conjunction with the Young Investigators’ Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, offered to APA members only.

You will note in the Program Book that we are continuing with an expanded series of noon Forums. This format allows us to schedule sessions that may not fit in the usual formats or that focus on late-breaking topics of importance to the field.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year’s Annual Meeting.

Once again, welcome to New Orleans. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Philip R. Muskin, M.D.
Chairperson
Scientific Program Committee
KEY LOCATIONS - CONVENTION CENTER

Administrative Office  Room 242, Level 2
American Journal of Psychiatry  APA Resource Center
APA Communications Center  Lobby Level
APA Resource Center  Exhibit Halls D/E/F, Lobby Level
A/V Preview Room  Room 240, Level 2
CME Course Enrollment  Lobby Level
Computerized Evaluation  APA Resource Center
Daily Bulletin  Rooms 244/245, Level 2
Education Office  Room 255, Level 2
Exhibit Office  Lobby Level
Information/Locator Center  Lobby Level
Lost & Found  Lobby Level
Meetings Management  Rooms 235/236, Level 2
Message Center  Lobby Level
On-Site Job Bank and Placement Center  APA Resource Center
Psychiatric Services  APA Resource Center
Registration  Exhibit Halls D/E/F, Lobby Level
Scientific Program Office  Room 237, Level 2

FIRST AID
Located on the Lobby Level (across from Exhibit Hall F), Convention Center. Hours of operation: Tuesday, May 1, through Thursday, May 10, opens one hour prior to show opening and closes one hour after the last event of the evening. This station will be manned by Registered Nurses. Information on emergency services may be found on page 4 of the Leisure Time Activities Brochure.

COURTESY SHUTTLE BUS SERVICE
Service will begin on Saturday, May 5, at approximately 7:30 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule, including nighttime activities, and will conclude on Thursday, May 10, at 6:00 p.m. The Convention Center will serve as the “hub” for all shuttle bus routes. A detailed Shuttle Bus Service Schedule will be included in each registration packet and posted in the lobbies of participating hotels. Refer to the city map on page XII for the location of hotels in relation to the Convention Center.

LOCAL ARRANGEMENTS COMMITTEE

HOSPITALITY CENTER
Located on the Lobby Level, Convention Center. Hours of operation: Saturday, May 5, 12 noon-5:30 p.m.; Sunday, May 6, to Wednesday, May 9, 9:00 a.m.-5:30 p.m.; and Thursday, May 10, 9:00 a.m.-12 noon. Tickets for leisure time activities will be available at the Tour Desk also located in the Lobby Level, Convention Center.

EXHIBITS
Commercial and educational exhibits are located in Exhibit Halls D/E/F, Lobby Level, Convention Center, along with the Publishers’ Bookfair and the APA Resource Center. As a convenience to registrants, the APA Resource Center and Publishers’ Bookfair will open on Saturday, May 5, 11:00 a.m.-5:00 p.m. Hours for commercial and educational exhibits: Sunday, May 6, 11:00 a.m.-4:30 p.m.; Monday and Tuesday, May 7-8, 10:00 a.m.-6:00 p.m., and Wednesday, May 9, 10:00 a.m.-3:00 p.m. All exhibits will close on Wednesday, May 9. Please refer to the APA Exhibits Guide for additional information on participating companies.

INFORMATION/LOCATOR CENTER
Located on the Lobby Level, Convention Center and staffed during registration hours. Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained there. Meeting participants also can find out where colleagues who are registered for the meeting are staying.

MESSAGE CENTER
Located on the Lobby Level, Convention Center and staffed during registration hours. Messages can be left and picked up at the Message Center. Message monitors will be strategically located in the Exhibit Hall and elsewhere at the Convention Center. Registrants whose names appear on these messages should pick up their messages at the Center.

APA RESOURCE CENTER
Located in Exhibit Halls D/E/F, Lobby Level, Convention Center. Hours of operation will be: Saturday, May 5, 10:00 a.m.-5:00 p.m.; Sunday, May 6, 8:00 a.m.-4:30 p.m.; Monday and Tuesday, May 7-8, 10:00 a.m.-6:00 p.m.; and Wednesday, May 9, 10:00 a.m.-3:00 p.m. A few of the many APA activities exhibited include: membership, APA’s internet-based programs, continuing medical education, quality improvement, psychiatric services, managed care services, APA Job Bank, and APA Periodicals.

APA JOB BANK
Located in the APA Resource Center and open during the Center’s hours of operation. The all-new, on-line APA Job Bank will power the popular on-site Job Bank providing improved tools for both employers and candidates at the APA’s Annual Meeting. With new features such as résumé posting, enhanced job searching, and response tracking, the Job Bank provides the best opportunity available for career research and on-site interviews. Candidates and employers are encouraged to activate their resume and jobs postings in advance of the meeting for best results. For more information on the Job Bank go to the APA web site, www.psych.org, and click on the Job Bank icon. You may also contact us by phone (888-884-6242) or e-mail (employers@healthecareers.com) prior to the meeting, or stop by the Job Bank booth on-site.

PRESS OFFICE
Located in the APA Communications Center, Rooms 244/245, Level 2, Convention Center. Hours of operation: Saturday, May 5, 12 noon-5:00 p.m.; Sunday-Wednesday, May 6-9, 8:00 a.m.-6:00 p.m.; and Thursday, May 10, 8:00 a.m.-12 noon.

The Press Office is for the use of registered press only. All Annual Meeting sessions are open to the press except CME Courses, the Business Meeting, Clinical and Continuous Clinical Case Conferences, and Master Educator Clinical Consultations.

DAILY BULLETIN
The Daily Bulletin accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. Since the issue for Saturday/Sunday is preprinted, information cannot be added on site. Copy for the Monday-Tuesday, Wednesday/Thursday issues can be dropped off at the APA Communications Center. The deadlines are 12 noon prior to the date of publication.
CENTER FOR INTERNATIONAL GUESTS
Bienvenidos, Wilkommen, Bienvenue, Welcome!
Located in the Ile de France Ballroom, Le Meridien Hotel. Hours of operation: Saturday, May 5, through Wednesday, May 9, 8:00 a.m.-6:00 p.m.; and Thursday, May 10, from 8:00 a.m.-3:00 p.m. All international visitors are invited. These activities are supported by Pfizer Pharmaceuticals Group.

BUSINESS CENTERS
Convention Center - Rhino Business Center
Location: Lobby F, Lobby Level
Times of operation: Monday-Sunday, 8:00 a.m.-6:00 p.m.

Hilton
Location: 2nd Floor Riverside (Across from Kabby’s Restaurant)
Times of operation: Monday-Friday, 7:00 a.m.-8:00 p.m.
Saturday-Sunday, 10:00 a.m.-3:00 p.m.

Marriott
Location: Main Lobby
Times of operation: Monday-Friday, 7:00 a.m.-6:00 p.m.
Saturday-Sunday, 8:00 a.m.-5:00 p.m.

Sheraton
Location: 3rd Floor
Times of operation: Monday-Friday, 7:00 a.m.-6:00 p.m.
Saturday-Sunday, 9:00 a.m.-1:00 p.m.

REGISTRATION
ADMISSION TO ALL SESSIONS BY REGISTRATION BADGE
Located in Exhibit Halls D/E/F, Lobby Level, Convention Center. Hours of operation: Saturday, May 5, 10:00 a.m.-5:00 p.m.; Monday through Wednesday, May 7-9, 7:30 a.m.-6:00 p.m.; and Thursday, May 10, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

APA MEMBERS
Full-Time Registration.................................................................$185.00
Members-in-Training (Member Class MT) .................................. 70.00
Daily Registration.................................................................95.00
(all "Member" categories except Medical Students)
Medical Students no charge

NONMEMBERS
Full-Time Registration.............................................................$650.00
Nonmember Residents, Students, Advocacy
Group Members or Mental Health Chaplains ...................... 90.00
Daily Registration (all "Nonmember" categories).................... 30.00
Medical Students no charge

GUEST REGISTRATION
One only per full-time registrant ........................................... 95.00
Only one guest is allowed to register with each full-time meeting registrant. The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest"; they must register as an APA member.

One-Day Exhibit Hall Only Pass (18 and older) .................. 10.00
On-site fees can be paid by cash, check, money order, American Express, Visa or MasterCard. Registration fees are waived only for CME Course Faculty, APA Honorary or Distinguished Fellows (does not include APA Life Fellows or Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the days they present).

NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER FULL-TIME STUDENTS must present documentation of their qualifications to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book, APA Exhibits Guide, and New Research Program and Abstracts Books, and for most categories, a copy of the Syllabus.

NAME BADGES
Badges are required for all sessions including the Opening Session and exhibit area. Only an APA member badge will admit you to the Business Meeting.

Badges are color-coded:
Blue-Members, Yellow-Nonmembers, Silver-Press, Red-Exhibitors, Green-APA Staff, and Black-Temporary Convention Personnel.

CME COURSE ENROLLMENT
TICKET PURCHASE REQUIRED
FOR CME COURSES
Located in Exhibit Halls D/E/F, Lobby Level, Convention Center. Hours of operation: Saturday, May 5, 10:00 a.m.-5:00 p.m.; Sunday, May 6, 7:30 a.m.-5:00 p.m.; Monday through Wednesday, May 7-9, 7:30 a.m.-6:00 p.m.; and Thursday, May 10, 7:30 a.m.-2:00 p.m.

Tickets for CME Courses not sold by March 30 will be on sale to all registrants beginning at 10:00 a.m. on Saturday, May 5. You must show your registration badge before you can enroll in courses.

APA ART ASSOCIATION
Located in the APA Resource Center and staffed during the Resource Center’s hours. The exhibit includes paintings, photography, ceramics, and crafts done by APA members and/or their significant others. Please stop by the exhibit for information on joining the APA Art Association.

APA AUXILIARY BOOTH
Located on the Lobby Level, Convention Center. Hours of operation: Saturday, May 5, through Wednesday, May 9, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Auxiliary’s program schedule and information on membership.

APA PERIODICALS
Complimentary copies of the latest issues of the American Journal of Psychiatry, Psychiatric Services, and Psychiatric News may be obtained at the APA Periodicals Exhibit in the APA Resource Center. Staff of the American Journal of Psychiatry and Psychiatric Services will be available to answer authors’ questions and to receive papers submitted for publication; six copies are required as well as a PC-compatible disk. The American Journal of Psychiatry and Psychiatric Services publish only original material not published elsewhere in any form and not being considered for publication elsewhere. Staff will also sell subscriptions to all APA journals and demonstrate on-line access for subscribers. Persons who wish to contact editors or reporters of Psychiatric News should inquire at the APA Administrative Office, Room 242, Level 2, Convention Center, where an editor can be paged. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper’s consideration may be left with staff at the Periodicals Exhibit.

III
CONTINUING MEDICAL EDUCATION

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for up to 66 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions of the official Annual Meeting program, with some exceptions, meet the criteria for Category 1 CME credit. Sessions in the following program formats are designated as Category 1: Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Forums, Industry-Supported Symposia, most Lectures, some Media Sessions, Medical Updates, New Research Oral/Slide Sessions, Research Advances in Medicine, Round Table Discussion, the Presidential Symposium, Review of Psychiatry, Scientific and Clinical Reports, Symposia, Telecommunication sessions, and Workshops. Other program activities are designated Category 2: Research Consultations With, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, some Media Sessions, and some Lectures. Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

Please note: APA members are required to maintain their own records of CME hours. Reporting of CME credit is on an honor basis.

To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the Certificate of Attendance found in the front of the 2001 Annual Meeting CME Syllabus & Proceedings Summary Book. Credit is earned on an hour-for-hour basis.

The Certificate of Attendance (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires participation in a total of 150 hours of CME activities within a three-year reporting period. At least 60 hours must be in Category 1 activities.

CME report forms may be obtained from the Office of Education at the APA. Staff will be available at the Office of Education booth in the APA Resource Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year’s Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. BEFORE YOU LEAVE THE MEETING, PLEASE COMPLETE YOUR FORM AND DROP IT IN ONE OF THE EVALUATION BOXES LOCATED THROUGHOUT THE MEETING SITES. You can receive a parchment Certificate of Attendance at the Annual Meeting by returning your completed form (to the APA Administrative Staff Office, Scientific Program Office, Information/Locator Center or APA Resource Center, all located in the Convention Center) or by completing the computerized general evaluation in the APA Resource Center.

SESSION CAPACITY

We expect “sell out” attendance for many of the scientific sessions. So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

• Please find seating as far forward as possible.
• Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
• Store materials under chairs to maximize seating capacity.
• Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
• If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

Thank you for your cooperation.

AUDIOTAPES

Audiotapes of most sessions are available shortly after each session concludes and may be purchased at the Mobiltape Booth located in the Convention Center.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use and by members of the media. Registrants are welcome to use their own small, portable audiotape recorders to record any session except the Master Educator Clinical Consultations, Clinical Case Conferences, and the Continuous Clinical Case Conference, or unless prohibited by the presenters. Larger professional tape recorders, however, are not permitted other than those utilized by members of the media and personnel representing the professional taping firm authorized by APA to audiotape sessions. The badges of personnel representing this firm and members of the media will clearly identify them. Non-media registrants are not permitted to videotape any session because the intrusive nature of the recording may disrupt the session.

SMOKING POLICY

There will be NO SMOKING in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.

CHILD CARE SERVICE

Drastically reduced child care costs for APA members. Limited to the first 50 children!

ACCENT on Children’s Arrangements, Inc., the official youth program provider for APA, has planned an exciting on-site children’s activity program called Camp APA. Camp APA offers both parents and their children a safe, nurturing, and positive experience. ACCENT’s professional, specially trained supervisors are certified in both CPR and pediatric first aid. The ACCENT staff are teachers, professional child care providers, or mothers who simply love working with children and have completed ACCENT’s specialized training program.

Camp APA is headquartered at the Hilton for the exclusive use of APA registrants and their families. Children aged 6 months to 17 years are welcome and will be provided with developmentally appropriate programs designed specifically for their age group. Activities will take place on site for all children under 6 years old. The older children have the option of uniquely experiencing New Orleans through sure-to-be-talked-about youth tours. On site, children will enjoy arts and crafts projects, active games, and much
Youth tours will depart from and return to the on-site Camp APA activity center each day.

ACCENT provides an exceptional caregiver to child ratio: 1:2 for children ages 6 months – 30 months, 1:4 ages 31 months – 4 years, 1:6 ages 4 – 6 years, and 1:8 ages 7 – 17 years.

GUIDE TO THE PROGRAM BOOK
Below, you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day’s sessions is listed by start time with the formats listed alphabetically under those times. NOTE: To make it easier for you to plan your day, we have prepared a separate “Days-at-a-Glance,” which is included in your registration packet.

If you have any questions about this book or the scientific sessions, please feel free to stop by the Scientific Program Office in the Convention Center, and we will be glad to help you. Also, all central office APA staff members will be wearing green ribbons on their badges. Please feel free to direct your questions to them.

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

2002 May 18-23 Philadelphia, PA
2003 May 17-22 San Francisco, CA
2004 May 1-6 New York, NY
2005 May 21-26 Atlanta, GA
2006 May 20-25 Toronto, Canada
2007 May 19-24 San Diego, CA
2008 May 3-8 Washington, DC
2009 May 16-21 San Francisco, CA

APA CLINICAL MEETINGS

THE INSTITUTE ON PSYCHIATRIC SERVICES

2001 October 10-14 Orlando, FL
2002 October 9-13 Chicago, IL
2003 October 29-Nov. 2 Boston, MA
2004 October 6-10 Atlanta, GA
2005 October 5-9 San Diego, CA

Tentative program schedules and hotel information for the 2001 Institute on Psychiatric Services are available at the Future Meetings Booth in the APA Resource Center and the Information/Locator Center, both located in the Convention Center.

TABLE OF CONTENTS

Floor Plans for Convention Center, Hilton, Marriott, and Sheraton .......................................................... VI-XI
City Map .......................................................................................................................... XII
Special Acknowledgments .................................................................................................. XIII-XIV
Format Descriptions ........................................................................................................ XV-XVI
Disclosure Information ..................................................................................................... XVII-XXIX
Saturday Sessions .................................................................................................................. 1-3
Audiotape Sales Information .............................................................................................. 4
Sunday Sessions .................................................................................................................... 5-12
Monday Sessions .................................................................................................................. 13-37
Call for 2002 Annual Meeting Papers .................................................................................. 38
Tuesday Sessions ................................................................................................................ 39-65
2001 Institute on Psychiatric Services .................................................................................... 66
Wednesday Sessions ............................................................................................................ 67-91
Audiotape Sales Information .............................................................................................. 92
Thursday Sessions ................................................................................................................ 93-107
Topic Index .......................................................................................................................... 108-122
Participant Index .................................................................................................................. 123-133
American Psychiatric Publishing Group ........................................................................... 134-135
Industry-Supported Symposia ............................................................................................. 136-159
APA Resource Center ......................................................................................................... Back Cover

Refer to the APA Exhibits Guide for information on: Exhibits, Publishers’ Bookfair, Hospitality Lounge, and Dining Facilities in the Convention Center.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

*American Psychiatric Association.
SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: support of the Industry-Supported Breakfast Symposia, "The Impulsive Aggressive Spectrum: Challenging Populations," Monday, May 7 and Tuesday, May 8, 7:00 a.m.; the Industry-Supported Symposium, "Plasticity as Efficacy: Neurotrophic Effects of Mood Stabilizers," Wednesday, May 9, 7:00 p.m.; and co-support of the American Psychiatric Foundation Benefit Evening, Saturday, May 5, 8:00 p.m.

Alza Corporation: support of the Industry-Supported Symposium, "Advances in ADHD: Navigating Comorbidity," Wednesday, May 9, 7:00 p.m.; and the registration portfolio.

American Academy of Psychiatry and the Law: co-sponsorship of the Manfred S. Guttmacher Award Lecture, Sunday, May 6, 2:30 p.m.

American Association of Psychiatric Administrators: co-sponsorship of the Administrative Psychiatry Award Lecture, Wednesday, May 9, 9:00 a.m.

American Foundation for Suicide Prevention: co-support of the Industry-Supported Symposium, "Suicide Risk and Bipolar Disorder: Neurobiology and Treatment," Saturday, May 5, 7:00 p.m.

American Psychiatric Foundation: co-support of the APA Award for Research in Psychiatry, and co-support of the Disaster Psychiatry Fellowship.

Association of Mental Health Clergy: co-support of the Oskar Pfister Award Lecture, Monday, May 7, 9:00 a.m.

Association of Women Psychiatrists: co-support of the Joint AWP/APA Women's Career Reception and Meeting.

AstraZeneca Pharmaceuticals: support of the Industry-Supported Symposia, "Atypical Antipsychotic Drugs: How Do They Work?" Sunday, May 6, 1:30 p.m.; "Men, Women, and Schizophrenia: Does Anatomy Determine Destiny?" Tuesday, May 8, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Comparing Atypical Antipsychotic Therapies: Making Sense of the Data," Monday, May 7 and Tuesday, May 8, 7:00 a.m.; the AstraZeneca Fellowship and reception; and co-support of the American Psychiatric Foundation Benefit Evening, Saturday, May 5, 8:00 p.m.

Aventis: support of the Women Residents Travel Program and Luncheon, Monday, May 7, 1:00 p.m.; and co-support of the American Psychiatric Foundation Benefit Evening, Saturday, May 5, 8:00 p.m.

Bristol-Myers Squibb: support of the Industry-Supported Symposium, "Treating Psychotic Disorders: What Is the State of the Art?" Sunday, May 6, 1:30 p.m.; "Everyday Challenges in Managing Patients on Psychotropic Medications," Tuesday, May 8, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Optimizing Treatment Outcomes in Patients with Chronic Depression," Monday, May 7 and Tuesday, May 8, 7:00 a.m.; the Solomon Carter Fuller Award Lecture, Tuesday, May 8, 9:00 a.m.; the Reception for the Solomon Carter Fuller Award Recipient; and the President's Dessert and Reception.

Center for Mental Health Services: sponsorship of the APA/CMHS Minority Fellowship Program; support of Practice Research Network (PRN) Annual Meeting activities; and training activities of the AIDS Education Project.

Center for Substance Abuse and Treatment: support of the Industry-Supported Breakfast Symposia, "Excessive Daytime Sleepiness: Evaluation and Management in Psychiatry," Wednesday, May 9, 7:00 p.m.

Cephalon Inc.: support of the Industry-Supported Symposium, "Excessive Daytime Sleepiness: Evaluation and Management in Psychiatry," Wednesday, May 9, 7:00 p.m.

Eli Lilly and Company: support of the Industry-Supported Symposium, "Advances in the Treatment of Depression in Women: Beyond Clinical Lore," Saturday, May 5, 7:00 p.m.; "Critical Decisions in the Lifetime Treatment of Schizophrenia," Sunday, May 6, 8:00 a.m.; co-support of the Industry-Supported Symposium, "Providing Complete Treatment for Patients with Bipolar Disorder," Sunday, May 6, 1:30 p.m.; support of the Industry-Supported Breakfast Symposium, "Depression: Gender, Age, and Special Populations," Wednesday, May 9 and Thursday, May 10, 7:00 a.m.; the Adolf Meyer Award Lecture, Wednesday, May 9, 9:00 a.m.; the APA/Lilly Resident Research Awards; partial support of the New Research Abstracts and New Research Program Books; co-support of the American Psychiatric Foundation Benefit Evening, Saturday, May 5, 8:00 p.m.; and support of the Daniel Freedman Congressional Fellowship.

Forest Laboratories, Inc.: support of the Industry-Supported Symposium, "The New Biology of Depression and Antidepressant Treatment," Saturday, May 5, 7:00 p.m.; "Men Over 50: An Endangered Species," Sunday, May 6, 8:00 a.m.; support of the Industry-Supported Breakfast Symposium, "Women’s Mental Health: Antidepressant Therapy During the Childbearing Years," Monday, May 7 and Tuesday, May 8, 7:00 a.m.; and co-support of the American Psychiatric Foundation Benefit Evening, Saturday, May 5, 8:00 p.m.

Glaxo Wellcome Inc.: support of the Industry-Supported Symposium, "Issues in the Long-Term Treatment of Depression," Sunday, May 6, 8:00 a.m.; "Responding to the Challenge of Treating Bipolar Disorder," Tuesday, May 8, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Weighing the Options for Managing Bipolar Depression," Monday, May 7 and Tuesday, May 8, 7:00 a.m.; and the APA/Glaxo Wellcome Fellowship Program and reception.

Harding Foundation: co-support of the Oskar Pfister Award Lecture, Monday, May 7, 9:00 a.m.

International Academy for Biomedical and Drug Research: support of the Industry-Supported Symposium, "Bipolar Spectrum Disorders: U.S. and European Perspectives," Wednesday, May 9, 7:00 p.m.

Ittleson Foundation, Inc.: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutica and Research Foundation: support of the Industry-Supported Symposium, "Glucose Control and Diabetes Mellitus During Antipsychotic Treatment," Saturday, May 5, 7:00 p.m.; "Chemical Restraints: Clinical, Research, and Ethical Implications," Sunday, May 6, 1:30 p.m.; "Psychosis of Alzheimer's Disease: New Knowledge, New Treatment Strategies," Sunday, May 6, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "A New Era for Managing
Special Acknowledgments

Pfyche: Rebuilding Lives for Patients and Families, Wednesday, May 9 and Thursday, May 10, 7:00 a.m.; the American Psychiatric Institute for Research and Education/Jansen Research Scholars on Severe Mental Illness Program; and the International Leadership Dinner, Wednesday, May 9, 6:00 p.m.

Lilly Research Laboratories, a division of Eli Lilly & Company: support of the APA/Lilly Psychiatric Research Fellowship.


Merck & Co., Inc.: support of the William C. Menninger Memorial Convocation Lecture, Monday, May 7, 7:30 p.m.; and an unrestricted educational grant in support of various scientific sessions.

National Depressive and Manic-Depressive Association: co-support of the Industry-Supported Symposium, "Providing Complete Treatment for Patients with Bipolar Disorder," Sunday, May 6, 7:30 p.m.

National Institute of Mental Health: co-support of the APA/NIMH Vettermark Psychiatry Educator Award Lecture, Monday, May 7, 11:00 a.m.; APA Office of Research Annual Meeting activities for research trainees; and the Program for Minority Research Training in Psychiatry (PMRTP).

National Institute on Drug Abuse: support of the APA Office of Research/Research Training activities and the Drug Abuse Research Scholars in Psychiatry Program (DARSP).

Novartis Pharmaceuticals Corporation: support of the Industry-Supported Symposium, "Meeting the Challenge of Schizophrenia and Co-Occurring Addictions," Sunday, May 6, 8:00 a.m.; and "Off Label on the Table: Using New Pharmacological Agents," Tuesday, May 8, 7:00 p.m.

Organon Inc.: support of the Industry-Supported Symposium, "Advances in Treatment of Geriatric Depression," Sunday, May 6, 1:30 p.m.; and "Neurobiology, Depression, and the Specificity of Treatment Response," Sunday, May 6, 7:00 p.m.

Ortho-McNeil Pharmaceuticals: support of the Industry-Supported Symposium, "An Evidence-Based Medicine Approach to Pediatric Psychiatry," Wednesday, May 9, 7:00 p.m.

Professional Risk Management Services, Inc.: support of the Manfred S. Guttmacher Award Lecture, Sunday, May 6, 2:30 p.m.

Pfizer Inc.: support of the Industry-Supported Symposium, "PTSD: Clinical Characteristics and Treatment Options," Saturday, May 5, 7:00 p.m.; "Alcoholism and Bipolar Disorder: Treatment Options Circa 2001," Sunday, May 6, 8:00 a.m.; "Moving Towards a More Comprehensive Management of Patients with Schizophrenia," Sunday, May 6, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Clinical Challenges in Anxiety," Wednesday, May 9 and Thursday, May 10, 7:00 a.m.; the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 7, 7:00 a.m.; the "Abstracts-On-Disk" Program; the Psychiatric Services Achievement Awards; and the APA Daily Bulletin newspaper.

The Pfizer Pharmaceuticals Group: support of the International Hospitality Suite, a daily visitors' center for international delegates.

Pharmacia Corporation: support of the Industry-Supported Symposium, "To Switch or Augment? Contemporary Approaches to Resistant Depression," Saturday, May 5, 7:00 p.m.; "Treatment-Resistant Depression Across the Life Span," Sunday, May 6, 7:00 p.m.

Sanofi-Synthelabo, Inc.: support of the Industry-Supported Symposium, "Current and Future Management of Insomnia and Psychiatric Illnesses," Tuesday, May 7, 8:00 p.m.

Sheppard Pratt Health System: support of the Warren Williams Speaker's Awards.

SmithKline Beecham Pharmaceuticals: support of the Industry-Supported Symposium, "To Work and to Love: Focus on Quality of Life in Mood and Anxiety Disorders," Sunday, May 6, 8:00 a.m.; "Images of Anxiety: A New Look at GAD and PTSD," Tuesday, May 8, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Mood and Anxiety Disorders in Understudied Populations," Monday, May 7 and Tuesday, May 8, 7:00 a.m.; the annual contribution to the APA Presidential Fund; and the APA/SmithKline Beecham Young Faculty Award for Research Development in Biological Psychiatry.

Solvay Pharmaceuticals, Inc.: co-support of the Industry-Supported Symposium, "Suicide Risk and Bipolar Disorder: Neurobiology and Treatment," Saturday, May 5, 7:00 p.m.; support of the Industry-Supported Symposium, "Management of Anxiety: An International Perspective," Sunday, May 6, 7:00 p.m.; and the beverage service in the exhibit hall.

Somerset Pharmaceuticals, Inc.: support of the Industry-Supported Symposium, "MAOIs Revisited," Sunday, May 6, 1:30 p.m.

van Ameringen Foundation, Inc.: support of the Division of Research Annual Meeting activities for research trainees and health services researchers.

Wyeth-Ayerst Laboratories: support of the Industry-Supported Symposium, "Sleep: A Window on Mind and Brain," Saturday, May 5, 7:00 p.m.; "Symptomatic and Functional Recovery: Attainable Goals in Treating Depression?" Sunday, May 6, 8:00 a.m.; "Critical Questions in Anxiety Disorders," Sunday, May 6, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Treatment of Depression in Women From Acute Remission to Sustained Recovery," Wednesday, May 9 and Thursday, May 10, 7:00 a.m.; the Reception to launch the Jeanne M. Spurlin Congressional Fellowship, Monday, May 7, 5:30 p.m.; the APA/Wyeth-Ayerst M.D./Ph.D. Psychiatric Research Fellowship; the Women's Resource Center and Display; the newsletter Psychiatric Practice and Managed Care; and the daily in-house TV program, "APA News Network."
ADVANCES IN RESEARCH
This two-hour session is traditionally chaired by the Chairperson of the Council on Research and co-chaired by the Chairperson of the Scientific Program Committee. After a brief overview of major advances in research in psychiatry and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers presented the latest developments in four different, clinically-relevant areas of research.

CLINICAL CASE CONFERENCES
During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCES
The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday-Tuesday, beginning at 9:00 a.m.). Audience participation will be encouraged throughout. Participants are requested to attend both sessions in their entirety. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES
Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day) and six-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Enrollment is limited, and participants must purchase tickets to attend.

DISCUSSION GROUPS
This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the experts. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

LECTURES
Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

MASTER EDUCATOR CLINICAL CONSULTATIONS
These 90-minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS
In these sessions, a videotape of educational value is shown. Videotapes may illustrate innovation in: patient assessment, diagnosis, treatment, and education; practice management, medical records, information systems, and research; professional education; public awareness and education; psychiatric interpretations of meaning in media; assessment of the biopsychosocial effects of media on individuals; social/cultural issues and mental health/illness; and the human spirit as seen in the arts and humanities.

MEDICAL UPDATES
These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

NEW RESEARCH
This format allows for presentation of the very recent findings obtained from ongoing research. The three types of presentations include: Posters, which are visual, self-explanatory presentations; and Young Investigators’ Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators’ Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

RESEARCH ADVANCES IN MEDICINE
This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

RESEARCH CONSULTATIONS WITH...
This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it’s one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

REVIEW OF PSYCHIATRY
There will be five, three-and-one-half hour sessions presented, based on the annual American Psychiatric Press Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.

ROUNDTABLE
This 90-minute format is designed to establish a dialogue between psychiatrists and other citizens about controversial issues of special interest to our profession. The moderator presents a panel of experts with hypothetical scenarios that highlight controversial and problematic situations with which psychiatrists interface.
SCIENTIFIC AND CLINICAL REPORT SESSIONS
Scientific and Clinical Reports (formerly Paper Sessions) are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

TELECOMMUNICATION SESSIONS
These three-hour sessions are presented in a computer software demonstration format (i.e., on computer and LCD projector provided for projection on a large screen), or a "hands-on" format limited to 30 participants. Topic areas include telepsychiatry, virtual reality, internet, electronic medical records, and information technology.

SYMPOSIA
Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposium" in this Program Book.

WORKSHOPS
Workshops are 90-minute sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.
The American Psychiatric Association requires disclosure by presenters at CME activities of any significant financial or other affiliation with commercial organization(s) that may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include, holding a position on an advisory committee or some other role or benefit to a supporting organization. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if AV equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigative use of a product not yet approved for this purpose.

The following presenters have indicated a significant financial interest or other affiliation with a commercial supporter of the session and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial service(s). The presenter's name, the manufacturer's name, and the page number(s) the presenter appears on in this Program Book are listed below:

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene G. Abel, M.D.</td>
<td>Abel Screening, Inc.</td>
<td>69</td>
</tr>
<tr>
<td>Hagop S. Akiskal, M.D.</td>
<td>International Academy for Biomedical and Drug Research</td>
<td>56, 86, 90, 104</td>
</tr>
<tr>
<td>Mark J. Albanese, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>60</td>
</tr>
<tr>
<td>George S. Alexopoulos, M.D.</td>
<td>GlaxoSmithKline; Bristol-Myers Squibb; Organon Inc.</td>
<td>11</td>
</tr>
<tr>
<td>Jonathan E. Alpert, M.D.</td>
<td>GlaxoSmithKline; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories</td>
<td></td>
</tr>
<tr>
<td>Jay D. Amsterdam, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td></td>
</tr>
<tr>
<td>James C. Ballenger, M.D.</td>
<td>Psychiartrists Mutual Insurance Company</td>
<td>2</td>
</tr>
<tr>
<td>Lori L. Altshuler, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td></td>
</tr>
<tr>
<td>Steven J. Altshuler, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td></td>
</tr>
<tr>
<td>Lon L. Altshuler, M.D.</td>
<td>Autism Research Federation</td>
<td></td>
</tr>
<tr>
<td>Xavier Amador, Ph.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>30</td>
</tr>
<tr>
<td>Michael G. Aman, Ph.D.</td>
<td>Ortho-McNeil Pharmaceutical, Janssen Pharmaceutica and Research Foundation</td>
<td>90</td>
</tr>
<tr>
<td>Jay D. Amsterdam, M.D.</td>
<td>Somerset Pharmaceuticals, Inc.</td>
<td></td>
</tr>
<tr>
<td>Kimberly A. Arlinghaus, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lily and Company; Forest Laboratories, Inc.; Wyeth-Ayerst Laboratories; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals</td>
<td>73</td>
</tr>
<tr>
<td>Moe Armstrong, M.B.A.</td>
<td>Peer Educator, Project Vinfe (employee)</td>
<td>51</td>
</tr>
<tr>
<td>Evelyn Attia, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>58, 84</td>
</tr>
<tr>
<td>Peter M. Aupperle, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Bayer Corporation, Pharmaceutical Division; Eli Lilly and Company</td>
<td>15</td>
</tr>
<tr>
<td>Claudia Baldessano, M.D.</td>
<td>GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S.</td>
<td></td>
</tr>
<tr>
<td>Ross J. Baldessarini, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Eli Lilly and Company</td>
<td>13</td>
</tr>
<tr>
<td>James C. Ballenger, M.D.</td>
<td>Sandos Pharmaceuticals; Bristol-Myers Squibb; Hoffman-LaRoche; Abbott Laboratories; Pharmacia Corporation; Forest Laboratories, Inc.; Eli Lilly and Company; GlaxoSmithKline; Wyeth-Ayerst Laboratories; Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Ciba Geigy Corporation, Pharmaceutical Division; Orion Pharma</td>
<td>3</td>
</tr>
<tr>
<td>Nigel M. Bark, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Sanofi Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation</td>
<td>64</td>
</tr>
<tr>
<td>Barbara D. Bartlik, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; UroMetrics</td>
<td>29</td>
</tr>
<tr>
<td>Rhonda J.R. Beale, M.D.</td>
<td>Blue Cross/Blue Shield of Michigan</td>
<td>96</td>
</tr>
<tr>
<td>Ruth M. Benca, M.D.</td>
<td>Sanofi-Synthelabo, Inc.; Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Merck &amp; Co., Inc.; Searle</td>
<td>64</td>
</tr>
<tr>
<td>Laura Berman, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Proctor and Gamble; Solvay Pharmaceuticals, Inc.; UroMetrics</td>
<td>20</td>
</tr>
<tr>
<td>Sally A. Berry, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>9</td>
</tr>
<tr>
<td>Joseph Biederman, M.D.</td>
<td>Alza Pharmaceuticals; Shire Richwood Pharmaceuticals; Gliatec, Inc.; Cephalon, Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>77, 90</td>
</tr>
<tr>
<td>Bernard J. Biemann, M.D.</td>
<td>GlaxoSmithKline</td>
<td>18, 25</td>
</tr>
<tr>
<td>Renee L. Binder, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Sanofi Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation</td>
<td>9, 27, 43</td>
</tr>
<tr>
<td>Pierre Blies, M.D.</td>
<td>Forest Laboratories, Inc.; Somerset Pharmaceuticals, Inc.; Solvay Pharmaceuticals, Inc.; Organon Inc.; Eli Lilly and Company; Pierre Fabre Medicaments</td>
<td>3, 9</td>
</tr>
<tr>
<td>Sandra L. Bloom, M.D.</td>
<td>Universal Health Services, Inc. (employer)</td>
<td>44</td>
</tr>
<tr>
<td>J. Alexander Bodkin, M.D.</td>
<td>Somerset Pharmaceuticals, Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Michael J. Bohn, M.D.</td>
<td>Drug Abuse Sciences; Central Pharma</td>
<td>25</td>
</tr>
</tbody>
</table>

XVII
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Howard E. Book, M.D.</td>
<td>American Psychological Association Press Inc.</td>
<td>8</td>
</tr>
<tr>
<td>Soo Borson, M.D.</td>
<td>Jansen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>67</td>
</tr>
<tr>
<td>Charles L. Bowden, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Jansen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; National Institute of Mental Health; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; R.W. Johnson Pharmaceutical Institute; Sanofi Pharmaceuticals Inc.; Stanley Foundation; UCB Pharma, Inc.</td>
<td>29</td>
</tr>
<tr>
<td>Theron C. Bowers, Jr., M.D.</td>
<td>Cadmus Medical Software</td>
<td>63</td>
</tr>
<tr>
<td>Kathleen T. Brady, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company</td>
<td>3, 32, 93, 103</td>
</tr>
<tr>
<td>Alan F. Breier, M.D.</td>
<td>Eli Lilly and Company (employer)</td>
<td>106</td>
</tr>
<tr>
<td>Richard P. Brown, M.D.</td>
<td>Pharmavite Corporation</td>
<td>41</td>
</tr>
<tr>
<td>Thomas E. Brown, Ph.D.</td>
<td>American Psychiatric Press Inc.; The Psychological Corporation; Novartis Pharmaceuticals Corporation; Shire Richwood Pharmaceuticals, GlaxoSmithKline</td>
<td>7, 27, 40</td>
</tr>
<tr>
<td>Peter F. Buckley, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Jansen Pharmaceutica</td>
<td>64</td>
</tr>
<tr>
<td>Gregory C. Bunt, M.D.</td>
<td>Pass the Boards, Inc.</td>
<td>7, 24</td>
</tr>
<tr>
<td>Vivien K. Burt, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>13, 69</td>
</tr>
<tr>
<td>Marian I. Butterfield, M.D.</td>
<td>Organon Inc.; Eli Lilly and Company; GlaxoSmithKline</td>
<td>32, 50, 51, 81, 100</td>
</tr>
<tr>
<td>Daniel J. Buyse, M.D.</td>
<td>Sanofi-Synthelabo, Inc.; Sealed; Wyeth-Ayerst Laboratories; Cephalon</td>
<td>64</td>
</tr>
<tr>
<td>Joseph R. Calabrese, M.D.</td>
<td>GlaxoSmithKline; National Institute of Mental Health; Abbott Laboratories; Ciba Geigy Corporation, Pharmaceutical Division; Merck &amp; Co., Inc.; Jansen Pharmaceutica and Research Foundation; Eli Lilly and Company; MacArthur Foundation; National Alliance for Research in Schizophrenia and Affective Disorders; Parke-Davis, Division of Warner-Lambert Company; Robert Wood Johnson Pharmaceutical Research Institute; Sandoz Pharmaceuticals Corporation; Stanley Foundation; TAP Pharmaceuticals; Wyeth-Ayerst Laboratories; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; UCB Pharma</td>
<td>27, 64</td>
</tr>
<tr>
<td>Mary A. Casskadon, Ph.D.</td>
<td>Cephalon, Inc.</td>
<td>90</td>
</tr>
<tr>
<td>Diana Carter, M.B.</td>
<td>GlaxoSmithKline</td>
<td>8</td>
</tr>
<tr>
<td>Daniel E. Casey, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; AstraZeneca Pharmaceuticals; Jansen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation</td>
<td>11, 12, 39</td>
</tr>
<tr>
<td>David Castle, M.D.</td>
<td>Eli Lilly and Company; AstraZeneca Pharmaceuticals; Jansen Pharmaceutica and Research Foundation</td>
<td>61, 103</td>
</tr>
<tr>
<td>Dennis S. Charney, M.D.</td>
<td>Forest Laboratories, Inc.; AstraZeneca Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Comprehensive Neuroscience; Cyberonics, Inc.; Dow Pharmaceutical; Infoscriber, Jansen Pharmaceutica and Research Foundation; Eli Lilly and Company; Merck &amp; Co., Inc.; Mindsense; Mitsubishi Chemical; Novartis Pharmaceuticals Corporation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation GlaxoSmithKline; Solvay Pharmaceuticals, Inc.</td>
<td>3, 52, 62</td>
</tr>
<tr>
<td>K.N. Roy Chengappa, M.D.</td>
<td>Eli Lilly and Company; Jansen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals</td>
<td>9</td>
</tr>
<tr>
<td>James C.Y. Chou, M.D.</td>
<td>Jansen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Otsuka Pharmaceuticals; Bristol-Myers Squibb; Merck &amp; Co., Inc.; Eli Lilly and Company; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pass the Boards, Inc.</td>
<td>7</td>
</tr>
<tr>
<td>Henry Chung, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company</td>
<td>58</td>
</tr>
<tr>
<td>Leslie L. Citrome, M.D.</td>
<td>Jansen Pharmaceutica and Research Foundation; Abbott Laboratories; Novartis Pharmaceuticals Corporation</td>
<td>49, 103</td>
</tr>
<tr>
<td>Gordon H. Clark, Jr., M.D.</td>
<td>Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.</td>
<td>88</td>
</tr>
<tr>
<td>Cathryn M. Clary, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc. (employer)</td>
<td>20</td>
</tr>
<tr>
<td>Anita L.H. Clayton, M.D.</td>
<td>GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Pharmacia Corporation; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Bristol-Myers Squibb</td>
<td>6, 35, 99</td>
</tr>
<tr>
<td>Paula J. Clayton, M.D.</td>
<td>Merck &amp; Co., Inc.; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.</td>
<td>48</td>
</tr>
<tr>
<td>Thomas G. Cobb, M.D.</td>
<td>GlaxoSmithKline</td>
<td>18</td>
</tr>
<tr>
<td>Emil P. Coccaro, M.D.</td>
<td>Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Abbott Laboratories</td>
<td>87</td>
</tr>
<tr>
<td>Lee S. Cohen, M.D.</td>
<td>Eli Lilly and Company; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Jansen Pharmaceutica and Research Foundation; Solvay Pharmaceuticals, Inc.; Organon Inc.</td>
<td>2, 30, 62, 67, 93</td>
</tr>
<tr>
<td>Jeremy D. Coplan, M.D.</td>
<td>Eli Lilly and Company; Jansen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>32, 64</td>
</tr>
<tr>
<td>Leonardo Cortese, M.D.</td>
<td>Eli Lilly and Company; Jansen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>1</td>
</tr>
<tr>
<td>Paul T. Costa, Jr., Ph.D.</td>
<td>Psychological Assessment Resources, Inc.</td>
<td>105</td>
</tr>
<tr>
<td>Francine Cournois, M.D.</td>
<td>Norton and Penguin-Plum Publishers</td>
<td>31, 47, 60</td>
</tr>
<tr>
<td>XVIII</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
DISCLOSURE INDEX

Presenter | Manufacturer(s) | Program Page #
--- | --- | ---
M. Lynn Crismon, Pharm.D. | U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc. | 34
Harry A. Croft, M.D. | U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Pharmacacia Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Forest Laboratories, Inc.; Searle | 55
Jeffrey L. Cummings, M.D. | Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Sanofi Pharmaceuticals, Inc. | 63
Glenn W. Currier, M.D. | Janssen Pharmaceutica and Research Foundation | 9
Amaresda Das, M.D. | GlaxoSmithKline | 72
Jonathan R.T. Davidson, M.D. | Wyeth-Ayerst Laboratories; Warner-Lambert; Parke-Davis; Bristol-Myers Squibb; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Merck & Co., Inc.; Pharmacacia Corporation; Hoffman-LaRoche; Lichtwer Pharma; Organon Inc.; Solvay Pharmaceuticals, Inc. | 10
Jonathan S. Davinc, M.D. | Solvay Pharmaceuticals, Inc.; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Lundbeck | 20
Mary H. Davis, M.D. | U.S. Pharmaceuticals, Pfizer Inc., Parke-Davis, Division of Warner-Lambert Company; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline 18, 99
Ian C. Dawe, M.D. | GlaxoSmithKline; Eli Lilly and Company | 34, 97
Deborah Deas, M.D. | U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; GlaxoSmithKline | 25
Charles DeBattista, M.D. | Pharma Corporation | 3
Jose de Leon, M.D. | Eli Lilly and Company, Janssen Pharmaceutica and Research Foundation | 45
Pedro L. Delgado, M.D. | Organon Inc.; National Institute of Mental Health; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Otsuka Pharmaceuticals; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation; Boehringer Ingelheim; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc., Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals | 11
Davangere P. Devanand, M.D. | Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation | 63
Mantosh J. Dewan, M.D. | Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc. | 40, 104
Lisa B. Dixon, M.D. | Novartis Pharmaceuticals Corporation | 5, 44
Karl Doghramji, M.D. | Cephalon; Lorex; Devilbiss | 90
Rachelle S. Doody, M.D. | Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc. | 63
P. Murali Doraiswamy, M.D. | GlaxoSmithKline; Merck & Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Eisai, Forest Laboratories, Inc., Novartis Pharmaceuticals Corporation; Bayer Corporation, Pharmaceutical Division | 6
Robert E. Drake, M.D. | Novartis Pharmaceuticals Corporation | 5
Wayne C. Drevets, M.D. | Pharmacia Corporation; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company | 3, 71
Roxanne Dryden-Edwards, M.D. | Abbott Laboratories | 25
Jacques M. Dubuis, M.D. | U.S. Pharmaceuticals, Pfizer Inc. | 102
David L. Dunner, M.D. | Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; Mitsubishi; Cyberonics | 67, 93
Donard S. Dwyer, Ph.D. | Janssen Pharmaceutica and Research Foundation | 3
Stuart J. Eisenrat, M.D. | U.S. Pharmaceuticals, Pfizer Inc. | 19
Graham J. Emslie, M.D. | Eli Lilly and Company; Bristol-Myers Squibb; Forest Laboratories, Inc.; Organon Inc.; GlaxoSmithKline; Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories | 34, 67
Jean Endicott, Ph.D. | GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Pharmacia Corporation; Boehringer-Ingeheim; Abbott Laboratories; Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation | 5
Eliss Eriksson, Ph.D. | Forest Laboratories, Inc.; Lundbeck; GlaxoSmithKline; Bristol-Myers Squibb | 13
Milton K. Erman, M.D. | Wyeth-Ayerst Laboratories; Searle; Cephalon; Taiheda Pharmaceuticals; Ancile; Sanofi Pharmaceuticals, Inc.; Neurocrine Biosciences; Orphan Medical | 2
Javier I. Escobar, M.D. | U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Bayer Corporation, Pharmaceutical Division; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; GlaxoSmithKline; Bayer Corporation, Pharmaceutical Division | 78, 102, 103
Dwight L. Evans, M.D. | GlaxoSmithKline; Abbott Laboratories; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; TAP Pharmaceuticals; Wyeth-Ayerst Laboratories | 39
Raymond A. Faber, M.D. | U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company | 26, 40

XIX
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen V. Faraone, Ph.D.</td>
<td>Alza Pharmaceuticals; Shire Richwood Pharmaceuticals; Wyeth-Ayerst Laboratories; Eli Lilly and Company</td>
<td>77, 90</td>
</tr>
<tr>
<td>Larry R. Faulkner, M.D.</td>
<td>American Board of Psychiatry and Neurology, Inc.</td>
<td>19</td>
</tr>
<tr>
<td>Maurizio Fava, M.D.</td>
<td>GlaxoSmithKline; Pharmacare Corporation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Organon Inc.; Bristol-Myers Squibb; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Landbeck; Knoll Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Somerset Pharmaceuticals; Abbott Laboratories; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation; Pharmavite; Loxex Pharmaceuticals; Synnofe Synthelabo Pharmaceuticals; Lichtwer Pharma</td>
<td>56, 95</td>
</tr>
<tr>
<td>Jacqueline M. Feldman, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Zenith Goldline Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>80, 88</td>
</tr>
<tr>
<td>Stephen J. Ferrando, M.D.</td>
<td>Merck &amp; Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>31, 96</td>
</tr>
<tr>
<td>Donna Festa, C.S.W.</td>
<td>Westchester Medical Center-Behavioral Health Center (employee)</td>
<td>19</td>
</tr>
<tr>
<td>Robert L. Findling, M.D.</td>
<td>Ortho-McNeil Pharmaceutical; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Organon Inc.; Abbott Laboratories; Somerset Pharmaceuticals, Inc.; Shire Richwood Pharmaceuticals; Medeva; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; Eli Lilly and Company</td>
<td>90</td>
</tr>
<tr>
<td>Lois T. Flaherty, M.D.</td>
<td>Merck &amp; Co., Inc.</td>
<td>18</td>
</tr>
<tr>
<td>Lytle B. Forehand, Jr., M.D.</td>
<td>GlaxoSmithKline</td>
<td>18</td>
</tr>
<tr>
<td>Richard J. Frances, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Charter Behavioral; Merck &amp; Co., Inc.; Forest Laboratories, Inc.; Human Genome Services; Schering-Plough; Aventis; Abbott Laboratories</td>
<td>60, 74, 97</td>
</tr>
<tr>
<td>Ellen Frank, Ph.D.</td>
<td>GlaxoSmithKline; McArthur Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Pfizer Italia; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company;</td>
<td>39</td>
</tr>
<tr>
<td>Frances R. Frankenburg, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company</td>
<td>60</td>
</tr>
<tr>
<td>Matthew J. Friedman, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>62</td>
</tr>
<tr>
<td>Mark A. Frye, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; GlaxoSmithKline</td>
<td>6, 27, 55, 56</td>
</tr>
<tr>
<td>Glen O. Gabbard, M.D.</td>
<td>Merck &amp; Co., Inc.</td>
<td>15, 51, 61</td>
</tr>
<tr>
<td>Sara K. Gardner, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>50</td>
</tr>
<tr>
<td>David R. Gastfriend, M.D.</td>
<td>Bristol-Myers Squibb; Dupont Pharma; Earley Corp.</td>
<td>74, 87</td>
</tr>
<tr>
<td>Alan J. Gelenberg, M.D.</td>
<td>Bristol-Myers Squibb; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Merck Sharp &amp; Dohme; GlaxoSmithKline; Wyeth-Ayerst Laboratories; Hoechst Marion Roussel; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Janus Pharmaceuticals; Best Practice; Novartis Pharmaceuticals Corporation; Scios Nova Pharmaceuticals</td>
<td>55</td>
</tr>
<tr>
<td>Mark S. George, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Dupont Pharma; GlaxoSmithKline; Solvay Pharmaceuticals; Inc.; Parke-Davis, Division of Warner-Lambert Company</td>
<td>15</td>
</tr>
<tr>
<td>Hertzel C. Gerstein, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>3</td>
</tr>
<tr>
<td>S. Nasir Ghosemi, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Abbott Laboratories; Eli Lilly and Company; GlaxoSmithKline; Forest Laboratories, Inc.</td>
<td>33, 55, 93</td>
</tr>
<tr>
<td>Leslie H. Gise, M.D.</td>
<td>Merck Medco Managed Care</td>
<td>22, 50</td>
</tr>
<tr>
<td>Alexander H. Glassman, M.D.</td>
<td>Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Eli Lilly and Company</td>
<td>11</td>
</tr>
<tr>
<td>William M. Glatzer, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Eli Lilly and Company; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb</td>
<td>5, 63</td>
</tr>
<tr>
<td>Ira D. Glick, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Johnson and Johnson; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb</td>
<td>26, 67, 93</td>
</tr>
<tr>
<td>Donald C. Goff, M.D.</td>
<td>Cortex Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>83</td>
</tr>
<tr>
<td>Robert M. Gosman, M.D.</td>
<td>GlaxoSmithKline</td>
<td>1</td>
</tr>
<tr>
<td>Joseph F. Goldberg, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; Shire Richwood Pharmaceuticals; Pharmacia Corporation</td>
<td>6, 9, 55, 100</td>
</tr>
<tr>
<td>Robert N. Golden, M.D.</td>
<td>Bristol-Myers Squibb; Carolina Behavioral Health Alliance, LLC; Foundation of Hope for Research and Treatment of Mental Illness; National Depressive and Manic-Depressive Association; National Institute of Mental Health; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Organon Inc.; Parke-Davis, Division of Warner-Lambert Company; Searle; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>8</td>
</tr>
</tbody>
</table>

XX
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>David B. Goldenberg, M.D.</td>
<td>Dupont Pharma</td>
<td>101</td>
</tr>
<tr>
<td>Stephen M. Goldfinger, M.D.</td>
<td>Eli Lilly and Company; Zenith Goldline Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals</td>
<td>80</td>
</tr>
<tr>
<td>Patricia S. Goldstein-Rakic, Ph.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>9</td>
</tr>
<tr>
<td>R. Jeffrey Goldsmith, M.D.</td>
<td>Schering-Plough, Roche Laboratories, a member of the Roche Group; GlaxoSmithKline; Wyeth-Ayerst Laboratories</td>
<td>19, 46</td>
</tr>
<tr>
<td>Jill M. Goldstein, Ph.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>64</td>
</tr>
<tr>
<td>Karl Goodkin, M.D.</td>
<td>Pharmacia Corporation; GlaxoSmithKline; Merck &amp; Co., Inc.; Advance Immune; Phylomed</td>
<td>101</td>
</tr>
<tr>
<td>Frederick K. Goodwin, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Abbott Laboratories; GlaxoSmithKline; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Scios Nova Pharmaceuticals</td>
<td>3, 55, 81, 104</td>
</tr>
<tr>
<td>Jack M. Gorman, M.D.</td>
<td>Wyeth-Ayerst Laboratories; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; National Institute of Mental Health; NARSAD; Bristol-Myers Squibb, AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Organon Inc.; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Lundbeck; Solvay Pharmaceuticals, Inc.; Merck &amp; Co., Inc.; Synthelabo; International Academy for Biomedical and Drug Research</td>
<td>64, 90</td>
</tr>
<tr>
<td>Tana A. Grady-Weliky, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>5, 30, 64</td>
</tr>
<tr>
<td>Kevin F. Gray, M.D.</td>
<td>Elia Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation</td>
<td>32, 44</td>
</tr>
<tr>
<td>John F. Greden, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth-Ayerst Laboratories; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>26, 63</td>
</tr>
<tr>
<td>Alan I. Green, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Otsuka Pharmaceuticals</td>
<td>16, 29, 106</td>
</tr>
<tr>
<td>Michael F. Green, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>5</td>
</tr>
<tr>
<td>David J. Greenblatt, M.D.</td>
<td>Sarog Pharmaceuticals, Inc.; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Searle; Lexicon Pharmaceuticals</td>
<td>12</td>
</tr>
<tr>
<td>Laurence L. Greenhill, M.D.</td>
<td>Alza Pharmaceuticals; Shire Richwood Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Medeva</td>
<td>64</td>
</tr>
<tr>
<td>John H. Greist, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth-Ayerst Laboratories; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>77, 85</td>
</tr>
<tr>
<td>Carlos M. Grilo, Ph.D.</td>
<td>National Institute of Mental Health; National Institutes of Health; Eli Lilly and Company; Dana Foundation Medical Research Foundation</td>
<td>106</td>
</tr>
<tr>
<td>Mark S. Groves, M.D.</td>
<td>GlaxoSmithKline</td>
<td>83</td>
</tr>
<tr>
<td>Goran Hajak, M.D.</td>
<td>Sanofi-Synthelabo, Inc.</td>
<td>18</td>
</tr>
<tr>
<td>Uriel Halbreich, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Berlex</td>
<td>64</td>
</tr>
<tr>
<td>Robert E. Hales, M.D.</td>
<td>Bristol-Myers Squibb; Forest Laboratories, Inc.; GlaxoSmithKline, U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>49</td>
</tr>
<tr>
<td>Ellen Haller, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>19, 68</td>
</tr>
<tr>
<td>Thomas E. Hansen, M.D.</td>
<td>Sanofi Pharmaceuticals, Inc.; Abbott Laboratories; Hoechst Marion Roussel; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>18</td>
</tr>
<tr>
<td>Robert S. Henderson, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb; Forest Laboratories, Inc.; Dist Products, Wyeth-Ayerst Laboratories</td>
<td>48</td>
</tr>
<tr>
<td>Victoria Hendrick, M.D.</td>
<td>GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Eli Lilly and Company; National Depressive and Manic-Depressive Association</td>
<td>3</td>
</tr>
<tr>
<td>Robert M.A. Hirschfeld, M.D.</td>
<td>Bristol-Myers Squibb; Abbott Laboratories; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Forest Laboratories, Inc.; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Pharmacia Corporation; Janssen Pharmaceutica and Research Foundation</td>
<td>39</td>
</tr>
<tr>
<td>Jammie C. Holland, M.D.</td>
<td>Eli Lilly and Company</td>
<td>36</td>
</tr>
<tr>
<td>Ron Holland, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Abbott Laboratories; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories; Eli Lilly and Company</td>
<td>11, 14, 39</td>
</tr>
<tr>
<td>Douglas H. Hughes, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>25</td>
</tr>
<tr>
<td>Michael Y. Hwang, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company</td>
<td>9, 72</td>
</tr>
<tr>
<td>Steven E. Hyman, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>102</td>
</tr>
<tr>
<td>Richard S. Jackson, M.D.</td>
<td>Bristol-Myers Squibb; Forest Laboratories, Inc.; Organon Inc.; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>3, 70</td>
</tr>
<tr>
<td>Kay R. Jamison, Ph.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Abbott Laboratories; Eli Lilly and Company</td>
<td>40, 104</td>
</tr>
</tbody>
</table>

XXI
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philip G. Janicak, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Bristol-Myers Squibb; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; Genentech</td>
<td>1</td>
</tr>
<tr>
<td>James W. Jefferson, M.D.</td>
<td>Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Forest Laboratories, Inc.; GlaxoSmithKline; Eli Lilly and Company; Organon Inc.; Janssen Pharmaceutica and Research Foundation; Parke-Davis, Division of Warner-Lambert Company; Solvay Pharmaceuticals, Inc.; Warner-Lambert; Novartis Pharmaceuticals Corporation; Scios Nova Pharmaceuticals; TAP Pharmaceuticals; Sciele; Pharmacia Corporation; Wyeth-Ayerst Laboratories; Healthcare Technology Systems, LLC</td>
<td>8, 67, 93</td>
</tr>
<tr>
<td>Dilip V. Jeste, M.D.</td>
<td>Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>8, 64</td>
</tr>
<tr>
<td>David C. Jimerson, M.D.</td>
<td>Knoll Pharmaceutical Company</td>
<td>7, 105</td>
</tr>
<tr>
<td>Hadine Joffe, M.D.</td>
<td>Eli Lilly and Company; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Society for Women’s Health</td>
<td>2, 30</td>
</tr>
<tr>
<td>Russell T. Joffe, M.D.</td>
<td>GlaxoSmithKline; Eli Lilly Canada; Wyeth-Ayerst Laboratories; Lundbeck Canada</td>
<td>13, 104</td>
</tr>
<tr>
<td>Lewis L. Judd, M.D.</td>
<td>International Academy for Biomedical and Drug Research; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company</td>
<td>90</td>
</tr>
<tr>
<td>Jeffrey P. Kahn, M.D.</td>
<td>Work Psych. Associates, Inc.</td>
<td>88</td>
</tr>
<tr>
<td>Eric R. Kandel, M.D.</td>
<td>Memory Pharmaceuticals</td>
<td>16</td>
</tr>
<tr>
<td>John M. Kane, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>30</td>
</tr>
<tr>
<td>Shinij Kapur, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>9</td>
</tr>
<tr>
<td>Roger G. Kathol, M.D.</td>
<td>Cartesian Solutions</td>
<td>16</td>
</tr>
<tr>
<td>Jra R. Katz, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; Bristol-Myers Squibb; Sanofi Pharmaceuticals, Inc.; Eli Lilly and Company; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>11</td>
</tr>
<tr>
<td>Walter H. Kaye, M.D.</td>
<td>Biogenesis U.S., Ltd.</td>
<td>31, 84, 105</td>
</tr>
<tr>
<td>Terence M. Krane, Ph.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>9</td>
</tr>
<tr>
<td>Paul E. Keck, Jr., M.D.</td>
<td>Abbott Laboratories; Solvay Pharmaceuticals, Inc.; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation</td>
<td>8, 9, 56, 63</td>
</tr>
<tr>
<td>Richard S.E. Keeffe, Ph.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals</td>
<td>5</td>
</tr>
<tr>
<td>Gabor I. Keitner, M.D.</td>
<td>GlaxoSmithKline; Organon Inc.; Wyeth-Ayerst Laboratories; Merck &amp; Co., Inc.; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Abbott Laboratories</td>
<td>6</td>
</tr>
<tr>
<td>Martin B. Keller, M.D.</td>
<td>Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Wyeth-Ayerst Laboratories; Merck &amp; Co., Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Organon Inc.; Pharmacia Corporation; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Mitsubishi Pharmaceuticals; Scirex</td>
<td>13</td>
</tr>
<tr>
<td>Ronald C. Kessler, Ph.D.</td>
<td>Wyeth-Ayerst Laboratories; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline</td>
<td>10</td>
</tr>
<tr>
<td>Terence A. Ketter, M.D.</td>
<td>Bristol-Myers Squibb; Abbott Laboratories; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Parke-Davis, Division of Warner-Lambert Company</td>
<td>8, 27, 90</td>
</tr>
<tr>
<td>Steven A. King, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation; Purdue</td>
<td>53</td>
</tr>
<tr>
<td>Brian Kirkpatrick, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Eli Lilly and Company</td>
<td>83</td>
</tr>
<tr>
<td>Herbert D. Kleber, M.D.</td>
<td>Schering-Plough</td>
<td>7, 32, 60</td>
</tr>
<tr>
<td>Richard Kogan, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; GlaxoSmithKline; Bristol-Myers Squibb; Forest Laboratories, Inc.</td>
<td>18, 46, 58</td>
</tr>
<tr>
<td>Robert Kohn, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Organon Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Forest Laboratories, Inc.</td>
<td>22</td>
</tr>
<tr>
<td>Rebecca A. Kornbluh, M.D.</td>
<td>GlaxoSmithKline</td>
<td>18</td>
</tr>
<tr>
<td>Susan G. Kornstein, M.D.</td>
<td>Eli Lilly and Company; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Parke-Davis, Division of Warner-Lambert Company; Biovail Laboratories; Wyeth-Ayerst Laboratories; Berlex</td>
<td>2, 35, 39</td>
</tr>
<tr>
<td>Thomas R. Kosten, M.D.</td>
<td>Schering Pharmaceuticals</td>
<td>7</td>
</tr>
<tr>
<td>K. Ranga R. Krishnan, M.D.</td>
<td>Forest Laboratories, Inc.; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Merck &amp; Co., Inc.; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Organon Inc.</td>
<td>6, 63</td>
</tr>
<tr>
<td>Meir H. Kryger, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>2</td>
</tr>
<tr>
<td>John H. Krystal, M.D.</td>
<td>GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>105</td>
</tr>
<tr>
<td>Elisabeth J. S. Kunkel, M.D.</td>
<td>Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.</td>
<td>35</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>David J. Kupfer, M.D.</td>
<td>Forest Laboratories, Inc.; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>52, 106</td>
</tr>
<tr>
<td>Helen H. Kyomen, M.D.</td>
<td>Wyeth-Ayerst Laboratories; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation</td>
<td>50</td>
</tr>
<tr>
<td>Lawrence A. Labbate, M.D.</td>
<td>GlaxoSmithKline; Eli Lilly and Company; Forest Laboratories, Inc.</td>
<td>55</td>
</tr>
<tr>
<td>Raymond W. Lam, M.D.</td>
<td>Pfizer Canada; Eli Lilly Canada; Uplift Canada</td>
<td>8</td>
</tr>
<tr>
<td>Timothy Lambert, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Sanofi Pharmaceuticals, Inc.; Lundbeck; Kendall</td>
<td>1</td>
</tr>
<tr>
<td>William B. Lawson, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals</td>
<td>45, 62</td>
</tr>
<tr>
<td>Harold E. Lebovitz, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; GlaxoSmithKline; Aventis; Bayer Corporation, Pharmaceutical Division; Bayer Corporation, Pharmaceutical Division; Aynlin; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Ellen Leibenluft, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories</td>
<td>27, 69</td>
</tr>
<tr>
<td>Lydia J. Lewis</td>
<td>Eli Lilly and Company; Abbott Laboratories; Bristol-Myers Squibb; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Merck &amp; Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories</td>
<td>9, 50, 59</td>
</tr>
<tr>
<td>Jeffrey A. Lieberman, M.D.</td>
<td>Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Hoenhe Marion Roussel; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation</td>
<td>5, 8, 106</td>
</tr>
<tr>
<td>Michael R. Liebowitz, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company; Bristol-Myers Squibb; Merck &amp; Co., Inc.; Wyeth-Ayerst Laboratories; Eli Lilly and Company; Sanofi Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Pharmacia Corporation</td>
<td>11</td>
</tr>
<tr>
<td>Michael Linden, M.D.</td>
<td>Janssen-Cilag; Oranon-Akzo-Nobel</td>
<td>59</td>
</tr>
<tr>
<td>Jean-Pierre Lindenmayer, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>19</td>
</tr>
<tr>
<td>Paul S. Linko, M.D.</td>
<td>GlaxoSmithKline</td>
<td>60, 97</td>
</tr>
<tr>
<td>Barbara K. Lipska, Ph.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>9</td>
</tr>
<tr>
<td>Wilson M. Le., M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Ortho-McNeil; AstraZeneca Pharmaceuticals Bristol-Myers Squibb; Solvay Pharmaceuticals, Inc.</td>
<td>45</td>
</tr>
<tr>
<td>Lance P. Longo, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Lipha Pharmaceuticals</td>
<td>25</td>
</tr>
<tr>
<td>Juan F. Lopez, M.D.</td>
<td>Pharma Corporation</td>
<td>3</td>
</tr>
<tr>
<td>Constantine G. Lyketsos, M.D.</td>
<td>Dupont Pharma; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Parke-Davis, Division of Warner-Lambert Company; Abbott Laboratories; Bayer Corporation, Pharmaceutical Division; Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Neurologie, Inc.</td>
<td>11, 15, 20, 56, 57</td>
</tr>
<tr>
<td>Avram H. Mack, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>44</td>
</tr>
<tr>
<td>Gerald A. Maguire, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories</td>
<td>5</td>
</tr>
<tr>
<td>Mark W. Mahowald, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Cephalon</td>
<td>2</td>
</tr>
<tr>
<td>Husseini K. Manji, M.D.</td>
<td>GlaxoSmithKline; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Pharmacia Corporation; AstraZeneca Pharmaceuticals; Organon Inc.; Solvay Pharmaceuticals, Inc.; Meck &amp; Co., Inc.; Millennium; Oxford Glycosides; Chiron</td>
<td>64, 90</td>
</tr>
<tr>
<td>J. John Mann, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>2, 34</td>
</tr>
<tr>
<td>Lauren B. Marangell, M.D.</td>
<td>Pharmacy Corporation; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Martek Biosciences; Cyberonics; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.; Bristol-Myers Squibb; Abbott Laboratories; GlaxoSmithKline</td>
<td>3, 5</td>
</tr>
<tr>
<td>Donatella Marazziti, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>1, 11</td>
</tr>
<tr>
<td>Stephen R. Marder, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; Lundbeck; Bristol-Myers Squibb</td>
<td>1, 30, 67, 93</td>
</tr>
<tr>
<td>John C. Markowitz, M.D.</td>
<td>Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Organon Inc.; National Institute of Mental Health; Pritzker Research Network; Basic Books; American Psychiatric Press Inc.; Franco Angeli</td>
<td>6</td>
</tr>
<tr>
<td>Charles R. Marmar, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.</td>
<td>3, 32</td>
</tr>
<tr>
<td>Randall D. Marshall, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Bristol-Myers Squibb</td>
<td>23, 32, 52, 53, 74, 102</td>
</tr>
<tr>
<td>Rick A. Martinez, M.D.</td>
<td>Johnson and Johnson</td>
<td>106</td>
</tr>
<tr>
<td>Christine F. Marx, M.D.</td>
<td>Eli Lilly and Company</td>
<td>43</td>
</tr>
<tr>
<td>Prakash S. Masand, M.D.</td>
<td>Pharmacia Corporation; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Bristol Myers Squibb; Hoechst Marion Roussel; Novartis Pharmaceuticals Corporation; Searle; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories</td>
<td>11</td>
</tr>
<tr>
<td>Barbara J. Mason, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Lipha Pharmaceuticals; Dupont Pharma</td>
<td>6</td>
</tr>
</tbody>
</table>

XXIII
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>John D. Matthews, M.D.</td>
<td>Eli Lilly and Company</td>
<td>78</td>
</tr>
<tr>
<td>Helen S. Mayberg, M.D.</td>
<td>Forest Laboratories, Inc.; Eli Lilly and Company</td>
<td>3</td>
</tr>
<tr>
<td>Laurel Mayer, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>58, 84</td>
</tr>
<tr>
<td>Robert W. McArdle, M.D.</td>
<td>Cephalon</td>
<td>90</td>
</tr>
<tr>
<td>David M. McDowell, M.D.</td>
<td>Bristol-Myers Squibb; Wyeth-Ayerst Laboratories</td>
<td>32, 33, 75, 102</td>
</tr>
<tr>
<td>Susan L. McGlynn, M.D.</td>
<td>Wyeth-Ayerst Laboratories; International Academy for Biomedical and Drug Research; Abbott Laboratories; Solvay Pharmaceuticals, Inc.; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; AstraZeneca Pharmaceuticals; Alza Pharmaceuticals</td>
<td>11, 56, 90</td>
</tr>
<tr>
<td>Alexander McFarlane, M.D.</td>
<td>GlaxoSmithKline; Solvay Pharmaceuticals, Inc.</td>
<td>84</td>
</tr>
<tr>
<td>Patrick D. McGorry, Ph.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>67</td>
</tr>
<tr>
<td>Patrick J. McGrath, M.D.</td>
<td>Pharmacia Corporation; GlaxoSmithKline; Drug Abuse Sciences; Somerset Pharmaceuticals, Inc.</td>
<td>11</td>
</tr>
<tr>
<td>Jacqueline Melonas, J.D.</td>
<td>Professional Risk Management Services, Inc.; APA-sponsored Professional Liability Program</td>
<td>44, 81</td>
</tr>
<tr>
<td>Herbert Y. Melzer, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Merck &amp; Co., Inc.</td>
<td>3, 5</td>
</tr>
<tr>
<td>Alan J. Mendelowitz, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceuticals and Research Foundation</td>
<td>12, 13</td>
</tr>
<tr>
<td>Julien Mendlewicz, M.D.</td>
<td>International Academy for Biomedical and Drug Research</td>
<td>90</td>
</tr>
<tr>
<td>Ricardo P. Mendoza, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.</td>
<td>45, 79</td>
</tr>
<tr>
<td>Matthew A. Menza, M.D.</td>
<td>Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>85</td>
</tr>
<tr>
<td>Emmanuel Mignot, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Cephalon</td>
<td>2</td>
</tr>
<tr>
<td>Alexander L. Miller, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Eli Lilly and Company; Novartis Pharmaceuticals Corporation</td>
<td>34</td>
</tr>
<tr>
<td>Jacobo E. Mintzer, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb, Abbott Laboratories; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>11, 15, 50, 79</td>
</tr>
<tr>
<td>Shaila Misra, M.D.</td>
<td>GlaxoSmithKline; Pharmaceuticals Corporation; Bristol-Myers Squibb Canada</td>
<td>8, 83</td>
</tr>
<tr>
<td>James E. Mitchell, M.D.</td>
<td>Knoll Pharmaceuticals; Eli Lilly and Company</td>
<td>7, 31, 105</td>
</tr>
<tr>
<td>Perry Moninoff, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>20</td>
</tr>
<tr>
<td>Stuart A. Montgomery, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Eli Lilly and Company; Lundbeck; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Abbott Laboratories; Bristol-Myers Squibb; Solvay Pharmaceuticals, Inc.; Elanco Animal Health; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Schering-Plough; Dana Foundation</td>
<td>6, 90</td>
</tr>
<tr>
<td>Leslie C. Morey, Ph.D.</td>
<td>National Institutes of Health; National Institute of Mental Health</td>
<td>83</td>
</tr>
<tr>
<td>Philip Morgan, Ph.D.</td>
<td>GlaxoSmithKline (employer)</td>
<td>20</td>
</tr>
<tr>
<td>Carles Muntaner, M.D.</td>
<td>University of Maryland (employer)</td>
<td>72</td>
</tr>
<tr>
<td>Greer M. Murphy, M.D.</td>
<td>Organon Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Robin M. Murray, M.B.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceuticals and Research Foundation; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>29</td>
</tr>
<tr>
<td>Dominique L. Musselman, M.D.</td>
<td>GlaxoSmithKline; National Institutes of Health; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Schering-Plough; Dana Foundation</td>
<td>39</td>
</tr>
<tr>
<td>Hugh Myrick, M.D.</td>
<td>Parke-Davis, Division of Warner-Lambert Company; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>6, 90</td>
</tr>
<tr>
<td>Joseph C. Napoli, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline</td>
<td>71</td>
</tr>
<tr>
<td>Henry A. Naarallah, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; National Institute of Mental Health</td>
<td>39, 49, 61, 63</td>
</tr>
<tr>
<td>J. Craig Nelson, M.D.</td>
<td>Organon Inc.; Abbott Laboratories; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Wyeth-Ayerst Laboratories</td>
<td>9</td>
</tr>
<tr>
<td>Charles B. Nemeroff, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Abbott Laboratories; Forest Laboratories, Inc.; Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharamcia Corporation; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Merck &amp; Co., Inc.; Mitsubishi; Neurocine Biosciences; Otsuka Pharmaceuticals; Solvay Pharmaceuticals, Inc.</td>
<td>9, 56, 63</td>
</tr>
<tr>
<td>Eric J. Nestler, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>3</td>
</tr>
<tr>
<td>John W. Newcomer, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; AstraZeneca Pharmaceuticals</td>
<td>3</td>
</tr>
</tbody>
</table>

XXIV
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cassandra F. Newkirk, M.D.</td>
<td>Bristol-Myers Squibb; GlaxoSmithKline</td>
<td>96</td>
</tr>
<tr>
<td>Donald J. Newport, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Eli Lilly and Company; GlaxoSmithKline</td>
<td>93</td>
</tr>
<tr>
<td>Andrew A. Nierenberg, M.D.</td>
<td>Pharmacia Corporation; Somerset Pharmaceuticals, Inc.; Bristol-Myers Squibb; Forest Laboratories, Inc.; GlaxoSmithKline; Eli Lilly and Company; Lichtwer Pharma; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Sanofi Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories</td>
<td>3, 9, 50</td>
</tr>
<tr>
<td>Carol S. North, M.D.</td>
<td>GlaxoSmithKline; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company</td>
<td>53, 79</td>
</tr>
<tr>
<td>Colleen J. Northcutt, M.D.</td>
<td>Servier Pharmaceutical, France</td>
<td>79</td>
</tr>
<tr>
<td>Kristin J. O'Dell, M.D.</td>
<td>GlaxoSmithKline</td>
<td>72</td>
</tr>
<tr>
<td>Mark Offson, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Eli Lilly and Company; GlaxoSmithKline; Freedom From Fear</td>
<td>11</td>
</tr>
<tr>
<td>Lewis A. Opler, M.D.</td>
<td>Multi-Health Systems, Inc.</td>
<td>25, 40, 74, 103</td>
</tr>
<tr>
<td>Maria A. Oquendo, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>78, 87</td>
</tr>
<tr>
<td>Patricia I. Odericis, M.D.</td>
<td>Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>46, 66, 90</td>
</tr>
<tr>
<td>Michael W. Otto, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Psychological Corp.; Ancile</td>
<td>93</td>
</tr>
<tr>
<td>Barbara L. Parry, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>2</td>
</tr>
<tr>
<td>Robert D. Patterson, M.D.</td>
<td>Mental Health Connections, Inc.</td>
<td>71</td>
</tr>
<tr>
<td>Debra Patton, R.N.</td>
<td>Schering-Plough; Roche Laboratories, a member of the Roche Group</td>
<td>46</td>
</tr>
<tr>
<td>Teri B. Pearlstein, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>2</td>
</tr>
<tr>
<td>Diana O. Perkins, M.D.</td>
<td>Eli Lilly and Company; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Hoechst Marion Roussel; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>5, 63, 64</td>
</tr>
<tr>
<td>Katharine A. Phillips, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Gate Pharmaceuticals; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; GlaxoSmithKline</td>
<td>21, 61, 79, 83</td>
</tr>
<tr>
<td>Edmond H.T. Pi, M.D.</td>
<td>Eli Lilly and Company</td>
<td>45, 50</td>
</tr>
<tr>
<td>Daniel S. Pine, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb, Wyeth-Ayerst Laboratories</td>
<td>52, 71, 85</td>
</tr>
<tr>
<td>Mark H. Pollack, M.D.</td>
<td>GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth-Ayerst Laboratories; Parke-Davis, Division of Warner-Lambert Company; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.</td>
<td>5, 67, 93</td>
</tr>
<tr>
<td>Bruce G. Pollock, M.D.</td>
<td>Organon Inc.; National Institute of Mental Health; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; GlaxoSmithKline; Pharmacia Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Lundbeck; Janus Pharmaceuticals</td>
<td>9</td>
</tr>
<tr>
<td>Robert M. Post, M.D.</td>
<td>Abbott Laboratories; Bayer Corporation, Pharmaceutical Division; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Johnson and Johnson; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Pharmacia Corporation; AstraZeneca Pharmaceuticals; Bayer Corporation, Pharmaceutical Division</td>
<td>53, 86, 104</td>
</tr>
<tr>
<td>David W. Preven, M.D.</td>
<td>Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>19, 77</td>
</tr>
<tr>
<td>Andres J. Pumarega, M.D.</td>
<td>Forest Laboratories, Inc.; Solvay Pharmaceuticals, Inc.</td>
<td>44, 56, 89</td>
</tr>
<tr>
<td>Frederick M. Quikkin, M.D.</td>
<td>Organon Inc.</td>
<td>79</td>
</tr>
<tr>
<td>Giorgio Racagni, Ph.D.</td>
<td>International Academy for Biomedical and Drug Research</td>
<td>90</td>
</tr>
<tr>
<td>Luis F. Ramirez, M.D.</td>
<td>Ono Pharma Inc.; TAP Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company</td>
<td>41</td>
</tr>
<tr>
<td>Paul M. Ramirez, Ph.D.</td>
<td>Multi-Health Systems, Inc.</td>
<td>40</td>
</tr>
<tr>
<td>Neal G. Ranen, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eisai Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>85</td>
</tr>
<tr>
<td>Mark H. Rapaport, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Abbott Laboratories; Sanofi Pharmaceuticals, Inc.; Pharmacia Corporation; Organon Inc.; Wyeth-Ayerst Laboratories</td>
<td>5</td>
</tr>
<tr>
<td>Judith H.L. Rapoport, M.D.</td>
<td>Bristol-Myers Squibb, Ortho-McNeil, Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Richmond, Novartis Pharmaceuticals Corporation</td>
<td>8, 91</td>
</tr>
<tr>
<td>Valerie Davis Raskin, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Merck &amp; Co., Inc.; GlaxoSmithKline</td>
<td>100</td>
</tr>
<tr>
<td>William E. Reichman, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Bristol-Myers Squibb</td>
<td>15, 57</td>
</tr>
<tr>
<td>Mark A. Riddle, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Quintiles Pacific; Best Practice; Bristol-Myers Squibb, Solvay Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Shire Richwood Pharmaceuticals</td>
<td>85</td>
</tr>
<tr>
<td>Robert G. Robinson, M.D.</td>
<td>DuLab Pharmaceutical Co.</td>
<td>85</td>
</tr>
<tr>
<td>Catherine A. Roca, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>58, 93</td>
</tr>
<tr>
<td>Mercedes M. Rodriguez, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>22, 100</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Steven P. Roose, M.D.</td>
<td>Forest Laboratories, Inc.; Organon Inc.; GlaxoSmithKline; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Eli Lilly and Company</td>
<td>6, 11, 21</td>
</tr>
<tr>
<td>Raymond C. Rosen, Ph.D.</td>
<td>Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; TAP Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>6</td>
</tr>
<tr>
<td>Jerrold F. Rosenbaum, M.D.</td>
<td>Forest Laboratories, Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; Eli Lilly and Company; Organon Inc.; Lichtwer Pharma; Wyeth-Ayerst Laboratories; Pharmacia Corporation; Millennium Pharmaceuticals</td>
<td>3, 63</td>
</tr>
<tr>
<td>Kenneth P. Rosenberg, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>22</td>
</tr>
<tr>
<td>Erik J. Roskes, M.D.</td>
<td>GlaxoSmithKline</td>
<td>96</td>
</tr>
<tr>
<td>Barbara O. Rothbaum, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>3</td>
</tr>
<tr>
<td>David R. Rubinow, M.D.</td>
<td>Thera Tech; Bristol-Myers Squibb; Woman’s Pharmacy of Madison Wisconsin; Janus Pharmaceuticals; Berlex Pharmaceuticals</td>
<td>30, 58</td>
</tr>
<tr>
<td>A. John Rush, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Abbott Laboratories; Cyberonics; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutical and Research Foundation; Robert Wood Johnson Foundation; Meadows Foundation; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Stanley Foundation; AstraZeneca Pharmaceuticals; Merck &amp; Co., Inc.; Mitsubishi Pharmaceuticals; Yamanouchi, Inc.</td>
<td>5, 13, 34, 59, 106</td>
</tr>
<tr>
<td>Donna H. Ryan, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Knoll Pharmaceuticals; Boots Pharmaceuticals; Roche Laboratories, a member of the Roche Group; Amgen; Bristol-Myers Squibb; Ergon; GlaxoSmithKline; Parke-Davis, Division of Warner-Lambert Company; Regeneron Pharmaceuticals; Schering-Plough Pharmaceuticals; Koll Pharmaceutical Company; Warner-Lambert Company; Janssen Pharmaceutical and Research Foundation; Eli Lilly and Company; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutical and Research Foundation; Scio Nova Pharmaceuticals; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; Solvay Pharmaceuticals, Inc.; Sanofi Pharmaceuticals, Inc.; Bristol-Myers Squibb; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Janssen Pharmaceutical and Research Foundation</td>
<td>13, 39, 57, 106</td>
</tr>
<tr>
<td>Harold A. Sackeim, Ph.D.</td>
<td>Organon Inc.</td>
<td>11, 71</td>
</tr>
<tr>
<td>Martha Sajatovic, M.D.</td>
<td>Janssen Pharmaceutical and Research Foundation; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>41</td>
</tr>
<tr>
<td>Cynthia W. Santos, M.D.</td>
<td>Janssen Pharmaceutical and Research Foundation</td>
<td>23</td>
</tr>
<tr>
<td>Lawrence D. Scallill, M.D.</td>
<td>Ortho-McNeil</td>
<td>91</td>
</tr>
<tr>
<td>Michael A. Scharf, M.D.</td>
<td>GlaxoSmithKline</td>
<td>18</td>
</tr>
<tr>
<td>Alan F. Shatzberg, M.D.</td>
<td>Organon Inc.; Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutical and Research Foundation; Merck &amp; Co., Inc.; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Vermont Life Sciences; Concept Therapeutics, Inc.</td>
<td>9, 11</td>
</tr>
<tr>
<td>Peter J. Schmidt, M.D.</td>
<td>Thera Tech; Bristol-Myers Squibb; Women’s Pharmacy of Madison, Wisconsin; Berlex Pharmaceuticals</td>
<td>30</td>
</tr>
<tr>
<td>Leon S. Schneider, M.D.</td>
<td>Janssen Pharmaceutical and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Abbott Laboratories</td>
<td>11, 56</td>
</tr>
<tr>
<td>Nina R. Schooley, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Janssen Pharmaceutical and Research Foundation</td>
<td>11, 12, 103</td>
</tr>
<tr>
<td>Marcia Scott, M.D.</td>
<td>Prudential Insurance (employer)</td>
<td>72</td>
</tr>
<tr>
<td>Mary V. Seeman, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>64</td>
</tr>
<tr>
<td>Stuart N. Seidman, M.D.</td>
<td>Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>6, 22</td>
</tr>
<tr>
<td>David Shaffer, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>3, 76</td>
</tr>
<tr>
<td>Zafar Sharifi, M.D.</td>
<td>Janssen Pharmaceutical and Research Foundation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>19</td>
</tr>
<tr>
<td>Rajiv P. Sharma, M.D.</td>
<td>Parke-Davis, Division of Warner-Lambert Company; Abbott Laboratories; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutical and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>1</td>
</tr>
<tr>
<td>Shawn C. Shea, M.D.</td>
<td>Wyeth-Ayerst Laboratories; GlaxoSmithKline; Abbott Laboratories; AstraZeneca Pharmaceuticals; Boehringer Ingelheim; Boots Pharmaceuticals; Bristol-Myers Squibb; Burroughs Wellcome; Charter Hospitals; Gilb Gwy Corporation; Pharmaceutical Division; ICI; Kali-Duphar; Marion Merrell Dow; Mc Neill Pharmaceuticals; Mead Johnson; Merck Sharp &amp; Dohme; Organon Inc.; Novo Nordisk; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Rhone-Poulenc Rorer Pharmaceuticals; Roche Laboratories, a member of the Roche Group; Roent; Sander; Schering Corporation; Solvay Pharmaceuticals, Inc.; TAP Pharmaceuticals, Inc.; TCH-University Psychiatry Center; American Medical Association; Anclote Foundation; Eisai Inc.; Forest Laboratories, Inc.; International Clinical Research; Janssen Pharmaceutical and Research Foundation; National</td>
<td>7</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Richard C. Shelton, M.D.</td>
<td>Institute of Drug Abuse; National Institutes of Health; Novartis Pharmaceuticals Corporation; Quinules; Sanofi Pharmaceuticals Corporation; Warner-Chilcott</td>
<td>10, 31, 64</td>
</tr>
<tr>
<td>Alan P. Siegel, M.D.</td>
<td>Janssen Pharmaceuticals Research Foundation; Abbott Laboratories; Eisai Inc.; Bayer Corporation, Pharmaceutical Division; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; AstraZeneca Pharmaceuticals</td>
<td>93</td>
</tr>
<tr>
<td>Linmarie Sikich, M.D.</td>
<td>Eli Lilly and Company, Ortho-McNeil Pharmaceutical</td>
<td>67</td>
</tr>
<tr>
<td>Kenneth R. Silk, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>5, 91</td>
</tr>
<tr>
<td>Michael A. Silver, M.D.</td>
<td>Eli Lilly and Company; Zenith Goldline Pharmaceuticals</td>
<td>78</td>
</tr>
<tr>
<td>Naomi M. Simon, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>93</td>
</tr>
<tr>
<td>Samuel G. Sinis, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Merck &amp; Co., Inc.</td>
<td>102</td>
</tr>
<tr>
<td>Gary W. Small, M.D.</td>
<td>Forest Laboratories, Inc.; Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Searle; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; Novartis Pharmaceuticals Corporation; Dupont Pharma; GlaxoSmithKline</td>
<td>6, 63</td>
</tr>
<tr>
<td>Michael W. Smith, M.D.</td>
<td>Janssen Pharmaceuticals Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Otaka Pharmaceuticals</td>
<td>52</td>
</tr>
<tr>
<td>Joseph M. Smurda, M.D.</td>
<td>GlaxoSmithKline</td>
<td>18</td>
</tr>
<tr>
<td>Lionel P. Solunsh, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>97</td>
</tr>
<tr>
<td>Steven M. Southwick, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation</td>
<td>3</td>
</tr>
<tr>
<td>Thomas J. Spencer, M.D.</td>
<td>AstraZeneca Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Richwood Pharmaceuticals</td>
<td>35, 90</td>
</tr>
<tr>
<td>Stephen M. Stahl, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Janssen Pharmaceutica and Research Foundation; Bayer Corporation, Pharmaceutical Division; Boehringer Ingelheim; Yamanouchi; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Roche Laboratories, a member of the Roche Group; Ciba Geigy Corporation, Pharmaceutical Division; Pharmacia Corporation; Hoechst Marion Roussel; Abbott Laboratories; Organon Inc.; Sanofi Pharmaceuticals, Inc.; Pierre Fabre; Merck; Sumitomo; Watson Laboratories, Inc.; Neurocrine, Lundbeck; Sano; Searle; Solvay Pharmaceuticals, Inc.; Takeda Pharmaceuticals; Fabre-Kramer, AstraZeneca Pharmaceuticals</td>
<td>20</td>
</tr>
<tr>
<td>Dan J. Stein, M.D.</td>
<td>MRC Unit on Anxiety Disorders (employer)</td>
<td>32</td>
</tr>
<tr>
<td>Murray B. Stein, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Hoffman-LaRoche; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Roche Laboratories; a member of the Roche Group; Ciba Geigy Corporation; Pharmaceutical Division; Pharmacia Corporation; Hoechst Marion Roussel; Abbott Laboratories; Organon Inc.; Sanofi Pharmaceuticals, Inc.; Pierre Fabre; Merck; Sumitomo; Watson Laboratories, Inc.; Neurocrine, Lundbeck; Sano; Searle; Solvay Pharmaceuticals, Inc.; Takeda Pharmaceuticals; Fabre-Kramer, AstraZeneca Pharmaceuticals</td>
<td>39</td>
</tr>
<tr>
<td>Hans Steiner, M.D.</td>
<td>Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>21, 50, 53, 83</td>
</tr>
<tr>
<td>Donna E. Stewart, M.D.</td>
<td>Eli Lilly and Company</td>
<td>15, 26, 45, 72, 79, 100</td>
</tr>
<tr>
<td>Nada L. Stotland, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Forest Laboratories, Inc.; Procter &amp; Gamble</td>
<td>13, 39, 62</td>
</tr>
<tr>
<td>Zachary N. Stowe, M.D.</td>
<td>Forest Laboratories, Inc.; GlaxoSmithKline; Eli Lilly and Company; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Warner-Lambert Comprucorc, 1000</td>
<td>44</td>
</tr>
<tr>
<td>James J. Strain, M.D.</td>
<td>AstraZeneca Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Pharmacia Corporation; GlaxoSmithKline</td>
<td>14</td>
</tr>
<tr>
<td>Stephen M. Strakowski, M.D.</td>
<td>Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Otsuka Pharmaceuticals; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline</td>
<td>15</td>
</tr>
<tr>
<td>David L. Sultzer, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pharma; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Pharmaceutical Research Institute</td>
<td>14</td>
</tr>
<tr>
<td>Patricia Suppes, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pharma; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Pharmaceutical Research Institute</td>
<td>15</td>
</tr>
<tr>
<td>Alan C. Swann, M.D.</td>
<td>Abbott Laboratories; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Pharmacia Corporation; Shire Richwood Pharmaceuticals; Robert Wood Johnson</td>
<td>6, 34, 57, 64</td>
</tr>
<tr>
<td>Holly A. Swartz, M.D.</td>
<td>GlaxoSmithKline; Ortho-McNeil Pharmaceutical</td>
<td>5</td>
</tr>
<tr>
<td>Robert M. Swift, M.D.</td>
<td>Dupont Pharma; U.S. Pharmaceuticals, Pfizer Inc.; Lipha Pharmaceuticals; OY Control Pharma</td>
<td>25</td>
</tr>
<tr>
<td>Rajiv Tandon, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>1, 13, 39</td>
</tr>
<tr>
<td>Rosemary Tanneck, Ph.D.</td>
<td>Eli Lilly and Company</td>
<td>35</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Pierre N. Tariot, M.D.</td>
<td>Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Pharmacia Corporation; Eli Lilly and Company; Berlex; Schweb; AstraZeneca Pharmaceuticals; Bayer Corporation, Pharmaceutical Division; Lundbeck; Sanofi Pharmaceuticals, Inc.</td>
<td>15, 63, 90</td>
</tr>
<tr>
<td>David H. Taylor, M.D.</td>
<td>GlaxoSmithKline</td>
<td>41, 19</td>
</tr>
<tr>
<td>Clifton R. Tennonson, Jr., M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; AstraZeneca Pharmaceuticals</td>
<td>87</td>
</tr>
<tr>
<td>Michael E. Thase, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Merck &amp; Co., Inc.; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation, Wyeth-Ayerst Laboratories; Lipta Pharmaceuticals, Inc.; Parke-Davis, Division of Warner-Lambert Company; Solvay Pharmaceuticals, Inc.; Sanofi Pharmaceuticals, Inc.</td>
<td>5, 14, 57, 64, 106</td>
</tr>
<tr>
<td>Troy L. Thompson II, M.D.</td>
<td>GlaxoSmithKline</td>
<td>70</td>
</tr>
<tr>
<td>Jean L. Tignol, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline</td>
<td>22</td>
</tr>
<tr>
<td>Martin G. Tracy, J.D.</td>
<td>Professional Risk Management Services, Inc.</td>
<td>44</td>
</tr>
<tr>
<td>Madhukar H. Trivedi, M.D.</td>
<td>Abbott Laboratories; Bayer Corporation, Pharmaceutical Division; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Johnson and Johnson; Mead Johnson; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation; Solvay Pharmaceuticals, Inc.</td>
<td>19, 34, 59</td>
</tr>
<tr>
<td>L. Lee Tynes, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Novartis Pharmaceuticals Corporation; GlaxoSmithKline</td>
<td>41</td>
</tr>
<tr>
<td>Amy M. Ursano, M.D.</td>
<td>GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>18</td>
</tr>
<tr>
<td>Bessel A. Van Der Kolk, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>52, 84</td>
</tr>
<tr>
<td>Sanjeev Venkataraman, M.D.</td>
<td>Organon Inc.; Forest Laboratories, Inc.</td>
<td>40</td>
</tr>
<tr>
<td>Adele C. Viguera, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Eli Lilly and Company; Sanofi Pharmaceuticals, Inc.</td>
<td>67, 93</td>
</tr>
<tr>
<td>Benedetto Vitello, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>11, 85</td>
</tr>
<tr>
<td>Karen D. Wagner, M.D.</td>
<td>GlaxoSmithKline; Bristol-Myers Squibb; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Organon Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>13, 39, 63</td>
</tr>
<tr>
<td>John T. Walkup, M.D.</td>
<td>GlaxoSmithKline; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation</td>
<td>13, 85</td>
</tr>
<tr>
<td>B. Timothy Walsh, M.D.</td>
<td>Eli Lilly and Company; Knoll Pharmaceuticals</td>
<td>84, 105</td>
</tr>
<tr>
<td>Maralee Walsh, Ph.D.</td>
<td>Westchester Medical Center-Behavioral Health Center (employer)</td>
<td>19</td>
</tr>
<tr>
<td>Lynn Wecker, Ph.D.</td>
<td>Somerset Pharmaceuticals, Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Peter J. Weiden, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation</td>
<td>12, 39</td>
</tr>
<tr>
<td>Daniel R. Weinberger, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>9</td>
</tr>
<tr>
<td>Richard D. Weiner, M.D.</td>
<td>Melta Corporation</td>
<td>14</td>
</tr>
<tr>
<td>Margaret D. Weiss, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals, Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Checkmate Plus; Celgene</td>
<td>7, 27, 40</td>
</tr>
<tr>
<td>Myrna M. Weissman, Ph.D.</td>
<td>Guilford Press (Publisher); Basic Books (Publisher)</td>
<td>34, 79</td>
</tr>
<tr>
<td>Diane K. Whitney, M.D.</td>
<td>Eli Lilly and Company; Bristol-Myers Squibb</td>
<td>45</td>
</tr>
<tr>
<td>Timothy E. Wilens, M.D.</td>
<td>Alza Pharmaceuticals; Medeva; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Richwood Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
<td>35, 90</td>
</tr>
<tr>
<td>Daniel Wilson, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>59</td>
</tr>
<tr>
<td>Rodgers M. Wilson, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Johnson and Johnson</td>
<td>73</td>
</tr>
<tr>
<td>John W. Winkelman, M.D.</td>
<td>Cephalon; Eli Lilly and Company; Wyeth-Ayerst Laboratories</td>
<td>90</td>
</tr>
<tr>
<td>Daniel K. Winstead, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; CoCensys; Dista Products; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Pharmacia Corporation; Wyeth-Ayerst Laboratories</td>
<td>19, 20, 99</td>
</tr>
<tr>
<td>Donna A. Wirsching, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Organon Inc.; Sanofi Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; PPO Pharmco</td>
<td>13</td>
</tr>
<tr>
<td>Thomas N. Wise, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Bristol-Myers Squibb</td>
<td>20</td>
</tr>
<tr>
<td>Katherine L. Wisner, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.</td>
<td>62, 83, 101</td>
</tr>
<tr>
<td>Scott W. Woods, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories</td>
<td>86</td>
</tr>
<tr>
<td>Janet Wozniak, M.D.</td>
<td>Eli Lilly and Company; Alza Pharmaceuticals; Pharmacia Corporation</td>
<td>11, 90</td>
</tr>
<tr>
<td>Jesse H. Wright, M.D.</td>
<td>Mindatree</td>
<td>14, 97</td>
</tr>
<tr>
<td>Lawson R. Wulsin, M.D.</td>
<td>Forest Laboratories, Inc.; GlaxoSmithKline</td>
<td>22, 98</td>
</tr>
<tr>
<td>Joel Yager, M.D.</td>
<td>Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>7, 19, 31, 58, 73</td>
</tr>
<tr>
<td>William R. Yates, M.D.</td>
<td>Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>61</td>
</tr>
</tbody>
</table>

XXVIII
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rachel Yehuda, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb; Abbott Laboratories</td>
<td>25, 32, 43, 64, 105</td>
</tr>
<tr>
<td>Kimberly A. Yonkers, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories; GlaxoSmithKline</td>
<td>62, 67</td>
</tr>
<tr>
<td>Douglas L. York, M.P.H.</td>
<td>Westchester Medical Center-Behavioral Health Center</td>
<td>19</td>
</tr>
<tr>
<td>Stuart C. Yudofsky, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Diamond Healthcare Corporation</td>
<td>13, 39, 44, 47</td>
</tr>
<tr>
<td>John M. Zajecka, M.D.</td>
<td>Bristol-Myers Squibb; Abbott Laboratories; Eli Lilly and Company; GlaxoSmithKline; Organon Inc.; Otsuka Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Sanofi Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories</td>
<td>63</td>
</tr>
<tr>
<td>Mary C. Zamarini, Ed.D.</td>
<td>Abbitt Laboratories; Eli Lilly and Company</td>
<td>23, 60</td>
</tr>
<tr>
<td>Carlos A. Zarate, Jr., M.D.</td>
<td>GlaxoSmithKline; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Abbitt Laboratories; Astazeneca Pharmaceuticals</td>
<td>64</td>
</tr>
<tr>
<td>Kathryn J. Zerbe, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories</td>
<td>32, 70, 94</td>
</tr>
<tr>
<td>Douglas M. Ziedonis, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; GlaxoSmithKline</td>
<td>5, 54, 87, 102</td>
</tr>
<tr>
<td>Sidney Zisook, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Forest Laboratories, Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories</td>
<td>59</td>
</tr>
<tr>
<td>Frans G. Zitman, M.D.</td>
<td>GlaxoSmithKline; Organon Inc</td>
<td>61</td>
</tr>
<tr>
<td>Neil A. Zolkind, M.D.</td>
<td>Westchester Medical Center-Behavioral Health Center</td>
<td>19</td>
</tr>
</tbody>
</table>

Voting members of the Board of Trustees, Assembly officers, and members of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participation in Industry-Supported Symposia. In accordance with this policy, the following member is participating in an Industry-Supported Symposium and will not receive any compensation:

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul S. Appelbaum, M.D.</td>
<td>9</td>
</tr>
</tbody>
</table>

The following presenters on this year's scientific program failed to return the APA disclosure form. The presenter's name and the page number(s) the presenter appears on in this Program Book are listed below:

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Bardey, M.D.</td>
<td>43</td>
</tr>
<tr>
<td>Anders Bonde-Jensen, Ph.D.</td>
<td>36</td>
</tr>
<tr>
<td>H. Westley Clark, M.D.</td>
<td>7</td>
</tr>
<tr>
<td>Michael A. Cole, M.D.</td>
<td>14</td>
</tr>
<tr>
<td>Gerald A. Cooney</td>
<td>35</td>
</tr>
<tr>
<td>Ariek D. Dalten, M.D.</td>
<td>18</td>
</tr>
<tr>
<td>Andrea Eberle, M.D.</td>
<td>89</td>
</tr>
<tr>
<td>Bruce Ebert, Ph.D.</td>
<td>107</td>
</tr>
<tr>
<td>Brian A. Fallon, M.D.</td>
<td>83</td>
</tr>
<tr>
<td>Henry T. Harman, M.D.</td>
<td>17</td>
</tr>
<tr>
<td>Ronald L. Kamm, M.D.</td>
<td>35</td>
</tr>
<tr>
<td>Reverend James LeBaz</td>
<td>107</td>
</tr>
<tr>
<td>Alberto G. Lopez, M.D.</td>
<td>79</td>
</tr>
<tr>
<td>Alexandra MacLean, M.D.</td>
<td>88</td>
</tr>
<tr>
<td>Nestor F. Marchant, M.D.</td>
<td>33</td>
</tr>
<tr>
<td>Sheila Marcus, M.D.</td>
<td>29, 43, 71</td>
</tr>
<tr>
<td>Alonso Montoya-Pulido, M.D.</td>
<td>101</td>
</tr>
<tr>
<td>Georg Northoff, M.D.</td>
<td>88</td>
</tr>
<tr>
<td>Jason T. Olin, Ph.D.</td>
<td>106</td>
</tr>
<tr>
<td>Raymond L. Owenby, M.D.</td>
<td>7</td>
</tr>
<tr>
<td>Stefano Pallante, M.D.</td>
<td>103</td>
</tr>
<tr>
<td>Francesco J. Primeau</td>
<td>29</td>
</tr>
<tr>
<td>Ronald O. Reider, M.D.</td>
<td>79</td>
</tr>
<tr>
<td>Everett Rogers, Ph.D.</td>
<td>85</td>
</tr>
</tbody>
</table>

XXIX
This page intentionally left blank
SATURDAY, MAY 5, 2001

154TH ANNUAL MEETING

8:00 a.m. Sessions

COURSES 1-4
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 1  8:00 a.m.-12 noon
Room 336, Level 3, Convention Center

BEHAVIORAL NEUROANATOMY: AN INTRODUCTION
Director: Nashaat N. Boutros, M.D.
Faculty: David L. Clark, Ph.D., Edward C. Lauterbach, M.D.

COURSE 2  8:00 a.m.-12 noon
Rooms 338/339, Level 3, Convention Center

DRUG TREATMENT OF SCHIZOPHRENIA
Director: Philip G. Janicak, M.D.
Faculty: John M. Davis, M.D., Stephen R. Marder, M.D., Rajiv P. Sharma, M.D., Rajiv Tandon, M.D.

COURSE 3  8:00 a.m.-12 noon
Room 341, Level 3, Convention Center

AN INTRODUCTION TO USING THE WORLD WIDE WEB
Psychiatric Society of Informatics
Director: Milton Huang, M.D.
Faculty: Norman E. Alessi, M.D., Daniel A. Deutschman, M.D., Naakesh A. Dewan, M.D., Charles J. Rainey, M.D., John Luo, M.D.

COURSE 4  8:00 a.m.-12 noon
Room 342, Level 3, Convention Center

NEUROLEPTIC-INDUCED MOVEMENT DISORDERS: ASSESSMENT AND TREATMENT
Director: Leonardo Cortese, M.D.
Faculty: Richard Williams, M.D., Michael Caligiuri, Ph.D., Timothy Lambert, M.D.

9:00 a.m. Sessions

COURSES 5-10
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 5  9:00 a.m.-4:00 p.m.
Room 252, Level 2, Convention Center

DISORDERS OF THE SELF: DIFFERENTIAL DIAGNOSIS AND TREATMENT
Director: James F. Masterson, M.D.

COURSE 6  9:00 a.m.-4:00 p.m.
Room 253, Level 2, Convention Center

THE PRACTICAL MANAGEMENT OF PERSONALITY DISORDER
Director: John Livesley, M.D.

COURSE 7  9:00 a.m.-4:00 p.m.
Room 335, Level 3, Convention Center

SUBJECTIVITY: CRUCIAL KEY TO THERAPY AND THE UNIQUENESS OF THE HUMAN MIND
Director: Vincenzo R. Sanguineti, M.D.
Faculty: Donatella Marazziti, M.D.

COURSE 8  9:00 a.m.-4:00 p.m.
Room 340, Level 3, Convention Center

PERSONALITY AND POLITICAL BEHAVIOR
APA Commission on International Psychiatry and International Society for Political Psychology
Director: Jerrold M. Post, M.D.

COURSE 9  9:00 a.m.-4:00 p.m.
Rooms 350/351, Level 3, Convention Center

COGNITIVE-BEHAVIOR THERAPY: AN OVERVIEW
Co-Directors: Robert M. Goisman, M.D., Philip G. Levendusky, Ph.D.
| COURSE 10 | 9:00 a.m.-4:00 p.m. | BASIC HYPNOSIS: PRINCIPLES AND APPLICATIONS |
| Room 352, Level 3, Convention Center |
| Director: Jose R. Maldonado, M.D. |
| Faculty: David Spiegel, M.D. |

1:00 p.m. Sessions

| COURSE 11 | 1:00 p.m.-5:00 p.m. | TREATING MEDICAL STUDENTS AND PHYSICIANS |
| Room 254, Level 2, Convention Center |
| Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D. |

| COURSE 12 | 1:00 p.m.-5:00 p.m. | THE ONLY COMPUTER COURSE YOU WILL EVER NEED |
| Room 341, Level 3, Convention Center |
| Director: Robert S. Kennedy, M.A. |
| Faculty: Carlyle H. Chan, M.D. |

| COURSE 13 | 1:00 p.m.-5:00 p.m. | IRRESISTIBLE SLEEP: NARCOLEPSY UPDATE |
| Room 342, Level 3, Convention Center |
| Director: Lois E. Krahn, M.D. |
| Faculty: Jarrett W. Richardson, M.D., Mark R. Hansen, M.D., Steven I. Altchuler, M.D. |

7:00 p.m. Sessions

| INDUSTRY-SUPPORTED SYMPOSIA 1-7 |
| INDUSTRY-SUPPORTED SYMPOSIUM 1 |
| 7:00 p.m.-10:00 p.m. |
| Grand Ballroom A/B, Street Level, Hilton |

| SLEEP: A WINDOW ON MIND AND BRAIN |
| Supported by Wyeth-Ayerst Laboratories |

Chp.: Milton K. Erman, M.D.

A | The Pathogenesis of Narcolepsy and Hypersomnia |
Emmanuel Mignot, M.D. |

B | Influences of Light on Sleep and Mood |
Barbara L. Parry, M.D. |

C | Violent Behaviors Arising from the Sleep Period |
Mark W. Mahowald, M.D. |

D | Sleep Apnea: Why Treat It? |
Meir H. Kryger, M.D. |

E | New Options in the Treatment of Insomnia |
Milton K. Erman, M.D. |

| INDUSTRY-SUPPORTED SYMPOSIUM 2 |
| 7:00 p.m.-10:00 p.m. |
| Grand Ballroom C/D, Street Level, Hilton |

| ADVANCES IN THE TREATMENT OF DEPRESSION IN WOMEN: BEYOND CLINICAL LORE |
Supported by Eli Lilly and Company |

Chp.: Teri B. Pearlstein, M.D. |
Co-Chp.: Lee S. Cohen, M.D. |

A | Gender-Based Differences in the Treatment of Depressed Women |
Susan G. Kornstein, M.D. |

B | Treatment Strategies of PMS and PMDD |
Teri B. Pearlstein, M.D. |

C | Challenges and Controversies in the Treatment of Childbearing Women |
Lee S. Cohen, M.D. |

D | Critical Issues in Mood and Cognition for Menopausal Women |
Hadine Joffe, M.D. |

| INDUSTRY-SUPPORTED SYMPOSIUM 3 |
| 7:00 p.m.-10:00 p.m. |
| Napoleon Ballroom, Third Floor, Hilton |

| SUICIDE RISK AND BIPOLAR DISORDER: NEUROBIOLOGY AND TREATMENT |
Supported by the American Foundation for Suicide Prevention and Solvay Pharmaceuticals, Inc. |

Chp.: J. John Mann, M.D. |

A | Clinical Factors Affecting Suicide Risk in Bipolar Disorder |
Kay R. Jamison, Ph.D. |

B | Neurobiology of Suicide and Bipolar Disorder |
J. John Mann, M.D. |
C Efficacy of Mood Stabilizers in Suicide Prevention
Ross J. Baldessarini, M.D., Leonardo Tondo, M.D., John Hennen, Ph.D.

D Clinical Management of the Suicidal Bipolar Patient
Frederick K. Goodwin, M.D.

E Evaluation of Suicide Risk in Bipolar Disorder in Children
David Shaffer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 4
7:00 p.m.-10:00 p.m.
Acadia Ballroom, Third Floor, Marriott

TO SWITCH OR AUGMENT? CONTEMPORARY APPROACHES TO RESISTANT DEPRESSION
Supported by Pharmacia Corporation

Chp.: Andrew A. Nierenberg, M.D.

A Neurological Mechanisms of Treatment Resistance: The Role of Stress
Juan P. Lopez, M.D.

B The Neural Basis of Antidepressant Response and Nonresponse
Wayne C. Drevets, M.D.

C When to Augment Antidepressants
Andrew A. Nierenberg, M.D.

D The Use of Switching in Depression Treatment
Charles DeBattista, M.D.

E The Role of Nonpharmacological Intervention for Treatment-Resistant Depression
Lauren B. Marangell, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 5
7:00 p.m.-10:00 p.m.
Carondelet Ballroom, Third Floor, Marriott

THE NEW BIOLOGY OF DEPRESSION AND ANTIDEPRESSANT TREATMENT
Supported by Forest Laboratories, Inc.

Chp.: Jerrold F. Rosenbaum, M.D.

A The Depressed Brain Imaged
Helen S. Mayberg, M.D.

B The Neurobiology of Mood Disorders
Dennis S. Charney, M.D.

C What Do Antidepressants Do? Understanding Antidepressant Molecules, Neurotransmitters, and Receptors
Pierre Blier, M.D.

D Healing the Depressed Brain: Signal Transduction and Neural Plasticity
Eric J. Nestler, M.D., Ronald S. Duman, Ph.D.

Discussant: Steven E. Hyman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 6
7:00 p.m.-10:00 p.m.
Mardi Gras Ballroom, Third Floor, Marriott

GLUCOSE CONTROL AND DIABETES MELLITUS DURING ANTIPSYCHOTIC TREATMENT
Supported by Janssen Pharmaceuticals

Chp.: John W. Newcomer, M.D.

A Diagnosis, Classification, and Pathogenesis of Hyperglycemia
Harold E. Lebovitz, M.D.

B Cardiovascular Risk Increases with Glucose Levels Regardless of Diabetes Status
Hertzel C. Gerstein, M.D.

C Antipsychotic-Related Change in Glucose Regulation
John W. Newcomer, M.D.

D Atypical Antipsychotic Agents: Diabetes and Bergman's Minimal Model Analysis
David C. Henderson, M.D.

E Inhibition of Glucose Transport by Antipsychotic Drugs
Donard S. Dwyer, Ph.D., Timothy D. Ardizzone, B.S., Harold B. Pinkofsky, M.D., Arthur M. Freeman III, M.D., Ronald J. Bradley

Discussant: Herbert Y. Meltzer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 7
7:00 p.m.-10:00 p.m.
Grand Ballroom A-C, Fifth Floor, Sheraton

PTSD: CLINICAL CHARACTERISTICS AND TREATMENT OPTIONS
Supported by Pfizer Inc.

Chp.: Kathleen T. Brady, M.D.

A PTSD: Diagnostic Issues and Comorbidity
Kathleen T. Brady, M.D.

B Sympathetic Nervous System Dysregulation in PTSD
Steven M. Southwick, M.D.

C Advances in the Pharmacotherapy of PTSD
Charles R. Marmar, M.D., Thomas C. Neylan, M.D., Frank B. Schoenfeld, M.D.

D Psychotherapy of PTSD
Barbara O. Rothbaum, Ph.D.
Audiotapes Recorded Live!

High Quality Continues for the 2001 Annual Meeting ...

Live recordings will be available for most of the following:

- Lectures • Advances in Research
- Presidential Symposium • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Research Advances in Medicine

Tapes may be purchased on site at Mobiltape’s booth in the Convention Center, Lobby Level.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504  (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com
SUNDAY, MAY 6, 2001

154TH ANNUAL MEETING

8:00 a.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 8-14

INDUSTRY-SUPPORTED SYMPOSIUM 8
8:00 a.m.-11:00 a.m.
Grand Ballroom A/B, Street Level, Hilton

SYMPTOMATIC AND FUNCTIONAL RECOVERY: ATTAINABLE GOALS IN TREATING DEPRESSION?
Supported by Wyeth-Ayerst Laboratories
Chp.: A. John Rush, M.D.
A What Is Remission; Why Is It Important; and When Does It Occur?
Lauren B. Marangell, M.D.
B Are All Antidepressant Medications Equivalent in Attaining Remission?
Michael E. Thase, M.D.
C Does Combining Medications or Medication Sequences Lead to Remissions?
Jack M. Gorman, M.D.
D What Is the Role of Psychotherapy in Attaining Remission?
A. John Rush, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 9
8:00 a.m.-11:00 a.m.
Grand Ballroom C/D, Street Level, Hilton

CRITICAL DECISIONS IN THE LIFETIME TREATMENT OF SCHIZOPHRENIA
Supported by Eli Lilly and Company
Chp.: Diana O. Perkins, M.D.
Co-Chp.: Jeffrey A. Lieberman, M.D.
A First Episode: Establishing Neuroprotection
Diana O. Perkins, M.D.
B Consequences and the Cost of Relapse
Gerald A. Maguire, M.D.
C Neuropsychiatric and the Development of Treatment Resistance in Patients with Schizophrenia: Strategies for Prevention
Jeffrey A. Lieberman, M.D.
D Critical Decisions in the Treatment of Adolescent and Pediatric Psychosis
Linmarie Sikich, M.D.
E Cognition Across the Lifetime
Richard S.E. Keefe, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 10
8:00 a.m.-11:00 a.m.
Napoleon Ballroom, Third Floor, Hilton

TO WORK AND TO LOVE: FOCUS ON QUALITY OF LIFE IN MOOD AND ANXIETY DISORDERS
Supported by SmithKline Beecham Pharmaceuticals
Chp.: Mark H. Rapaport, M.D.
Co-Chp.: Mark H. Pollack, M.D.
A Measures of Quality of Life
Jean Endicott, Ph.D.
B Improving Quality of Life for Patients with Bipolar Disorders
Holly A. Swartz, M.D.
C Quality of Life in the Anxiety Disorders
Mark H. Pollack, M.D.
D The Impact of Depression and Its Treatment
Mark H. Rapaport, M.D., Cathryn M. Clary, M.D., Lewis L. Judd, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 11
8:00 a.m.-11:00 a.m.
Acadia Ballroom, Third Floor, Marriott

MEETING THE CHALLENGE OF SCHIZOPHRENIA AND CO-OCCURRING ADDICTIONS
Supported by Novartis Pharmaceuticals Corporation
Chp.: Alan I. Green, M.D.
Co-Chp.: William M. Glazer, M.D.
A Schizophrenia and Co-Occurring Disorders: The Scope of the Problem and Impact on Outcomes
Lisa B. Dixon, M.D.
B The Neurobiology of Addiction and Schizophrenia in Relation to the Action of Antipsychotic Drugs
Herbert Y. Meltzer, M.D.
C Pharmacotherapy of Comorbid Substance Use Disorders
Alan I. Green, M.D.
D Integrating Pharmacotherapy and Dual Recovery Therapy
Douglas M. Ziedonis, M.D.
E Best Systems and Practices for Dual Diagnosis
Robert F. Drake, M.D., Kim T. Mueser, Ph.D.
Discussant: William M. Glazer, M.D.
SUNDAY

INDUSTRY-SUPPORTED SYMPOSIUM 12
8:00 a.m.-11:00 a.m.
Carondelet Ballroom, Third Floor, Marriott

MEN OVER 50: AN ENDANGERED SPECIES
Supported by Forest Laboratories, Inc.

Chp.: Steven P. Roose, M.D.

A Testosterone Decline in Aging Men: Does Andropause Exist?
Stuart N. Seidman, M.D.

B Sexual Functioning Past 50
Raymond C. Rosen, Ph.D.

C Vascular Disease and Depression
K. Ranga R. Krishnan, M.D.

D Depression and Dementia in Older Men
Gary W. Small, M.D.

E Suicide in Men Over 50: An Epidemic
Steven P. Roose, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 13
8:00 a.m.-11:00 a.m.
Mardi Gras Ballroom, Third Floor, Marriott

ISSUES IN THE LONG-TERM TREATMENT OF DEPRESSION
Supported by Glaxo Wellcome Inc.

Chp.: Anita L.H. Clayton, M.D.
Co-Chp.: Maurizio Fava, M.D.

A Weight Changes During Long-Term Antidepressant Treatment
Maurizio Fava, M.D.

B Antidepressant-Induced Sexual Dysfunction
Anita L.H. Clayton, M.D.

C The Role of Psychotherapy in the Long-Term Treatment of Depression
Gabor I. Keitner, M.D.

D Identification of Depressive Relapse
P. Murali Doraiswamy, M.D.

E Management of Depressive Breakthrough During Long-Term Treatment
Jonathan E. Alpert, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 14
8:00 a.m.-11:00 a.m.
Grand Ballroom A-C, Fifth Floor, Sheraton

ALCOHOLISM AND BIPOLAR DISORDER: TREATMENT OPTIONS CIRCA 2001
Supported by Pfizer Inc.

Chp.: Mark A. Frye, M.D.

A New Pharmacotherapies for Alcohol Dependence
Barbara J. Mason, Ph.D.

B Suicidality, Impulsivity, and Alcoholism
Joseph F. Goldberg, M.D.

C Antiepileptic Drugs in Alcohol Withdrawal and Relapse
Hugh Myrick, M.D.

D Bipolar Disorder and Comorbid Alcoholism: Course of Illness and Treatment Implication
Mark A. Frye, M.D.

E Antiepileptic Drugs and Lithium in the Treatment of Bipolar Illness and Alcohol Use Disorders
Patricia Suppes, M.D.

COURSES 15-20
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 15 8:00 a.m.-12 noon
Room 252, Level 2, Convention Center
INTERPERSONAL PSYCHOTHERAPY

Director: John C. Markowitz, M.D.

COURSE 16 8:00 a.m.-12 noon
Room 254, Level 2, Convention Center
CURRENT CODING AND DOCUMENTATION REQUIREMENTS

Director: Chester W. Schmidt, Jr., M.D.

COURSE 17 8:00 a.m.-12 noon
Room 337, Level 3, Convention Center
BALINT GROUP: UNDERSTANDING THE DOCTOR AND PATIENT

Director: Geoffrey M. Margo, M.D.
Faculty: Katherine Margo, M.D., Laurel C. Milberg, Ph.D., C. Paul Scott, M.D.

COURSE 18 8:00 a.m.-12 noon
Rooms 338/339, Level 3, Convention Center
THE PSYCHIATRIST AS EXPERT WITNESS

Director: Phillip J. Resnick, M.D.
SUNDAY

COURSE 19  8:00 a.m.-12 noon
Room 341, Level 3, Convention Center

MAKING A HOME ON THE WORLD WIDE WEB
Psychiatric Society of Informatics

Director: Milton Huang, M.D.
Faculty: Norman E. Alessi, M.D., Daniel A. Deutschman, M.D.,
Robert C. Hsiung, M.D., Charles J. Rainey, M.D., Raymond L.
Ownby, M.D.

COURSE 20  8:00 a.m.-12 noon
Room 352, Level 3, Convention Center

ADD IN CHILDREN AND ADOLESCENTS
Director: Thomas E. Brown, Ph.D.
Faculty: Margaret D. Weiss, M.D.

SEE COURSE 24 BELOW. SPECIAL 8:00 A.M. START

TIME.

9:00 a.m. Sessions

COURSES 21-26
Course descriptions are available in the CME
Course Brochure included in your
registration packet. Admission by ticket
only.

COURSE 21  9:00 a.m.-4:00 p.m.
Room 253, Level 2, Convention Center

THERAPEUTIC INTERVENTIONS IN EATING
DISORDERS
Director: David C. Jimerson, M.D.
Faculty: W. Stewart Agras, M.D., Katherine A. Halmi, M.D.,
James E. Mitchell, M.D., Joel Yager, M.D.

COURSE 22  9:00 a.m.-4:00 p.m.
Room 336, Level 3, Convention Center

MONEY MATTERS: USING THEORY IN CLINICAL
PRACTICE
Director: Cecilia M. Mikalac, M.D.

COURSE 23  9:00 a.m.-4:00 p.m.
Room 342, Level 3, Convention Center

ADVANCED INTERVIEWING TECHNIQUES
Director: Shawn C. Shea, M.D.

COURSE 24  8:00 a.m.-4:30 p.m.
Rooms 343-345, Level 3, Convention Center

OFFICE-BASED TREATMENT OF OPIATE
DEPENDENT PATIENTS
APA Council on Addiction Psychiatry and American Academy of
Addiction Psychiatry

Director: Thomas R. Kosten, M.D.
Faculty: Eric C. Strain, M.D., Laura F. McNicholas, M.D.,
Herbert D. Kleber, M.D., David Fiellin, M.D., Joseph G.
Liberto, M.D., H. Westley Clark, M.D.

NOTE SPECIAL TIME OF THIS COURSE

COURSE 25  9:00 a.m.-4:00 p.m.
Rooms 348/349, Level 3, Convention Center

PASS THE BOARDS! THE PART II ORAL EXAM
Director: James C.Y. Chou, M.D.
Faculty: Gregory C. Bunt, M.D.

COURSE 26  9:00 a.m.-4:00 p.m.
Rooms 350/351, Level 3, Convention Center

MEDICAL ETHICS 101
Director: Edmund G. Howe, M.D.

12:30 p.m. Session

BUSINESS MEETING
(Voting Members Only*)
12:30 p.m.-1:30 p.m.
LaNouvelle Ballroom B/C, Level 2, Convention
Center

CALL TO ORDER
Daniel B. Borenstein, M.D., President

MEMORIAL TO DECEASED MEMBERS
ANNOUNCEMENT OF ELECTION RESULTS
Fred G. Hilkert, M.D., Chairperson,
Committee of Tellers

REPORTS TO THE MEMBERSHIP
Secretary: Michelle Riba, M.D.
Treasurer: Carol A. Bernstein, M.D.
Speaker, Assembly: R. Michael Pearce, M.D.
Speaker, Elect, Assembly: Nada L. Stotland, M.D.
Chairperson, By-Laws Committee:
Jo-Ellyn M. Ryall, M.D.
Chairperson, Elections Committee:
Mary Jane Massie, M.D.
Chairperson, Membership Committee:
Bernard A. Katz, M.D.
Medical Director: Steven M. Mirin, M.D.

ANNUAL FORUM

ADJOURNMENT

*Members-in-Training, General Members, Fellows, Life
Fellows, and Life Members. Badge or APA membership card
necessary for admission. No cameras or tape recorders will
be permitted.
1:00 p.m. Sessions

COURSES 27-34
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 27 1:00 p.m.-5:00 p.m.
Room 252, Level 2, Convention Center
EVIDENCE-BASED TREATMENT OF SAD: FOCUS ON LIGHT THERAPY
Co-Directors: Raymond W. Lam, M.D., Anthony J. Levitt, M.D.

COURSE 28 1:00 p.m.-5:00 p.m.
Room 254, Level 2, Convention Center
DUAL DIAGNOSIS: BASIC PRINCIPLES OF SUCCESSFUL INTERVENTION
Director: Kenneth Minkoff, M.D.

COURSE 29 1:00 p.m.-5:00 p.m.
Room 335, Level 3, Convention Center
DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH
Director: Milton Kramer, M.D.

COURSE 30 1:00 p.m.-5:00 p.m.
Rooms 338/339, Level 3, Convention Center
PSYCHIATRIC DISORDERS IN PREGNANCY AND POSTPARTUM
Co-Directors: Shaila Misri, M.D., Kristin S. Sivertz, M.D.
Faculty: Diana Carter, M.B., Maria R. Corral, M.D., Deirdre M. Ryan, M.B.

COURSE 31 1:00 p.m.-5:00 p.m.
Room 340, Level 3, Convention Center
SHAME AND SOCIAL ANXIETY DISORDER
Director: Paul B. Bohn, M.D.

COURSE 32 1:00 p.m.-5:00 p.m.
Room 341, Level 3, Convention Center
USING OPEN INFRASTRUCTURE FOR OUTCOME: A CUSTOMIZABLE WEB-BASED CLINICAL AND RESEARCH RECORD SYSTEM
Director: Andrew P. Ho, M.D.
Faculty: David Haponski, M.S.W., Carol Giannini, R.N., Christy Finazzo, M.S.W.

1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 15-20

INDUSTRY-SUPPORTED SYMPOSIUM 15
1:30 p.m.-4:30 p.m.
Grand Ballroom A/B, Street Level, Hilton
TREATING PSYCHOTIC DISORDERS: WHAT IS THE STATE OF THE ART?
Supported by Bristol-Myers Squibb Company
Chp.: Jeffrey A. Lieberman, M.D.
A Issues in Managing Psychosis in Geriatric Patients
Dilip V. Jeste, M.D., Jonathan P. Lacro, Pharm.D., Michael Caligiuri, Ph.D., Sidney Zisook, M.D.
B Treatment of Depression with Psychosis
Robert N. Golden, M.D.
C Emerging Treatments in Acute Mania and Bipolar Disorders
Terence A. Ketter, M.D., Po W. Wang, M.D.
D Treating the Spectrum of Symptoms in Schizophrenia
Jeffrey A. Lieberman, M.D.
E Treatment of Pediatric Psychosis
Judith H.L. Rapoport, M.D.
Discussant: James W. Jefferson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 16
1:30 p.m.-4:30 p.m.
Grand Ballroom C/D, Street Level, Hilton
PROVIDING COMPLETE TREATMENT FOR PATIENTS WITH BIPOLAR DISORDER
Supported by the National Depressive and Manic-Depressive Association and Eli Lilly and Company
Chp.: Paul E. Keck, Jr., M.D.
A Manic and Mixed Episodes: The Challenge of Improving Functional Outcome
Paul E. Keck Jr., M.D.

B New Horizons in the Treatment of Bipolar Disorder
K.N. Roy Chengappa, M.D.

C Women and Bipolar Disorder
Lori L. Altshuler, M.D., Mark A. Frye, M.D., Victoria Hendrick, M.D.

D Maintenance Treatments for Patients with Bipolar Disorder
Joseph F. Goldberg, M.D.

E The Face of Bipolar Illness: Results of a National Depressive and Manic-Depressive Association Survey
Lydia J. Lewis

INDUSTRY-SUPPORTED SYMPOSIUM 17
1:30 p.m.-4:30 p.m.
Acadia Ballroom, Third Floor, Marriott

MAOIS REVISITED
Supported by Somerset Pharmaceuticals, Inc.

Chp.: Jay D. Amsterdam, M.D.

A An Update on MAO and Behavior
Lynn Wecker, Ph.D.

B Cellular Antidepressant Mechanism of MAO Inhibitors
Pierre Blier, M.D.

C Clinical Use of MAO Inhibitors
Jay D. Amsterdam, M.D.

D Next Generation of MAO Inhibitors
Andrew A. Nierenberg, M.D.

E Transdermal Selegiline in Depression
J. Alexander Bodkin, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 18
1:30 p.m.-4:30 p.m.
Carondelet Ballroom, Third Floor, Marriott

ADVANCES IN THE TREATMENT OF GERIATRIC DEPRESSION
Supported by Organon Inc.

Chp.: J. Craig Nelson, M.D.
Co-Chp.: Greer M. Murphy, M.D.

A Diagnosis and Treatment of Depression in the Older Patient
J. Craig Nelson, M.D.

B Benefits of Different Classes of Antidepressants for Geriatric Depression
Alan F. Schatzberg, M.D.

C DNA Microarray Technology and the Treatment of Depression
Greer M. Murphy, M.D.

D Pharmacology of Antidepressants Pertinent to Older Patients
Bruce G. Pollock, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 19
1:30 p.m.-4:30 p.m.
Mardi Gras Ballroom, Third Floor, Marriott

CHEMICAL RESTRAINTS: CLINICAL, RESEARCH, AND ETHICAL IMPLICATIONS
Supported by Janssen Pharmaceuticals

Chp.: Douglas H. Hughes, M.D.

A Preventing Psychological Trauma Following Forced Medication
Terence M. Keane, Ph.D.

B Atypical Antipsychotics in the Emergency Setting
Glenn W. Currier, M.D.

C Depot Antipsychotics: An Alternative to Forced Medications
Sally A. Berry, M.D.

D Historical Legal Trends and Civil Liberties in Forced Medications
Renee L. Binder, M.D.

E Dealing with the New Legal Framework for Chemical Restraints
Paul S. Appelbaum, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 20
1:30 p.m.-4:30 p.m.
Grand Ballroom A-C, Fifth Floor, Sheraton

ATYPICAL ANTIPSYCHOTIC DRUGS: HOW DO THEY WORK?
Supported by AstraZeneca Pharmaceuticals

Chp.: Shitij Kapur, M.D.
Co-Chp.: Daniel R. Weinberger, M.D.

A What Really Is "Atypical" About Atypical Antipsychotics: Lessons from PET Imaging Studies
Shitij Kapur, M.D., Robert B. Zipursky, M.D., Gary J. Remington, M.D., Philip Seeman, Ph.D.

B Understanding the Action of Antipsychotic Drugs at the Level of Gene Expression
Barbara K. Lipska, Ph.D.

C Intrinsic Circuitry in Cortex: Receptors, Drug Action, and Cognition
Patricia S. Goldman-Rakic, Ph.D.

D Behavioral and Neurochemical Predictors of Antipsychotic Drug Action
Charles B. Nemeroff, M.D.

E Therapeutic Insights from the Clinical Search for Genes
Daniel R. Weinberger, M.D.
2:30 p.m. Session

LECTURE 1

2:30 p.m.-4:00 p.m.
Rooms 353-355, Level 3, Convention Center

AAPL/APA'S MANFRED S. GUTTMACHER
AWARD LECTURE

Paul E. Mullen, M.B., Michelle Pathé, M.D.
and Rosemary Purcell

Stalkers and Their Victims

Chp.: Brian Crowley, M.D.
Co-Chp.: Elissa P. Benedek, M.D.

Stalking includes brief, albeit distressing incidents of harassment as well as patterns of pursuit that continue for months or years. Both the victims of stalking and their pursuers may experience disturbances of mental and social health, and psychiatrists may find themselves called on to assist victims and to manage perpetrators. Paul E. Mullen, M.B., Michelle Pathé, M.D., and Ms. Rosemary Purcell, authors of the recent book Stalkers and Their Victims, discuss the psychological and social impact of stalking, present a typology of stalkers based on what initiates and what sustains stalking behavior, and offer clinicians suggestions for treating victims and perpetrators of stalking. Dr. Mullen is Professor of Forensic Psychiatry at Monash University Medical School and Clinical Director of the Victorian Institute of Forensic Mental Health in Melbourne, Australia. He is the author of more than 100 scholarly publications and has contributed chapters to the standard British textbooks on forensic psychiatry. He is the co-author of the books Sexual Theory, Research, and Clinical Strategies and Child Sexual Abuse: An Evidence-Based Perspective. Dr. Pathé is a consultant forensic psychiatrist and Assistant Clinical Director at the Victorian Institute of Forensic Mental Health. She is an Honorary Senior Lecturer at Monash University and a Fellow in the Department of Criminology at the University of Melbourne. Ms. Purcell is a registered psychologist currently completing a doctoral program in the Department of Psychological Medicine at Monash University. She is employed as a project officer at the Victorian Institute of Forensic Mental Health, where she is coordinating a pilot therapeutic support group for victims of stalking, and works as a sessional psychologist for the Institute's Community Forensic Mental Health Service, where she provides clinical services for stalkers and victims of stalking.

THIS SESSION WILL BE AUDIOTAPED.

5:00 p.m. Session

OFFICIAL OPENING SESSION

5:00 p.m.-6:30 p.m.
Hall G, Lobby Level, Convention Center

CALL TO ORDER
Daniel B. Borenstein, M.D.
President

INTRODUCTION OF STAGE GUESTS

INTRODUCTION OF CHAIRPERSONS OF
THE SCIENTIFIC PROGRAM COMMITTEE
AND THE TASK FORCE ON LOCAL
ARRANGEMENTS

Philip R. Muskin, M.D.
Chairperson, Annual Meeting Scientific Program Committee

Edward F. Foulks, M.D.
Co-Chairperson, Task Force on Local Arrangements

INTRODUCTION OF VISITING
DIGNITARIES

PRESIDENTIAL ADDRESS
Daniel B. Borenstein, M.D.
To be introduced by Leo Rangell, M.D.

RESPONSE OF THE PRESIDENT-ELECT
Richard K. Harding, M.D.
To be introduced by Steven M. Mirin, M.D.

ADJOURNMENT

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 21-26

INDUSTRY-SUPPORTED SYMPOSIUM 21
7:00 p.m.-10:00 p.m.
Grand Ballroom A/B, Street Level, Hilton

CRITICAL QUESTIONS IN ANXIETY DISORDERS
Supported by Wyeth-Ayerst Laboratories

Chp.: David V. Sheehan, M.D.

A Cost Burden of Anxiety Disorders
Ronald C. Kessler, Ph.D.

B Antidepressants and Anxiolytics: Do They All Work in Social Phobia?
Jonathan R.T. Davidson, M.D.

C Should GAD Be Treated Long Term?
David V. Sheehan, M.D.
SUNDAY

D Treatment of Comorbid Anxiety and Bipolar Disorders
Susan L. McElroy, M.D.

E Barriers to the Effective Treatment of Anxiety Disorders
Mark Olfson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 22
7:00 p.m.-10:00 p.m.
Grand Ballroom C/D, Street Level, Hilton

MANAGEMENT OF ANXIETY: AN INTERNATIONAL PERSPECTIVE
Supported by Solvay Pharmaceuticals, Inc.

Chp.: Murray B. Stein, M.D.
Co-Chp.: Eric Hollander, M.D.

A The Functional Impact of Anxiety Disorders: Focus on Social Phobia
Murray B. Stein, M.D.

B Integrating Neuroscience and Psychotherapy: The Study of Human Emotions
Donatella Marazziti, M.D.

C Childhood Anxiety Disorders: NIMH Initiatives
Benedetto Vitiello, M.D.

D Refractory OCD: An International Perspective
Eric Hollander, M.D., Stefano Pallanti, M.D., Sherie L. Nowotny, M.D., Daphne Simeon, M.D., Sallie Jo Hadley, M.D., Carol Bienstock, B.A.

E Anxiety and Suicide
Jan A. Fawcett, M.D.

Discussant: Michael R. Liebowitz, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 23
7:00 p.m.-10:00 p.m.
Acadia Ballroom, Third Floor, Marriott

TREATMENT-RESISTANT DEPRESSION ACROSS THE LIFE SPAN
Supported by Pharmacia Corporation

Chp.: Maurizio Fava, M.D.

A The Phenomenology and Course of Treatment-Resistant Depression
Patrick J. McGrath, M.D., Jonathan W. Stewart, M.D.

B Pharmacological Treatment Options
Maurizio Fava, M.D.

C Management of Depression in the Medically Ill: Practical Approaches to Treatment
Prakash S. Masand, M.D.

D Juvenile Bipolar Disorder: An Overlooked Condition
Janet Wozniak, M.D.

E Treatment Advances in Geriatric Depression
George S. Alexopoulos, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 24
7:00 p.m.-10:00 p.m.
Carondelet Ballroom, Third Floor, Marriott

NEUROBIOLOGY, DEPRESSION, AND THE SPECIFICITY OF TREATMENT RESPONSE
Supported by Organon Inc.

Chp.: Alexander H. Glassman, M.D.
Co-Chp.: Pedro L. Delgado, M.D.

A 5HT and Norepinephrine in Depression
Pedro L. Delgado, M.D., Francisco A. Moreno, M.D.

B The Role of Dopamine in Depression and Antidepressant Treatment
Alexander H. Glassman, M.D.

C Brain Structure and Function in Major Depression
Harold A. Sackeim, Ph.D.

D The Biology of Depressive Subtypes and Treatment Response
Steven P. Roose, M.D.

Discussant: Alan F. Schatzberg, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 25
7:00 p.m.-10:00 p.m.
Mardi Gras Ballroom, Third Floor, Marriott

PSYCHOSIS IN ALZHEIMER’S DISEASE: NEW KNOWLEDGE, NEW TREATMENT STRATEGIES
Supported by Janssen Pharmaceutica

Chp.: Ira R. Katz, M.D.

A Psychosis of Dementia
Lon S. Schneider, M.D.

B Efficacy of Antipsychotic Agents
Ira R. Katz, M.D.

C Effects of Other Psychotherapeutic Medications
Constantine G. Lyketsos, M.D.

D Practical Strategies for the Treatment of Psychoses Due to Dementia
Jacobo E. Mintzer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 26
7:00 p.m.-10:00 p.m.
Grand Ballroom A-C, Fifth Floor, Sheraton

MOVING TOWARDS A MORE COMPREHENSIVE MANAGEMENT OF PATIENTS WITH SCHIZOPHRENIA
Supported by Pfizer Inc.

Chp.: Daniel E. Casey, M.D.
Co-Chp.: Nina R. Schooler, Ph.D.

(Continued on next page)
Acute Psychotic Agitation: Exploring New Options
Alan J. Mendelowitz, M.D.

Beyond the Acute Phase: Issues in Stabilization
Peter J. Weiden, M.D.

Psychosocial Treatment for Schizophrenia: Strategies for the New Era
Nina R. Schooler, Ph.D.

Raising the Bar from Symptom Reduction to Disability Reduction
Michael F. Green, Ph.D.

Improving the Overall Health of Patients with Schizophrenia
Daniel E. Casey, M.D.

MEDIA SESSIONS 1-2

MEDIA SESSION 1 7:00 p.m.-10:00 p.m.
Napoleon Ballroom, Third Floor, Hilton

FOUR STORIES OF MOTHER/DAUGHTER RESILIENCE
Chp.: Francis G. Lu, M.D.

1 The Joy Luck Club
(138 minutes)

Distributor: Buena Vista Video
Department CS
Burbank, CA 91521

The Joy Luck Club depicts four stories of the transmission of resilience from Chinese mothers to their American-born daughters. The film shows not only the mothers' courage in facing their collective traumas of war, arranged marriages, infidelity, infanticide, and abandonment of babies, but also scenes of great epiphany when previously estranged mothers and daughters achieve an "I-Thou" level of intimacy which transforms the lives of the four daughters. While rooted in the particular life circumstances and customs of the Chinese, the film explores universal themes of resilience in the face of trauma and the eventual reconciliation of mothers and daughters through hope and love.

Versailles Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES
American Psychoanalytic Association

Co-Chps.: Bruce H. Sklarew, M.D., Harvey R. Greenberg, M.D.

2 The Conformist
(115 minutes)

Distributor: Swank Motion Pictures, Inc.
350 Vanderbilt Motor Parkway
Hauppauge, NY 11787

The Conformist is a film directed by Bernardo Bertolucci. The film is set in the 1930s and stars Jean-Louis Trintignant and Stefania Sandrelli. Trintignant portrays Marcello Clerici, an ambitious professor in 1938 Italy. As Mussolini comes into power, Clerici lets it be known that he is a fascist, and a blind friend has gotten him an assignment with the secret police. Clerici soon marries Giulia, portrayed by actress Stefania Sandrelli, and receives his assignment during his honeymoon in Paris to assassinate the head of an antifascist resistance group. While in Paris, Clerici is assailed by doubts. He faces many challenges in his endeavor, and his desperate attempt to find acceptance in society leads him to commit an act of murder. The Conformist is a fine blend of drama and suspense that boasts several strong performances.
7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 27-32

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 27, PART 1
7:00 a.m.-8:30 a.m.
La Nouvelle Ballroom, Level 2, Convention Center

OPTIMIZING TREATMENT OUTCOMES IN PATIENTS WITH CHRONIC DEPRESSION
Supported by Bristol-Myers Squibb Company
Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Pharmacotherapy and Psychotherapy: New Data on the Long-Term Treatment of Chronic Depression
Martin B. Keller, M.D.

B Achieving Remission in the Treatment of Chronic Depression
A. John Rush, M.D.
Discussant: Robert M.A. Hirschfeld, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom A/B, Street Level, Hilton

WOMEN'S MENTAL HEALTH: ANTIDEPRESSANT THERAPY DURING THE CHILDBEARING YEARS
Supported by Forest Laboratories, Inc.
Chp.: Lori L. Altshuler, M.D.

A The Epidemiology of Depression Throughout the Female Life Cycle
Vivien K. Burt, M.D.

B Diagnosis and Treatment of PMDD
Elias Eriksson, Ph.D.

C The Implications of Antidepressant Therapy During Pregnancy
Lori L. Altshuler, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom C/D, Street Level, Hilton

COMPARING ATYPICAL ANTIPSYCHOTIC THERAPIES: MAKING SENSE OF THE DATA
Supported by AstraZeneca Pharmaceuticals
Chp.: Rajiv Tandon, M.D.

A Examining the Efficacy of Atypical Antipsychotics: Is There a Difference?
Alan J. Mendelowitz, M.D.

B EPS and the Essence of Atypicality: Are All Atypical Antipsychotics the Same?
Rajiv Tandon, M.D.

C Relative Tolerability of Novel Antipsychotics: Impact on Weight Gain and Sexual Function
Donna A. Wirshing, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 1
7:00 a.m.-8:30 a.m.
Acadia Ballroom, Third Floor, Marriott

MOOD AND ANXIETY DISORDERS IN UNDERSTUDIED POPULATIONS
Supported by SmithKline Beecham Pharmaceuticals
Chp.: Karen D. Wagner, M.D.

A Major Depression in Children and Adolescents
Karen D. Wagner, M.D.

B OCD and Social Anxiety Disorder in Children and Adolescents
John T. Walkup, M.D.

C Use of Antidepressants in Pregnant and Breastfeeding Women
Zachary S. Stowe, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 1
7:00 a.m.-8:30 a.m.
Carondelet Ballroom, Third Floor, Marriott

WEIGHING THE OPTIONS FOR MANAGING BIPOLAR DEPRESSION
Supported by Glaxo Wellcome Inc.
Chp.: Gary S. Sachs, M.D.

A Initial Treatment Options for Bipolar Depression
Russell T. Joffe, M.D.

B Alternatives for Patients Refractory to an Initial Course of Treatment
Claudia Baldessano, M.D.
MONDAY

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 1
7:00 a.m.-8:30 a.m.
Mardi Gras Ballroom, Third Floor, Marriott

THE IMPULSIVE AGGRESSIVE SPECTRUM: CHALLENGING POPULATIONS
Supported by Abbott Laboratories

Chp.: Eric Hollander, M.D.

A The Impulsive Affective Spectrum
   Alan C. Swann, M.D.

B Very Bad Behaviors
   Eric Hollander, M.D.

C Substance Abuse, Sensitization, and Impulsivity
   Stephen M. Strakowski, M.D.

RESIDENTS' SESSION
7:00 a.m.-8:30 a.m.
Kabby's Restaurant Riverside, Hilton

MEET THE EXPERTS: SUNNY SIDE-UP
Chp.: Daniel B. Borenstein, M.D.
Co-Chp.: Richard K. Harding, M.D.

Nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include psychotherapy, cultural competency, public and community psychiatry, academic psychiatry, psychiatric aspects of HIV/AIDS, child and adolescent psychiatry, board preparation, neuropsychiatry, women's mental health, forensic psychiatry, leadership development, and technology and psychiatry, among others.

8:00 a.m. Sessions

COURSES 35-43
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 35 8:00 a.m.-12 noon
La Galerie 2, Second Floor, Marriott
RISK ASSESSMENT FOR VIOLENCE
Director: Phillip J. Resnick, M.D.

COURSE 36 8:00 a.m.-12 noon
La Galerie 3, Second Floor, Marriott
ECT PRACTICE UPDATE
Director: Charles H. Kellner, M.D.
Faculty: Richard L. Jaffe, M.D., W. Vaughn McCall, M.D., Richard D. Weiner, M.D.

COURSE 37 8:00 a.m.-12 noon
La Galerie 6, Second Floor, Marriott
COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS
Director: Jesse H. Wright, M.D.
Faculty: Michael E. Thase, M.D., Monica A. Basco, Ph.D.

COURSE 38 8:00 a.m.-12 noon
Bacchus Room, Fourth Floor, Marriott
FAMILIES AND MEDICAL ILLNESS: AN INTEGRATIVE TREATMENT APPROACH
Director: John S. Rolland, M.D.

COURSE 39 8:00 a.m.-12 noon
Balcony N, Fourth Floor, Marriott
ASSESSMENT AND TREATMENT OF TRAUMATIC GRIEF
Director: Edward K. Rynearson, M.D.
Faculty: Jennifer L. Favell, Ph.D.

COURSE 40 8:00 a.m.-12 noon
Iberville Room, Fourth Floor, Marriott
OUTPATIENT GROUP THERAPY FOR THE SERIOUSLY MENTALLY ILL
American Group Psychotherapy Association
Director: Walter N. Stone, M.D.

COURSE 41 8:00 a.m.-12 noon
Rhythms Ballroom I, Second Floor, Sheraton
MEDICAL AND PSYCHIATRIC IMPLICATIONS OF CYTOCHROME P450: AN UPDATE
Co-Directors: Scott C. Armstrong, M.D., Kelly L. Cozza, M.D.
Faculty: Michael A. Cole, M.D., Jessica R. Oesterheld, M.D.

COURSE 42 8:00 a.m.-12 noon
Edgewood Rooms A/B, Fourth Floor, Sheraton
USING HUMANITIES TO UNDERSTAND MOOD DISORDERS
Co-Directors: Steven D. Targum, M.D., Emilie Passow, Ph.D.
Faculty: Jerome S. Gans, M.D.

COURSE 43 8:00 a.m.-12 noon
Ellendale Room, Fourth Floor, Sheraton
TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!
Director: Steven E. Hyler, M.D.
Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.
9:00 a.m. Sessions

**CLINICAL CASE CONFERENCE 1**
9:00 a.m.-10:30 a.m.
Room 263, Level 2, Convention Center

A NEUROSCIENCE PERSPECTIVE ON TRANSFERENCE IN PSYCHOTHERAPY

**Moderator:** Glen O. Gabbard, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

**CONTINUOUS CLINICAL CASE CONFERENCE: PART 1**
9:00 a.m.-12 noon
Room 262, Level 2, Convention Center

COGNITIVE-BEHAVIORAL THERAPY: A CASE OF COMORBID MAJOR DEPRESSION, PERSONALITY DISORDER, AND EPISODIC ALCOHOL ABUSE

**Presenter:** Anton C. Trinidad, M.D.
**Discussant:** Stephen P. McDermott, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

COURSES 44-50
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

**COURSE 44**
9:00 a.m.-4:00 p.m.
Balcony J, Fourth Floor, Marriott

THE MULTIPLE PERSPECTIVES OF COUPLES THERAPY: SKILLS AND TECHNIQUES

**Co-Directors:** Lois S. Slovik, M.D., James L. Griffith, M.D.

**COURSE 45**
9:00 a.m.-4:00 p.m.
Balcony M, Fourth Floor, Marriott

PERSONNEL MANAGEMENT FOR CLINICIANS/MANAGERS

**Director:** Stephen M. Soltys, M.D.
**Faculty:** Mark Binkley, J.D., William Noyes, M.P.A., Joseph J. Parks, M.D., Brenda Ratliff, M.D., Thomas W. Hester, M.D.

**DISCUSSION GROUPS 1-2**
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

1. **Nada L. Stotland, M.D.**, on Treating Women Patients: What Clinicians Need to Know
Chequers Suite, Second Floor, Hilton

2. **Maurice D. Steinberg, M.D.**, on Psychiatric Aspects of End-of-Life Care
Norwich Suite, Third Floor, Hilton
LECTURE 2
9:00 a.m.-10:30 a.m.
Hall G, Lobby Level, Convention Center
APA'S MARMOR AWARD LECTURE
Eric R. Kandel, M.D.
Genes, Synapses, and Long-Term Memory
Co-Chps.: Steven M. Mirin, M.D., John F. Greden, M.D.
Advances in cognitive psychology and molecular biology have allowed scientists to combine the disciplines to study the neurobiology of mental processes such as memory. Eric R. Kandel, M.D., reviews recent studies in Aplysia, Drosophila, and mice showing that the synthesis of new proteins required for long-term memory is reflected in gene activation leading to the growth of new synaptic connections. Dr. Kandel is University Professor at Columbia University College of Physicians and Surgeons in New York City and a Senior Investigator at the Howard Hughes Medical Institute. His research has been concerned with the molecular mechanisms of memory storage in Aplysia and mice, and recent work has focused on the genetic switch for converting short-term to long-term memory and on how long-term memory can be synapse specific. In 2000, he was awarded the Nobel Prize for Physiology or Medicine in recognition of his work on synaptic function in memory. A member of the United States National Academy of Sciences and national science academies of Germany and France, Dr. Kandel has also received the Albert Lasker Award, the Wolf Prize of Israel, and the National Medal of Science. A graduate of New York University School of Medicine, Dr. Kandel trained in neurobiology at the National Institutes of Health and in psychiatry at Harvard Medical School.

LECTURE 3
9:00 a.m.-10:30 a.m.
Rooms 338/339, Level 3, Convention Center
APA'S OSKAR PFISTER AWARD LECTURE
Irvin D. Yalom, M.D.
Existential Psychotherapy and Religious Consolation: Convergence and Divergence
Chp.: Irving S. Wiesner, M.D.
Co-Chp.: Reverend Clark S. Aist, Ph.D.
Both religious consolation and existential therapy seek to minister to anxiety emanating from concerns rooted in the human condition, including death, meaninglessness, freedom, and isolation. Irvin D. Yalom, M.D., discusses these concerns and explores differences and similarities between an existential psychotherapeutic and a religious consolatory approach to amelioration of anxiety. Dr. Yalom is Emeritus Professor of Psychiatry at Stanford University School of Medicine, and the author of several best-selling books, both clinical works and novels, centered on the therapist-patient relationship. His first book, The Theory and Practice of Group Psychotherapy, currently in its fourth edition, has been widely used as a text for training therapists. His novel, When Nietzsche Wept, was awarded the Commonwealth Club Gold Medal Award for Best Novel of 1992. His other books include Every Day Gets a Little Closer, Love's Executioner and Other Tales of Psychotherapy, Lying on the Couch, and Mommie and the Meaning of Life. Dr. Yalom has been awarded the APA's Foundations' Fund Prize for Research in Psychiatry and the Edward Strecker Award from the Institute of Pennsylvania Hospital for his contributions to psychiatric patient care. A graduate of Boston University School of Medicine, Dr. Yalom completed his residency in psychiatry at the Henry Phipps Clinic of Johns Hopkins Hospital in Baltimore.

MASTER EDUCATOR
CLINICAL CONSULTATIONS 1-3
9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.
1 Leah J. Dickstein, M.D., on Unique Gender Issues in All of Psychiatric Assessment and Treatment
Room 337, Level 3, Convention Center
2 Mary Jane Massie, M.D., on the Psychiatric Aspects of Breast Cancer
Room 340, Level 3, Convention Center
3 Roger G. Kathol, M.D., on Psychiatric Problems in Medical/Surgical Patients
Room 341, Level 3, Convention Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 3-4
MEDIA SESSION 3
9:00 a.m.-11:00 a.m.
Napoleon Ballroom, Third Floor, Hilton
PSYCHIATRY GOES TO THE MOVIES
Chp.: Cheryl A. Kennedy, M.D.
**Boys Don’t Cry**
(114 minutes)

**Distributor:** Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

_Boys Don’t Cry_ is a compelling and absorbing film for general audiences and the kind of movie that can reach and touch anyone. It’s the story of a girl named Teena Brandon who decided to become a boy named Brandon Teena. Moving to a small town, she, now he, falls in with a crowd of redneck pool players and their girls. Brandon begins dating and falls in love with Lana, a girl about her age. They live in a violent world of drinking and drugging macho bullies, who at first accepted Brandon and then eventually discover his secret that leads to murder. This film, directed by Kimberly Pierce, is a sad and beautiful story of two star-crossed lovers.

**MEDIA SESSION 4**
9:00 a.m.-11:00 a.m.
Versailles Ballroom, Third Floor, Hilton

**WHEN MENTAL ILLNESS HITS HOME**
Chp.: Ian E. Alger, M.D.

**Out of My Mind**
(27 minutes)

**Distributor:** Filmmakers Library
for V4 & V5:
Attn: Linda Gottesman
124 East 40th Street
New York, NY 10016

_Out of My Mind_ is an intimate portrait of twenty-three year old John Cadigan, the filmmaker’s brother who became seriously mentally ill while he was an art student at college. Soon after his first psychotic break, John asked his sister, the filmmaker and his primary caretaker, to document his story. Filmed over three years, the sibling narrates the story of John’s painful deterioration despite various therapies. Rarely has the family experience of the early stages of schizophrenia been articulated so clearly. Day to day John struggles with a steady stream of paranoid and violent thoughts. He continues to battle his illness, which has now been diagnosed as schizoaffective disorder. Obtaining an accurate diagnosis, medical benefits, and housing were part of the arduous process of searching for help. Despite multiple hospitalizations he tries to lead as normal a life as possible, relying on the love and support of his family.

**A Journey Back: Coping with a Parent’s Suicide**
(24 minutes)

When a parent commits suicide, he or she leaves behind a wake of pain and guilt for children and spouse. It may take years for the survivors to resolve their feelings. Louise Gallup, the filmmaker, was nine years old when her father shot himself. She and her brothers and sisters grew into productive human beings, upstanding members of the community, but never spoke of the personal tragedy that engulfed their family. _A Journey Back_ is a moving account of her coming to terms, 15 years later, with her father’s suicide.

**Means of Grace**
(57 minutes)

**Distributor:** Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

_Means of Grace_ is a haunting and evocative documentary written by J. Clements. It takes an inside look at one woman writer’s struggle with mental illness. Clements’ mother, Ann, was hospitalized for paranoid schizophrenia in the 1950s. She was one of more than a million American women who were committed to mental hospitals during that period and often treated with massive doses of tranquilizers or electric shock treatments. Told through Ann’s journals, diaries and fiction, interwoven with medical records, home movies, archival footage, and dramatizations, the film raises provocative questions about social control, the nuclear family, women’s roles, definitions of madness, and our treatment of the mentally ill.

**NEW RESEARCH YOUNG INVESTIGATORS’ POSTER SESSION 1**
9:00 a.m.-10:30 a.m.
Exhibition Center, Second Floor, Hilton

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

**ROUNDTABLE DISCUSSION**
9:00 a.m.-10:30 a.m.
Room 356, Level 3, Convention Center

**THE FUTURE OF BEHAVIORAL HEALTHCARE**
Moderators: Robert Michels, M.D., Robert K. Schreter, M.D.
Participants: Henry T. Harbin, M.D., Steven S. Sharfstein, M.D.,
Miles F. Shore, M.D., Howard H. Goldman, M.D., Richard Frank, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

**WORKSHOPS**

**COMPONENTS 1-10**

**COMPONENT WORKSHOP 1**
9:00 a.m.-10:30 a.m.
Rooms 265/266, Level 2, Convention Center

**PHYSICIAN DISABILITY: TREATMENT, INSURANCE, AND CONFLICTS**
APA Committee on Physician Health, Illness, and Impairment
Co-Chps: Michael H. Gendel, M.D., Linda Logsdon, M.D.
Participants: Richard F. Limoges, M.D., Michael F. Myers, M.D.

**COMPONENT WORKSHOP 2**
9:00 a.m.-10:30 a.m.
Room 270, Level 2, Convention Center

**CONTINUING THE DIALOGUE ON RACISM AND PSYCHOPATHOLOGY**
APA Committee of Black Psychiatrists
Chp.: Michelle O. Clark, M.D.
Participants: George L. Mallory, M.D., Carl C. Bell, M.D.
<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 3</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 271, Level 2, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MEDICARE AND MEDICAID: PROBLEMS AND PROGRESS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>APA Medicare Advisory Committee</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Edward Gordon, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Irvin L. Muszynski, Seth P. Stein, J.D., Lloyd I. Sederer, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 4</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 272, Level 2, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>THE GREAT BEYOND: MAKING CAREER DECISIONS AT THE END OF RESIDENCY TRAINING</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>APA Committee of Early Career Psychiatrists</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Chps: Ronald C. Albucher, M.D., Keith W. Young, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participant: Samson J. Cho, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 5</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Rooms 333/334, Level 3, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>THE INTERPRETATION OF DREAMS: FANTASY AND REALITY IN RESIDENCY TRAINING</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>APA/GlaxoWellcome Fellows</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Michael A. Scarf, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Thomas G. Cobb, M.D., Rebecca A. Kornbluh, M.D., Mark S. Groves, M.D., Ariel K. Dalfen, M.D., Laura B. Dunn, M.D., Lyle B. Forehand, Jr., M.D., Joseph M. Smurda, M.D., Bernard J. Biermann, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 6</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 352, Level 3, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PSYCHIATRISTS IN THE SCHOOLS: REDUCING THE IMPACT OF TRAUMA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>APA Committee on Psychiatry and Mental Health in the Schools</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Lois T. Flaherty, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Veronica L. Williams, M.D., Edward M. Stephens, M.D., Amy M. Ursano, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 7</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 357, Level 3, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PSYCHIATRIC VIEWS ON TALKING ABOUT HOMOSEXUALITY TO KIDS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>APA Committee on Gay, Lesbian, and Bisexual Issues</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Jack Drescher, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Diana C. Miller, M.D., Daniel W. Hicks, M.D., Kenneth B. Ashley, M.D., Howard C. Rubin, M.D., Serena Y. Volpp, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 8</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Grand Salon Sections 9 &amp; 12, Street Level, Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MAKE THE MEDIA WORK FOR YOU: TELEVISION INTERVIEW TIPS AND TECHNIQUES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>APA Joint Commission on Public Affairs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Chps: Michael Blumenfield, M.D., Mary H. Davis, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: William E. Callahan, Jr., M.D., John Blamphin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 9</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Jasperwood Room, Third Floor, Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TO RETIRE OR NOT TO RETIRE, THAT IS THE QUESTION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>APA Committee on Senior Psychiatrists and APA Lifers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Irvin M. Cohen, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Abram M. Hostetter, M.D., Hugo Van Dooren, M.D., Philip M. Margolis, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 10</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Belle Chasse Room, Third Floor, Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>STUDENTS AND SCHOOLS AT RISK: WHERE IS THE VIOLENCE?</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>APA Alliance</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Gail S. Fuller, R.N.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Betty Ann J. Muller, M.D., Joseph M. Bertrand, A.T.T.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE 1-22</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 1</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 264, Level 2, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PSYCHIATRIC ILLNESS AND THE WORKPLACE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Steven E. Pflanz, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 2</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Rooms 267-268, Level 2, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SCHUMANN, MANIC-DEPRESSIVE ILLNESS, AND THE CREATIVE PROCESS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Richard Kogan, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participant: Kay R. Jamison, Ph.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 3</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 269, Level 2, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WORKING-THROUGH IN PSYCHOTHERAPY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Steven H. Lipsius, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| ISSUE WORKSHOP 4 — CANCELLED | | |
|-------------------------------|----------------------------------|

18
ISSUE WORKSHOP 5  9:00 a.m.-10:30 a.m.
Rooms 335/336, Level 3, Convention Center

HOSPITAL-BASED PROGRAM FOR LESBIAN, GAY, BISEXUAL, AND TRANSGENDER PATIENTS

Chp.: Douglas L. York, M.P.H.
Participants: Neil A. Zolkind, M.D., Maralee Walsh, Ph.D., Donna Festa, C.S.W.

ISSUE WORKSHOP 6  9:00 a.m.-10:30 a.m.
Room 342, Level 3, Convention Center

E-SUPPORTING CLINICAL PRACTICE: GUIDELINES AND THE PSYCHIATRIC RESEARCH NETWORK

Chp.: Joel Yager, M.D.
Participants: Kenneth Z. Altshuler, M.D., Madhukar H. Trivedi, M.D., G. Richard Smith, Jr., M.D.

ISSUE WORKSHOP 7  9:00 a.m.-10:30 a.m.
Rooms 346/347, Level 3, Convention Center

ABPN UPDATE: REQUIREMENTS FOR ABPN EXAMINATION

Chp.: Thomas A.M. Kramer, M.D.
Participants: Glenn C. Davis, M.D., Michael H. Ebert, M.D., Larry R. Faulkner, M.D., Burton V. Reifler, M.D., Pedro Ruiz, M.D., James H. Scully, Jr., M.D., Elizabeth B. Weller, M.D., Daniel K. Winstead, M.D.

ISSUE WORKSHOP 8  9:00 a.m.-10:30 a.m.
Rooms 348/349, Level 3, Convention Center

TOWARDS A RATIONAL, INTEGRATED TREATMENT APPROACH TO MENTALLY RETARDED AND DEVELOPMENTALLY DISABLED PATIENTS

Co-Chps: Harvey Stabinsky, M.D., Susan Stabinsky, M.D.
Participants: Michael M. Scimeca, M.D., Sheldon Travin, M.D., David W. Preven, M.D.

ISSUE WORKSHOP 9  9:00 a.m.-10:30 a.m.
Rooms 350/351, Level 3, Convention Center

SLEEP PROBLEMS IN DUAL-DIAGNOSIS PATIENTS: PHYSIOLOGY AND MANAGEMENT

Chp.: R. Jeffrey Goldsmith, M.D.

ISSUE WORKSHOP 10  9:00 a.m.-10:30 a.m.
Grand Salon Sections 3 & 6, Street Level, Hilton

NONSEXUAL BOUNDARY VIOLATIONS

Chp.: Malkah T. Notman, M.D.
Participants: Linda M. Jorgenson, J.D., Carl P. Malmquist, M.D., Carol C. Nadelson, M.D.

ISSUE WORKSHOP 11  9:00 a.m.-10:30 a.m.
Grand Salon Section 4, Street Level, Hilton

NEUROANATOMY AND NEUROPHYSICS OF THE UNCONSCIOUS

Chp.: Vincenzo R. Sanguineti, M.D.

ISSUE WORKSHOP 12  9:00 a.m.-10:30 a.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

CLOzapine Augmentation in Refractory Schizophrenia

Chp.: Jean-Pierre Lindenmayer, M.D.
Participants: John W. Rosenberger, M.D., Joseph I. Friedman, M.D., Richard H. McCarthy, M.D., Zafar Sharif, M.D.

ISSUE WORKSHOP 13  9:00 a.m.-10:30 a.m.
Grand Salon Sections 13 & 16, Street Level, Hilton

Making Telepsychiatry Work for Your System
Psychiatric Society of Informatics

Chp.: William M. Tucker, M.D.
Participants: Alan Q. Radke, M.D., Harry Karlinsky, M.D., Gerald Segal, M.S.

ISSUE WORKSHOP 14  9:00 a.m.-10:30 a.m.
Grand Salon Sections 15 & 18, Street Level, Hilton

From Play Therapy to Pills and Back Again: Child Treatment in the Decade of the Mind

Chp.: Peter D. Ganime, M.D.
Participants: Joanne Dunnigan, M.S.W., Grace Hickey, Psy.D., Phillip Repasky, M.A., Diane Beebe, M.S.

ISSUE WORKSHOP 15  9:00 a.m.-10:30 a.m.
Grand Salon Sections 19 & 22, Street Level, Hilton

A University Depression-Management Program

Chp.: Stuart J. Eisenbrath, M.D.
Participants: Ellen Haller, M.D., Jonathan E. Lichtmacher, M.D., David H. Taylor, M.D., Anne M. Fleming, M.D., L. Alison McInnes, M.D., Yoon K. Jung, B.S., Margaret Fritch, M.S., Sharon Hall, Ph.D.

ISSUE WORKSHOP 16  9:00 a.m.-10:30 a.m.
Grand Salon Sections 21 & 24, Street Level, Hilton

Disaster Psychiatry: LAPA Flight 3142

Chp.: Daniel L. Mosca, M.D.
Participants: Marcelo R. Muro, M.D., Liliana Sanchez, Psy.D.
ISSUE WORKSHOP 17  9:00 a.m.-10:30 a.m.
Prince of Wales Suite, Second Floor, Hilton
TWO DOGMAS OF PSYCHOANALYSIS
Chp.: Avak A. Hovsepian, M.D.

ISSUE WORKSHOP 18  9:00 a.m.-10:30 a.m.
Melrose Room, Third Floor, Hilton
THE IMPACT OF SUICIDE ON CLINICIANS
Chp.: Eric M. Plakun, M.D.
Participants: Jane Tillman, Ph.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 19  9:00 a.m.-10:30 a.m.
Rosedown Room, Third Floor, Hilton
HOW TO DEVELOP A LECTURE
Chp.: Marianne T. Guschwan, M.D.
Participants: Susan Tapert, Ph.D.

ISSUE WORKSHOP 20  9:00 a.m.-10:30 a.m.
Magnolia Room, Third Floor, Hilton
RECENT ADVANCES IN FEMALE SEXUAL MEDICINE
Chp.: Barbara D. Bartlik, M.D.
Participants: Laura Berman, Ph.D., Marina Rozenberg

ISSUE WORKSHOP 21  9:00 a.m.-10:30 a.m.
Oak Alley Room, Third Floor, Hilton
THE ART OF HEALING: USE OF ART THERAPY AND GROUP PSYCHOTHERAPY FOR TREATMENT OF TRAUMATIZED IMMIGRANT POPULATIONS
Co-Chps: Abbas Azadian, M.D., Mary E. Sanderson, R.A.T.
Participant: Rosemary Meier, M.D.

ISSUE WORKSHOP 22  9:00 a.m.-10:30 a.m.
Elmwood Room, Third Floor, Hilton
TEACHING BEHAVIORAL SCIENCES TO FAMILY DOCTORS
Chp.: Jonathan S. Davine, M.D.

10:30 a.m. Session

ADVANCES IN RESEARCH
10:30 a.m.-12:30 p.m.
Rooms 343-345, Level 3, Convention Center
FROM THEORY TO THERAPY: DRUG DISCOVERY, TESTING, AND CLINICAL USE
APA Scientific Program Committee and APA Council on Research
Chp.: Herbert Pardes, M.D.
Co-Chp.: Daniel K. Winstead, M.D.

Participants: Perry Molinoff, M.D., on Drug Discovery in the Year 2000 and Beyond
Philip Morgan, Ph.D., on Lead Optimization and the Role of In Vitro and In Vivo in Testing
Cathryn M. Clary, M.D., on New Molecules, New Markets: Update on Clinical Drug Development
Stephen M. Stahl, M.D., on From Clinical Trials to Clinical Practice: Can You Get There From Here?
THIS SESSION WILL BE AUDIOTAPED.

11:00 a.m. Sessions

DISCUSSION GROUPS 3-5
11:00 a.m.-12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

3 Edward F. Foulks, M.D., on Psychiatrists in Mental Health Advocacy Groups
Chequers Suite, Second Floor, Hilton

4 Clarice J. Kestenbaum, M.D., on Risk Factors for Adolescent Psychotic Disorders
Trafalgar Suite, Third Floor, Hilton

5 Sara C. Charles, M.D., on the Professional Ethic and Current Psychiatric Practice
Norwich Suite, Third Floor, Hilton

LECTURES 4-5

LECTURE 4
11:00 a.m.-12:30 p.m.
Rooms 252-254, Level 2, Convention Center
Paul R. McHugh, M.D.
Beyond DSM IV: From Appearances to Essences
Co-Chps.: Thomas N. Wise, M.D., Gertha Jayaram, M.D., Constandine Lyketsos, M.D.

Psychiatry faces three major problems in taking its place as a medical discipline: the mind/brain problem, factionalism in the discipline, and a classification system based on appearances. Paul R. McHugh, M.D., discusses how coherence in psychiatric practice, teaching, and research can be advanced by a structure of reasoning that links clinical presentations to distinct groups of disorders with particular issues of evaluation, research, and treatment. Dr. McHugh is Henry Phipps Professor and Chair of the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine and Johns Hopkins Hospital and Professor of Mental Hygiene at the Johns Hopkins University School of Hygiene and Public Health. In 1992 he assumed leadership of the Blades
Lecture 5
11:00 a.m.-12:30 p.m.
Rooms 353-355, Level 3, Convention Center

APA/NIMH VESTERMARK PSYCHIATRY
EDUCATOR AWARD LECTURE

Jerald Kay, M.D.

Why Play on Only Three Strings, When You Can
Play on the Whole Violin? The Importance of
Psychotherapy Education

Chp.: Michelle Riba, M.D.
Co-Chp.: Katharine A. Phillips, M.D.

Psychotherapy instruction in residency training programs
has been increasingly limited, and managed care organi-
zations have pressed many psychiatrists to adopt a split-
treatment model in which psychotherapy is provided by
a nonphysician mental health professional. However,
recent research has supported the critical importance of
psychotherapy conducted by psychiatrists. Jerald Kay,
M.D., reviews aspects of the neurobiology of psycho-
therapy and discusses ways to strengthen psychiatrists'
education in psychotherapy. Dr. Kay is Professor and
Chairman of the Department of Psychiatry at Wright
State University School of Medicine in Dayton, Ohio.
A Fellow of the American Psychiatric Association, Dr.
Kay is a member of the APA Editorial Advisory
Committee, Distinguished Service Award Committee,
and Commission on the Practice of Psychotherapy by
Psychiatrists. He is the Founding Editor of the Journal
of Psychotherapy Practice and Research and the editor of five
books, including the Handbook of Psychiatry Residency
Training. He has been named an Exemplary Psychiatrist
by the National Alliance for the Mentally Ill and
Psychiatric Educator of the Year by the Association for
Academic Psychiatry. A graduate of the University of
Maryland School of Medicine in Baltimore, Dr. Kay
completed his general and child and adolescent
psychiatry residencies at the University of Cincinnati.
He is a graduate and faculty member of the Cincinnati
Psychoanalytic Institute.

This session will be audiotaped.

MASTER EDUCATOR CLINICAL
CONSULTATIONS 4-6

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-
come, first-served basis.

4 Ruth E. Levine, M.D., on Using Cinema to Enhance the
Teaching of Psychiatry and Behavioral Sciences (ADMSEP
Council on Education Master Teacher)
Room 337, Level 3, Convention Center

5 Steven P. Roose, M.D., on Medication and Psychodynamic
Therapies: Can Treatments in Conflict Be Integrated?
Room 340, Level 3, Convention Center

6 Donna E. Stewart, M.D., on Use of Psychotropic Drugs in
Pregnancy and Lactation
Room 341, Level 3, Convention Center

These sessions are open to APA members
only. Blue registration badge or APA
membership card required for
admittance.

MEDIA SESSION 5
11:00 a.m.-12:30 p.m.
Versailles Ballroom, Third Floor, Hilton

INNOCENCE FOR SALE

Chp.: John K. Burton, M.D.

7 Stolen Lives
(46 minutes)

Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

It has been estimated that over 300,000 children work in the sex
trade in North America. Every year, in the United States and
Canada, several billion dollars are generated by the sexual
exploitation of children under the age of 18. Stolen Lives takes a
hard look at this world through the eyes of the teenaged boys
and girls who are being exploited in the fast-growing business of
child prostitution. While many die before they can leave the
industry, there are some survivors. Their stories, diverse,
poignant, courageous, and compelling, expose the painful reality
of this modern form of slavery, while interviews with pimps and
johns make clear the realities of economics and power which
fuel this growing crisis.
MEDICAL UPDATE 1
11:00 a.m.-12:30 p.m.
Grand Salon Sections 3 & 6, Street Level, Hilton

CAN STEM CELLS FROM BONE MARROW SERVE AS A FOUNTAIN OF YOUTH FOR THE BRAIN?
Chp.: Leslie H. Gise, M.D.
Presenter: Darwin J. Prockop, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-12

SCIENTIFIC AND CLINICAL REPORT SESSION 1
11:00 a.m.-12:30 p.m.
Room 264, Level 2, Convention Center

ISSUES IN SEXUAL DYSFUNCTION
Chp.: Stuart N. Seidman, M.D.
Co-Chp.: Richard Balon, M.D.

2 Correlation Between Patient Self-Assessment of Erectile Function and the International Index of Erectile Function (IIEF-5)
Joseph Cappelleri, Ph.D., Richard L. Siegel, M.D.,
Raymond C. Rosen, Ph.D.

11:30 a.m.
3 Sildenafil Citrate Effectively Treats Erectile Dysfunction in Men Who Have Been Successfully Treated for Depression
Jean L. Tignol, M.D., Otto Benkert, M.D.

12 noon
4 Psychotropic-Induced Sexual Dysfunction Among Outpatients
Kenneth P. Rosenberg, M.D., Kathryn Bleiberg, Ph.D.,
James H. Kocsis, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 2
11:00 a.m.-12:30 p.m.
Rooms 265/266, Level 2, Convention Center

PRESIDENTIAL THEME: "MIND MEETS BRAIN"
Chp.: David A. Casey, M.D.
Co-Chp.: Mercedes M. Rodriguez, M.D.

11:00 a.m.
5 Self, Object, and Neurobiology
Richard M. Brockman, M.D.

11:30 a.m.
6 Conceptual Integration of Mind and Brain in Philosophy and Psychiatry
David H. Brendel, M.D.

12 noon
7 Dreaming Contributes to Adaptation in the Depressed: A Review
Milton Kramer, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 3
11:00 a.m.-12:30 p.m.
Room 270, Level 2, Convention Center

DEPRESSION IN THE MEDICALLY ILL
Chp.: Aretta J. Rathmell, M.D.
Co-Chp.: Julie K. Schulman, M.D.

8 A Systematic Review of Depression as a Risk Factor for Coronary Disease
Lawson R. Wulsin, M.D., Bonita Singal, M.D., Charles Hattemer, M.D.

11:30 a.m.
9 Training Primary Care Physicians in the Diagnosis and Treatment of Depression
Robert Kohn, M.D., Izhak Levav, M.D., Norman Sartorious, M.D.,
Ivan Mantoya, M.D., Claudio Miranda, M.D., Benjamin Vicente, M.D.

12 noon
10 Screening for Depression in Head and Neck Cancer Patients
Mark R. Katz, M.D., Neil Kopek, B.S.C., John Waldron, M.D.,
Gerald M. Devins, Ph.D., George Tomlinson, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 4
11:00 a.m.-12:30 p.m.
Room 271, Level 2, Convention Center

SECLUSION, RESTRAINT, AND EMERGENCY ISSUES
Chp.: Susan Stabinsky, M.D.
Co-Chp.: Roy V. Varner, M.D.

11:00 a.m.
11 Reducing Restraint and Seclusion: One Hospital’s Experience
Paul Plasky, M.D.

11:30 a.m.
12 Reducing Restraint Use in a Public Psychiatric Hospital
Robert E. McCue, M.D., Leonel Urcuyo, M.D., Yehezkel Lilu, Ph.D., Teresa Tobias, R.N., Michael Chambers, M.P.A.

12 noon
13 Factors Influencing the Psychiatric Emergency Room
Davin A. Agustines, B.A., Christopher K. Chung, M.D.,
Jambur V. Ananth, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 5  
11:00 a.m.-12:30 p.m.  
Rooms 335/336, Level 3, Convention Center  
SPECIAL ISSUES IN FAMILY AND CHILD PSYCHIATRY  
Chp.: Cynthia W. Santos, M.D.  
Co-Chp.: Julie Holman, M.D.  

11:00 a.m.  
14 Some Long-Term Consequences of Orphanage Care  
John J. Sigal, Ph.D., Michel Rossignol, Ph.D., John C. Perry, M.D.,  
Marie-Claude Ouimet, M.A.  

11:30 a.m.  
15 Familial Background and Literary Creativity  
Albert Rothenberg, M.D.  

12 noon  
16 Self-Comforting Strategies Used by Adolescent Males and Females  
Paul C. Horton, M.D.  

THIS SESSION WILL BE AUDIOTAPED.  

SCIENTIFIC AND CLINICAL REPORT SESSION 6  
11:00 a.m.-12:30 p.m.  
Rooms 346/347, Level 3, Convention Center  
ANXIETY DISORDERS  
Chp.: Irma J. Bland, M.D.  
Co-Chp.: Anand Pandya, M.D.  

11:00 a.m.  
17 PTSD Versus Panic Disorder: Differences in HPA  
Axis/Noradrenergic Functioning  
Randall D. Marshall, M.D., Carlos Blanco-Jerez, M.D.,  
Michael R. Liebowitz, M.D., David Printz, M.D., Donald F.  
Klein, M.D., Jeremy D. Coplan, M.D.  

11:30 a.m.  
18 Beyond One-Year Imipramine Maintenance in Panic  
Disorder with Agoraphobia  
Matig R. Mavissakalian, M.D., James M. Perel, Ph.D.  

12 noon  
19 Social Phobia Treatment Survey  
Michael A. Van Ameringen, M.D., Catherine L. Mancini, M.D.,  
Peter Farvolden, Ph.D., Jonathan Oakman, Ph.D.  

THIS SESSION WILL BE AUDIOTAPED.  

SCIENTIFIC AND CLINICAL REPORT SESSION 7  
11:00 a.m.-12:30 p.m.  
Rooms 348/349, Level 3, Convention Center  
PERSONALITY DISORDERS  
Chp.: Roslyn Seligman, M.D.  
Co-Chp.: Mara S. Goldstein, M.D.  

11:00 a.m.  
20 Psychiatric Treatment of Borderline Patients Following  
for Four Years  
Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D.,  
John Hennes, Ph.D.  

11:30 a.m.  
21 Predictors of Outcome in a 27-Year Follow-Up of BPD  
Joel F. Paris, M.D., Hallie Zweig-Frank, Ph.D.  

12 noon  
22 Confirmatory Factor Analysis of DSM-IV Schizotypal  
Personality Disorder Criteria  
Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D., Leslie C.  
Morey, Ph.D., Donna S. Bender, Ph.D., Thomas H.  
McGlashan, M.D.  

THIS SESSION WILL BE AUDIOTAPED.  

SCIENTIFIC AND CLINICAL REPORT SESSION 8  
11:00 a.m.-12:30 p.m.  
Room 357, Level 3, Convention Center  
ALCOHOL AND DRUG-RELATED DISORDERS  
Chp.: Joel M. Silberberg, M.D.  
Co-Chp.: Earl L. Loschen, M.D.  

11:00 a.m.  
23 Longitudinal Predictors of Adolescent Alcohol Disorder  
Onset  
Martha A. Rueter, Ph.D., K. A. S. Wickrama, Ph.D.  

11:30 a.m.  
24 Delirium Tremens: Diagnosis, Misdiagnosis, and  
Terminology  
Milton Rosenbaum, M.D., Teresita A. McCarty, M.D.  

12 noon  
25 Cigarette Smoking and Risk for Anxiety Disorders  
Jeffrey G. Johnson, Ph.D., Patricia R. Cohen, Ph.D.,  
Donald F. Klein, M.D., Daniel S. Pine, M.D.  

THIS SESSION WILL BE AUDIOTAPED.  

SCIENTIFIC AND CLINICAL REPORT SESSION 9  
11:00 a.m.-12:30 p.m.  
Grand Salon Sections 15 & 18, Street Level, Hilton  
COMORBIDITY IN MOOD DISORDERS  
Chp.: Paul J. Goodnick, M.D.  
Co-Chp.: Patrick T. O'Neill, M.D.  

11:00 a.m.  
26 Does Medical Comorbidity Impact the Severity of  
Depression and Its Treatment?  
Dan V. Iosifescu, M.D., Megan M. Smith, B.A., Stella Bitran, B.A.,  
Jonathan E. Alpert, M.D., Andrew A. Nierenberg, M.D.,  
John J. Worthington III, M.D., Maurizio Fava, M.D.  

(Continued on next page)
11:30 a.m.
27 Treatment-Resistant Depression and Axis I Comorbidity
Timothy J. Petersen, Ph.D., Johanna A. Gordon, B.A., Alexis Kant, Maurizio Fava, M.D., Jerrold F. Rosenbaum, M.D., Andrew A. Nierenberg, M.D.

12 noon
28 The Complex Comorbidity Between Bipolar Illness and OCD: Clinical Implications and Treatment Outcome
Giulio Perugi, M.D., Cristina Toni, M.D., Hagop S. Akiskal, M.D.

THIS SESSION WILL BE AUDIOTAPEED.

SCIENTIFIC AND CLINICAL REPORT SESSION 10
11:00 a.m.-12:30 p.m.
Rosedown Room, Third Floor, Hilton

PSYCHOPHARMACOLOGY TOXICITIES
Chp.: Arthur L. Lazarus, M.D.
Co-Chp.: Roberto A. Dominguez, M.D.

11:00 a.m.
29 Myotoxicity and Neurotoxicity During Clozapine Treatment
Ilya Reznik, M.D., Roberto Mester, M.D., Lior Volchek, M.D., Moshe Kotler, M.D., Ida Sarova-Pinhas, M.D., Baruch Spivak, M.D., Abraham Weizman, M.D.

11:30 a.m.
30 Olanzapine and NMS: Case Report and Literature Review
Cristinel M. Coconcea, M.D., Nicoleta Coconcea, M.D.

12 noon
31 A Case of Ketamine Psychosis
Seema Kochhar, M.D., Edward A. Volkman, M.D., David Wald, D.O.

THIS SESSION WILL BE AUDIOTAPEED.

SCIENTIFIC AND CLINICAL REPORT SESSION 11
11:00 a.m.-12:30 p.m.
Magnolia Room, Third Floor, Hilton

ADDITIONAL PSYCHIATRY
Chp.: Richard T. Suchinsky, M.D.
Co-Chp.: Lydia O. Fazzio, M.D.

11:00 a.m.
32 Polymorphisms in the 5HT Transporter Gene and Cocaine Dependence
Ashwin A. Patkar, M.D., Wade H. Berrettini, M.D., Edward Gottheil, M.D., Robert C. Sterling, Ph.D., Kevin P. Hill, B.A., Stephen P. Weinstein, Ph.D.

11:30 a.m.
33 Addictions Psychiatry and Treatment Outcomes in a Therapeutic Community
Gregory C. Bunt, M.D., A. Jonathan Porteus, Ph.D.,

12 noon
34 Spirituality in the Detoxification Phase of Substance Abuse Treatment
Camilo A. Martin, M.D., Charlie A. Gass, D.M., Alice T. Allen, M.S.

THIS SESSION WILL BE AUDIOTAPEED.

SCIENTIFIC AND CLINICAL REPORT SESSION 12
11:00 a.m.-12:30 p.m.
Belle Chasse Room, Third Floor, Hilton

PREDICTORS IN SCHIZOPHRENIA
Chp.: Harvey Stabins, M.D.
Co-Chp.: Ronald C. Albuher, M.D.

11:00 a.m.
35 What Predicts Functioning Across 10 Years of Schizophrenic Illness?
Ellen S. Herbener, Ph.D., Martin Harrow, Ph.D.

11:30 a.m.
36 Perinatal Brain Damages and Slower Development Interact as Risks for Psychosis
Peter B. Jones, Ph.D., Tim J. Croudace, Ph.D., Kristiina Molanen, M.D., Marjo-Riitta Jarvelin, M.D., Jari Jokelainen, B.S.C., Paula Rantakallio, M.D., Matti K. Isohanni, M.D.

12 noon
37 Social Sequels of Mental Disorders in the 1966 North Finland Birth Cohort
Matti K. Isohanni, M.D., Irene Isohanni, M.Ed., Peter B. Jones, Ph.D., Tim J. Croudace, Ph.D., Marjo-Riitta Jarvelin, M.D., Jari Jokelainen, B.S.C., Kaisa Riala, M.D.

THIS SESSION WILL BE AUDIOTAPEED.

WORKSHOPS

COMPONENTS 11-16

COMPONENT WORKSHOP 11 11:00 a.m.-12:30 p.m.
Rooms 267-268, Level 2, Convention Center

MUSIC IN THE LIVES OF PSYCHIATRISTS
APA San Diego Psychiatric Society

Chp.: Edward A. Siegel, M.D.
Participants: John P. Feighner, M.D., Dominick Addario, M.D., Stephen R. Shuchter, M.D.

COMPONENT WORKSHOP 12 11:00 a.m.-12:30 p.m.
Room 269, Level 2, Convention Center

A MODEL INFANT PSYCHIATRY PROGRAM FOR ABUSE AND NEGLECT CASES
APA Committee on Pre-School Children

Co-Chps: Michael S. Scheeringa, M.D., Charles H. Zeanah, M.D.
Participants: Julie A. Larrieu, Ph.D., Anna T. Smyke, Ph.D.
COMPONENT WORKSHOP 13  11:00 a.m.-12:30 p.m.
Rooms 338/339, Level 3, Convention Center

THE INTERFACE BETWEEN RELIGION AND EXISTENTIAL PSYCHOTHERAPY
APA Committee on Religion, Spirituality, and Psychiatry

Chp.: George T. Harding IV, M.D.
Participants: Irvin D. Yalom, M.D., T. Byram Karasu, M.D.,
William N. Grosch, M.D., Reverand Clark S. Aist, Ph.D.

COMPONENT WORKSHOP 14  11:00 a.m.-12:30 p.m.
Grand Salon Section 4, Street Level, Hilton

RBRVS CODING AND DOCUMENTATION UPDATE
APA Committee on RBRVS, Codes, and Reimbursements

Chp.: Chester W. Schmidt, Jr., M.D.
Participants: Tracy R. Gordy, M.D., Edward Gordon, M.D.,
Melodie Morgan-Minott, M.D., Joseph M. Schwartz, M.D.,
Steven S. Sharfstein, M.D.

COMPONENT WORKSHOP 15  11:00 a.m.-12:30 p.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

XTCA ND K, ETC.: THE NEW ABC'S OF ADOLESCENT SUBSTANCE USE
APA Committee on Treatment Services for Addicted Patients

Co-Chps: Bernard J. Bierman, M.D., Sheila B. Blume, M.D.
Participants: Teresa Frausto, M.D., Ramon Solhkhah, M.D.,
Deborah Deas, M.D., Pamela Swedlow, M.D.

COMPONENT WORKSHOP 16  11:00 a.m.-12:30 p.m.
Grand Salon Sections 19 & 22, Street Level, Hilton

MISSION IMPOSSIBLE: TREATING THE UNDIAGNOSED CHILD
APA Committee on Children with Mental or Developmental Disorders

Chp.: Carl B. Feinstein, M.D.
Participants: Roxanne Dryden-Edwards, M.D., Gabrielle
Carlson, M.D., Robert L. Hendren, D.O., Donald J. Mordecai, M.D.

ISSUES 23-31

ISSUE WORKSHOP 23  11:00 a.m.-12:30 p.m.
Room 272, Level 2, Convention Center

ALCOHOLISM PHARMACOTHERAPY: A CASE-BASED REVIEW FOR CLINICIANS

Chp.: Lance P. Longo, M.D.
Participants: Michael J. Bohn, M.D., Robert M. Swift, M.D.

ISSUE WORKSHOP 24  11:00 a.m.-12:30 p.m.
Room 273, Level 2, Convention Center

BALANCING CAREER AND FAMILY

Chp.: Margery S. Sved, M.D.
Participants: Emily A. McCort, M.D., Karl M. Jacobs, M.D.

ISSUE WORKSHOP 25  11:00 a.m.-12:30 p.m.
Rooms 333/334, Level 3, Convention Center

NARCISSISM BELOW SEA LEVEL: A DUTCH VIEW OF FUTURE GAY DEVELOPMENTS

Co-Chps: Nicolaas F.J. Hettinga, M.D., Rudolf A.M. Feijen, M.D.
Participants: Wilco Tuinebreijer, Bastiaan L. Oele, M.D.,
Wilhelm G.W. Vanderplaats, M.D.

ISSUE WORKSHOP 26  11:00 a.m.-12:30 p.m.
Room 342, Level 3, Convention Center

COMPUTER ODYSSEY 2001: UPDATES FOR NEW COMPUTER PURCHASERS

Co-Chps: Lawrence K. Richards, M.D., Alan W. Newman, M.D.

ISSUE WORKSHOP 27  11:00 a.m.-12:30 p.m.
Rooms 350/351, Level 3, Convention Center

UNDERSTANDING THE DYNAMICS OF ABUSIVE RELATIONSHIPS

Chp.: Gary J. Maier, M.D.

ISSUE WORKSHOP 28  11:00 a.m.-12:30 p.m.
Prince of Wales Suite, Second Floor, Hilton

MENTAL HEALTH EDUCATION FOR THE PRIMARY CARE PHYSICIAN

Co-Chps: Linda Gask, M.D., Amelia E. Musacchio de Zan, M.D.
Participants: Pedro Ruiz, M.D., Rodolfo D. Fahrer, M.D.,
David A. Baron, D.O.

ISSUE WORKSHOP 29  11:00 a.m.-12:30 p.m.
Melrose Room, Third Floor, Hilton

INTERGENERATIONAL ASPECTS OF TRAUMA AND AGGRESSIVE BEHAVIOR

Chp.: Andrei Novac, M.D.
Participants: Rita R. Newman, M.D., Rachel Yehuda, Ph.D.

ISSUE WORKSHOP 30  11:00 a.m.-12:30 p.m.
Oak Alley Room, Third Floor, Hilton

FUNDING OPPORTUNITIES FROM THE NATIONAL INSTITUTES OF HEALTH

Chp.: Lucinda Miner, Ph.D.
Participants: Ernestine Vanderveen, Ph.D., Walter Goldsmiths, Ph.D.

ISSUE WORKSHOP 31  11:00 a.m.-12:30 p.m.
Elmwood Room, Third Floor, Hilton

CURRENT AND FUTURE TRENDS IN PSYCHIATRY AND EMPLOYMENT LAW

Chp.: Michael M. Welner, M.D.
Participants: Joseph P. Merlino, M.D., Ron Honberg, J.D.,
Lewis A. Opler, M.D., William F. Foote, Ph.D.
### 12 noon Sessions

#### FORUMS 1-3

**FORUM 1**
12 noon-1:30 p.m.  
Room 263, Level 2, Convention Center

**ALONG THE DEATH TRAIL: INSIDE THE MIND OF AN EXECUTION TEAM**

Chp.: Ira D. Glick, M.D.  
Co-Chp.: Howard J. Osofsky, M.D.  
Participants: Michael J. Osofsky, Robert Michels, M.D., Robert S. Pynoos, M.D.

**FORUM 2**
12 noon-1:30 p.m.  
Room 352, Level 3, Convention Center

**WHY HARRY? WHY NOW? UNDERSTANDING THE HARRY POTTER PHENOMENON**

Chp.: Leah J. Dickstein, M.D.  
Participants: Professor JoAnne M. Isbey, Elissa P. Benedek, M.D., Daniel P. Dickstein, M.D.

**FORUM 3**
12 noon-1:30 p.m.  
Grand Salon Sections 13 & 16, Street Level, Hilton

**DAYCARE: IMPACT ON KIDS**

Chp.: Nada L. Stotland, M.D.  
Participants: Carol C. Nadelson, M.D., Tanya R. Anderson, M.D., David S. Rue, M.D., Silvia W. Olarte, M.D.

#### MEDIA SESSION 6
12 noon-2:00 p.m.  
Napoleon Ballroom, Third Floor, Hilton

**JAZZ AT LUNCH**

Chp.: Bruce B. Raeburn, Ph.D.  
Co-Chp.: Herbert W. Peterson, M.D.

**8 A Century of Satchmo**

*A Century of Satchmo* is an audio-visual lecture on the life, musical career, and significance of New Orleans trumpeter, Louis Armstrong. There will be a viewing of video clips from films, excerpts from oral history interviews, and sample audio recordings to illustrate aspects of his musical style and life story. The lecture will examine such topics as the special contextual features of the New Orleans music scene in the early 20th century; the factors contributing to the development of Armstrong's instrumental and vocal styles; his relationships with Joe Oliver, Lil Hardin, Sidney Bechet, Bessie Smith, and other musicians; and his emergence as one of the dominant musical personalities of the 20th century.

**Discussant:** Edward K. Rynearson, M.D.

### 12:30 p.m. Session

#### MEDIA SESSION 7
12:30 p.m.-2:00 p.m.  
Versailles Ballroom, Third Floor, Hilton

**PAIN AND THE MIND: ART AND THE SOUL**

Chp.: Sandra C. Walker, M.D.

**9 The Art of Being Human**  
(28 minutes)

Distributor: Bullfrog Films  
for V9 & V10: P.O. Box 149  
Oley, PA 19547

*The Art of Being Human* is an inspirational portrait of the artist, Frederick Franck, author of "The Zen of Seeing." Born on the border of Holland and Belgium, where both World Wars began, Franck has seen first hand the horrors of modern warfare. Living now in upstate New York, his life's work, through painting, sculpture, and books, has been to help people see the humanity in others, so that they will not be able to tolerate or be involved in violence towards others. It's a message with particular significance in the wake of Bosnia, Rwanda, and Oklahoma City.

**10 Faces of the Hand**  
(41 minutes)

There is nothing more intriguing than what is hidden behind the obvious. The human hand is a miracle, which we completely take for granted. The work of our hands, in their eloquence, silence, restlessness, creativity, and violence have made human history and continue to shape the present and future. *Faces of the Hand* takes you on a visual journey through different cultures and a range of human experiences and shows the many faces of our hands; working, communicating, creating art and music, expressing our sensuality, used as weapons for defense or aggression; and as instruments for healing and worship. This film is both poetry and anthropology, science and art, sacred and profane. It is an odyssey from cave art thirty millennia ago to robot hands controlled by computers.

### 1:00 p.m. Sessions

#### COURSES 51-56
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

**COURSE 51**
1:00 p.m.-5:00 p.m.  
La Galerie 2, Second Floor, Marriott

**THE EVALUATION AND IDENTIFICATION OF THE MAJOR DEMENTIAS**

Director: Raymond A. Faber, M.D.  
Faculty: Kevin F. Gray, M.D., Randolph B. Schiffer, M.D.
MONDAY

COURSE 52  1:00 p.m.-5:00 p.m.
Balcony K, Fourth Floor, Marriott

INTEGRATIVE PSYCHOTHERAPY SUPERVISION:
BASIC TOOLS

Director: Paul Rodenhauser, M.D.
Faculty: Ramona Dvorak, M.D., Albert F. Painter, Psy.D.,
John R. Rudisill, Ph.D.

COURSE 53  1:00 p.m.-5:00 p.m.
Waterbury Ballroom, Second Floor, Sheraton

ADD IN ADULTS

Director: Thomas E. Brown, Ph.D.
Faculty: Margaret D. Weiss, M.D.

COURSE 54  1:00 p.m.-5:00 p.m.
Pontchartrain Ballroom A, Third Floor, Sheraton

ANTICONVULSANTS IN BIPOLAR DISORDER

Co-Directors: Joseph R. Calabrese, M.D., Terence A. Ketter, M.D.
Faculty: Mark A. Frye, M.D.

COURSE 55  1:00 p.m.-5:00 p.m.
Pontchartrain Ballroom D, Third Floor, Sheraton

PERSONALITY DISORDERS IN THE WORKPLACE

Director: James H. Reich, M.D.
Faculty: David P. Bernstein, Ph.D., Elsa F. Ronningstam, Ph.D.,
Per Vaglum, M.D.

COURSE 56  1:00 p.m.-5:00 p.m.
Bayside Room C, Fourth Floor, Sheraton

SEXUAL HARASSMENT: PSYCHOLOGICAL AND
LEGAL ASPECTS

Director: Gail E. Robinson, M.D.
Faculty: Renee L. Binder, M.D., Sharyn A. Lenhart, M.D.,
Michael F. Myers, M.D.

NEW RESEARCH YOUNG INVESTIGATORS’
ORAL/SLIDE SESSIONS 2-4
1:00 p.m.-2:30 p.m.

2 BIOLOGICAL PSYCHIATRY AND
NEUROSCIENCE OF DEPRESSION
Grand Salon Section 4, Street Level, Hilton

3 FRONTIERS OF PSYCHIATRY
Marlborough Suite A/B, Second Floor, Hilton

4 BIOLOGICAL PSYCHIATRY AND NEURO-
SCIENCE OF SCHIZOPHRENIA, PEDIATRIC
DEPRESSION, AND PREGNANCY
Melrose Room, Third Floor, Hilton

For further information on New Research Sessions, please refer
to the New Research Program and Abstracts Book included in your
registration packet.

2:00 p.m. Sessions

LECTURES 6-7

LECTURE 6
2:00 p.m.-3:30 p.m.
Rooms 252-254, Level 2, Convention Center
Ellen Leibenluft, M.D.

Bipolar Disorder: Using Affective Neuroscience to
Bridge the Gap Between Children and Adults

Chp.: Carolyn B. Robinson, M.D.
Co-Chp.: Brian B. Doyle, M.D.

The increasing frequency with which the diagnosis of
Bipolar Disorder is being assigned to young children
has sparked considerable controversy. Is the diagnosis
being applied too liberally, or has the prevalence of
Bipolar Disorder increased? The existence of a significant
cohort of children with severe behavioral and emotional dysregulation is unquestioned; the challenge is to identify which children have, or will develop, Bipolar Disorder. Ellen Liebenluft, M.D., discusses recent developments in affective neuroscience that are relevant to understanding the manifestations of Bipolar Disorder across the developmental spectrum. Dr. Liebenluft is Chief of the Unit on Affective Disorders in the Pediatrics and Developmental Neuropsychiatry Branch of the Mood and Anxiety Disorders Program at the National Institute of Mental Health in Bethesda, Maryland. She is also Clinical Associate Professor of Psychiatry at Georgetown University School of Medicine in Washington, D.C. Nationally recognized for her research on Bipolar Disorder, Dr. Liebenluft has also published and spoken widely on issues concerning women in academic psychiatry. She is a member of the Council on Research and the Research Training Committee of the American Psychiatric Association and has served as President of the Association for Academic Psychiatry. Dr. Liebenluft received her medical degree from Stanford University and completed her residency in psychiatry at Georgetown University School of Medicine.

Distinguished Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.
MEDIA SESSIONS 8-9

MEDIA SESSION 8
2:00 p.m.-5:00 p.m.
Napoleon Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES

Chp.: Alan A. Stone, M.D.

11 Girl, Interrupted: The Film and the Book
(150 minutes)

Distributor: Columbia Pictures
Sony Entertainment
10202 W. Washington Boulevard
Culver City, CA 90232

The memoir, Girl, Interrupted, was published in 1993, 26 years after Susanna Kaysen’s 1967 hospitalization for treatment of her BPD. It described an era of long-term inpatient treatment in psychiatry that no longer exists. Nonetheless, the book won critical acclaim and became a national bestseller. A film version starring Winona Ryder and Angelina Jolie was released in 1999. It is a flawed and banal version of Kaysen’s memoir, but is typical of cinematic portrayals of mental disorders and those who try to treat them.

Discussant: Lawrence Hartman, M.D.

MEDIA SESSION 9
2:00 p.m.-5:00 p.m.
Versailles Ballroom, Third Floor, Hilton

IN SPITE OF ADVERSITY: HEALING BY CHALLENGE

Chp.: William G. Reiner, M.D.

12 King Gimp
(47 minutes)

13 Soop on Wheels
(52 minutes)

Distributor: Video Press
University of Maryland
School of Medicine
100 North Greene Street, Suite 300
Baltimore, MD 21201

King Gimp follows the life of Dan Keplinger for 13 years as he moves from a special elementary school to the mainstream. Through his battle with cerebral palsy, he is confined to a wheelchair and unable to communicate easily with words; however, Dan’s emotional life explodes on to canvas when he discovers art. This documentary, which is exhilarating in its way, tells the story leading up to how Daniel Keplinger, the flailing man in the wheelchair, tries to force the world to see only the man.

Discussant: Richard E. D’Alli, M.D.

14 The Remarkable Story of John/Joan
(30 minutes)

Eight-month old baby John was the victim of an accident during circumcision, which left him with almost no penis. The next year, when he was almost two, the family brought him to Dr. John Money at Johns Hopkins University Medical School, who advised them to have his testicles surgically removed. The theory was that John could be brought up as a girl; that nurture rather than nature created sexual identity, a theory that had gained some acceptance in the sixties. Following the doctor’s advice, the family renamed him Joan, dressed him in frilly dresses and treated him like a little girl. However, beneath the curls and dresses, John/Joan was miserable in his female persona. His twin brother recalls that he was never “feminine.” When John was an adolescent, he learned the truth about his birth. Now in his thirties, he had undergone reconstructive surgery that has enabled him to live his life as a man and have a normal sex life.

Discussant: Richard E. D’Alli, M.D.
MONDAY

PRESIDENTIAL SYMPOSIUM
2:00 p.m.-5:00 p.m.
Room 356, Level 3, Convention Center

THE ROYAL ROAD REVISITED: DREAMS IN THE 21ST CENTURY
Chp.: Daniel B. Borenstein, M.D.
Presenters: Harold P. Blum, M.D., Morton F. Reiser, M.D., Eve Caligor, M.D., Mark L. Solms, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

REVIEW OF PSYCHIATRY: SECTION 1
2:00 p.m.-5:30 p.m.
Rooms 343-345, Level 3, Convention Center

TREATMENT OF RECURRENT DEPRESSION: A CALL TO ARMS
Chp.: John F. Greden, M.D.
1 Recurrent Depression and Mania: Their Overwhelming Burden
   John F. Greden, M.D.
2 Recurrent Depression in Women Through the Lifespan
   Sheila Marcus, M.D., Heather A. Flynn, Ph.D.
3 Chronic and Recurrent Depression: Pharmacotherapy and Psychotherapy Combinations
   Robert J. Boland, M.D.
4 Prevention of Recurrences in Bipolar Patients: The Best of the Old and the New
   Charles L. Bowden, M.D.
5 Clinical Prevention of Recurrent Depression: The Need for Paradigm Shifts
   John F. Greden, M.D.

SYMPOSIA 1-29

SYMPOSIUM 1  2:00 p.m.-5:00 p.m.
Room 262, Level 2, Convention Center

RESIDENTS AND THE PHARMACEUTICAL INDUSTRY: HOW TO MAINTAIN ETHICAL INTEGRITY
Chp.: Ashley D. Wazana, M.D.
Co-Chp.: Annette Granich, M.D.
A Deontological and Ethical Considerations in Resident-Industry Interactions
   Francois J. Primeau, M.D.
B Residents and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?
   Ashley D. Wazana, M.D.
C Induction, Seduction, and Deduction: Teaching the Resident About Physician-Industry Interactions
   Nadeem Bhanji, M.D.
D The Pharmaceutical Industry Relations Committee at McGill
   Annette Granich, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 2  2:00 p.m.-5:00 p.m.
Room 263, Level 2, Convention Center

RISK FACTORS FOR SCHIZOPHRENIA AND PREVENTION
Chp.: Nigel M. Bark, M.D.
Co-Chp.: Dolores Malaspina, M.D.
A Early Associates of Schizophrenia in the 1966 North Finland Birth Cohort
   Juha M. Veijola, M.D., Peter B. Jones, Ph.D., Jula Moring, M.D., Taru H. Makkaryo, M.D., Paula Rantakallio, M.D., Matti K. Isohanni, M.D.
B Prenatal Infection and Adult Schizophrenia
   Alan S. Brown, M.D.
C Risk Factors for the Brain Deviations Associated with Schizophrenia
   Robin M. Murray, M.B., Colm MacDonald, Tonmoy Sharma, M.D., Chiara Nosarit
D Traumatic Brain Injury and Risk for Schizophrenia
   Dolores Malaspina, M.D., Cheryl M. Corcoran, M.D., Stephen V. Faraone, Ph.D., Ming T. Tsuang, M.D., C. Robert Cloninger, M.D., John I. Nurnberger, Jr., M.D., Mary Blehar, Ph.D.
E Neurodevelopmental Genes and Risk of Schizophrenia
   Hiroshi Kunugi, M.D., Akihisa Akahane, M.D., Kumiko Fujii, M.D., Hiroshi Tanaka, M.D., Mineko Hattori, Ph.D., Tadaomi Kato, M.D., Shinichiro Nanko, M.D.
F Predicting Schizophrenia and Depression: Would You Help or Harm?
   Peter B. Jones, Ph.D., Tim J. Crowe, Ph.D., Jim J. Vanos
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 3  2:00 p.m.-5:00 p.m.
Room 264, Level 2, Convention Center

NEW APPROACHES TO IMPROVE LONG-TERM TREATMENT ADHERENCE IN SCHIZOPHRENIA
Chp.: Steven J. Siegel, M.D.

(Continued on next page)
29
A Treatment Adherence in Schizophrenia
John M. Kane, M.D.

B Psychosocial and Pharmacological Strategies for Improving Treatment Adherence in Schizophrenia
Stephen R. Marder, M.D., Donna A. Wirshing, M.D., William C. Wirshing, M.D.

C "I Am Not Sick, I Don't Need Help!": Helping Patients Accept Treatment
Xavier Amador, Ph.D.

D Caduceus on the Scales of Justice: Legal Interventions to Provide Treatment
Jonathan A. Stanley, J.D.

E A Role for Surgically Implanted Long-Term Neuroleptic Delivery System
Steven J. Siegel, M.D., Karen Winey, Ph.D., Raquel E. Gur, M.D., Robert H. Lenox, M.D., Neel Ghandi, Debbie Ikeda, B.A., Wendy Zhang, M.A.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 4 2:00 p.m.-5:00 p.m.
Rooms 265/266, Level 2, Convention Center

PTSD: A BIOPSYCHOSOCIAL APPROACH
Chp.: Joel F. Paris, M.D.

A The Stressor Criterion in DSM-IV
Naomi Breslau, Ph.D.

B Individual Difference in Post-Traumatic Response
Marilyn L. Bowman, Ph.D.

C Has PTSD Become a Post-Traumatic Neurosis?
Allan Young, Ph.D.

D Culture, Trauma, and PTSD
Laurence J. Kirmayer, M.D., G. Eric Jarvis, M.D.

E Personality Factors in Susceptibility to PTSD
Joel F. Paris, M.D.

Discusant: Jack M. Gorman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 5 2:00 p.m.-5:00 p.m.
Rooms 267-268, Level 2, Convention Center

PERIMENOPAUSE, MOOD, AND COGNITION: THE ROLE OF REPRODUCTIVE HORMONES
Chp.: Claudio N. Soares, M.D.
Co-Chp.: Hadine Joffe, M.D.

A The Modulation of Neurotransmitters by Gonadal Steroids: An Update
David R. Rubinow, M.D.

B The Relationship Between Depression and the Transition to Menopause: Results from a Cohort Study
Lee S. Cohen, M.D., Claudio N. Soares, M.D., Michael W. Otto, Ph.D., Bernard L. Harlow, Ph.D.

C The Role of Estrogen as an Antidepressant Strategy for Perimenopausal Depression
Claudio N. Soares, M.D., Osvaldo P. Almeida, M.D., Lee S. Cohen, M.D.

D The Impact of Estrogen Therapy on Cognition in Perimenopausal and Postmenopausal Women
Hadine Joffe, M.D.

Discusant: Peter J. Schmidt, M.D.
THIS SESSION WILL BE AUDIOTAPED.
B The Arab Family Structures in Arab Civilizations: A Historical Review
Nasser F. Loza, M.B.

C The Current Status of Child Psychiatry: An Egyptian Perspective
Ahmed M.F. Okasha, M.D.

D Mental Health in Children and Adolescents in Morocco
Driss Moussaoui, M.D., K.H. Chihabeddine

E Disciplinary Practices and Child Maltreatment Among Egyptian Families in an Urban Area in Ismailia
Mohamed H. El-Defrawi, M.D., Fatma Hassan, M.D., Amany Refaat, M.D., Hesham El-Sayed

Discussant: David V. Sheehan, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 8
2:00 p.m.-5:00 p.m.
Room 271, Level 2, Convention Center

EATING DISORDERS: NEW FEATURES AND NEW TREATMENTS
Chp.: Joel Yager, M.D.
Co-Chp.: David B. Herzog, M.D.

A Cognitive Functioning in Anorexia Nervosa

B Eating Behavior While Driving a Car
James E. Mitchell, M.D., John B. Glass, M.D.

C Cognitive-Behavior Therapy Relapse Predictors for Bulimia Nervosa
Katherine A. Halmi, M.D., W. Stewart Agras, M.D., James E. Mitchell, M.D., Scott J. Crow, M.D., G. Terrence Wilson, Ph.D.

D New Treatment Strategies for Anorexia Nervosa
Walter H. Kaye, M.D., Maria Lavia, M.D., Guido Frank, M.D., Amanda Molina, B.S.

E Adjunctive Treatment of Anorexia Nervosa by E-Mail
Joel Yager, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 9
2:00 p.m.-5:00 p.m.
Room 272, Level 2, Convention Center

PSYCHODYNAMIC PSYCHOTHERAPY:
CONTEMPORARY ISSUES
A.P.A. Commission on Psychotherapy by Psychiatrists and American College of Psychoanalysts

Chp.: Jerald Kay, M.D.
MONDAY

D Characteristics of Patients with Substance Use Disorders Affected by Financial Constraints
Diane M. Herbeck, M.A., Steven C. Marcus, Ph.D., Clifton R. Tennison, Jr., M.D., Laura J. Fochtman, M.D.

Discussant: Joyce C. West, M.P.P.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 12  2:00 p.m.-5:00 p.m.
Rooms 335/336, Level 3, Convention Center

PTSD IN WOMEN: INTEGRATING MIND AND BRAIN IN TREATMENT
Chp.: Leah J. Dickstein, M.D.
Co-Chp.: Marian I. Butterfield, M.D.

A Immune Neuroanatomic Neuroendocrine Gender Differences in PTSD
Rachel Yehuda, Ph.D.

B The Psychodynamics of Trauma in Women
Kathryn J. Zerbe, M.D.

C Domestic Violence, PTSD, and Women of Color
Tana A. Grady-Weliky, M.D.

D Treatment of PTSD in Women: Lessons from Women Veterans
Marian I. Butterfield, M.D., Paula G. Panzer, M.D., Catherine Forneris, Ph.D.

E Pharmacotherapeutic Treatment for Women with PTSD
Kathleen T. Brady, M.D.

Discussant: Carol C. Nadelson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 13  2:00 p.m.-5:00 p.m.
Room 342, Level 3, Convention Center

PSYCHIATRY, THE INTERVIEW, AND MEDICAL OUTCOMES
Chp.: Joseph S. Weiner, M.D.
Co-Chp.: Steven A. Cole, M.D.

A New Concepts and Data on the Relationship of the Interview to Outcomes
Geoffrey H. Gordon, M.D.

B Adherence and Behavior Change Skills for the Practicing Psychiatrist
Michael G. Goldstein, M.D.

C Teaching Skeptical Medical Housestaff Communication Skills with Patients
M. Philip Luber, M.D.

D Depression Education for Primary Care: The MacArthur Foundation Initiative
Steven A. Cole, M.D., Mary Raju, N.P.

E Learning and Teaching Listening Skills
Joseph S. Weiner, M.D.

Discussant: Don R. Lipsett, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 14  2:00 p.m.-5:00 p.m.
Rooms 346/347, Level 3, Convention Center

TRAUMA AND THE LIFE CYCLE: MULTIDISCIPLINARY PERSPECTIVES
Chp.: Randall D. Marshall, M.D.

A Contemporary Psychodynamic Perspectives on Trauma and Development
Arieh Y. Shalev, M.D.

B Integrating Medication and Psychosocial Therapeutic Models in PTSD
Randall D. Marshall, M.D.

C Variable Foraging Demand Rearing in Primates: Biobehavioral Sequelae
Jeremy D. Coplan, M.D., Eric L. P. Smith, Ph.D., Bruce A. Scharf, Shinn Baptist, Atamash I. Oureshi, M.D., Jack M. Gorman, M.D., Leonard A. Rosenbaum, Ph.D.

D Ethnocultural Factors in PTSD
Roberto Lewis-Fernandez, M.D., Bruce Dohrenwend, M.D., J. Blake Turner, Ph.D., Randall D. Marshall, M.D.

E The Cognitive-Affective Science of Trauma and Development
Dan J. Stein, M.D.

Discussant: Charles R. Marmar, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 15  2:00 p.m.-5:00 p.m.
Rooms 348/349, Level 3, Convention Center

ADDICTIONS: GAMBLING AND SUBSTANCE ABUSE: CUTTING-EDGE TREATMENT
Chp.: Herbert D. Kleber, M.D.
Co-Chp.: David M. McDowell, M.D.

A Treatment of Cocaine Dependence
Marian W. Fischman, Ph.D.

B Treatment of Heroin Dependence
Herbert D. Kleber, M.D.
C Marijuana Dependence and Club Drug Use: Future Concerns and Possible Strategies for a Generation at Risk
David M. McDowell, M.D.

D Gambling Addictions
Robert W. Johnson, M.D.

E Treatment of Comorbid Conditions
Frances R. Levin, M.D.

Discussants: Edward V. Nunes, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.
Room 352, Level 3, Convention Center

CHILDHOOD SEXUAL ABUSE: PERPETRATORS AND VICTIMS
Chp.: Igor I. Galynker, M.D.
Co-Chp.: J. Douglas Bremner, M.D.

A Personality Profiles and Childhood Sexual Histories of Male Perpetrators
Lisa J. Cohen, Ph.D., Igor I. Galynker, M.D., Erik Klein, B.A., Aleksey Ten, M.D., Carrie Weaver, M.A., Enid Geretman-King, B.A., Kenneth Cullen, M.S.W.

B Cerebral Glucose Metabolism and Deviant Sexual Arousal in Male Pedophiles

C Psychophysiological Reactivity to Stressful Scripts in BPD and PTSD
Christian G. Schmahl, M.D., Bernet M. Elzinga, M.S.C., Thomas H. McGlashan, M.D., J. Douglas Bremner, M.D.

D Role of Hippocampus and Medical Prefrontal Cortex in Abuse-Related PTSD
J. Douglas Bremner, M.D., Meena Narayan, M.D., Eric Vermetten, M.D., Steven M. Southwick, M.D., Thomas H. McGlashan, M.D., L. Viola Vaccarino, M.D., Lawrence H. Staib

Discussants: Clinton D. Kilts, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 17 2:00 p.m.-5:00 p.m.
Room 357, Level 3, Convention Center

PSYCHOTHERAPY IN THE AMERICAS
Inter-American Council of Psychiatric Organizations
Chp.: Roberto E. Chaskel, M.D.
Co-Chp.: Nestor F. Marchant, M.D.

A Psychotherapy in the General Hospital Setting: A Cultural Experience in Liaison Psychiatry
Rodolfo D. Fahrer, M.D., Amelia E. Musacchio de Zan, M.D.

B Folkloric Roots of Psychiatry and Development of Psychotherapy
Carlos Leon-Andrade, M.D., Ricardo Heinlein, Miguel R. Jorge, M.D.

C Psychotherapy Among Indigenous Caribbean Patients: Folk Traditions and Future
Sharon C. Harvey, M.D.

D Psychotherapy in a Violent Society
Ruben J. Hernandez-Serrano, M.D., Antonio Pacheco, M.D., Roberto E. Chaskel, M.D.

E Phenomenological and Descriptive Legacies in Latin-American Psychiatry
Renato D. Alarcon, M.D.

Discussants: Carlos Berganza, Pedro Ruiz, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 18 2:00 p.m.-5:00 p.m.
Grand Salon Sections 3 & 6, Street Level, Hilton

MIND AND BRAIN: THE CONCEPTS OF PSYCHIATRY
Association for the Advancement of Philosophy and Psychiatry
Chp.: S. Nassir Ghaemi, M.D.

A The Methodological View of Neuroscience and Psychoanalysis
Marshall F. Folstein, M.D.

B Overt and Covert Theories of Mind in Psychiatric Education
John Z. Sadler, M.D.

C Mind and Brain Do Not Have to Be Integrated if We Don't Segregate Them in the First Place
Michael A. Schwartz, M.D.

D Mind/Brain Theories in Clinical Psychiatry
S. Nassir Ghaemi, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 19 2:00 p.m.-5:00 p.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

HOW CAN PSYCHIATRISTS IMPACT THE PROBLEM OF SUICIDE AT THE COMMUNITY LEVEL?
APA Alliance
Chp.: Gail S. Fuller, R.N.

A How to Prevent Youth Suicide: Challenges for Psychiatrists
Cynthia L. Pfeffer, M.D.

B Awareness of Suicide Risk in the Community
Jan A. Fawcett, M.D.

C Youth Suicide: Understanding and Prevention
Paul J. Fink, M.D.

Discussants: Paul J. Fink, M.D.
THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 20

2:00 p.m.-5:00 p.m.
Grand Salon Sections 9 & 12, Street Level, Hilton

THINKING ABOUT MIND AND BRAIN:
PSYCHOANALYSTS AND NEUROSCIENTISTS
CONVERSE: PART I
American Academy of Psychoanalysis and American Psychoanalytic
Association

Chp.: Edward Nersessian, M.D.
Co-Chp.: Ann-Louise S. Silver, M.D.

A Is There a Place for an Unconscious in Biological Psychiatry?
Howard Shevrin, Ph.D.

B Affective Neuroscience and Socioemotional Systems of the Brain: Implications for Understanding Psychiatric Disorders
Jaak Panksepp, Ph.D.

C Toward A Neurobiology of the Unconscious
Richard M. Brockman, M.D.

D Psychoanalytic and Neurobiologic Perspectives on Alexithymia
Graeme J. Taylor, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 21

2:00 p.m.-5:00 p.m.
Grand Salon Sections 13 & 16, Street Level, Hilton

ACHIEVING COMPREHENSIVE CARE FOR THE SUICIDAL INDIVIDUAL

Chp.: Ian C. Dawe, M.D.

A A Needs-Based Approach to the Care of Suicidal Individuals
Ian C. Dawe, M.D.

B Journey of Care of the Suicidal Patient: St. Michael's-Style Crisis Perspective
Michele K. Cook, R.N.

C Inpatient Management of the Suicidal Patient
Kenneth E. Balderson, M.D.

D Comprehensive Care for the Suicidal Individual: Outpatient Group Intervention
Yvonne Bergmans, M.S.W., Ian C. Dawe, M.D.

E Comprehensive Care for the Suicidal Patient: Research Perspectives
Anne E. Rhodes, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 22

2:00 p.m.-5:00 p.m.
Grand Salon Sections 15 & 18, Street Level, Hilton

FRONTIERS OF DEPRESSION IN CHILDREN AND ADOLESCENTS

Chp.: Mohammad Shafii, M.D.

A Neurobiology of Depression and Suicidal Behavior
J. John Mann, M.D.

B Depressed Mothers Identified in Primary Care
Myrna M. Weissman, Ph.D., Adriana Feder, M.D., Daniel J. Pilowsky, M.D., Mark Olsson, M.D., Milton Fuentes, Psy.D.

C Trends in Current Clinical Research on Child and Adolescent Major Depression
Maria Kovacs, Ph.D., Joel T. Sherrill, Ph.D.

D Pharmacology of Child and Adolescent Depression
Neal D. Ryan, M.D.

E Treatment Guidelines and Algorithms in Depressed Children and Adolescents
Graham J. Emslie, M.D.

F Cognitive-Behavioral Treatment and Prevention of Adolescent Depression
Greg Clarke, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 23

2:00 p.m.-5:00 p.m.
Grand Salon Sections 21 & 24, Street Level, Hilton

RESULTS FROM THE TEXAS MEDICATION ALGORITHM PROJECT (TMAP)

Chp.: A. John Rush, M.D.
Co-Chp.: Steven P. Shon, M.D.

A The Texas Medication Algorithm Project (TMAP): Rationale and Study Design
A. John Rush, M.D.

B Issues and Tensions in Specifying and Developing Medication Algorithms
M. Lynn Crismon, Pharm.D.

C Results from the Texas Medication Algorithm Project (TMAP) Schizophrenia Treatment Module
Alexander L. Miller, M.D.

D Results from the Texas Medication Algorithm Project (TMAP) Bipolar Disorder Treatment Module
Patricia Suppes, M.D.

E Results from the Texas Medication Algorithm Project (TMAP) Major Depressive Disorder Treatment Module
Madhukar H. Trivedi, M.D.

Discussant: Kenneth Z. Altshuler, M.D.

THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 24 2:00 p.m.-5:00 p.m.
Rosedown Room, Third Floor, Hilton

FIELD TESTING DIMENSIONAL MODELS FOR DSM-V AXIS II

Chp.: Robert L. Spitzer, M.D.
Co-Chp.: Michael B. First, M.D.

A Dimensional Representation of DSM-IV Personality Disorders
Andrew E. Skodol II, M.D., John M. Oldham, M.D., Donna S. Bender, Ph.D., Mary C. Zanarini, Ed.D., Ingrid R. Dyk, M.P.H., Charles A. Sanislow, Ph.D., Regina T. Dolan, Ph.D.

B A Stepwise Psychobiological Classification
C. Robert Cloninger, M.D.

C A Two-Component Adaptational Model for Classifying Personality Disorders
John Livesley, M.D., Kerry L. Jang, Ph.D.

D Clinical Application of the Five Factors of Personality
Thomas A. Widiger, Ph.D.

E A Prototype-Matching Approach to Diagnosis of Personality Disorders
Drew Westen, Ph.D., Jonathon Shedler, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 25 2:00 p.m.-5:00 p.m.
Magnolia Room, Third Floor, Hilton

ADHD: A LIFE CYCLE PERSPECTIVE

Chp.: Thomas J. Spencer, M.D.

A ADHD Across the Life Cycle: Symptomatology and Validity
Thomas J. Spencer, M.D.

B Neuropsychology Deficits and Symptomatology of ADHD
Rosemary Tanneck, Ph.D.

C ADHD and Alcohol or Drug Abuse
Timothy E. Wilens, M.D.

D A Novel Nonstimulant Therapy for ADHD: New Data from Controlled Trials
David Michelson, M.D., Joachim Wernicke, M.D., Thomas J. Spencer, M.D., John H. Heiligenstein, M.D., Douglas Faries, Ph.D.

SYMPOSIUM 26 2:00 p.m.-5:00 p.m.
Jasperwood Room, Third Floor, Hilton

EXERCISE, ATHLETIC PARTICIPATION, AND MENTAL HEALTH: WHEN IT WORKS AND WHEN IT DOESN'T
International Society for Sport Psychiatry

Chp.: Ronald L. Kamm, M.D.

A Exercise and Its Positive Impact on Mental Health
Robert W. Burton, M.D., Ronald L. Kamm, M.D.

B When the Athlete Has an Emotional Disorder: Special Psychopharmacological Considerations
Antonia L. Baum, M.D.

C The Role of the Family in an Athlete's Emotional Life
Ian R. Tofter, M.D.

Discussants: Derrick Adkins, Gerald A. Cooney, Julie Krone
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 27 2:00 p.m.-5:00 p.m.
Oak Alley Room, Third Floor, Hilton

WOMEN'S MENTAL HEALTH: A CURRENT PERSPECTIVE

Chp.: Susan G. Kornstein, M.D.
Co-Chp.: Mary Blehar, Ph.D.

A Psychiatric Aspects of Hormonal Contraception
Julia K. Warnock, M.D.

B Depression in Women
Susan G. Kornstein, M.D.

C Female Sexual Dysfunction
Anita L.H. Clayton, M.D.

D Women with Cancer: Psychosocial Issues in Breast, Gynecologic, and Lung Cancer
Elisabeth J. S. Kunkel, M.D., Emmie Chen, M.S.

E Career and Workplace Issues for Women
Diane K. Shrier, M.D.

Discussant: Mary Blehar, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 28 2:00 p.m.-5:00 p.m.
Elmwood Room, Third Floor, Hilton

CULTURAL IDENTITY AND QUALITY OF LIFE
The World Psychiatric Association

Chp.: Juan E. Mezzich, M.D.
Co-Chp.: Harold I. Eist, M.D.

A Asian-American Culture, Spirituality, and Quality of Life
Nalini V. Juthani, M.D.

B Identification at a Different Place and Time
Ezra E.H. Griffith, M.D.

(Continued on next page)
C Latino Biculturality and Quality of Life  
Juan E. Mezzich, M.D., Maria A. Ruiperez, Ph.D.

D European Cultures, Identity, and Quality of Life  
Heinz Katschnig, M.D.

E Australian Cultures and Quality of Life  
Helen E. Herrman, M.D., Hilary L. Schofield, Ph.D., Barbara Murphy, Ph.D.

Discussants: Marianne C. Kastrup, M.D., John L. Cox, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 29  2:00 p.m.-5:00 p.m.
Belle Chasse Room, Third Floor, Hilton

GROUP THERAPY FOR BREAST CANCER: INTERNATIONAL RANDOMIZED TRIALS
Chp.: David Spiegel, M.D.

A Australian RCTs of Group Therapy for Breast Cancer: Outcome Data  
David W. Kissane, M.D., Sydney Bloch, M.D., David M. Clarke, Ph.D., Graeme C. Smith, M.D., Dean P. McKenzie, B.A., Anthony Love, Ph.D., Jillian Ilkin, B.A.

B Group Therapy for Metastatic Breast Cancer: A Randomized Trial  
David Spiegel, M.D., Catherine Classen, Ph.D., Lisa Butler, Ph.D., Janine Giese-Davis, Ph.D., Robert Carlson, M.D., Cheryl Koopman, Ph.D.

C Supportive-Expressive Group Therapy for Women with Breast Cancer: A Danish Experience  
Anders Bonde-Jensen, Ph.D., Marianne Lau, Ph.D., Carsten Rose, M.D.

D Support Group for Women at Genetic Risk for Breast and Ovarian Cancer  
Kathryn M. Kash, Ph.D., Mary-Kay Dabney, M.S., Jimmie C. Holland, M.D.

E Psychosocial Distress and Group Intervention Among Breast Cancer Patients  
Luigi Grassi, M.D., Katia Magnani, Ph.D., Marino Gatti, M.D., Diletta Aguiari, Ph.D., Silvana Sabato, Ph.D., Alessandra Marsillo, M.D.

F Group Therapy for Primary Breast Cancer: A Randomized, Multicenter Trial  
Catherine Classen, Ph.D., David Spiegel, M.D., Cheryl Koopman, Ph.D., Gail Stonisch-Riggs, M.S.W., Joan Westendorf, R.N., Gary Morrow, Ph.D.

Discussant: Jimmie C. Holland, M.D.
THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 5  
3:00 p.m.-5:00 p.m.
Exhibition Center, Second Floor, Hilton

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

7:30 p.m. Session

CONVOCATION OF FELLOWS  
7:30 p.m.  
Hall G, Lobby Level, Convention Center
All Fellows, members, and registered guests are invited.

Presiding: Daniel B. Borenstein, M.D., President

Grand Marshals: Max Sugar, M.D., Gene L. Usdin, M.D.

Marshals: Irma J. Bland, M.D., Dudley M. Stewart, Jr., M.D.

INTRODUCTION OF LIFE FELLOWS  
Richard K. Harding, M.D., President-Elect

INDUCTION OF FELLOWS  
Richard K. Harding, M.D.

INTRODUCTION OF FIFTY-YEAR LIFE FELLOWS, LIFE MEMBERS, INTERNATIONAL FELLOWS, AND DISTINGUISHED FELLOW  
Daniel B. Borenstein, M.D.

PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS  
Daniel B. Borenstein, M.D.

PRESENTATION OF DISTINGUISHED SERVICE AWARDS  
Daniel B. Borenstein, M.D.

INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARD BOARD CHAIRPERSONS  
Daniel B. Borenstein, M.D.

PRESENTATION OF AWARDS  
Daniel B. Borenstein, M.D.

APA Award for Research in Psychiatry
APA/Lilly Resident Research Awards
Human Rights Award
A Trip to the Moon and Beyond

Harrison H. Schmitt, Ph.D., a native of Silver City, NM, has the diverse experience of a geologist, pilot, astronaut, administrator, businessman, writer, and U.S. Senator. He received his B.S. in Science at Caltech, studied as a Fulbright Scholar at Oslo, and attended graduate school at Harvard. He received his Ph.D. in geology in 1964 based on geological field studies in Norway. As a civilian, he received Air Force jet pilot wings in 1965 and Navy helicopter wings in 1967. Selected for the Scientist-Astronaut program in 1965, he organized the lunar science training for the Apollo Astronauts, represented the crews during the development of hardware and procedures for lunar surface exploration, and oversaw the final preparation of the Apollo Lunar Module Descent Stage. He was designated Mission Scientist in support of the Apollo 11 mission. After training as back-up Lunar Module Pilot for Apollo 15, Dr. Schmitt served in that same capacity on Apollo 17 - the last Apollo mission to the moon. On December 11, 1972, he landed in the Valley of Taurus-Littrow as the only scientist and the last of 12 men to step on the Moon. In 1975, after two years managing NASA’s Energy Program Office, Dr. Schmitt fulfilled a long-standing personal commitment by entering politics in 1976. He served in the U.S. Senate from 1977 through 1982, representing his home state of New Mexico. Senator Schmitt was a member of the Senate Commerce, Banking, Appropriations, Intelligence, and Ethics Committees. In his last two years in the Senate, he held the position of Chairman of the Subcommittee on Science, Technology, and Space and of the Appropriations Subcommittee on Labor, Health and Human Services, and Education. He later served on the President's Foreign Intelligence Advisory Board, the President's Commission on Ethics Law Reform, as Co-Chairman of the International Intelligence Advisory Board for the 1992 Romanian elections, as Vice Chairman of the U.S. delegation to the 1992 World Administrative Radio Conference in Spain, and as chairperson of the International Advisory Board for the U.S. Army Research Laboratory. Harrison Schmitt consults, speaks, and writes on policy issues of the future, space, and the American Southwest. He presently is Chair Emeritus of The Annapolis Center (risk assessment evaluation) and holds an appointment as Adjunct Professor in the Department of Engineering, University of Wisconsin-Madison, teaching "Resources from Space." His corporate board memberships include Orbital Sciences Corporation, PhDx Systems, Inc., Magplane Technology, Inc., and he is a Member of the Corporation of the Draper Laboratory. He is a founder and the Chairman of Interlune-Intermars Initiative, Inc., advancing the private sector’s acquisition of lunar resources and He-three fusion power and broad clinical use of medical isotopes produced by fusion-related processes. Dr. Schmitt’s honors include 1973 Arthur S. Fleming Award, 1973 Distinguished Graduate of Caltech, 1973 Caltech Sherman Fairchild Scholar, NASA Distinguished Service Award, Fellow of the AIAA, Honorary Member of the Norwegian Geographical Society and Geological Association of Canada, 1989 Lovelace Award (space biomedicine), 1989 G.K. Gilbert Award (planetology), and Honorary Fellow of the Geological Society of America, American Institute of Mining, and Geological Society of London. Dr. Schmitt has received several honorary degrees from U.S. and Canadian Universities.

THIS SESSION WILL BE AUDIOTAPED.
CALL FOR PAPERS

PRESIDENT'S THEME:
The 21st Century Psychiatrist

Richard K. Harding, M.D.
President

Philip R. Muskin, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry-Supported</td>
<td>June 4, 2001</td>
</tr>
<tr>
<td>Symposium</td>
<td></td>
</tr>
<tr>
<td>Course</td>
<td>September 4, 2001</td>
</tr>
<tr>
<td>Media</td>
<td>September 4, 2001*</td>
</tr>
<tr>
<td>Reports</td>
<td>September 4, 2001</td>
</tr>
<tr>
<td>Symposium</td>
<td>September 4, 2001</td>
</tr>
<tr>
<td>Workshops</td>
<td>Issue: September 4, 2001</td>
</tr>
<tr>
<td></td>
<td>Component: September 17, 2001</td>
</tr>
<tr>
<td>New Research</td>
<td>January 4, 2002</td>
</tr>
</tbody>
</table>

Incomplete and/or Incorrect Forms Will Not Be Considered.

*A single copy of the media item must be included with submission material.

For complete submission forms, contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator.

If you want to volunteer to chair a session, please send a letter to the attention of Dr. Muskin at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.
7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 27-32

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 27, PART 2
7:00 a.m.-8:30 a.m.
La Nouvelle Ballroom, Level 2, Convention Center

OPTIMIZING TREATMENT OUTCOMES IN PATIENTS WITH CHRONIC DEPRESSION
Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Maximizing Patient Satisfaction During the Long-Term Treatment of Depression
Susan G. Kornstein, M.D.

B Pharmacoeconomic and Psychosocial Outcomes in the Management of Chronic Depression
Robert M.A. Hirschfeld, M.D.

Discussant: Robert M.A. Hirschfeld, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 2
7:00 a.m.-8:30 a.m.
Grand Ballroom A/B, Street Level, Hilton

WOMEN'S MENTAL HEALTH: ANTIDEPRESSANT THERAPY DURING THE CHILDBEARING YEARS
Supported by Forest Laboratories, Inc.

Chp.: Lori L. Altshuler, M.D.

A The Treatment of Postpartum Depression: Risks and Benefits to Mother and Child
Victoria Hendrick, M.D.

B Treatment Guidelines for Breastfeeding
Zachary S. Stowe, M.D., Amy L. Hostetter, B.A.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 2
7:00 a.m.-8:30 a.m.
Grand Ballroom C/D, Street Level, Hilton

COMPARING ATYPICAL ANTIPSYCHOTIC THERAPIES: MAKING SENSE OF THE DATA
Supported by AstraZeneca Pharmaceuticals

Chp.: Rajiv Tandon, M.D.

A Beyond Efficacy and Symptom Control: Effectiveness as the Best Measure of Antipsychotic Drug Therapy
Henry A. Nasrallah, M.D.

B Optimizing Optimistically: Getting the Most Out of the Atypical Antipsychotics
Peter J. Weiden, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 2
7:00 a.m.-8:30 a.m.
Acadia Ballroom, Third Floor, Marriott

MOOD AND ANXIETY DISORDERS IN UNDERSTUDIED POPULATIONS
Supported by SmithKline Beecham Pharmaceuticals

Chp.: Karen D. Wagner, M.D.

A The Cancer Patient with Depression
Dominique L. Musselman, M.D.

B Psychiatric Implications of Menopause
Dwight L. Evans, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 2
7:00 a.m.-8:30 a.m.
Carondelet Ballroom, Third Floor, Marriott

WEIGHING THE OPTIONS FOR MANAGING BIPOLAR DEPRESSION
Supported by Glaxo Wellcome Inc.

Chp.: Gary S. Sachs, M.D.

A Interpersonal and Social Rhythm Therapy Prevents Depressive Symptomatology for Bipolar I Disorder
Ellen Frank, Ph.D.

B Bipolar Depression: Continuation-Phase Options
Gary S. Sachs, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 2
7:00 a.m.-8:30 a.m.
Mardi Gras Ballroom, Third Floor, Marriott

THE IMPULSIVE AGGRESSIVE SPECTRUM: CHALLENGING POPULATIONS
Supported by Abbott Laboratories

Chp.: Eric Hollander, M.D.

A Anticonvulsants as Adjunctive Treatment in Psychosis
Daniel E. Casey, M.D.

B Aggression, Violence, and Psychopathology: From Adolescence to Adulthood
Hans Steiner, M.D.
8:00 a.m. Sessions

COURSES 57-64
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 57 8:00 a.m.-12 noon
La Galerie 2, Second Floor, Marriott
THE DETECTION OF MALINGERED MENTAL ILLNESS
Director: Phillip J. Resnick, M.D.

COURSE 58 8:00 a.m.-12 noon
La Galerie 4, Second Floor, Marriott
ECT IN NEUROLOGICAL DISORDERS
American Neuropsychiatric Association
Co-Directors: Georgios Petrides, M.D., Charles H. Kellner, M.D.
Faculty: C. Edward Coffey, M.D., Max Fink, M.D., Keith Rasmussen, M.D., Raymond A. Faber, M.D.

COURSE 59 8:00 a.m.-12 noon
La Galerie 5, Second Floor, Marriott
FUNDAMENTAL KNOWLEDGE NEEDED FOR CLINICAL WORK WITH INFANTS AND TODDLERS
Harris Center for Infant Mental Health
Co-Directors: Martin J. Drell, M.D., Howard J. Osofsky, M.D.
Faculty: Joy D. Osofsky, Ph.D., Jean M. Thomas, M.D.,
Harry H. Wright, M.D., Charles H. Zeanah, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 2
9:00 a.m.-10:30 a.m.
Room 263, Level 2, Convention Center
A VITAL ROLE FOR PSYCHOTHERAPY IN NEUROPSYCHIATRY: BODY IMAGE ANXIETY IN HUNTINGTON'S DISEASE
Presenter: Stuart W. Taylor, M.D.
Discussant: Gary J. Tucker, M.D.
THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE: PART 2
9:00 a.m.-12 noon
Room 262, Level 2, Convention Center
COGNITIVE-BEHAVIORAL THERAPY: A CASE OF COMORBID MAJOR DEPRESSION, PERSONALITY DISORDER, AND EPISODIC ALCOHOL ABUSE
Presenter: Anton C. Trinidad, M.D.
Discussant: Stephen P. McDermott, M.D.
THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.
COURSES 65-70
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 65 9:00 a.m.-4:00 p.m.
La Galerie 6, Second Floor, Marriott

ADVANCED HYPNOSIS: APPLICATIONS IN PSYCHIATRY
Director: Jose R. Maldonado, M.D.
Faculty: David Spiegel, M.D.

COURSE 66 9:00 a.m.-4:00 p.m.
Balcony K, Fourth Floor, Marriott

TRANSPERSONAL PSYCHIATRY: CLINICAL APPLICATIONS
Co-Directors: John F. Hiatt, M.D., William W. Foote, M.D.

COURSE 67 9:00 a.m.-4:00 p.m.
Pontchartrain Ballroom A, Third Floor, Sheraton

A PRACTICAL APPROACH TO HERBS AND NUTRIENTS IN PSYCHIATRY
Director: Richard P. Brown, M.D.
Faculty: Patricia L. Gerbarg, M.D.

COURSE 68 9:00 a.m.-4:00 p.m.
Pontchartrain Ballroom D, Third Floor, Sheraton

WORKING WITH EMOTION IN PSYCHOTHERAPY
Director: Richard D. Lane, M.D.
Faculty: Leslie S. Greenberg, Ph.D.

COURSE 69 9:00 a.m.-4:00 p.m.
Bayside Room B, Fourth Floor, Sheraton

INTERPERSONAL PSYCHOTHERAPY
Co-Directors: Scott P. Stuart, M.D., Michael W. O'Hara, Ph.D.
Faculty: Michael D. Robertson, M.D.

COURSE 70 9:00 a.m.-4:00 p.m.
Grand Ballroom E, Fifth Floor, Sheraton

OUTCOMES: USE OF RATING SCALES
Co-Directors: Luis F. Ramirez, M.D., Martha Sajatovic, M.D.
Faculty: Sudeep Kundu, Ph.D., C. Raymond Bingham, Ph.D.

DISCUSSION GROUPS 6-9
9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

6 Deborah Spitz, M.D., on Why Hospitalize?
Chequers Suite, Second Floor, Hilton

7 Catherine A. Crane, M.D., on Consultation Liaison Psychiatry: Career and Subspecialization Opportunities at the Medicine-Psychiatry Interface (For Residents Only)
Trafalgar Suite, Third Floor, Hilton

8 L. Lee Tynes, M.D., on Screening and Treating Depression in Primary Care: Let's Be Realistic!
Norwich Suite, Third Floor, Hilton

9 James H. Scully, Jr., M.D., on Academic-Public Psychiatry: Thriving and/or Surviving
Durham Suite, Third Floor, Hilton

LECTURES 9-10

LECTURE 9
9:00 a.m.-10:30 a.m.
Rooms 252-254, Level 2, Convention Center
Robert Sapolsky, Ph.D.

Gene Therapy and Its Potential Applications to Psychiatry
Chp.: Joel J. Wallack, M.D.
Co-Chp.: David H. Taylor, M.D.

Gene therapy involves the transfer into diseased tissue of protective transgenes or of antisense sequences meant to block expression of native genes that results in pathology. Such interventions in the central nervous system are particularly challenging. Robert Sapolsky, Ph.D., reviews the techniques underlying gene therapy in the nervous system, discusses the use of gene therapy to protect neurons from neurological diseases, and explores the potential applicability of gene therapy to psychiatric disorders. Dr. Sapolsky is Professor of Biological Sciences at Stanford University and Professor of Neurology and Neurological Sciences at Stanford University School of Medicine. A Fellow of the American Association for the Advancement of Science, he has received the John D. and Catherine T. MacArthur Foundation Fellowship, the A.B. Bennett Award from the Society of Biological Psychiatry, the C. Richter Award from the International Society of Psychoneuroendocrinology, and the Young Investigator Award from the Society for Neuroscience. He is
the author of the books Stress, the Aging Brain, and the Mechanisms of Neuron Death and Why Zebras Don't Get Ulcers: An Updated Guide to Stress, Stress-Related Disease, and Coping, as well as more than 250 scientific papers and book chapters. Dr. Sapolsky received his doctoral degree in neuroendocrinology from Rockefeller University in New York City. Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 10
9:00 a.m.-10:30 a.m.
Rooms 338/339, Level 3, Convention Center
APA'S SOLOMEN CARTER FULLER
AWARD LECTURE
Ezra E.H. Griffith, M.D.

Authentie Representation, Belonging, and the Narrative of Self-Identification
Chp.: Patrice A. Harris, M.D.
Co-Chp.: Michelle O. Clark, M.D.

The minority professional's task of self-identification occurs in the context of pragmatic influences, including the social insistence that minority professionals must be aware that they represent a minority community and that such representation must be authentic. Ezra E. H. Griffith, M.D., uses narrative discourse to explore the process of minority individuals' self-identification and the context of enmeshed colonialism, racism, and religion that impacts that process. Dr. Griffith is Professor and Deputy Chairman for Clinical Affairs in the Department of Psychiatry at Yale University School of Medicine and Professor of African-American Studies at Yale University. His most recent book, Race and Excellence: My Dialogue with Chester Pierce, was published in 1998. He was named Editor of the Journal of the American Academy of Psychiatry and the Law in 1999. Dr. Griffith has served as President of the American Board of Forensic Psychiatry, the Council on Psychiatry and Law, the Council on International Affairs, and the Ethics Committee. Dr. Griffith has served as President of the American Board of Forensic Psychiatry, Black Psychiatrists of America, the American Academy of Psychiatry and the Law, and the American Orthopsychiatric Association. He received his medical degree at the University of Strasbourg in Strasbourg, France, and completed his residency in psychiatry at Albert Einstein College of Medicine in the Bronx, New York.

MASTER EDUCATOR CLINICAL CONSULTATIONS 7-8
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

7 Eric R. Marcus, M.D., on Adult Patients with Comorbid Mood and Personality Disorders
Room 340, Level 3, Convention Center

8 Donald C. Fidler, M.D., on the Journey: Exploring Learning with Our Students (AAP Council on Education Master Teacher)
Room 341, Level 3, Convention Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 10-11

MEDIA SESSION 10 9:00 a.m.-11:00 p.m.
Napoleon Ballroom, Third Floor, Hilton

HATE, RACISM, AND YOUTH
Chp.: Jonathan M. Metzl, M.D.

15 Invisible Revolution
(55 minutes)

Distributor: Filmakers Library
Attn: Linda Gottesman
124 East 40th Street
New York, NY 10016

This disturbing documentary profiles a chilling subculture among American youth. For over a decade, the clash between racist and antiracist youth has been virtually invisible, but now, younger members are taking control of the white supremacy movement. Rising against them are a group of antiracist skinheads, punk rockers, and mainstream kids who call themselves the Antiracist Action (ARA). These groups are often indistinguishable as they battle each other. This hard-hitting film, with its strong language and extreme expressions of racism, will awaken audiences to a frightening adolescent phenomenon.

MEDIA SESSION 11 9:00 a.m.-11:00 a.m.
Versailles Ballroom, Third Floor, Hilton

POISONING THE BRAIN, ALTERING THE MIND
Chp.: Cheryl A. Kennedy, M.D.

16 Methamphetamine: From the Streets of San Diego
(27 minutes)

Distributor: University of California Extension Center
for Media and Independent Learning
2000 Center Street, 4th Floor
Berkeley, CA 94704

Lurking behind San Diego's sunny image of swaying palm trees and beautiful beaches is a drug subculture that is so pervasive that it affects the lives of most Americans. This subculture knows no social boundaries. School-age children, affluent women, and the working class have all been seduced by the intoxicating effects of methamphetamine, only to lose control of their lives.
This chilling investigative documentary explores the reasons why San Diego became the center of methamphetamine production and distribution in America. The film traces the history of the drug, examines its effects on the user, and demonstrates how it has been a factor in some of the nation’s most bizarre and violent crimes and contributed to the flooding of courts, jails, and hospital emergency rooms with meth-related cases.

17 Drinking Apart: Families Under the Influence
(71 minutes)

Distributor: Films for Humanities & Science
P.O. Box 2053
Princeton, NJ 08543

Millions of Americans wrestle with a drug or alcohol problem during their lives, usually without the aid of counseling, but at Ackerman Institute for the Family, teams of counselors help many to regain their freedom. This program tracks the progress of a husband and wife, a mother and teenage daughter, and a young couple over a three-year period as they fight their way to recovery. Candidly filmed at Ackerman, at Addicts Rehabilitation Center in New York City, and even in the subjects’ homes, the documentary provides valuable insights into both the devastating effects of drug and alcohol dependence on different types of relationships and the methods being used to assist in breaking addictions.

Discussant: Kenneth P. Rosenberg, M.D.

RESEARCH ADVANCES IN MEDICINE
9:00 a.m.-11:00 a.m.
Rooms 265/266, Level 2, Convention Center

BRAIN SCIENCE: FROM IMAGING TO IMPLANTS
Chp.: Michelle L. Kramer, M.D.
Co-Chp.: Kathleen G. Lapp, M.D.

Participants: Carol A. Tamminga, M.D., on New Direction in Invivo Brain Imaging
Larry A. Carver, M.D., on Schizophrenia and the Thalamus: A New Paradigm
Christine E. Marx, M.D., on Neurosteroids in Psychiatry
Bryan Payne, M.D., on The Expanding Role of CNS Electrical Stimulation

REVIEW OF PSYCHIATRY: SECTION 2
9:00 a.m.-12 noon
Rooms 343-345, Level 3, Convention Center

PTSD IN CHILDREN AND ADOLESCENTS
Chp.: Spencer Eth, M.D.

6 Evaluation and Assessment of PTSD in Children and Adolescents
Wilfred G. van Gorp, Ph.D.

7 Forensic Aspects of PTSD in Children and Adolescents
James E. Rosenberg, M.D.

8 PTSD in Children and Adolescents in the Juvenile Justice System
William Arroyo, M.D.

9 Biological Treatment of PTSD in Children and Adolescents
Soraya Seedat, M.D.

10 The Relationship Between Childhood Traumatic Experiences and PTSD in Adults
Rachel Yehuda, Ph.D.

TELECOMMUNICATIONS SESSION 1
9:00 a.m.-12 noon
Rooms 260/261, Level 2, Convention Center

DIGITAL PROSPECTS: TELEPSYCHIATRY AND MULTIMEDIA APPLICATIONS
Chp.: Norman E. Alessi, M.D.

9:15 a.m.
1 Evaluation of a Web-Based Intervention for Depression in Pregnant Women
Sheila Marcus, M.D., Heather A. Flynn, Ph.D., Kristen L. Barry, Ph.D.

10:00 a.m.
2 Use of a CD-ROM Multimedia Interactive System to Teach Interviewing Skills
Alfredo Calcedo-Barba, M.D., Juan J. Lopez-Ibor, Jr., M.D., Maria I. Lopez-Ibor, M.D.

11:00 a.m.
3 Prison Telepsychiatry: Realities and Prospects
Zebulon C. Taintor, M.D., Susan Ducate, M.D., Robert D. Miller, M.D., William M. Tucker, M.D., Alexander Bardey, M.D.

WORKSHOPS

COMPONENTS 17-27

COMPONENT WORKSHOP 17 9:00 a.m.-10:30 a.m.
Room 264, Level 2, Convention Center

DEFINING BOUNDARIES IN MEDICAL EDUCATION: ETHICS APPLIED BY ROLE PLAYING
APA Rhode Island Psychiatric Society’s Committee on Women
Co-Chps.: Alison M. Heru, M.D., Christine E. Rayner, M.D.

Participants: Patricia R. Recupero, M.D., Marilyn Price, M.D.

COMPONENT WORKSHOP 18 9:00 a.m.-10:30 a.m.
Rooms 267-268, Level 2, Convention Center

PREDICTION OF DANGEROUSNESS IN PATIENTS
APA Task Force on Psychiatric Aspects of Violence
Co-Chps.: Paul J. Fink, M.D., Bradley R. Johnson, M.D.
Participants: Renee L. Binder, M.D., Judith Becker, Ph.D.
<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 19</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 270, Level 2, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>THE INDIVIDUAL VERSUS THE STATE: PATIENTS' PRIVACY AND ABUSES OF PSYCHIATRY</td>
<td></td>
<td>APA Committee on Misuse and Abuse of Psychiatry and Psychiatrists</td>
</tr>
<tr>
<td>Chp.: Renato D. Alarcon, M.D.</td>
<td>Participants: Abraham L. Halpern, M.D., John H. Halpern, M.D., Jose E. De La Gandara, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 20</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 271, Level 2, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEGAL, ETHICAL, AND PRACTICE IMPLICATIONS OF DOT-COM PSYCHIATRY</td>
<td></td>
<td>APA Council on Psychiatry and Law and APA Committee on Information Technology</td>
</tr>
<tr>
<td>Chp.: Jeffrey L. Metzner, M.D.</td>
<td>Participants: Ronnie S. Stangler, M.D., Nicholas Terry, J.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 21</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 273, Level 2, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>THE COLOR OF DEATH: SUICIDE AND ITS MYTHS IN SPECIAL POPULATIONS</td>
<td></td>
<td>APA/Center for Mental Health Services Minority Fellows and APA/ AstraZeneca Minority Fellows</td>
</tr>
<tr>
<td>Co-Chps.: N. Kalaya Okereke, M.D., F. Ada Ifesinachukwu, M.D.</td>
<td>Participants: Serena Y. Volpp, M.D., Veronica L. Williams, M.D., Angelica J. Long-Harrell, M.D., Andres J. Pumariega, M.D., Debbie R. Carter, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 22</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Rooms 346/347, Level 3, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>THE COST OF PTSD: A CRISIS WE CAN PREVENT</td>
<td></td>
<td>APA Consortium on Treatment Issues</td>
</tr>
<tr>
<td>Co-Chps.: Robert F. Dobyns, M.D., Sandra L. Bloom, M.D.</td>
<td>Participants: Richard J. Kessler, D.O., Lawrence C. Sack, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 23</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Rooms 348/349, Level 3, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEAR, FANTASY, AND THE REALITY OF PSYCHIATRIC PRACTICE IN THE NEW MILLENNIUM FOR IMGs</td>
<td></td>
<td>APA Committee of International Medical Graduates</td>
</tr>
<tr>
<td>Chp.: Gopalakrishna K. Upadhya, M.D.</td>
<td>Participants: Chowallur D. Chacko, M.D., Fructuoso R. Irigoyen-Rascon, M.D., Moitri N. Datta, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 24</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Rooms 350/351, Level 3, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>STALKING: THE PSYCHIATRIC TRAINEE AT RISK</td>
<td></td>
<td>APA Committee of Residents and Fellows</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 25</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Grand Salon Section 4, Street Level, Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOVEL CAREER DEVELOPMENTS IN ADDICTION PSYCHIATRY</td>
<td></td>
<td>APA Council on Addiction Psychiatry</td>
</tr>
<tr>
<td>Co-Chps.: Lydia O. Fazio, M.D., Marianne T. Guschwan, M.D.</td>
<td>Participants: Shelly F. Greenfield, M.D., Sheldon I. Miller, M.D., Jonathan I. Ritvo, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 26</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Grand Salon Sections 7 &amp; 10, Street Level, Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART I</td>
<td></td>
<td>APA Committee of Early Career Psychiatrists</td>
</tr>
<tr>
<td>Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.</td>
<td>Participants: Jacqueline Melonas, J.D., Martin G. Tracy, J.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 27</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Prince of Wales Suite, Second Floor, Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDIES ON INTEGRATION OF MENTAL HEALTH AND PRIMARY CARE IN THE VETERANS ADMINISTRATION</td>
<td></td>
<td>APA Consortium on Organized Service Systems</td>
</tr>
<tr>
<td>Co-Chps.: Laurent S. Lehmann, M.D., Frederick G. Guggenheim, M.D.</td>
<td>Participants: Benjamin G. Druss, M.D., Bradford L. Felker, M.D., Lisa B. Dixon, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 32</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 269, Level 2, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOES THE MIND MEET THE BRAIN IN RESIDENCY? AND WHAT ABOUT THE BODY?</td>
<td></td>
<td>APA Committee on Pediatric Psychiatry</td>
</tr>
<tr>
<td>Chp.: Avram H. Mack, M.D.</td>
<td>Participants: Stuart C. Yudofsky, M.D., William E. Greenberg, M.D., James J. Strain, M.D., Tana A. Grady-Weliky, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 33</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Rooms 333/334, Level 3, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>REINVENTING DEINSTITUTIONALIZATION IN THE 21ST CENTURY</td>
<td></td>
<td>APA Committee on Deinstitutionalization</td>
</tr>
<tr>
<td>Chp.: Richard H. McCarthy, M.D.</td>
<td>Participants: Rami Kaminsky, M.D., Steven M. Silverstein, Ph.D., Andrew Bloch, M.S.W.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 34</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Rooms 335/336, Level 3, Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEUROPSYCHOTHERAPY</td>
<td></td>
<td>APA Committee on Neuropsychology</td>
</tr>
<tr>
<td>Co-Chps.: David M. Roane, M.D., Elizabeth S. Ochoa, Ph.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ISSUE WORKSHOP 35 9:00 a.m.-10:30 a.m.
Room 342, Level 3, Convention Center
WOMEN'S LEADERSHIP AND CAREER DEVELOPMENT
Chp.: Linda F. Pessar, M.D.
Participants: Carol A. Bernstein, M.D., Carol C. Nadelson, M.D., Carolyn B. Robinowitz, M.D.

ISSUE WORKSHOP 36 9:00 a.m.-10:30 a.m.
Room 352, Level 3, Convention Center
COGNITIVE THERAPY FOR PERSONALITY DISORDERS
Chp.: Judith S. Beck, Ph.D.

ISSUE WORKSHOP 37 9:00 a.m.-10:30 a.m.
Room 357, Level 3, Convention Center
BALANCING POWER IN THE PSYCHIATRIST-PATIENT ALLIANCE FOR THERAPEUTIC SUCCESS
Co-Chps.: Steve S. Abdool, M.A., Diane K. Whitney, M.D.
Participant: Wilson M. Lit, M.D.

ISSUE WORKSHOP 38 9:00 a.m.-10:30 a.m.
Grand Salon Sections 3 & 6, Street Level, Hilton
ETHNICITY AND PSYCHOPHARMACOLOGY: RECENT RESEARCH ADVANCES
Co-Chps.: Pedro Ruiz, M.D., Keh-Ming Lin, M.D.
Participants: William B. Lawson, M.D., Edmond H.T. Pi, M.D., Ricardo P. Mendoza, M.D.

ISSUE WORKSHOP 39 9:00 a.m.-10:30 a.m.
Grand Salon Sections 9 & 12, Street Level, Hilton
CHILDREN OF PSYCHIATRISTS
Co-Chps.: Leah J. Dickstein, M.D., Michelle Riba, M.D.
Participants: David Benedek, M.D., Luisa Isbell, Daniel Weintraub, M.D., Katherine H. Johnson

ISSUE WORKSHOP 40 9:00 a.m.-10:30 a.m.
Grand Salon Sections 13 & 16, Street Level, Hilton
WOMEN AND SUICIDE: HORMONES AND GENES
Co-Chps.: Jose de Leon, M.D., Kay R. Jamison, Ph.D.
Participant: Enrique Baca-Garcia, M.D.

ISSUE WORKSHOP 41 9:00 a.m.-10:30 a.m.
Grand Salon Sections 15 & 18, Street Level, Hilton
GRAPHOTECHNOLOGY: HOW TO SAVE TIME AND REVEAL CLUES IN HANDWRITING ANALYSIS
Co-Chps.: Sheila M. Kurtz, M.S., Barnard L. Collier, B.A.

ISSUE WORKSHOP 42 9:00 a.m.-10:30 a.m.
Grand Salon Sections 19 & 22, Street Level, Hilton
THE USE OF THE MOCK TRIAL IN PSYCHIATRIC STAFF EDUCATION
Chp.: Stewart Levine, M.D.
Participants: Harold I. Schwartz, M.D., Henry Pinsker, M.D., Raphael A. Morris, M.D., Jose A. Genua, M.D.

ISSUE WORKSHOP 43 9:00 a.m.-10:30 a.m.
Grand Salon Sections 21 & 24, Street Level, Hilton
ECSTASY AND THE RAVE SCENE: A CANADIAN PERSPECTIVE
Co-Chps.: Clare Roscoe, M.D., Antonia Seli, M.D.

ISSUE WORKSHOP 44 9:00 a.m.-10:30 a.m.
Melrose Room, Third Floor, Hilton
INTEGRATED TREATMENT PROGRAMS FOR PREGNANT, MOTHERING WOMEN AND THEIR CHILDREN
Co-Chps.: Linda L.M. Worley, M.D., Barbara A. Schindler, M.D.

ISSUE WORKSHOP 45 9:00 a.m.-10:30 a.m.
Rosedown Room, Third Floor, Hilton
DYNAMIC THERAPY WITH SELF-DESTRUCTIVE BPD
Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 46 9:00 a.m.-10:30 a.m.
Magnolia Room, Third Floor, Hilton
HEALING OF SPIRIT AND BODY THROUGH DANCE AFTER TRAUMA
Chp.: Russell J. Gardner, Jr., M.D.
Participants: Doug Rosenberg, M.F.A., Chiao-Ping Li, M.A.

ISSUE WORKSHOP 47 9:00 a.m.-10:30 a.m.
Jasperwood Room, Third Floor, Hilton
CLINICAL PATHS ACROSS CULTURAL AND RACIAL BARRIERS: HOW TO DO IT
Co-Chps.: Carl C. Bell, M.D., Nada L. Stotland, M.D.
Participant: Francis G. Lu, M.D.

ISSUE WORKSHOP 48 9:00 a.m.-10:30 a.m.
Oak Alley Room, Third Floor, Hilton
BEYOND THE LECTURE HALL: INTEGRATING EDUCATIONAL CONCEPTS
Chp.: Janet E. Osterman, M.D.
For Latin America and other regions with a large number of poor and marginalized people, mental health concerns include not only providing treatment for mental disorders but also ensuring that basic needs for adequate nutrition and clean living conditions are met so that human beings can develop to their potential. Increased immigration from Latin America to the United States and the growth of the U.S. Hispanic population have helped to make such international concerns into domestic issues. F. Moises Gaviria, M.D., discusses how U.S. institutions, including professional associations such as the APA, can foster increased regional leadership and cooperation to address these issues. Dr. Gaviria is Professor and Director of the Neuropsychiatric Division in the Department of Psychiatry at the University of Illinois at Chicago College of Medicine. The current Secretary of the International Neuropsychiatric Association and Past President of the American Society of Hispanic Psychiatrists, Dr. Gaviria has been active in mental health advocacy in the U.S. and Latin America. A native of Lima, Peru, Dr. Gaviria graduated from Universidad Nacional Mayor de San Marcos in Lima, completed his psychiatry residency at the University of Connecticut in Hartford, and completed a fellowship in social psychiatry at the University of Illinois.

**THIS SESSION WILL BE AUDIOTAPED.**
MASTER EDUCATOR CLINICAL CONSULTATIONS 9-11

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

9 Stuart C. Yudofsky, M.D., on Treatment of Patients with Psychiatric Symptoms Complicated with Neurologic Illness  
Room 337, Level 3, Convention Center

10 Francine Cournos, M.D., on Psychotherapy and Therapist Self-Disclosure  
Room 340, Level 3, Convention Center

11 Steven A. Cole, M.D., on Optimizing Your Relationship with Primary Care Physicians: Ways to Maximize Your Referral Network and Satisfaction  
Room 341, Level 3, Convention Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 12-13

MEDIA SESSION 12  
11:00 a.m.-2:00 p.m.

Napoleon Ballroom, Third Floor, Hilton

LIFE IN "THE GOLDEN YEARS"

Chp.: Ian E. Alger, M.D.

18 The Personals: Improvisations on Romance in the Golden Years  
(35 minutes)

Distributor: Fanlight Productions  
4196 Washington Street, Suite 2  
Boston, MA 02131

This outstanding video offers an extraordinary look at the emotional lives of elderly Americans. On stage, a drama group of seniors perform their roles with energy and laughter. Off stage, their lives are often lived alone and in silence. The Personals follows a group of senior citizens as they rehearse and present an original play at a community theater on Manhattan's Lower East Side. Drawn from the comedy and drama of their own lives, the play is structured around their quest for dates through the personal ads.

19 Bringing the Circle Together  
(56 minutes)

Distributor: Aquarius Healthcare Videos  
5 Powderhouse Lane, P.O. Box 1159  
Sherborn, MA 01770

There was a time when old people were known to have the greatest wisdom and were thus revered as teachers for the next generation. Bringing the Circle Together suggests that the time has come to return to this tradition. Coming from all walks of life and professions, four elderly men share their wisdom with us. They express their views on old age and its challenges, death, money, work, and the qualities they have come to find most essential in life.

20 A One and a Two  
(27 minutes)

Distributor: Filmakers Library  
Attn: Linda Gottesman  
124 East 40th Street  
New York, NY 10016

This film is a portrait of Angelo, a widower after 37 years of marriage, as he begins to build a new life. During the process of "starting over," he discovers afternoon ballroom dancing; a new passion that is becoming a senior phenomenon. Set against his adventures on the dance floor in search of female companionship, are his down-to-earth descriptions of the adjustments he has had to make. He had depended on his wife for so much in life, preparing his meals, balancing his checkbook, selecting his clothes, etc., and now he must deal with issues of loneliness, retirement, finances, courtship, and fathering all by himself. This is an encouraging film about the potential of people to grow and enjoy life in their later years.

21 As Time Goes By  
(23 minutes)

Distributor: Fanlight Productions  
4196 Washington Street, Suite 2  
Boston, MA 02131

The simple act of touching another human being, of expressing and receiving affection, companionship and love, is something that we all crave. Yet many of us share a common misconception that our needs for intimacy and romance fade as we grow older. How many of us are comfortable thinking of our parents or grandparents as sexual beings? This new video reminds us that sexuality remains a part of our lives until the very end. The seniors profiled in this documentary openly share their experiences with love, romance, and growing old. This film actively challenges our cultural assumptions that along with age come a disinterest in sex and an inability to share intimacy. As Time Goes By shows us a community of vital, social people who want what most of us want, love and affection.

MEDIA SESSION 13  
11:00 a.m.-12:30 p.m.

Versailles Ballroom, Third Floor, Hilton

THE CHALLENGES OF CULTURAL DIVERSITY

Chp.: Sandra C. Walker, M.D.

22 The Mirror Lied  
(27 minutes)

(Continued on next page)
How does a young African-American woman deal with the ideals of feminine beauty imposed by white society? This film shows the struggle of the filmmaker's 15-year-old sister, Jantre, to accept her appearance. Though she spends an hour each day trying to tame her unruly hair, she never feels attractive. She envies the white girls with "hair that blows in the wind." When she asks for a wig for her birthday, her mother accuses her of not accepting her blackness. Jantre's mother grew up in the segregated South and says it took many years to accept herself. One daughter questions whether her mother has really reached self-acceptance, since she herself wears "woven hair." In a bold move to challenge her classmates' standards, Jantre goes to school with her hair in its natural fullness. She finds it a liberating experience.

23 Struggle for Identity
(21 minutes)

Because of all the upheavals worldwide and the social problems in our country, many idealistic people are tempted to rescue children through foster care and adoption. However, people who provide care for children of a different race may not be prepared for the kinds of problems that can arise. This powerful new video brings into focus the issue of race, culture, and identity in adoptive or foster families.

MEDICAL UPDATE 2
11:00 a.m.-12:30 p.m.
Grand Salon Sections 3 & 6, Street Level, Hilton

BREAST CANCER PREVENTION: AN EXAMPLE OF TRANSLATIONAL RESEARCH
Chp.: Cheryl F. McCartney, M.D.
Presenter: Roy S. Weiner, M.D.
THIS SESSION WILL BE AUDIOTAPE

RESEARCH CONSULTATION WITH
11:00 a.m.-12:30 p.m.
This session is limited to 25 participants on a first-come, first-served basis.
1 Paula J. Clayton, M.D., on Mood Disorders
Cambridge Suite, Second Floor, Hilton

SCIENTIFIC AND CLINICAL REPORT
SESSIONS 13-22
SCIENTIFIC AND CLINICAL REPORT SESSION 13
11:00 a.m.-12:30 p.m.
Room 264, Level 2, Convention Center

ISSUES IN CROSS-CULTURAL PSYCHIATRY
Chp.: Giovanni Caracci, M.D.
Co-Chp.: Megan T. Marumoto, M.D.

11:00 a.m.
38 Body Dissatisfaction and BMI Across Ethnic Groups
Alayne Yates, M.D., Jeanne Edman, Ph.D., Mara Aruguete, Ph.D.

11:30 a.m.
39 Creativity as a Resource for Moving from Trauma Toward Connection
Carol L. Kessler, M.D.

12 noon
40 Hypersexuality in Hasidic-Jewish Inpatients
Nancy J. Needell, M.D., John C. Markowitz, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 14
11:00 a.m.-12:30 p.m.
Room 270, Level 2, Convention Center

CHILD AND ADOLESCENT DIAGNOSTIC ISSUES
Chp.: Jacqueline C. McGregor, M.D.
Co-Chp.: Teresa Frausto, M.D.

11:00 a.m.
41 Diagnostic Efficiency of BPD Criteria in Hospitalized Adolescents
Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D., William S. Edell, Ph.D., Thomas H. McGlashan, M.D.

11:30 a.m.
42 Overlap Between Child Depressive Inventory and Projectives in Uncovering a Child's Depression
Sidney Fein, M.D., Delrita Abercrombie, Ph.D., Shanev Jeanninton, B.S.

12 noon
43 Comorbidity in Conduct Disorder: Gender and Age Differences
Atilla Turgay, M.D., Ozlem Erman, M.D., Bedriye Onch, Rubaba Ansari, M.A., Verka Urdarevic, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 15
11:00 a.m.-12:30 p.m.
Room 271, Level 2, Convention Center

TREATMENT ISSUES WITH SSRIS
Chp.: Vinod Kumar, M.D.
Co-Chp.: Joel J. Wallack, M.D.

11:00 a.m.
44 Sildenafil Citrate in SSRI Antidepressant Treatment Emergent Sexual Dysfunction
H. George Nurnberg, M.D., Alan J. Gelenberg, M.D., Maurizio Fava, M.D., Paula L. Hensley, M.D., John Lauriello, M.D., Wilma M. Harrison, M.D., Richard L. Siegel, M.D.

11:30 a.m.
45 Do the SSRIs Make You "Better than Well"?
David J. Hellerstein, M.D.
SCIENTIFIC AND CLINICAL REPORT SESSION 18
11:00 a.m.-12:30 p.m.
Rooms 346/347, Level 3, Convention Center
TREATMENT OF SCHIZOPHRENIA
Chp.: Henry A. Nasrallah, M.D.
Co-Chp.: Joel L. Steinberg, M.D.
11:00 a.m.
53 Placebo-Controlled Trial of Omega-3 Fatty Acid in Schizophrenia
Wayne S. Fenton, M.D., Faith Dickerson, Ph.D., John J. Boronow, M.D., Joseph R. Hibbeln, M.D., Michael B. Knable, D.O.
11:30 a.m.
54 Atypical Antipsychotics and Hostility in Schizophrenia: A Double-Blind Study
Leslie L. Citrome, M.D., Jan Volavka, M.D., Pal Czobor, Ph.D., Brian B. Sheitman, M.D., Jean-Pierre Lindenmayer, M.D., Joseph P. McEvoy, M.D., Jeffrey A. Lieberman, M.D.
12 noon
55 Factors Associated with Medication Adherence in Persons with Schizophrenia
Ann L. Hackman, M.D., Lisa B. Dixon, M.D., Letitia T. Postrado, Ph.D., Janine C. Delahanty, MA., Julie A. Kreyenbuhl, Ph.D., Alicia Lucksted, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 19
11:00 a.m.-12:30 p.m.
Room 357, Level 3, Convention Center
BIOLOGICAL ISSUES IN PSYCHIATRY
Chp.: James Knowles, M.D.
Co-Chp.: Uriel Halbreich, M.D.
11:00 a.m.
56 Schizophrenia and Bipolar Disorder: Specific and Common Susceptibility Loci
Michel Maziaide, M.D., Marc-Andre Roy, M.D., Luc Bissonnette, Ph.D., Jean-Pierre Fournier, M.D., Denis Cliche, M.D., Noel Montgrain, M.D., Chantal Morette
11:30 a.m.
57 Comorbid Panic Disorder as a Marker of Genetic Heterogeneity in Bipolar Disorder
Alessandro Rotondo, M.D., Liliana Dell’osso, M.D., Siham Bouanani, M.D., Chiara Gonnelli, M.D., David Goldman, M.D., Lorella Pardini, M.D., Chiara Mazzanti, Ph.D., Giovanni B. Cassano, M.D.
12 noon
58 Antibodies to Prothrombin and Thrombin in First Psychotic Episode of Schizophrenia
Pinkas Sirotov, M.D., Irena Bogdanov, M.D., Amos D. Korczyn, Joel Chapman, M.D.
THIS SESSION WILL BE AUDIOTAPED.
TUESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 20
11:00 a.m.-12:30 p.m.
Grand Salon Sections 15 & 18, Street Level, Hilton

BIPOLAR DISORDERS
Chp.: Robert C. Marks, M.D.
Co-Chp.: Maria L. Tiamson, M.D.

11:00 a.m.
59 Perceptions and Impact of Bipolar Disorder: How Far Have We Really Come?
Lydia J. Lewis

11:30 a.m.
60 Unipolar Compared with Bipolar Depression: Similar Depressive Subtypes

12 noon
61 Cognitive Function in Euthymic Bipolar Patients, Schizophrenics, and Controls
Alessandro Rossi, M.D., Luca Arduini, M.D., Paolo Stratta, M.D., Enrico Daneluzzo, M.D., Osvaldo Rinaldi, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 21
11:00 a.m.-12:30 p.m.
Rosedown Room, Third Floor, Hilton

PSYCHIATRIC EDUCATION
Chp.: James H. Scully, Jr., M.D.
Co-Chp.: Kathy M. Vincent, M.D.

11:00 a.m.
62 Using the "Moral Accounting" Metaphor to Teach Psychodynamic Formulations
Rodney J.S. Deaton, M.D.

11:30 a.m.
63 A Comparison of Evaluations of Male and Female Psychiatry Supervisors
Janet M. de Groot, M.D., Aileen S. Brunet, M.D., Allan S. Kaplan, M.D.

12 noon
64 Training in Depression and Suicide: A National Survey of Primary Care
Donna M. Sudak, M.D., Howard S. Sudak, M.D., Alec Roy, M.D., Alan Lipschitz, M.D., Herbert Hendin, M.D., John T. Malsberger, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 22
11:00 a.m.-12:30 p.m.
Magnolia Room, Third Floor, Hilton

DANGEROUS OFFENDERS

WORKSHOPS

COMPONENTS 28-32

COMPONENT WORKSHOP 28 11:00 a.m.-12:30 p.m.
Room 273, Level 2, Convention Center
PUTTING YOUR BEST FOOT FORWARD: THE ART OF SELF-PRESENTATION
APA Committee on Women
Chp.: Smita H. Patel, M.D.
Participants: Donna E. Stewart, M.D., Leslie H. Gise, M.D., Marian I. Butterfield, M.D., Sara K. Gardiner, M.D.

COMPONENT WORKSHOP 29 11:00 a.m.-12:30 p.m.
Room 342, Level 3, Convention Center
CAREER DEVELOPMENT IN ACADEMIC PSYCHIATRY FOR ASIAN PSYCHIATRISTS
APA Committee of Asian-American Psychiatrists
Co-Chps.: Nang Du, M.D., Jacquelyn B. Chang, M.D.
Participants: Ming T. Tsuang, M.D., Francis G. Lu, M.D., Nalini V. Juthani, M.D., Edmond H.T. Pi, M.D.

COMPONENT WORKSHOP 30 11:00 a.m.-12:30 p.m.
Rooms 350/351, Level 3, Convention Center
GENETICS, ETHNICITY, AND ALZHEIMER'S DISEASE
APA Council on Aging and APA Committee on Ethnic Minority Elderly
Chp.: Josepha A. Cheong, M.D.
Participants: Jacobo E. Mintzer, M.D., Helen H. Kyomen, M.D., Kenneth M. Sakuye, M.D., Warachal E. Faison, M.D., Frank W. Brown, M.D.
**TUESDAY**

<table>
<thead>
<tr>
<th>Component Workshop 31</th>
<th>11:00 a.m.-12:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grand Salon Sections 7 &amp; 10, Street Level, Hilton</td>
<td></td>
</tr>
</tbody>
</table>
| **How to Launch a Successful Private Practice: Part II**  
*APA Committee of Early Career Psychiatrists* |
| Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.  
Participants: Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D. |

<table>
<thead>
<tr>
<th>Component Workshop 32</th>
<th>11:00 a.m.-12:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belle Chase Room, Third Floor, Hilton</td>
<td></td>
</tr>
</tbody>
</table>
| **Legal Issues in Psychiatric Private Practice**  
*APA Committee on Private Practice* |
| Chp.: Thomas K. Ciesla, M.D.  
Participant: Daniel H. Willick, J.D. |

<table>
<thead>
<tr>
<th>Issue Workshop 51</th>
<th>11:00 a.m.-12:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rooms 267-268, Level 2, Convention Center</td>
<td></td>
</tr>
<tr>
<td><strong>How the Theory of Evolution is Fundamental to Our Biopsychosocial Model</strong></td>
<td></td>
</tr>
<tr>
<td>Chp.: John R. Evaldson, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 52</th>
<th>11:00 a.m.-12:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 269, Level 2, Convention Center</td>
<td></td>
</tr>
<tr>
<td><strong>Cognitive-Behavioral Treatment: Prolonged Exposure for Treatment of Trauma Victims</strong></td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Abbas Azadian, M.D., Ari E. Zaretsky, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 53</th>
<th>11:00 a.m.-12:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rooms 333/334, Level 3, Convention Center</td>
<td></td>
</tr>
<tr>
<td><strong>The Consumer Perspective in Psychiatric Education</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Co-Chps.: Fernando Rodriguez-Villa, M.D., Anne Whitman, Ph.D.  
Participants: Kenneth S. Duckworth, M.D., Moe Armstrong, M.B.A. |

<table>
<thead>
<tr>
<th>Issue Workshop 54</th>
<th>11:00 a.m.-12:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grand Salon Section 4, Street Level, Hilton</td>
<td></td>
</tr>
<tr>
<td><strong>Folktales and Movies: Using the Media to Learn About Culture</strong></td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Sandra Sexson, M.D., Arden D. Dingle, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 55</th>
<th>11:00 a.m.-12:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grand Salon Sections 19 &amp; 22, Street Level, Hilton</td>
<td></td>
</tr>
<tr>
<td><strong>Poems on Psychiatry</strong></td>
<td></td>
</tr>
<tr>
<td>Chp.: Charles R. Joy, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 56</th>
<th>11:00 a.m.-12:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prince of Wales Suite, Second Floor, Hilton</td>
<td></td>
</tr>
<tr>
<td><strong>Community Psychiatry: How to Avoid Being a Psychotech Slave Chained to the Pill Box</strong></td>
<td></td>
</tr>
<tr>
<td>Chp.: Charles W. Huffine, Jr., M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 57</th>
<th>11:00 a.m.-12:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marlborough Suite A/B, Second Floor, Hilton</td>
<td></td>
</tr>
<tr>
<td><strong>Early Career Psychiatrist: Role of Mentorship</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Co-Chps.: Gabriela Cosa-Lochati, M.D., Edward F. Foulks, M.D.  
Participants: Linda B. Andrews, M.D., Vinay Kapoor, M.D.,  
Anu A. Matorin, M.D. |

<table>
<thead>
<tr>
<th>Issue Workshop 58</th>
<th>11:00 a.m.-12:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melrose Room, Third Floor, Hilton</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical and Forensic Aspects of Sexual Harassment in Schools</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Chp.: Malkah T. Notman, M.D.  
Participants: Elissa P. Benedek, M.D., Linda M. Jorgenson, J.D.,  
Carl P. Malmquist, M.D. |

<table>
<thead>
<tr>
<th>Issue Workshop 59</th>
<th>11:00 a.m.-12:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elmwood Room, Third Floor, Hilton</td>
<td></td>
</tr>
<tr>
<td><strong>Students Discussing Why They Have Chosen a Psychiatric Career in 2000</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.  
Participants: Asher B. Simon, Joyce Adams |

<table>
<thead>
<tr>
<th>12 noon Sessions</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Forum 4</th>
<th>12 noon-1:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 263, Level 2, Convention Center</td>
<td></td>
</tr>
<tr>
<td><strong>Substance Abuse in the Severely Mentally Ill</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Chp.: Rodrigo A. Munoz, M.D.  
Participants: Pedro Ruiz, M.D., Ivan D. Montoya, M.D.,  
Ismael Roldan, Maria Clara de Cleves, Marian J. Butterfield, M.D.,  
Guido Belsasso, M.D. |

<table>
<thead>
<tr>
<th>Forum 5</th>
<th>12 noon-1:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 352, Level 3, Convention Center</td>
<td></td>
</tr>
</tbody>
</table>
| **Here's Looking at You! Self-Reflection in Psychotherapy**  
*APA Commission on Psychotherapy by Psychiatrists* |
| Chp.: Jerald Kay, M.D.  
Participants: Bernard D. Beitman, M.D., Glen O. Gabbard, M.D.,  
James L. Griffith, M.D., Joan A. Lange, M.D. |
FORUM 6 12 noon-1:30 p.m.
Room 356, Level 3, Convention Center

PRESIDENTIAL FORUM: CONFIDENTIALITY AND MEDICAL RECORD PRIVACY IN THE 21ST CENTURY

Chp.: Daniel B. Borenstein, M.D.
Participants: Professor Latanya Sweeney, Margo P. Goldman, M.D., Richard K. Harding, M.D., Marcia K. Goin, M.D., Paul W. Mosher, M.D.

FORUM 7 12 noon-1:30 p.m.
Grand Salon Sections 9 & 12, Street Level, Hilton

TRAUMA, PTSD, AND PERSONALITY DISORDERS: UNDERSTANDING THE CONNECTIONS

Chp.: Randall D. Marshall, M.D.
Participants: Bessel A. Van Der Kolk, M.D., Kenneth R. Silk, M.D., Marylene Cloture, Ph.D.

FORUM 8 12 noon-1:30 p.m.
Grand Salon Sections 13 & 16, Street Level, Hilton

DIAGNOSTIC AND STATISTICAL MANUAL (DSM) RESEARCH PLANNING PROCESS

Chp.: David J. Kupfer, M.D.
Co-Chp.: Darrel A. Regier, M.D.,
Participants: Anthony P. Lehman, M.D., Michael B. First, M.D., Daniel S. Pine, M.D., Dennis S. Charney, M.D., Bruce J. Rounsaville, M.D., Renato D. Alarcon, M.D.

NEW RESEARCH POSTER SESSION 6
12 noon-2:00 p.m.
Exhibition Center, Second Floor, Hilton

SCHIZOPHRENIA, BRAIN IMAGING, NEUROPSYCHIATRY, SOCIAL AND COMMUNITY PSYCHIATRY, CREATIVITY, AND MANAGED CARE

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

12:30 p.m. Session

MEDIA SESSION 14
12:30 p.m.-2:00 p.m.
Versailles Ballroom, Third Floor, Hilton

A JOURNEY TO SELF
Chp.: Sandra C. Walker, M.D.

24 Fat Chance
(72 minutes)

Distributor: Bullfrog Films
P.O. Box 149
Oley, PA 19547

Fat Chance is the funny and sensitive story of Rick Zakowich who started on a diet to lose half his body weight and found all of himself along the way. Rick's journey is to a new identity, but in the process of discovery, he finds himself moving towards a destination he could not have anticipated. Values, assumptions, and perspectives are turned inside out where fat may be the issue but difference is the ultimate truth.

1:00 p.m. Sessions

COURSES 71-78
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 71 1:00 p.m.-5:00 p.m.
La Galerie 3, Second Floor, Marriott

COGNITIVE THERAPY: THE BASICS

Director: Dean Schuyler, M.D.

COURSE 72 1:00 p.m.-5:00 p.m.
La Galerie 4, Second Floor, Marriott

PSYCHIATRISTS AS TEACHERS OF BOUNDARIES TO PHYSICIANS

Director: Samia Barakat, M.D.
Faculty: Mark S. Edkin, M.D., Mark A. Prober, M.D.

COURSE 73 1:00 p.m.-5:00 p.m.
Bacchus Room, Fourth Floor, Marriott

ACHIEVING EFFECTIVE DUAL DIAGNOSIS TREATMENT

Director: John W. Tsuang, M.D.
Faculty: Andrew P. Ho, M.D.

COURSE 74 1:00 p.m.-5:00 p.m.
Balcony M, Fourth Floor, Marriott

DSM-IV CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY

Director: Russell F. Lim, M.D.
Faculty: Candace M. Fleming, Ph.D., J. Charles Ndlela, M.D., Francis G. Lu, M.D., Roberto Lewis-Fernandez, M.D., Michael W. Smith, M.D.
TUESDAY

COURSE 75 1:00 p.m.-5:00 p.m.
Rhythms Ballroom II, Second Floor, Sheraton
THE ADVANCED PRACTICE OF PSYCHOTHERAPY
Director: T. Byram Karasu, M.D.

COURSE 76 1:00 p.m.-5:00 p.m.
Pontchartrain Ballroom B, Third Floor, Sheraton
THE EVALUATION AND MANAGEMENT OF PAIN
Director: Steven A. King, M.D.

COURSE 77 1:00 p.m.-5:00 p.m.
Edgewood Rooms A/B, Fourth Floor, Sheraton
USE OF THE HUMANITIES IN PSYCHIATRIC EDUCATION
Co-Directors: Paul R. Miller, M.D., Jasmine Mackie-Magyar, M.D.
Faculty: Robert Dasher, M.D.

COURSE 78 1:00 p.m.-5:00 p.m.
Gallier Rooms A/B, Fourth Floor, Sheraton
INDIVIDUAL AND COMMUNITY INTERVENTIONS IN DISASTER
Director: Carol S. North, M.D.
Faculty: Betty Pfefferbaum, M.D., Phebe M. Tucker, M.D.

2:00 p.m. Sessions

LECTURES 13-14

LECTURE 13
2:00 p.m.-3:30 p.m.
Rooms 252-254, Level 2, Convention Center
Donna E. Stewart, M.D.
What Do Women Really Want?
Chp.: Mary Jane Massie, M.D.
Co-Chp.: Yvonne B. Ferguson, M.D.

In the latter years of the 20th century, psychiatrists' perspectives on women as both patients and health care providers developed in the context of increased efforts by women to establish ownership of their bodies, health, minds, and roles in society. Donna E. Stewart, M.D., discusses some of the ways organized psychiatry has dealt with changes in women's roles. Dr. Stewart holds the Lillian Love Chair in Women's Health at the University Health Network hospitals and the University of Toronto, where she is Professor in the Departments of Psychiatry, Obstetrics/Gynecology, Medicine, Anesthesia, Family and Community Medicine, and Surgery in the Faculty of Medicine. She chairs the Section on Women's Mental Health of the World Psychiatric Association and the Committee on Women of the American Psychiatric Association, and is a member of the Women's Health Council of the Ministry of Health of Canada. The author of more than 100 articles in peer-reviewed journals, Dr. Stewart is the editor of a textbook on the psychological aspects of women's health care and a book on menopause. She has served as a consultant to Health Canada and the U.S. Department of Health and Human Services.

Distinguished Psychiatrist Lecture Series

LECTURE 14
2:00 p.m.-3:30 p.m.
Rooms 338/339, Level 3, Convention Center
Mark L. Solms, Ph.D.
An Example of Neuropsychoanalytic Research: The Right Hemisphere Syndrome
Chp.: Randall D. Marshall, M.D.
Co-Chp.: Sheila Judge, M.D.

Dysfunction of the right cerebral hemisphere is associated with a group of striking neuropsychiatric symptoms: denial of illness, unawareness of the left side of space (including one's own body), and other abnormalities of spatial cognition and perception. Prevailing theories of right hemisphere function are based on neurobehavioral analyses of these symptoms. However, psychoanalytic findings concerning neurological patients' subjective experience of these symptoms reveal unexpected complications incompatible with the existing theories. Mark Solms, Ph.D., describes a new theory of right hemisphere functioning that reconciles the neurobehavioral and psychoanalytic data. A neuropsychologist and a psychoanalyst, Dr. Solms is Director of the Arnold Pfeffer Center for Neuro-Psychoanalysis of the New York Psychoanalytic Institute. His research has centered on examining the neurological origins of Freud's psychoanalytic concepts and developing methods to make psychoanalytic theories accessible to neuroscientific findings. His books include The Neuropsychology of Dreams and Clinical Studies in Neuropsychoanalysis. He is the editor and translator of the forthcoming four-volume series, The Complete Neuroscientific Works of Sigmund Freud and the co-editor of Neuro-Psychoanalysis, the interdisciplinary journal for psychoanalysis and neurosciences. Dr. Solms received his doctoral degree in neuropsychology from the University of the Witwatersrand in South Africa and his training in psychoanalysis from the Institute of Psychoanalysis in London.

International Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.
PSYCHIATRY GOES TO THE MOVIES

Chp.: Harvey R. Greenberg, M.D.

25 Mr. Death
(91 minutes)
Distributor: Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

Mr. Death tells the story of Fred A. Leuchter, Jr., an engineer who decided to become the “Florence Nightingale of death row.” His mission was to design and repair gas chambers, electric chairs, and lethal injection systems. But Leuchter became infamous for his work with anti-Holocaust writer Ernst Zundel, who commissioned Leuchter to conduct a forensic investigation into the use of poison gas in World War II Nazi concentration camps. Leuchter’s controversial findings eventually hypothesized that the Holocaust never happened. He fully expected his involvement with Zundel to be the crowning achievement of his career; instead, it ruined him.

26 The Italian Gardens of South Brooklyn
(26 minutes)
Distributor: University of California Extension Center for Media and Independent Learning
2000 Center Street, 4th Floor
Berkeley, CA 94704

The Italian Gardens of South Brooklyn is an infectiously enjoyable and inventive documentary that illustrates how a mixture of “old-world values and new-world horse sense” invigorates the traditional Italian-American community of South Brooklyn. It infuses it with a strong respect for family, friends, and neighborhood.

27 Delta Jews
(57 minutes)
Distributor: Filmakers Library
For V27 & Attn: Linda Gottesman
V28 124 East 40th Street
New York, NY 10016

Through the eyes of those who remain, Delta Jews, traces the history of the community and its relationship to its white Christian and black neighbors. We meet families who as merchants and farmers have taken on many characteristic speech patterns and social attitudes of their neighbors. Yet the families maintained their traditions, even if it took importing rabbis and traveling miles for services or seders. These families developed an active social network to reinforce their identity and keep the younger generation “in the fold.” This is a unique film, not only for Jewish and Southern studies, but also for anthropology and sociology courses dealing with cultural identity and assimilation.

28 A Wok in Progress
(56 minutes)

The third film of Paul Kwan’s odyssey interweaves a love of food with cultural and psychic survival. In A Wok in Progress, Paul triumphs over the demons with his sense of whimsy, lyricism, and of course, his enjoyment of food and family. This film is a joyous romp through memory, a touch of personal philosophy, and a distillation of sensory perceptions surrounding food and its preparation. Identity and a sense of well being are recreated in the kitchen. The film is a celebration of the powers of recovery.

REVIEW OF PSYCHIATRY: SECTION 3
2:00 p.m.-5:30 p.m.
Rooms 343-345, Level 3, Convention Center

INTEGRATED TREATMENT: AN OVERVIEW
Chp.: Jerald Kay, M.D.

11 CANCELLED

12 Integrated Treatment Planning for BPD
John M. Oldham, M.D.

13 Integrated Treatment of Substance Abuse Disorders
Douglas M. Ziedonis, M.D.

14 A Cognitive Therapy Approach to Medication Compliance
Judith S. Beck, Ph.D.

15 The Challenges of Split Treatment
Michelle Riba, M.D.

SYMPOSIA 30-63

SYMPOSIUM 30 2:00 p.m.-5:00 p.m.
Room 262, Level 2, Convention Center

PROFESSIONAL BOUNDARIES AND TRAINING IN PSYCHIATRY: A COMPREHENSIVE VIEW
Chp.: Gregg E. Gorton, M.D.
Co-Chp.: Linda M. Jorgenson, J.D.

A Critical Issues in Education About Boundaries for Physicians and Others
Gregg E. Gorton, M.D., Steven E. Samuel, Ph.D.
B Adapting and Expanding Boundaries: Training in and Outside Psychiatry  
Gail E. Robinson, M.D.

C Boundaries in a Broader Context: A Swiss Psychiatric Perspective  
Werner Tschan, M.D.

D Preventive and Remedial Boundaries Training: Effective Tools and Methods  
Gary R. Schoener, Psy.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 31 2:00 p.m.-5:00 p.m.  
Room 263, Level 2, Convention Center

THE ROLE OF ANTIDEPRESSANTS IN THE TREATMENT OF BIPOLAR DISORDER: PRO AND CON  
Chp.: S. Nassir Ghaemi, M.D.  
Co-Chp.: Frederick K. Goodwin, M.D.

A Antidepressant-Induced Mania: Overview of Current Controversies  
Joseph F. Goldberg, M.D.

B Efficacy and Safety of Antidepressants in Bipolar II Disorder  
Jay D. Amsterdam, M.D.

C Long-Term Risks with the Use of Antidepressants in Bipolar Disorder  
S. Nassir Ghaemi, M.D.

D Diagnosis and Treatment of the Bipolar Spectrum: A Clinician's Perspective  
Jacob J. Katzow, M.D.

Discussant: Frederick K. Goodwin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 32 2:00 p.m.-5:00 p.m.  
Room 264, Level 2, Convention Center

PHYSIOLOGY AND BEHAVIOR: THE CONNECTION IN EATING DISORDERS  
Chp.: Katherine A. Halmi, M.D.

A Personality Features and Monoamine Function in Eating Disorders  
Francesca Brambilla, M.D.

B Cognitive Dysfunction in Eating Disorders: Relationships with Neuroendocrine Indices  
Silvana Galderisi, M.D., Armida Mucci, M.D., Palmiero Monteleone, M.D., Annunziata Buongiovanni, M.D., Mario Maj, M.D.

C Role of Leptin in Eating Disorders  
Palmiero Monteleone, M.D., Antonio Fuschino, M.D., Mariadis Vassilis, M.D., Mario Maj, M.D.

D Fluvoxamine in Relapse Prevention of Bulimia Nervosa  
Manfred M. Fichter, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 33 2:00 p.m.-5:00 p.m.  
Rooms 265/266, Level 2, Convention Center

EVIDENCE-BASED MANAGEMENT OF SSRI ANTIDEPRESSANT-ASSOCIATED SEXUAL DYSFUNCTION  
Chp.: H. George Nurnberg, M.D.  
Co-Chp.: Julia K. Warnock, M.D.

A Sildenafil for Management of Antidepressant-Associated Sexual Dysfunction  
H. George Nurnberg, M.D., Paula L. Hensley, M.D.

B Avoidance of SSRI-Induced Sexual Dysfunction  
Harry A. Croft, M.D.

C The Prevalence, Assessment, and Course of Antidepressant-Associated Sexual Dysfunction  
Paula L. Hensley, M.D., H. George Nurnberg, M.D.

D Psychotropic Antidotes for Antidepressant-Related Sexual Dysfunction  
Lawrence A. Labbate, M.D.

E Assessing Sexual Dysfunction in Women: Impact of Sex Hormones  
Julia K. Warnock, M.D.

Discussant: Alan J. Gelenberg, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 34 2:00 p.m.-5:00 p.m.  
Rooms 267-268, Level 2, Convention Center

CLINICAL ISSUES IN BIPOLAR DISORDER: THE STANLEY FOUNDATION BIPOLAR NETWORK

Chp.: Robert M. Post, M.D.  
Co-Chp.: Mark A. Frye, M.D.

A The Treatment of Bipolar Depression  
Robert M. Post, M.D., Lori L. Akshuler, M.D., Patricia Suppes, M.D., Kirk D. Denicoff, M.D., Ralph Kupka, M.D., Willem A. Nolen, M.D.

B Early Trauma and Bipolar Disorder  
Gabriele S. Leverich, M.S.W., Patricia Suppes, M.D., Kirk D. Denicoff, M.D., Willem A. Nolen, M.D., Ralph Kupka, M.D., Karen A. Autio, B.A.
TUESDAY

**C Gender Difference in Bipolar Disorder: Alcohol Abuse Comorbidity**
Mark A. Frye, M.D., Lori L. Alshuler, M.D., Kirk D. Denicoff, M.D., Paul E. Keck, Jr., M.D., Susan L. McElroy, M.D., Patricia Suppes, M.D.

**D Correlates and Management of Overweight in Bipolar Disorder**
Susan L. McElroy, M.D.

**E New Antiepileptics in the Treatment of Bipolar Disorder**
Paul E. Keck, Jr., M.D.

Discussants: Hagop S. Akiskal, M.D.
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 35 2:00 p.m.-5:00 p.m.**
Room 269, Level 2, Convention Center

**SUBSTANCE USE AND PSYCHOSIS: TACKLING THE CHICKEN-AND-EGG PROBLEM**
Chp.: Michael B. First, M.D.

**A Using the Psychiatric Research Interview for Substance and Mental Disorders to Diagnose Psychotic Disorders in Substance Abusers**
Deborah S. Hasin, Ph.D., Sharon Samet, M.S.W., Jakob Meydan, M.S.

**B Autonomous Drug-Induced Psychosis: State of the Evidence**
Nashaat N. Boutros, M.D., Malcolm B. Bowers, Jr., M.D.

**C Illness Course of Substance-Induced and Primary Psychotic Disorders**
Carol L.M. Caton, Ph.D., Deborah S. Hasin, Ph.D., Michael B. First, M.D., Ellen M. Stevenson, M.D., James L. Curtis, M.D., Gary L. Lefer, M.D., Patrick Shrout, Ph.D.

**D Differential Diagnosis of Psychosis in Drug Abusers**
Richard N. Rosenthal, M.D.

**E The Impact of Substance Abuse: Dependence on Diagnosing Patients with Psychosis**
Mark J. Sedler, M.D., Joseph Schwartz, Evelyn Bromet, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 36 2:00 p.m.-5:00 p.m.**
Room 270, Level 2, Convention Center

**BLACK RAGE, WHITE SUPREMACISTS, PSYCHIATRY, AND CRIMINAL LAW**
Chp.: Michael M. Welner, M.D.

**A Black Rage: Myths and Realities**
Michael M. Welner, M.D.

**B White Supremacists: Psychiatry Beneath the Hate**
James F. Hooper, IV, M.D.

**C Ethnic Rage: Guidelines for Forensic Psychiatric Assessment**
Michael M. Welner, M.D.

**D Cross-Cultural Aspects of Ethnic Rage**
Andres J. Pumariega, M.D.

Discussant: Carl C. Bell, M.D.
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 37 2:00 p.m.-5:00 p.m.**
Room 271, Level 2, Convention Center

**THE BIOPSYCHOSOCIAL MODEL: SOCIAL PERSPECTIVES**
American Association for Social Psychiatry
Chp.: Pedro Ruiz, M.D.
Co-Chp.: Lawrence Hartmann, M.D.

**A Theoretical Perspectives**
Gerald J. Sarwer-Foner, M.D.

**B Integrational Perspectives**
Tanya M. Luhrmann, Ph.D.

**C Psychotherapy Perspectives**
Edward F. Foulks, M.D.

**D Biological Perspectives**
Charles B. Nemeroff, M.D.

**E Social Perspectives**
Joel S. Feiner, M.D.

Discussants: Steven S. Sharfstein, M.D., Kenneth S. Thompson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 38 2:00 p.m.-5:00 p.m.**
Room 272, Level 2, Convention Center

**THE USE OF CHOLINESTERASE INHIBITORS IN CLINICAL PRACTICE**
Chp.: Constantine G. Lyketsos, M.D.

**A Evidence-Based Medicine as Applied to Treatment Decisions in Alzheimer's Disease**
Lon S. Schneider, M.D.

**B Efficacy and Risks of Marketed Cholinesterase Inhibitors**
Pierre Tarriot, M.D.

**C Long-Term Treatment: Is There Evidence for Safety and Efficacy?**
Lon S. Schneider, M.D.
TUESDAY  

D Assessing Efficacy in Day-to-Day Practice: Opportunities and Barriers  
William E. Reichman, M.D.

E Using the Cholinesterase Inhibitors in Clinical Practice  
Constantine G. Lyketsos, M.D.

THIS SESSION WILL BE AUDIOTAPIED.

SYMPOSIUM 39 2:00 p.m.-5:00 p.m.  
Room 273, Level 2, Convention Center  
PERSONALITY AND PSYCHOPATHOLOGY: A BEHAVIOR-GENETIC PERSPECTIVE  
Chp.: John Livesley, M.D.  
Co-Chp.: Kerry L. Jang, Ph.D.

A Behavioral-Genetic Perspectives on the Comorbidity of Behavior  
Kerry L. Jang, Ph.D.

B Causal Connections Between Impulsive Personality Traits and Externalizing Disorders  
Robert F. Krueger, Ph.D., Brian M. Hicks, B.S., William G. Iacono, Ph.D., Christopher Patrick, Ph.D., Matt McGue, Ph.D., Scott R. Carlson, B.A.

C Born Fearful: Heritability of Avoidant and Social Anxiety Related Traits  
Murray B. Stein, M.D.

D Etiological Relationships Among Personality Disorders and Axis I Disorders  
John Livesley, M.D.

Discussant: Thomas A. Widiger, Ph.D.  
THIS SESSION WILL BE AUDIOTAPIED.

SYMPOSIUM 40 2:00 p.m.-5:00 p.m.  
Rooms 333/334, Level 3, Convention Center  
THE USE OF FORCE IN PSYCHIATRY: WHEN IS IT HELPFUL AND WHEN IS IT NOT: PART I  
American Association of Community Psychiatrists  
Chp.: David A. Pollack, M.D.

A Seclusion and Restraint Update  
Nicholas Meyers, J.D.

B Use of Force with Older Adults  
Cornelia K. Beck, Ph.D.

C Use-of-Force Issues for Persons in Police Custody and Corrections Settings  
Randolph T. Dupont, Ph.D., Fred C. Osher, M.D.

D The Use of Force: Consumer Perspective  
Frank D. Burgman

E The Use of Force: Staff Perspective  
Richard O'Dea, R.N.

Discussant: Paul S. Appelbaum, M.D.  
THIS SESSION WILL BE AUDIOTAPIED.

SYMPOSIUM 41 2:00 p.m.-5:00 p.m.  
Rooms 335/336, Level 3, Convention Center  
BIPOLAR DISORDER: CURRENT GUIDELINES, PRACTICES, AND EFFECTIVENESS RESEARCH  
Chp.: Gary S. Sachs, M.D.  
Co-Chp.: Michael E. Thase, M.D.

A Current Treatment Guideline Recommendations for Bipolar Disorder  
Robert M.A. Hirschfeld, M.D.

B Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Study Design and Sample Characteristics  
Gary S. Sachs, M.D., Michael E. Thase, M.D., Steve Wisniewski, Leslie F. Leahy, Ph.D., Jennifer Conley, M.A.

C The Texas Implementation of Medication Algorithms for Bipolar Disorder  
Patricia Suppes, M.D.

D Treatment of Bipolar Disorder in Routine Practice  
Joyce C. West, M.P.P., David A. Kahn, M.D., Deborah A. Zarin, M.D., Steven C. Marcus, Ph.D., Victoria E. Cosgrove, B.A., Mark H. Townsend, M.D.

THIS SESSION WILL BE AUDIOTAPIED.

SYMPOSIUM 42 2:00 p.m.-5:00 p.m.  
Room 342, Level 3, Convention Center  
TEACHING ETHICS TO PSYCHIATRIC RESIDENTS  
APA Ethics Committee  
Chp.: Donald G. Langsley, M.D.  
Co-Chp.: Richard D. Milone, M.D.

A Teaching About Boundary Violations in a Psychiatry Ethics Course  
Peter B. Gruenberg, M.D.

B Practical Ethics in Treatment of Children  
William Arroyo, M.D.

C Teaching About the Ethics of Confidentiality  
David S. Wahl, M.D.

D Ethical Aspects of Gifts from Patients  
Edward Hanin, M.D.

E Forensic Issues in the Practice of Ethical Psychiatry  
Wade C. Myers, M.D.

THIS SESSION WILL BE AUDIOTAPIED.
TUESDAY

SYMPOSIUM 43 2:00 p.m.-5:00 p.m.
Rooms 346/347, Level 3, Convention Center

MUSIC THERAPY: INTEGRATED ART AND SCIENCE IN HEALTH CARE

Chp.: John S. McIntyre, M.D.
Co-Chp.: Bryan C. Hunter, Ph.D.

A The Mozart Phenomenon: Myth and Reality
Bryan C. Hunter, Ph.D.

B Music Therapy in Neurologic Rehabilitation: A Scientific Model of Rhythmicity in Brain Function
Michael H. Thaut, Ph.D.

C Music Therapy Outcome Research in Patients with Alzheimer's Disease
Alicia A. Clair, Ph.D.

D Music Therapy in Psychosocial Care and Pain Management
Deforia L. Lane, Ph.D.

E The Effect of Drumming on Immune System Modulation
Barry B. Bittman, M.D.

Discussant: Richard Kogan, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 44 2:00 p.m.-5:00 p.m.
Rooms 348/349, Level 3, Convention Center

CULTURAL INFLUENCES ON THE PSYCHIATRIC TREATMENT OF WOMEN

Chp.: Nina E. Cerfolio, M.D.
Co-Chp.: Morisa Schiff-Mayer, M.D.

A Mental Health Treatment of Chinese Women: Issues and Opportunities
Henry Chung, M.D.

B Cultural Issues in the Psychiatric Treatment of Orthodox Jewish Women
Michelle E. Friedman, M.D.

C Cultural Influences in Psychiatric Treatment of Indian Women
Nalini V. Juthani, M.D.

D Treating Latino Women Patients: Clinical Challenges
Silvia W. Olarte, M.D.

E Emerging Issues in Psychiatric Treatment for African-American Women
Altha J. Stewart, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 45 2:00 p.m.-5:00 p.m.
Rooms 350/351, Level 3, Convention Center

FEEDING, EATING, AND EATING DISORDERS: THE DEVELOPMENT OF DISORDERED EATING

Chp.: Evelyn Attia, M.D.
Co-Chp.: Laurel Mayer, M.D.

A Early Influences on Disordered Eating
W. Stewart Agras, M.D.

B The Association of Television Exposure with Disordered Eating Among Ethnic Fijian Adolescent Girls
Anne E. Becker, M.D., Rebecca Burwell, M.P.H., Stephen E. Gilman, S.M., David B. Herzog, M.D., Paul Hamburg, M.D.

C Cultural Change as a Risk Factor for Eating Disorder: The Case of Eastern Europe
Katarzyna Bisaga, M.D.

D Gender Differences in 5HT Function: A Risk Factor for Anorexia Nervosa?
Evelyn Attia, M.D., Katherine G. Meehan

E Body-Fat Distribution Before and After Weight Gain in Anorexia Nervosa
Laurel Mayer, M.D., B. Timothy Walsh, M.D., Richard Pierson, Jr., M.D., Claire Barrett, B.A., Erin Killory

Discussant: Joel Yager, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 46 2:00 p.m.-5:00 p.m.
Room 352, Level 3, Convention Center

NATIONAL BIOETHICS ADVISORY COMMISSION (NBAC) REVISITED: IMPLEMENTATION OF INDEPENDENT CAPACITY ASSESSMENT

Chp.: Catherine A. Roca, M.D.
Co-Chp.: David R. Rubinow, M.D.

A National Bioethics Advisory Commission (NBAC) Recommendation for Independent Capacity Assessment: Overview and Implications for Research
Catherine A. Roca, M.D., Donald L. Rosenstein, M.D., David R. Rubinow, M.D.

B Methods to Assess Decision-Making Capacity
Paul S. Appelbaum, M.D.

C Validating Informed Consent: Process and Verification
William T. Carpenter, Jr., M.D., Robert R. Conley, M.D.

D Greater than Minimal Risk Research with Vulnerable Subjects: A View from the National Institute of Mental Health Intramural Research Program
Donald L. Rosenstein, M.D.

Discussant: E. Greg Koski, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 47 2:00 p.m.-5:00 p.m.
Room 356, Level 3, Convention Center

TREATMENT PATHWAYS (ALGORITHMS) IN MANAGING DEPRESSION

Chp.: A. John Rush, M.D.
Co-Chp.: Michael Bauer, M.D.

A Theory and Models of Treatment Algorithms
Michael Linden, M.D.

B Algorithm-Guided Treatment Versus Treatment as Usual: Randomized Trial in Inpatients with Depression
Michael Bauer, M.D., Mazda Adli, M.D., Ursula Kiesslinger, M.A., Peter Neu, M.D., Michael Smolka, M.D., Michael Linden, M.D.

C Texas Medication Algorithm Project (TMAP): Results for Major Depressive Disorder
Madhukar H. Trivedi, M.D.

D Issues in Implementing Algorithms: Texas Medication Algorithm Project (TMAP) and Star D Experiences
A. John Rush, M.D.

Discussant: Lydia J. Lewis
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 48 2:00 p.m.-5:00 p.m.
Room 357, Level 3, Convention Center

THE TRAUMA OF BEREAVEMENT: A NEW PARADIGM

Chp.: Edward K. Rynearson, M.D.

A Measurement and Diagnosis of Traumatic Grief
Holly G. Prigerson, Ph.D., Selby C. Jacobs, M.D., Paul K. Maciejewski, Ph.D., Stanislav Kasl, Ph.D., Gabriel K. Silverman, B.A.

B Traumatic Grief Therapy
M. Katherine Shear, M.D.

C Bereavement After Violent Dying: Description and Conceptual Frame
Edward K. Rynearson, M.D.

D Clinical Screening Battery, Treatment Implications, and Short-Term Group Intervention Outcomes
Jennifer L. Favell, Ph.D.

E Pharmacologic Treatment of Bereavement Complications
Sidney Zisook, M.D.

Discussants Selby C. Jacobs, M.D., Jennifer L. Favell, Ph.D.

SYMPOSIUM 49 2:00 p.m.-5:00 p.m.
Grand Salon Sections 3 & 6, Street Level, Hilton

PSYCHOTHERAPY VIEWED FROM A BASIC SCIENCE SOCIAL BRAIN PERSPECTIVE
The World Psychiatric Association

Chp.: Russell Gardner, M.D.
Co-Chp.: Frank G. Koerselman, M.D.

A Sociophysiological Exegesis of Michels' "Thinking While Listening"
Russell Gardner, M.D.

B Psychiatry and Biological Psychotherapy
Frank G. Koerselman, M.D.

C Memes, Mutual Suggestion, and Psychotherapy
John O. Beahrs, M.D.

Discussants: Daniel Wilson, M.D., Robert Michels, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 50 2:00 p.m.-5:00 p.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART III
APA Committee of Early Career Psychiatrists and APA Assembly Committee of Early Career Psychiatrists

Chp.: William E. Callahan, Jr., M.D.

A Personal Factors Leading to a Successful Private Practice
Ann S. Maloney, M.D.

B Office Location and Design for Efficiency and Success
Barry W. Wall, M.D.

C Streamlining Overhead and Managing Your Business in Private Practice
Keith W. Young, M.D.

D Marketing Your Unique Private Practice
William E. Callahan, Jr., M.D.

Discussants: Ann S. Maloney, M.D., Barry W. Wall, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 51 2:00 p.m.-5:00 p.m.
Grand Salon Sections 9 & 12, Street Level, Hilton

THINKING ABOUT MIND AND BRAIN: PSYCHOANALYSTS AND NEUROSCIENTISTS CONVERSE: PART II
American Academy of Psychoanalysis and American Psychoanalytic Association

Chp.: Ann-Louise S. Silver, M.D.

(Continued on next page)

59
TUESDAY

A Affect Theory: Neurobiological Findings and Psychological Structures
Otto F. Kernberg, M.D.

B A Biological Analysis of Transference
Mark G. Barad, M.D.

C Primitive Dreams and Neuropsychological Markers of Borderline or Psychotic States
Michael H. Stone, M.D.

D Early Empirical Psychoanalytic Research and Modern Neuroscience
Samuel Slipp, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 52 2:00 p.m.-5:00 p.m.
Grand Salon Sections 13 & 16, Street Level, Hilton

PSYCHOTHERAPEUTIC ASPECTS OF HIV
Chp.: Francine Cournos, M.D.

A Epidemiology: Shifting Populations, Shifting Cultural Concerns
Warren M. Liang, M.D.

B What Role Do Psychiatrists Have in Providing Baseline and Continuing HIV Counseling and Testing?
Robert S. Stasko, M.D.

C Psychotherapy with People Living with HIV
Marshall Forstein, M.D.

D Therapeutic Interventions with the High-Risk Patient
Kenneth B. Ashley, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 53 2:00 p.m.-5:00 p.m.
Grand Salon Sections 15 & 18, Street Level, Hilton

A MOST COMMON CHALLENGE: THE DUAL-DIAGNOSED PATIENT
Chp.: Roger Peele, M.D.

A Treatment of Patients with Bipolar Disorders and Alcoholism
Richard J. Frances, M.D., Avram H. Mack, M.D.

B Treatment of Comorbid Bipolar Disorder and Cocaine Addiction
David A. Gorelick, M.D.

C Treatment of Patients with Bipolar Disorders and Heroin Abuse
Herbert D. Kleber, M.D.

D Group Psychotherapy for Bipolar Patients with Substance Abuse
Mark J. Albay, M.D., Edward J. Khantzian, M.D.

E Individual Psychotherapy with the Dual-Diagnosed Patient
George E. Woody, M.D.

Discussant: Patricia I. Ordorica, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 54 2:00 p.m.-5:00 p.m.
Grand Salon Sections 19 & 22, Street Level, Hilton

PSYCHOPHARMACOLOGY OF BPD
Chp.: Mary C. Zanarini, Ed.D.
Co-Chp.: Kenneth R. Silk, M.D.

A Olanzapine Treatment of Female Borderline Patients
Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D.

B Divalproex Sodium Treatment of Women with BPD
Frances R. Frankenburg, M.D., Mary C. Zanarini, Ed.D.

C SSRIs in BPD: Unresolved Issues
Paul S. Links, M.D., Ian C. Dawe, M.D., Rahel Eynan-Harvey, M.A.

D Medication Choice in BPD
Kenneth R. Silk, M.D., Lawrence Thompson, Ph.D., Joann Heap, C.S.W., Naomi Lohr, Ph.D.

E Impulsivity: The Primary Target Symptom in BPD
Joel F. Paris, M.D.

Discussant: Bruce M. Pfohl, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 55 2:00 p.m.-5:00 p.m.
Grand Salon Sections 21 & 24, Street Level, Hilton

PSYCHOANALYSIS AND PSYCHOTHERAPY LONG-TERM OUTCOME
Chp.: John C. Perry, M.D.

A Therapist Interventions in Completed Psychoanalyses: The Penn Psychoanalytic Treatment Collection
Elisabeth Banon, M.D., John C. Perry, M.D., Lester Luborsky, M.D., Carmella Roy, M.D.

B Changes in Defensive Functioning in Completed Psychoanalyses: The Penn Collection
Carmella Roy, M.D., John C. Perry, M.D., Elisabeth Banon, M.D., Lester Luborsky, M.D.

C A Follow-Along Study of Change in Long-Term Psychotherapy
Michael P. Bond, M.D., John C. Perry, M.D., Joan Oppenheimer, B.A., Natali Sanlian, M.P.S.
The Austen Riggs Follow-Along Study: Five-Year Outcome
John C. Perry, M.D., Barbara Zheutlin, M.S., Eric M. Plakun, M.D., Stephen Beck, M.P.S., J. Christopher Fowler, Ph.D., Stephanie Speanberg, M.S.W.

The Impact of Psychotherapy on the Brain
Glen O. Gabbard, M.D.

SYMPOSIUM 56 2:00 p.m.-5:00 p.m.
Marlborough Suite A/B, Second Floor, Hilton
CLOSING THE EFFICACY/EFFECTIVENESS GAP IN PSYCHOPHARMACOLOGY
Chp.: Henry A. Nasrallah, M.D.
Co-Chp.: Greer Sullivan, M.D.

A The Gap Between Research Versus Clinical Outcomes of Pharmacotherapy
Henry A. Nasrallah, M.D.

B Policies Regarding Novel Antipsychotic Prescribing
Greer Sullivan, M.D., Dana M. Perry, B.A., Wen D. Grimes, M.A., Helen Weatherbee, J.D.

C Strategies for Implementing Schizophrenia Guidelines
Richard R. Owen, Jr., M.D., Teresa J. Hudson, Pharm.D.

D The Quality of Medication Treatment for Schizophrenia
Alexander S. Young, M.D., Greer Sullivan, M.D.

E Administrative Barriers to Closing the Efficacy and Effectiveness Gap
Kathryn J. Kotrla, M.D.

Discussant: Grayson S. Norquist, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 57 2:00 p.m.-5:00 p.m.
Melrose Room, Third Floor, Hilton
VOYEURISM IN THE NEW MILLENNIUM: A PRIME-TIME OBSESSION?
Chp.: Norman E. Alessi, M.D.

A From Scopophila to Survivor: Psychiatric Approaches to Voyeurism
Jonathan M. Metzl, M.D.

B Voyeurism and Cinema
Lee H. Rome, M.D.

C Voyeurism and the Internet
Robert A. Kowatch, M.D.

D Adolescents, Voyeurism, and the Internet
Norman E. Alessi, M.D.

SYMPOSIUM 58 2:00 p.m.-5:00 p.m.
Rosedown Room, Third Floor, Hilton
BEYOND MIND AND BRAIN: CONSIDERING THE PATIENT'S WORLD VIEW
Chp.: Allan M. Josephson, M.D.

A The Weltanschauung of Sigmund Freud: Clinical Implications
Armand M. Nicholi, Jr., M.D.

B Clinical Psychiatry and Spirituality: Another Level of Integration
Allan M. Josephson, M.D.

C Suffering and the Patient's World View
John R. Peteet, M.D.

D World Views and Hope in Psychiatry
Leigh C. Bishop, M.D.

E A Clinician Looks at Patients and Their World Views
Irving S. Wiesner, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 59 2:00 p.m.-5:00 p.m.
Magnolia Room, Third Floor, Hilton
BODY IMAGE DISORDERS IN MEN
Chp.: Katharine A. Phillips, M.D.
Co-Chp.: David Castle, M.D.

A The Prevalence of Body Image Disorders Among the Male Population
David Castle, M.D.

B Body Image in Males
Arnold Anderson

C BDD: An Underrecognized Body Image Disorder in Men
Katharine A. Phillips, M.D.

D Body Image and Muscle Dysmorphia in Men
Roberto Olivardia, M.A.

E Illicit Anabolic Steroid Use: Risk Factors and Psychosexual Effects
William R. Yates, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 60 2:00 p.m.-5:00 p.m.
Jasperwood Room, Third Floor, Hilton
REDUCTION OF CHRONIC BENZODIAZEPINE USE: A MYTH AND REALITY
Chp.: Frans G. Zitman, M.D.

(Continued on next page)
A Benzoredux Study: A Two-Phase Approach to Reduce Chronic Benzodiazepine Use
Richard C. Oude Voshaar, M.D., W. D. J. Gorgels, M.D.,
Audrey J. Mol, M.S.C., Anton J. L. M. Van Balkom, M.D.,
Rien M. Breteler, Ph.D., Frans G. Zitman, M.D.

B How to Stop Chronic Benzodiazepine Use in Depressed Patients
Jaap E. Couvee, M.S.C., Frans G. Zitman, M.D.

C Memory Impairment in Patients who Attempted Suicide by Benzodiazepine Overdose
Bas Verwey, M.D., Paul Eling, Ph.D., Henu Wientjes, Ph.D.,
Frans G. Zitman, M.D.

D Benzodiazepine Craving
Audrey J. Mol, M.S.C., Richard C. Oude Voshaar, M.D.,
W. D. J. Gorgels, M.D., Rien M. Breteler, Ph.D., Anton J. L. M.
Van Balkom, M.D., Eloy H. Van de Lisdonk, Ph.D.,
Frans G. Zitman, M.D.

E Assessing Benzodiazepine Dependence: Development of the Benzodiazepine Dependence Self-Report Questionnaire
Cornelis C. Kan, M.D., Frans G. Zitman, M.D., Rien M.
Breteler, Ph.D.

A Psychotropic Use During Pregnancy and Lactation: Weighing the Risks
Lee S. Cohen, M.D.

B Psychotropic Medication Use During the Peripartum Period
Kimberly A. Yonkers, M.D.

C Controversial Issues in the Treatment of Pregnant and Breastfeeding Women
Katherine L. Wisner, M.D.

D Monitoring the Nursing Infant: Measures and Interpretations
Zachary S. Stowe, M.D.

This session will be audi-taped.

Symposium 61 2:00 p.m.-5:00 p.m.
Oak Alley Room, Third Floor, Hilton

Reform, Resident Training, Contemporary Practice, and the Public's Health

Chp.: Leighton Y. Huey, M.D.
Co-Chp.: Michael Hoge, Ph.D.

A Aligning Resident Training and Workforce Proficiency: Is Reform Necessary?
Leighton Y. Huey, M.D.

B Changing Academic Psychiatry for Clinical Care
Joseph A. Flaherty, M.D.

C The Dartmouth Experience: Reform in Psychiatry Residency, Five Years Out
Ronald L. Green, M.D., Bradford Watts, M.D.

D Strategies for Catalyzing Change in Residency Training Programs
Michael Hoge, Ph.D.

Discussant: Mary Jane England, M.D.
This session will be audi-taped.

Symposium 62 2:00 p.m.-5:00 p.m.
Elmwood Room, Third Floor, Hilton

Psychotropic Use During Pregnancy and Lactation: More Data and Evolving Debate

Chp.: Lee S. Cohen, M.D.

4 Electronic Medical Record: Psychiatric Survival Tool for the Decade
Daniel A. Deutschman, M.D., Arnold M. Rosen, M.D.

5 The CAPER System: Patient Assessment and Treatment Planning Software
Peter F. Fore, M.D., Richard Weaver, Ph.D.
3:00 p.m. Session

NEW RESEARCH POSTER SESSION

3:00 p.m.-5:00 p.m.
Exhibition Center, Second Floor, Hilton

MOOD, DISSOCIATIVE, EATING, PREMENSTRUAL DYSPHORIC, AND SLEEP DISORDERS; DIAGNOSTIC AND RESEARCH ISSUES; GENETICS; AND SUICIDE

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIUM 33-39

INDUSTRY-SUPPORTED SYMPOSIUM 33
7:00 p.m.-10:00 p.m.
Hall G, Lobby Level, Convention Center

RECOGNITION AND TREATMENT OF ALZHEIMER'S DISEASE: PRACTICAL LESSONS FROM NEW RESEARCH
Supported by Eisai Inc., Pfizer Inc.

Chp.: Gary W. Small, M.D.
Co-Chp.: Jeffrey L. Cummings, M.D.

A Alzheimer's Disease: Integrating Mind and Brain
Jeffrey L. Cummings, M.D.

B An Update on Brain Imaging and Genetic Risk in Alzheimer's Disease Assessment
Gary W. Small, M.D.

C Pathogenesis and Treatment Strategies in Alzheimer's Disease
Rachelle S. Doody, M.D.

D The Interface of Depression and Dementia
Davangere P. Devanand, M.D.

E Long-Term Benefits of Early Pharmacologic Treatment
Pierre N. Tarot, M.D.

F Rediscovering Nonpharmacologic Approaches to Behavior and Function
Kevin F. Gray, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 34
7:00 p.m.-10:00 p.m.
La Nouvelle Ballroom, Level 2, Convention Center

EVERYDAY CHALLENGES IN MANAGING PATIENTS ON PSYCHOTROPIC MEDICATIONS
Supported by Bristol-Myers Squibb Company

Chp.: Charles B. Nemeroff, M.D.

A Approaches to Optimizing Therapies Across Psychiatric Diagnoses: Remission Is the Goal
Charles B. Nemeroff, M.D.

B Optimizing Patient Outcomes Across Psychiatric Diagnoses: Focus on Safety and Tolerability
John M. Zajecka, M.D.

C Special Challenges When Using Psychotropic Medications in Children and Adolescents
Karen D. Wagner, M.D.

D Special Challenges When Using Psychotropic Medications in the Geriatric Population
K. Ranga R. Krishnan, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 35
7:00 p.m.-10:00 p.m.
Grand Ballroom A/B, Street Level, Hilton

OFF-LABEL ON THE TABLE: USING NEW PHARMACOLOGICAL AGENTS
Supported by Novartis Pharmaceuticals Corporation

Chp.: William M. Glazer, M.D.
Co-Chp.: Jerrold F. Rosenbaum, M.D.

A Symptoms, Syndrome, or Spectrum: How Do We Select Medications? A Clinical Case Vignette
William M. Glazer, M.D., Jerrold F. Rosenbaum, M.D.

B Atypical Antipsychotics in the Treatment of Aggressive Behaviors
Paul E. Keck, Jr., M.D.

C The Role of Antidepressant Medications for Aggressive Behavior
Jonathan E. Alpert, M.D., Maurizio Fava, M.D.

D The Role of Mood Stabilizers for Aggressive Behavior
Alan C. Swann, M.D.

E Synthesis: Spectrum Versus Signal
Jerrold F. Rosenbaum, M.D., William M. Glazer, M.D.
Discussant: Hayne D. McMeekin, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 36
7:00 p.m.-10:00 p.m.
Grand Ballroom C/D, Street Level, Hilton

MEN, WOMEN, AND SCHIZOPHRENIA: DOES ANATOMY DETERMINE DESTINY?
Supported by AstraZeneca Pharmaceuticals

Chp.: Henry A. Nasrallah, M.D.
Co-Chp.: Diana O. Perkins, M.D.

(Continued on next page)
TUESDAY

A Normal Sexual Brain Dimorphisms: Impact on Schizophrenia in Men and Women
Jill M. Goldstein, Ph.D.

B Outcome and Treatment Response in Schizophrenia: Influences of Gender
Peter F. Buckley, M.D.

C Male-Female Difference in Schizophrenia: A Biopsychosocial Perspective
Mary V. Seeman, M.D.

D Neuroendocrine Side Effects of Antipsychotic Treatment on Men and Women
Diana O. Perkins, M.D.

E Gender Differences in Late-Life Schizophrenia and Its Treatment
Dilip V. Jeste, M.D., Laurie L. Lindamer, Ph.D., Jonathan P. Lacro, Pharm.D., Enid Rockwell, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 37
7:00 p.m.-10:00 p.m.
Acadia Ballroom, Third Floor, Marriott

IMAGES OF ANXIETY: A NEW LOOK AT GAD AND PTSD
Supported by SmithKline Beecham Pharmaceuticals

Chp.: Jack M. Gorman, M.D.

A Update on Neuroimaging
Jack M. Gorman, M.D.

B The Anxious Brain: GAD and PTSD
Jeremy D. Coplan, M.D.

C The Comorbidity Factor in GAD and PTSD
James C. Ballenger, M.D.

D An Update on PTSD
Rachel Yehuda, Ph.D.

E Current Concepts in the Diagnosis and Treatment of GAD
David V. Sheehan, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 38
7:00 p.m.-10:00 p.m.
Carondelet Ballroom, Third Floor, Marriott

RESPONDING TO THE CHALLENGE OF TREATING BIPOLAR DISORDER
Supported by Glaxo Wellcome Inc.

Chp.: Joseph R. Calabrese, M.D.

A Novel Aspects of Lithium Therapy in Bipolar Disorder
Guy M. Goodwin, M.D.

B Molecular Mechanisms Underlying Mood Stabilization in Bipolar Disorder
Husseini K. Manji, M.D.

C Exploring Novel Treatment Strategies for Bipolar Disorder
Patricia Suppes, M.D.

D Combination Treatment with Atypical Antipsychotic Agents in Bipolar Disorder
Carlos A. Zarate, Jr., M.D., Sarah R. Cavanagh, B.A.

INDUSTRY-SUPPORTED SYMPOSIUM 39
7:00 p.m.-10:00 p.m.
Mardi Gras Ballroom, Third Floor, Marriott

CURRENT AND FUTURE MANAGEMENT OF INSOMNIA AND PSYCHIATRIC ILLNESSES
Supported by Sanofi-Synthelabo, Inc.

Chp.: Michael E. Thase, M.D.

A The Correlation Between Insomnia and Psychiatric Illnesses
Ruth M. Benca, M.D.

B The Neurobiology of Sleep in Health and Psychiatric Illness
Daniel J. Buysse, M.D.

C Safety and Tolerability Issues in the Treatment of Insomnia
David J. Greenblatt, M.D.

D Comparative Management of Insomnia: Worldwide Perspectives
Goran Hajak, M.D.

Discussant: Michael E. Thase, M.D.

MEDIA SESSIONS 17-18

MEDIA SESSION 17
7:00 p.m.-10:00 p.m.
Napoleon Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES

Chp.: Harvey R. Greenberg, M.D.

29 The Matrix
(136 minutes)

Distributor: Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

The Matrix is a sci-fi thriller directed by Larry and Andy Wachowski starring Keanu Reeves and Laurence Fishburne. Reeves believes he is living a normal life in the 90s, but discovers he and the rest of humanity are living a delusion fed to them by
their computer captors in the future. Reeves breaks free and joins an underground group of computer hackers, led by Fishburne, to lead their enslaved society in a revolution against their machine masters.

MEDIA SESSION 18 7:00 p.m.-10:00 p.m.
Versailles Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES

Chp.: Sandra C. Walker, M.D.

30 Sankofa
(125 minutes)

**Distributor:** Myphedu Films, Inc.
P.O. Box 10035
Washington, DC 20018-0035

_Sankofa_ is an Akan word that means “one must return to the past in order to move forward.” In _Sankofa_ the video, Mona, a contemporary model, is possessed by spirits lingering in the Cape Coast Castle in Ghana. She travels to the past where as a house servant called Shola, she is constantly abused by the slave master. Nunu, an African-born field hand, and Shango, Shola’s West Indian lover, continuously rebel against the slave system. For Nunu this means direct conflict with her son, a mulatto benefiting from the system as a head slave. Inspired by Nunu and Shango’s determination to defy the system, Shola finally takes her fate into her own hands.
American Psychiatric Association
53rd Institute on Psychiatric Services
Wednesday, October 10 – Sunday, October 14, 2001
Orlando, FL

“Multidisciplinary Roles in the 21st Century”

INSTITUTE OBJECTIVES: At the conclusion of the 2001 Institute on Psychiatric Services, participants will:

1) Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care,
2) Better understand how the current health care system affects patient care;
3) Gain new knowledge and skills useful in public psychiatric settings; and
4) Better understand the usefulness of Multidisciplinary Roles in the 21st Century.

Did you know that...

★ The 2000 Institute received the highest attendee-rated evaluations?
★ APA members receive a 40% discount on their cost for registration?
★ All scientific sessions will be held in the Renaissance Orlando Resort Hotel?
★ Industry-Supported Breakfast, Lunch and Dinner Symposia are presented each day?
★ You can earn up to 48 hours of category 1 credit for attending the Institute?
★ There are prize drawings, beverages and receptions held daily in the exhibit hall?

For further information, please write to:

Annual Meetings Department
American Psychiatric Association
1400 K Street, N.W.
Washington, DC 20015
Telephone: 1 (888) 357-7924 (Toll Free)
Fax: (202) 682-6345
E-Mail: apa@psych.org

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 48 hours in category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
WEDNESDAY, MAY 9, 2001

154TH ANNUAL MEETING

7:00 a.m. Sessions

PART I OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 40-43

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 40, PART 1
7:00 a.m.-8:30 a.m.
Hall G, Lobby Level, Convention Center

CLINICAL CHALLENGES IN ANXIETY
Supported by Pfizer Inc.

Chp.: Mark H. Pollack, M.D.
Co-Chp.: James W. Jefferson, M.D.

A Anxiety Disorders: Moving from Better to Well
Mark H. Pollack, M.D.

B Innovative Pharmacological Approaches to Treatment-Resistant Anxiety Disorders
James W. Jefferson, M.D.

C Novel Anxiolytics in Development and Abroad
Stuart A. Montgomery, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 41, PART 1
7:00 a.m.-8:30 a.m.
La Nouvelle Ballroom, Level 2, Convention Center

A NEW ERA FOR MANAGING PSYCHOSIS: REBUILDING LIVES FOR PATIENTS AND FAMILIES
Supported by Janssen Pharmaceuticals

Chp.: Ira D. Glick, M.D.
Co-Chp.: Stephen R. Marder, M.D.

A Integrating Pharmacological and Psychosocial Treatments: Improving Social and Vocational Outcomes
Stephen R. Marder, M.D.

B The Treatment of Juvenile-Onset Psychosis
Patrick D. McGorry, Ph.D.

C The Older Patient and Family
Soo Borson, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom C/D, Street Level, Hilton

DEPRESSION: GENDER, AGE, AND SPECIAL POPULATIONS
Supported by Eli Lilly and Company

Chp.: David L. Dunner, M.D.

A Mood Disorders in the Child and Adolescent
Graham J. Emslie, M.D.

B Ethnic and Gender Issues in the Treatment of Depression
David L. Dunner, M.D.

C The Elderly Patient: A Delicate Balance
Alan P. Siegal, M.D.

8:00 a.m. Sessions

COURSES 79-87
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 79
La Galerie 2, Second Floor, Marriott

INNOVATIVE THERAPEUTICS IN CONSULTATION-LIAISON PSYCHIATRY

Co-Directors: Francisco Fernandez, M.D., Edwin H. Cassem, M.D.
Faculty: James L. Griffith, M.D.
WEDNESDAY

COURSE 80 8:00 a.m.-12 noon
La Galerie 4, Second Floor, Marriott

PSYCHIATRIC ASPECTS OF EPILEPSY

Co-Directors: David J. Goode, M.D., Christine Dean, M.D.

COURSE 81 8:00 a.m.-12 noon
La Galerie 5, Second Floor, Marriott

THE FORENSIC ASSESSMENT OF COMPETENCY TO MAKE A DECISION (IN SPANISH)

Director: Alfredo Calcedo-Barba, M.D.
Faculty: Julio E. Arboleda-Florez, M.D.

COURSE 82 8:00 a.m.-12 noon
Balcony L, Fourth Floor, Marriott

BEHAVIORAL NEUROANATOMY: AN INTRODUCTION

Director: Nashaat N. Boutros, M.D.
Faculty: David L. Clark, Ph.D., Edward C. Lauterbach, M.D.

COURSE 83 8:00 a.m.-12 noon
Balcony M, Fourth Floor, Marriott

DIALECTICAL BEHAVIOR THERAPY AND PARTIAL HOSPITAL IN THE DIFFICULT-TO-TREAT PATIENT

Director: Elizabeth B. Simpson, M.D.
Faculty: Karen J. Rosen, M.D., Ellen Costello, Ph.D., Marydale Stevens, R.N.

COURSE 84 8:00 a.m.-12 noon
Balcony N, Fourth Floor, Marriott

TREATMENT ISSUES FOR WOMEN IN MINORITY GROUPS

Director: Susan R. Downs, M.D.
Faculty: Ellen Haller, M.D., Michelle O. Clark, M.D., Silvia W. Olarte, M.D., Elisabeth C. Small, M.D.

COURSE 85 8:00 a.m.-12 noon
Bayside Room B, Fourth Floor, Sheraton

INSANITY DEFENSE EVALUATIONS

Director: Phillip J. Resnick, M.D.

COURSE 86 8:00 a.m.-12 noon
Bayside Room C, Fourth Floor, Sheraton

THE PSYCHOSOCIAL MANAGEMENT OF BIPOLAR DISORDER

Co-Directors: Michael D. Robertson, M.D., Lee K. Wolfson, M.Ed.

COURSE 87 8:00 a.m.-12 noon
Grand Ballroom E, Fifth Floor, Sheraton

PARTIAL HOSPITALIZATION FOR PATIENTS WITH BPD

Director: Lawrence L. Kennedy, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCES 3-4

CLINICAL CASE CONFERENCE 3
9:00 a.m.-10:30 a.m.
Room 263, Level 2, Convention Center

VOCAL CORD DYSKINESIA: A DYNAMIC INTERCHANGE BETWEEN MEDICINE AND PSYCHIATRY

Moderator: Geoffrey M. Gabriel, M.D.
Discussant: Harold J. Wain, Ph.D.

CLINICAL CASE CONFERENCE 4
9:00 a.m.-10:30 a.m.
Room 262, Level 2, Convention Center

ASSESSMENT OF PROGNOSTIC FACTORS IN THE ALCOHOLIC PATIENT

Presenter: Kathy L. Coffman, M.D.
Discussant: Thomas P. Beresford, M.D.

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 88-90
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 88 9:00 a.m.-4:00 p.m.
La Galerie I, Second Floor, Marriott

ASSESSMENT AND TREATMENT OF PATIENTS WITH MENTAL RETARDATION

Director: Ruth M. Ryan, M.D.
WEDNESDAY

COURSE 89 9:00 a.m.-4:00 p.m.
La Galerie 6, Second Floor, Marriott

PSYCHOTHERAPY OF BORDERLINE PERSONALITY

Co-Directors: Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.
Faculty: John F. Clarkin, Ph.D.

COURSE 90 9:00 a.m.-4:00 p.m.
Bacchus Room, Fourth Floor, Marriott

THE ASSESSMENT AND TREATMENT OF CHILD MOLESTERS

Director: John M.W. Bradford, M.B.
Faculty: Gene G. Abel, M.D., Graham G. Glancy, M.B.

DISCUSSION GROUPS 14-17
9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

14 Ellen Leibenluft, M.D., on Bipolar Disorder in Children and Adults: Clinical and Research Issues
Chequers Suite, Second Floor, Hilton

15 Vivien K. Burt, M.D., on Career Opportunities in Women's Mental Health (For Residents Only)
Trafalgar Suite, Third Floor, Hilton

16 Carl C. Bell, M.D., on Administrative Psychiatry: Leaderless Leadership
Norwich Suite, Third Floor, Hilton

17 James L. Levenson, M.D., on Psychiatric Drugs in the Medically Ill
Durham Suite, Third Floor, Hilton

LECTURES 15-17

LECTURE 15
9:00 a.m.-10:30 a.m.
Rooms 252-254, Level 2, Convention Center
Gerald M. Edelman, M.D.

How Matter Becomes Imagination: From Brain Dynamics to Consciousness

Chp.: Regina Pally, M.D.
Co-Chp.: Michael A. Gates, M.D.

Most approaches to understanding consciousness emphasize the contributions of specific brain areas or groups of neurons. Gerald M. Edelman, M.D., presents a contrasting model in which processes of neural integration account for key properties of conscious experience. The approach draws on a theory of neuronal group selection known as Neural Darwinism and leads to the dynamic core hypothesis, which is built on cortical mechanisms involving reentrant signaling. Dr. Edelman is Director of the Neurosciences Institute in San Diego, California, President of the Institute's parent organization, the Neurosciences Research Foundation, and Professor and Chairman of the Department of Neurobiology at the Scripps Research Institute in La Jolla, California. Dr. Edelman was awarded the 1972 Nobel Prize for Physiology or Medicine for his early studies on the structure and diversity of antibodies. His more recent work in theoretical neuroscience is the subject of his books Neural Darwinism, The Remembered Present, Bright Air, Brilliant Fire, and A Universe of Consciousness: How Matter Becomes Imagination, coauthored with Giulio Tononi. In addition, Dr. Edelman is the author of more than 450 research publications. Dr. Edelman received his medical degree from the University of Pennsylvania and his doctoral degree in biochemistry and immunology from Rockefeller University in New York City.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 16
9:00 a.m.-10:30 a.m.
Rooms 338/339, Level 3, Convention Center

APA'S ADMINISTRATIVE PSYCHIATRY AWARD LECTURE

Steven M. Mirin, M.D.

Surviving Organizational Change

Co-Chps.: William H. Reid, M.D., Dave M. Davis, M.D., Gordon H. Clark, Jr., M.D.

The last decade has been one of enormous change for both health care organizations and professional associations. Advances in technology and telecommunications, coupled with the need to respond to a rapidly changing health care environment, have challenged these organizations to review their strategic priorities and reconfigure their budgets to address current and future threats to their survival. Steven M. Mirin, M.D., Medical Director of the American Psychiatric Association in Washington, D.C., discusses the challenges faced by these organizations and the staff and volunteer leaders who work within them and describes survival strategies for coping with rapid organizational change. Dr. Mirin was President and Psychiatrist-in-Chief of McLean Hospital in Belmont, Massachusetts, and currently is Professor of Psychiatry at Harvard Medical School in (Continued on next page)
Boston. A Fellow of the APA, Dr. Mirin has served on numerous APA task forces and committees, including the work group that developed the Practice Guideline for the Treatment of Patients with Substance Use Disorders, which he chaired. He is the author of approximately 130 professional papers and the author or editor of seven books. He received his medical degree from the State University of New York Upstate Medical Center in Syracuse and completed his psychiatry residency at Boston University Medical Center.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 17
9:00 a.m.-10:30 a.m.
Rooms 353-355, Level 3, Convention Center

APA'S ADOLF MEYER AWARD LECTURE
Steven E. Hyman, M.D.

Psychiatric Diagnosis: Are We Prepared for a New Millennium?
Chp.: Darrel A. Regier, M.D.
Co-Chp.: Alan Langlieb, M.D.

Psychiatric diagnostic systems developed during the 20th century, including the APA Diagnostic and Statistical Manuals, were based largely on clusters of clinical symptoms and signs, in the absence of definitive biological markers and adequate family data for mental illness. The strength of such efforts lay in their reliability rather than their validity. Steven E. Hyman, M.D., Director of the National Institute of Mental Health, examines the nature of mental illness and the ways in which modern genomics, genetics, and neuroscience may ultimately yield diagnoses that are not only reliable, but also valid. In addition to his duties as NIMH director, Dr. Hyman directs an active research program in molecular neurobiology at the National Institutes of Health. He is the author of numerous scientific articles and the author or editor of several widely used clinical texts. He serves on several review and advisory boards, including those of the Riken Brain Sciences Institute in Japan, the Max Planck Institute in Germany, and the Howard Hughes Medical Institute in the United States. Dr. Hyman received his medical degree from Harvard Medical School and completed a residency in psychiatry at McLean Hospital in Belmont, Massachusetts, a clinical fellowship in neurology at Massachusetts General Hospital in Boston, and a postdoctoral fellowship in molecular biology at Harvard University.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 12-14

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

12 Kathryn J. Zerbe, M.D., on Psychotherapy for Women Room 337, Level 3, Convention Center

13 Paul R. McHugh, M.D., on Treatments Based on the Perspectives of Psychiatry Room 340, Level 3, Convention Center

14 Troy L. Thompson II, M.D., on Depression, Antidepressants, and Sexual Dysfunction: Differential Diagnosis, Avoiding, Treating Room 341, Level 3, Convention Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 19-20

MEDIA SESSION 19 9:00 a.m.-11:00 a.m.
Napoleon Ballroom, Third Floor, Hilton

PAIN IN CHILDHOOD: BODY AND MIND
Chp.: Richard E. D'Alli, M.D.

31 No Fears... No Tears: Thirteen Years Later (46 minutes)
Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

Thirteen years ago the award-winning video documented how eight children suffering from cancer go through painful medical treatments with the therapeutic support of clinical psychologist, Dr. Leora Kuttner. Now in No Fear... No Tears: Thirteen Years Later, Dr. Kuttner reconnects to determine the long-term benefits of learning as a child how to deal with pain and fear. These young adults vividly recollect their painful childhood experiences, dramatically showing how children can actively help themselves through taxing medical treatments and enhance their appreciation of life.

32 In Grandma's Hands (25 minutes)
Distributor: University of California Extension Center for Media and Independent Learning
2000 Center Street, 4th Floor
Berkeley, CA 94704
America's drug epidemic grabs headlines when addiction spirals into violence; but behind every story of addiction there is another story that is rarely investigated, a story of shattered families and the people who pick up the broken pieces. In America today some four million children are being raised by their grandparents. This intimate and gently probing documentary studies three diverse urban families in which grandparents are raising their grandchildren as a result of their own children's drug addiction. In candid, reflective interviews, the grandparents comment on the challenges of raising young children at a time in their lives when they expected to be enjoying a quiet retirement.

**MEDIA SESSION 20**
9:00 a.m.-11:00 a.m.
Versailles Ballroom, Third Floor, Hilton

**WHEN THE BRAIN HICUPPS**

Chp.: John T. Walkup, M.D.

33 Twitch and Shout
(59 minutes)

Distributor: New Day Films
22-D Hollywood Avenue
Ho Ho Kus, NJ 07423

*Twitch and Shout* provides an intimate journey into the startling world of Tourette's Syndrome (TS) told through the eyes of a photojournalist with TS. This film is an emotionally absorbing, sometimes unsettling, and ultimately uplifting film about people who must contend with a society that often sees them as crazy or bad and a body and mind that won't do what it's told.

**REVIEW OF PSYCHIATRY: SECTION 4**
9:00 a.m.-12 noon
Rooms 343-345, Level 3, Convention Center

**BRAIN IMAGING IN THE NEW MILLENNIUM**
Chp.: John M. Morihisa, M.D.

16 Neuroimaging Studies in Children: Implications for Research on Affect
Daniel S. Pine, M.D.

17 Imaging Human Cognition and Cognitive Disability in Mental Disorders
Cameron S. Carter, M.D.

18 Structural and Functional Imaging in Late-Life Depression
Harold A. Sackeim, Ph.D.

19 Future Applications for fMRI in Psychiatry
Joseph H. Callcott III, M.D.

20 Neuroimaging Abnormalities in Primary Mood Disorder
Wayne C. Drevets, M.D.

**TELECOMMUNICATIONS SESSION 3**
9:00 a.m.-12 noon
Rooms 260/261, Level 2, Convention Center

**DIGITAL EFFECTS: TECHNOLOGY IN THE CLINICAL PRACTICE**

Chp.: Ronnie S. Stangler, M.D.

9:15 a.m.
8 The Impact of Electronic Psychiatric Records on Patients and the Doctor-Patient Relationship
Heather A. Flynn, Ph.D., Sheila Marcus, M.D., Norman E. Alessi, M.D.

9:30 a.m.
9 Digital Phenomenology of Depression
Norman E. Alessi, M.D., Milton Huang, M.D.

9:50 a.m.
10 Using Virtual Reality to Treat Acrophobia
Milton Huang, M.D.

10:10 a.m.
11 Internet Algorithms for the Pharmacotherapy of Depression: Java Version
David N. Osser, M.D., Robert D. Patterson, M.D.

**WORKSHOPS**

**COMPONENTS 33-38**

**COMPONENT WORKSHOP 33** 9:00 a.m.-10:30 a.m.
Room 264, Level 2, Convention Center

**DEVELOPING A STATEWIDE PSYCHIATRIC DISASTER PLAN**
APA Committee on Psychiatric Dimensions of Disasters

Chp.: Sheila G. Jowsey, M.D.
Participants: Alan Q. Radke, M.D., Mark D. Williams, M.D., David R. Johnson, M.D., Steve M. Kubas, M.D., Jennifer S. Lahmann, M.D., Joseph C. Napoli, M.D.

**COMPONENT WORKSHOP 34** 9:00 a.m.-10:30 a.m.
Rooms 333/334, Level 3, Convention Center

**TRANSGENDER ISSUES: FEMALE TO MALE**
APA Northern California Psychiatric Society's Committee on Lesbian, Gay, Bisexual, and Transgender Issues

Chp.: Dan H. Karasic, M.D.
Participants: Robin A. Dea, M.D., Patrick Califia-Rice, M.A., Jamison Green, M.F.A.
WEDNESDAY

COMPONENT WORKSHOP 35  9:00 a.m.-10:30 a.m.
Room 342, Level 3, Convention Center

USING PRACTICE GUIDELINES IN RESIDENCY TRAINING
APA Steering Committee on Practice Guidelines

Chp.: John S. McIntyre, M.D.
Participants: David A. Garfield, M.D., Sheila H. Gray, M.D., Amarendra Das, M.D., Margaret T. Lin, M.D.

COMPONENT WORKSHOP 36  9:00 a.m.-10:30 a.m.
Rooms 346/347, Level 3, Convention Center

PSYCHIATRY IN THE NEUROSCIENCE CURRICULUM: PROMISE AND PERIL
APA Committee on Medical Student Education

Chp.: Carl B. Greiner, M.D.
Participants: H. Jonathan Polan, M.D., Linda F. Pessar, M.D., Kristin J. O'Dell, M.D., Michael J. Vergare, M.D.

COMPONENT WORKSHOP 37  9:00 a.m.-10:30 a.m.
Room 352, Level 3, Convention Center

MIND, BRAIN, AND ENVIRONMENT: HOW CAN CLINICIANS ADDRESS SOCIAL ILLS?
APA Committee on Poverty, Homelessness, and Psychiatric Disorders

Chp.: Hunter L. McQuistion, M.D.
Participants: Carl I. Cohen, M.D., Carles Muntaner, M.D., Leslie A. Horton, M.D.

COMPONENT WORKSHOP 38  9:00 a.m.-10:30 a.m.
Room 357, Level 3, Convention Center

CAREER CHANGE FOR PSYCHIATRISTS AND PATIENTS YOUNG AND OLD
APA Committee on Psychiatry in the Workplace

Chp.: Harry Prosen, M.D.
Participants: Leonard T. Sperry, M.D., Marcia Scott, M.D., Stephen H. Heidel, M.D.

ISSUES 60-86

ISSUE WORKSHOP 60  9:00 a.m.-10:30 a.m.
Rooms 265/266, Level 2, Convention Center

SPIRITUAL/RELIGIOUS ASSESSMENT IN CLINICAL WORK

Chp.: Francis G. Lu, M.D.
Participants: David B. Larson, M.D.

ISSUE WORKSHOP 61  9:00 a.m.-10:30 a.m.
Rooms 267-268, Level 2, Convention Center

HOMEOPATHIC MEDICINE AND PSYCHIATRY

Chp.: Edward B. Gogek, M.D.

ISSUE WORKSHOP 62  9:00 a.m.-10:30 a.m.
Room 269, Level 2, Convention Center

TREATING PHYSICIANS: CUTTING-EDGE ISSUES

Chp.: Michael F. Myers, M.D.
Participants: Gerald Schneiderman, M.D., Nada L. Stotland, M.D., Leah J. Dickstein, M.D., John D. Wynn, M.D.

ISSUE WORKSHOP 63  9:00 a.m.-10:30 a.m.
Room 270, Level 2, Convention Center

PSYCHODYNAMICS IN TREATMENT-REFRACTORY DEPRESSION

Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 64  9:00 a.m.-10:30 a.m.
Room 271, Level 2, Convention Center

NATURE AND NURTURE: DEVELOPING COMPREHENSIVE SERVICES FOR YOUNG CHILDREN

Chp.: Peter D. Ganime, M.D.
Participants: Joanne Dunnigan, M.S.W., Grace Hickey, Psy.D., Phillip Repasky, M.A., Diane Beebe, M.S.

ISSUE WORKSHOP 65  9:00 a.m.-10:30 a.m.
Room 272, Level 2, Convention Center

CRISIS-STABILIZATION UNITS: ALTERNATIVE TO HOSPITAL OR DE FACTO HOSPITAL?

Chp.: Neil D. Price, M.D.
Participants: Patrick S. Maidman, M.D., David A. Moltz, M.D.

ISSUE WORKSHOP 66  9:00 a.m.-10:30 a.m.
Room 273, Level 2, Convention Center

TREATING HAREDI (VERY ORTHODOX) JEWS IN THE UNITED STATES AND ISRAEL
The Mesorah Society for Traditional Judaism and Psychiatry

Chp.: Abba E. Borowich, M.D.
Participant: David Greenberg, M.D.

ISSUE WORKSHOP 67  9:00 a.m.-10:30 a.m.
Rooms 335/336, Level 3, Convention Center

A REVIEW OF PATIENT ASSAULTS ON STAFF

Co-Chps.: Brandon Z. Erdos, M.D., Douglas H. Hughes, M.D.
Participant: Janet E. Osterman, M.D.
WEDNESDAY

ISSUE WORKSHOP 68  9:00 a.m.-10:30 a.m.
Rooms 348/349, Level 3, Convention Center

SPIRITUAL STRUGGLES: THE NEW PRIORITY IN TREATMENT
Co-Chps.: Stephen M. Soltys, M.D., Larry R. Wagner, Ph.D.

ISSUE WORKSHOP 69  9:00 a.m.-10:30 a.m.
Rooms 350/351, Level 3, Convention Center

WHAT EVER HAPPENED TO PSYCHOTHERAPY?
Chp.: Edmundo J. Ruiz, M.D.
Participants: Homero R. Sanchez, M.D., James B. Stone, M.D.,
Higinio Zuniga, M.D.

ISSUE WORKSHOP 70  9:00 a.m.-10:30 a.m.
Room 356, Level 3, Convention Center

WORKING WITH SMALL BUSINESSES
Co-Chps.: R. Mark Webb, M.D., Melissa M. Hankins, M.D.

ISSUE WORKSHOP 71  9:00 a.m.-10:30 a.m.
Grand Salon Sections 3 & 6, Street Level, Hilton

EDUCATING PATIENTS AND FAMILIES ABOUT ECT
Chp.: Harold A. Sacheim, Ph.D.
Participant: Shoshana Feyser, Ph.D.

ISSUE WORKSHOP 72  9:00 a.m.-10:30 a.m.
Grand Salon Section 4, Street Level, Hilton

DO I NEED AN MBA TO TRANSFORM MY CAREER?
Chp.: Arthur L. Lazarus, M.D.

ISSUE WORKSHOP 73  9:00 a.m.-10:30 a.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

DISTANCE-LEARNING OPTIONS
Co-Chps.: Howard J. Osofsky, M.D., Paul M. Balson, M.D.
Participant: Andrew P. Twyman, M.S.W.

ISSUE WORKSHOP 74  9:00 a.m.-10:30 a.m.
Grand Salon Sections 9 & 12, Street Level, Hilton

MARIJUANA AND PSYCHIATRY: DILEMMAS FOR THE CLINICIAN
Chp.: David H. Friar, M.D.
Participants: David A. Wolkoff, M.D., Ernest P. Alaimalo, M.D.

ISSUE WORKSHOP 75  9:00 a.m.-10:30 a.m.
Grand Salon Sections 13 & 16, Street Level, Hilton

HOW TO DETECT DECEPTION
Chp.: Alan R. Hirsch, M.D.
Participants: Charles J. Wolf, M.D., Rodgers M. Wilson, M.D.,
Carl M. Wahlstrom, Jr., M.D., David E. Hartman, Ph.D.

ISSUE WORKSHOP 76  9:00 a.m.-10:30 a.m.
Grand Salon Sections 15 & 18, Street Level, Hilton

MID-CAREER PSYCHIATRY: STAYING FRESH AND CREATIVE
Chp.: Joel Yager, M.D.
Participants: Gerald Kay, M.D., Carol C. Nadelson, M.D.,
Carolyn B. Robinowitz, M.D., Zebulon C. Taintor, M.D.

ISSUE WORKSHOP 77  9:00 a.m.-10:30 a.m.
Grand Salon Sections 19 & 22, Street Level, Hilton

CURRENT AND FUTURE TRENDS IN PSYCHIATRY AND CRIMINAL LAW
Chp.: Michael M. Welner, M.D.
Participants: Robert D. Miller, M.D., Abraham L. Halpern, M.D.,
Ann Burgess, D.N., Robert L. Sadoff, M.D.

ISSUE WORKSHOP 78  9:00 a.m.-10:30 a.m.
Grand Salon Sections 21 & 24, Street Level, Hilton

USING HAMLET TO LEARN ABOUT TEACHING,
INTERVIEWING, AND THERAPEUTIC INTERACTION
Chp.: Dinko Podrug, M.D.

ISSUE WORKSHOP 79  9:00 a.m.-10:30 a.m.
Prince of Wales Suite, Second Floor, Hilton

INTERNATIONAL PROBLEMS WITH PERSONALITY DISORDERS IN THE WORKPLACE
Co-Chps.: James H. Reich, M.D., Giovanni de Girolamo, M.D.
Participants: Julien D. Guelfi, M.D., Lisa Ekselius, M.D.

ISSUE WORKSHOP 80  9:00 a.m.-10:30 a.m.
Melrose Room, Third Floor, Hilton

FOR BETTER OR FOR WORSE: SPOUSES OF PATIENTS WITH DEMENTIA
Chp.: Sheila M. Loboprabhu, M.D.
Participants: James W. Lomax II, M.D., Victor Molinari, Ph.D.,
Kimberly A. Arlinghaus, M.D., Kristin A. Kassaw, M.D.

ISSUE WORKSHOP 81  9:00 a.m.-10:30 a.m.
Rosedown Room, Third Floor, Hilton

DOES JOHNNY NEED METHYLPHENIDATE?
Chp.: Antonio J. Gracia, M.D.
Participants: Betsy Nix, L.M.S.W., Brenda McCorvey, R.N.,
Clint Stone, M.S.U.

73
WEDNESDAY

ISSUE WORKSHOP 82 9:00 a.m.-10:30 a.m.
Magnolia Room, Third Floor, Hilton
TREATING PTSD COMPLICATED BY MEDICAL PROBLEMS: MIND AND BRAIN MEET BODY
Co-Chps.: Gordon D. Strauss, M.D., Michelle A. Fiorella, D.O.

ISSUE WORKSHOP 83 9:00 a.m.-10:30 a.m.
Jasperwood Room, Third Floor, Hilton
TRAINING IMG RESIDENTS: CHALLENGES AND OPPORTUNITIES
Co-Chps.: Nalini V. Juthani, M.D., Richard Balon, M.D.
Participants: Vinay Kapoor, M.D., Anu A. Matorin, M.D., Pedro Ruiz, M.D., Tarek A. Okasha, M.D.

ISSUE WORKSHOP 84 9:00 a.m.-10:30 a.m.
Oak Alley Room, Third Floor, Hilton
NEUROIMAGING: INTEGRATING BIOETHICS WITH CLINICAL AND BASIC SCIENCES
Chp.: Igor Elman, M.D.
Participants: Hafs C. Breiter, M.D., David R. Gastfriend, M.D., Katherine Karlsgodt, B.A., Jasmin S. Roman, B.A.

ISSUE WORKSHOP 85 9:00 a.m.-10:30 a.m.
Elmwood Room, Third Floor, Hilton
IMPLEMENTING MULTIDISCIPLINARY DIAGNOSIS AND MANAGEMENT OF PSEUOSEIZURES
Co-Chps.: Martin A. Goldstein, M.D., Cynthia L. Harden, M.D.

ISSUE WORKSHOP 86 9:00 a.m.-10:30 a.m.
Belle Chasse Room, Third Floor, Hilton
BEYOND REDUCTIONISM: CLINICAL IMPLICATIONS
Chp.: Ian E. Alger, M.D.
Participants: Clarice J. Kestenbaum, M.D., Lewis A. Opler, M.D., Eric R. Marcus, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 18-21
11:00 a.m.-12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

18 Richard J. Frances, M.D., on Treating Addicted Patients with Psychiatric Comorbidity
Chequers Suite, Second Floor, Hilton

19 Ann R. Turkel, M.D., on Medicine, Marriage, and Motherhood
Trafalgar Suite, Third Floor, Hilton

20 Joel J. Wallack, M.D., on Psychiatry at the Medical Interface: Opportunities in the New Millennium
Norwich Suite, Third Floor, Hilton

21 Randall D. Marshall, M.D., on Integrating Pharmacotherapy and Psychotherapy in PTSD
Durham Suite, Third Floor, Hilton

LECTURES 18-19

LECTURE 18
11:00 a.m.-12:30 p.m.
Rooms 252-254, Level 2, Convention Center
Giulio Tononi, M.D.

Consciousness Integrated and Differentiated
Chp.: Regina Pally, M.D.
Co-Chp.: Michael A. Gales, M.D.

A useful way of identifying the neural basis of consciousness is to consider the kinds of neural processes that could account for its most fundamental properties, including both its unity and its complexity. Giulio Tononi, M.D., discusses a novel theory, the dynamic core hypothesis, which proposes that consciousness is a consequence of dynamic interactions of a continually changing functional cluster of nerve cells in the thalamus and cerebral cortex. Dr. Tononi is a Senior Fellow in Theoretical and Experimental Neurobiology at the Neurosciences Institute in San Diego, California, and Associate Professor at the Scripps Research Institute in La Jolla, California. In his recent research, he has used imaging techniques to study the mechanisms by which the brain gives rise to conscious experience and has examined the functions of sleep using electrophysiological and molecular biology methods. Dr. Tononi is the author of more than 120 scientific publications, a co-editor of Selectivism and the Brain, and the author, with Gerald M. Edelman, of A Universe of Consciousness: How Matter Becomes Imagination. Dr. Tononi received his medical degree at the University of Pisa, Italy, and received his doctoral degree in neuroscience as a fellow of the Scuola Superiore S. Anna in Pisa.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.
Lecture 19
11:00 a.m.-12:30 p.m.
Rooms 338/339, Level 3, Convention Center
Doug Wright
Quills: The Marquis on the Marquee
Chp.: David M. McDowell, M.D.

The renowned libertine and author of the Marquis de Sade has had many incarnations in the popular arts. Doug Wright, author of the play Quills, which is set during de Sade's confinement in an asylum, traces the experience of representing the notorious French philosopher, from the birth of the play at the New York Theater Workshop to its recent motion picture adaptation, for which Mr. Wright wrote the screenplay. He discusses key moments in de Sade's life, explores questions of poetic license in literary adaptation, and highlights research he undertook to recreate an early nineteenth-century asylum on stage and on film. Mr. Wright won an Obie Award for outstanding achievement in playwriting and the Keesheing Award for Best New American Play from the National Arts Club for Quills. In addition, his numerous awards include the William L. Bradley Fellowship at Yale University, the Charles MacArthur Fellowship at the Eugene O'Neill Theater Centre, and the Alfred Hodder Fellowship at Princeton University. His work has been published in The Best Short Plays series and in The Paris Review. He has also authored screenplays for Dreamworks, Warner Brothers, Universal Studios, and Artisan Entertainment. Mr. Wright holds a master's degree in playwriting from New York University.

Master Educator Clinical Consultations 15-17
11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

15 Ronald O. Rieder, M.D., on Teaching Psychopathology to Medical Students (AADPRT Council on Education Master Teacher)
Room 337, Level 3, Convention Center
16 Susan Lieff, M.D., on the Agitated Geriatric Patient
Room 340, Level 3, Convention Center
17 Francis G. Lu, M.D., on Cultural Issues in Clinical Case Formulation
Room 341, Level 3, Convention Center

These sessions are open to APA members only. Blue registration badge or APA membership card required for admittance.

Media Sessions 21-22

Media Session 21
11:00 a.m.-2:00 p.m.
Napoleon Ballroom, Third Floor, Hilton

Aging Brains, Fading Minds
Chp.: Peter V. Rabins, M.D.
34 Grace
(57 minutes)

Distributor: Video Press
University of Maryland School of Medicine
100 North Greene Street, Suite 300
Baltimore, MD 21201

This video follows the life of Grace Kirkland, who suffers from a progressive dementia disorder and the inspirational caregiving efforts of her husband for a period of seven years. At the onset, Grace is seen to be having difficulty with short-term memory. Nonetheless, her enthusiasm for life shines through her troubled moments. Four years later, Grace is no longer able to speak and pace through her home. Finally, Grace is no longer able to walk or eat without assistance. This program is a tribute to the spirit of Grace and the care provided by her husband.

35 Choices and Challenge: Caring for Aggressive Adults
(22 minutes)

Distributor: Aquarius Healthcare Videos
5 Powderhouse Lane, P.O. Box 1159
Sherborn, MA 01770

Choice and Challenge is a training program developed during a yearlong project sponsored by the American Psychiatric Nurses Association. This videotape provides a view of "real people" in "real life" settings and includes care challenges faced by hospital and nursing home personnel. Aggressive behavior is perhaps the most troubling, and at the same time, least understood of all behavioral problems. The program provides practical solutions to a variety of real-life problems experienced by older adults and their care providers.

36 Something Should Be Done About Grandma Ruthie
(54 minutes)

Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

Something Should Be Done About Grandma Ruthie is a moving and unsettling portrait of the filmmakers' family as they struggle to deal with her 85-year-old grandmother's deteriorating mental condition due to Alzheimer's Disease. Though still physically healthy, Ruth Hammer no longer can be relied on to bathe and feed herself, or even to remember where and with whom she is. Her children live out of town, and a series of compassionate caregivers find themselves unable to deal with her growing disorientation. Yet Ruthie refuses to leave her long-time home, and the family must confront the necessity of medicating her against her will and eventually forcing her to move to a long-term care facility.
MEDIA SESSION 22  11:00 a.m.-12:30 p.m.
Versailles Ballroom, Third Floor, Hilton

BETWEEN SANITY AND INSANITY: A FRAGILE BOUNDARY

Chp.: Jacquelyn B. Chang, M.D.

37 Through Madness
(30 minutes)

Distributor: Filmmakers Library
Attn: Linda Gottesman
124 East 40th Street
New York, NY 10016

This penetrating documentary demystified psychotic illnesses such as schizophrenia and manic depression, and humanizes those who suffer from them. It is essential viewing for mental health professionals and students who need to understand mental illness, as well as for general audiences. Through Madness documents the lives of three people who describe their bout with psychosis: Eileen, a once promising actress, who now lives in a halfway house and has a severe form of schizophrenia; Lionel, a former NFL football star who had been diagnosed with paranoid schizophrenia; and Joe, a troubled adolescent with delusions and hallucinations who had been diagnosed with manic depression.

38 Between the Lines
(21 minutes)

Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

Between the Lines is a visually lyrical experimental documentary about women who cut themselves. The film explores the gray areas in women's relationships to their bodies in the context of deliberately self-inflicted injury. The women in this film negotiate the fine line between self-destructive behavior and self-preserving coping mechanisms.

MEDICAL UPDATE 3
11:00 a.m.-12:30 p.m.
Grand Salon Sections 3 & 6, Street Level, Hilton

WILL MEDICALIZING OBESITY TREATMENT IMPROVE OUTCOMES?

Chp.: Lisa A. Kotler, M.D.
Presenter: Donna H. Ryan, M.D.

RESEARCH CONSULTATION WITH
11:00 a.m.-12:30 p.m.
This session is limited to 25 participants on a first-come, first-served basis.

2 David Shaffer, M.D., on Youth Suicide Research
Cambridge Suite, Second Floor, Hilton

SCIENTIFIC AND CLINICAL REPORT SESSIONS 23-32

SCIENTIFIC AND CLINICAL REPORT SESSION 23
11:00 a.m.-12:30 p.m.
Room 264, Level 2, Convention Center

DEPRESSION ACROSS CULTURES

Chp.: Renato D. Alarcon, M.D.
Co-Chp.: Jambur V. Ananth, M.D.

11:00 a.m.
68 Depression in Chinese Primary Care Patients
L.K. George Hsu, M.D., Yu M. Wan, M.A., William Tsang, M.A.,
William Rand, M.D., Elaine Choi, M.D.

11:30 a.m.
69 Illness Beliefs of Depressed Chinese Americans in Primary Care
Albert Yeung, M.D., Robert L. Gresham, Jr., B.A., David
Mischoulon, M.D., Raymond Chan, B.S., Shamsah B.
Sonawalla, M.D., Maurizio Fava, M.D., Andrew A.
Nierenberg, M.D.

12 noon
70 Depression in College Students in Bombay
Rajesh M. Parikh, M.D., Nabonita Chakravorthy, M.D.,
Shamsah B. Sonawalla, M.D., Gayatri Mehra, M.A., Sarah
Dracass, M.A., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPEED.

SCIENTIFIC AND CLINICAL REPORT SESSION 24
11:00 a.m.-12:30 p.m.
Room 270, Level 2, Convention Center

PSYCHOTHERAPY ISSUES

Chp.: Paul J. Goodnick, M.D.
Co-Chp.: Roslyn Seligman, M.D.

11:00 a.m.
71 A 45-Year Experience with OCD Patients Who Fear Harming Someone or Fear Harm or Humiliation to Themselves
Albert H. Schrut, M.D.
11:30 a.m.
72 Solving the Riddle of Working Through in Psychotherapy
Steven H. Lipsius, M.D.

12 noon
73 Telepsychiatry for Suicidal Outpatients: Lower Morbidity, Mortality, and Cost
Ann M. Oberkirch, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 25
11:00 a.m.-12:30 p.m.
Rooms 335/336, Level 3, Convention Center
RISK FACTORS IN SUICIDE
Chp.: David W. Preven, M.D.
Co-Chp.: Peter J. Drescher, M.D.
11:00 a.m.
74 Suicide Mortality in the Ukraine in 1999
Ludmila Kryzhanovskaya, Ph.D., Elizabeth L. McGarvey, Ed.D.,
Randolph J. Canterbury, M.D.
11:30 a.m.
75 Decreasing Suicide Mortality in Hungary: What Are the Main Causes?
Zoltan Rihmer, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 26
11:00 a.m.-12:30 p.m.
Rooms 346/347, Level 3, Convention Center
ETHICS AND JUSTICE
Chp.: Howard W. Telson, M.D.
Co-Chp.: Donald G. Langsley, M.D.
11:00 a.m.
77 Willingness and Competence of Depressed Inpatients to Consent to Research
Bruce J. Cohen, M.D., Ludmila Kryzhanovskaya, Ph.D.,
Elizabeth L. McGarvey, Ed.D., Relana C. Pinkerton, Ph.D.
11:30 a.m.
78 Arthur Kronfeld: Professional and Personal Tragedy of a Great Psychiatrist
Elena B. Bezuzbova, M.D.

12 noon
76 Suicide Risk Factors Among Treated Patients with BPD
Thomas M. Kelly, Ph.D., Paul H. Soloff, M.D., J. John Mann, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27
11:00 a.m.-12:30 p.m.
Rooms 348/349, Level 3, Convention Center
ISSUES IN VIOLENCE AND TRAUMA
Chp.: Jose M. Canive, M.D.
Co-Chp.: Rahn K. Bailey, M.D.
11:00 a.m.
80 Violence and Clinical Symptoms in Different Diagnoses
Menahem Krakowski, M.D.
11:30 a.m.
81 Post-Traumatic Spectrum Disorders: A Radical Revision of PTSD
K. Elan Jung, M.D.

12 noon
82 Open Study of Nefazodone in Depression with Anger Attacks
David Mischoulon, M.D., Kathryn A. Bottonari, B.A., Darin D.
Dougherty, M.D., Alan Fischman, M.D., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 28
11:00 a.m.-12:30 p.m.
Room 357, Level 3, Convention Center
PSYCHOPHARMACOLOGY AND CHILD AND ADOLESCENT PSYCHIATRY
Chp.: Laurence L. Greenhill, M.D.
Co-Chp.: Manoj R. Shah, M.D.
11:00 a.m.
83 Adderall and Methylphenidate in ADHD
Stephen V. Faraone, Ph.D., Steven R. Pliszka, M.D., Rene L.
Olvera, M.D., Joseph Biederman, M.D.
11:30 a.m.
84 Comparison of Duration of Effect of OROS MPH with MPH TID in ADHD Children
Sharon Wigal, Ph.D., James M. Swanson, Ph.D., Mark Lerner, M.D.

12 noon
85 Once-Daily-Dosed SL1381 for Pediatric ADHD
Joseph Biederman, M.D., Frank Lopez, M.D., Samuel
Boellner, M.D., Mark C. Chandler, M.D., L. Eugene
Arnold, M.D., Ward T. Smith, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 29
11:00 a.m.-12:30 p.m.
Grand Salon Sections 15 & 18, Street Level, Hilton
DEPRESSION
Chp.: Charles S. Price, M.D.
Co-Chp.: David A. Gutman, M.D.
11:00 a.m.
86 The Response of Psychotic-Like Symptoms to Fluoxetine in Nonpsychotic MDD
Christina M. Dording, M.D., Andrea H. Sickinger, B.A.,
Karen E. Kelly, B.A., Lindsay M. Dececco, B.A., John D.
Matthews, M.D., Andrew A. Nierenberg, M.D., Maurizio
Fava, M.D.
11:30 a.m.
87 Predictors of Stable Personality Disorders in Remitted Depressed Outpatients
Amy Farbaugh, M.A., Nicole B. Neault, B.A., Andrea H.
Sickinger, B.A., Joel A. Pava, Ph.D., Albert Yeung, M.D.,
Jonathan E. Alpert, M.D., Maurizio Fava, M.D.

(Continued on next page)
WEDNESDAY

12 noon
88 Personality Disorders in Psychotic Major Depression
John D. Matthews, M.D., Kathryn A. Bottonari, B.A.,
Robert L. Gresham, Jr., B.A., Christina M. Dording, M.D.,
Mark A. Blais, Psy.D., Jonathan E. Alpert, M.D., Maurizio
Fava, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 30
11:00 a.m.-12:30 p.m.
Rosedown Room, Third Floor, Hilton

INTERNATIONAL PERSPECTIVES ON PSYCHIATRY
Chp.: Javier I. Escobar, M.D.
Co-Chp.: Maria A. Oquendo, M.D.

11:00 a.m.
89 Lifetime and 12-Month Prevalence of Mental Illness in
Chile
Benjamin Vicente, M.D., Robert Kohn, M.D., Pedro
Rioseco, M.D.

11:30 a.m.
90 Race and Psychiatry in Post-Apartheid South Africa
Christopher P. Szabo, M.D., Robert Kohn, M.D., Alan L.
Gordon, M.D., Clifford W. Allwood, M.D.

12 noon
91 The World Psychiatric Association: An International
Survey of Urban Mental Health
Giovanni Caracci, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 31
11:00 a.m.-12:30 p.m.
Magnolia Room, Third Floor, Hilton

SOCIAL AND COMMUNITY PSYCHIATRY
Chp.: Michael A. Silver, M.D.
Co-Chp.: Hunter L. McQuistion, M.D.

11:00 a.m.
92 Mental Health and Stress in Highly Educated
Employees
Cheryl Koopman, Ph.D., Robert A. Matano, Ph.D., Stanley
Wanat, Ph.D., Darrah Westrup, Ph.D., Shelly Whitsett, B.A.

11:30 a.m.
93 The Next Step Group: Multimodal Strategies in Group
Therapy for Serious Illness
Victor McGregor, Ph.D.

12 noon
94 Psychiatric Issues in Space: Implications from the Space
Shuttle/MIR Program
Nick A. Kanas, M.D., Vyacheslav Salnitskiy, Ph.D., Ellen M.
Grund, M.S., Daniel S. Weiss, Ph.D., Vadim Gushin, M.D.,
Olga Kozerenko, M.D., Aleksander Sled, M.S., Charles R.
Marmar, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 32
11:00 a.m.-12:30 p.m.
Jasperwood Room, Third Floor, Hilton

ISSUES IN THE TREATMENT OF MOOD
DISORDERS
Chp.: Thomas K. Ciesla, M.D.
Co-Chp.: Eva M. Szigethy, M.D.

11:00 a.m.
95 Olanzapine Versus Divalproex Sodium for the
Treatment of Acute Mania
Mauricio F. Tohen, M.D., Robert W. Baker, M.D., Denai R.
Milton, M.S., Richard C. Risser, M.S., Julie A. Gilmore, Ph.D.,
Amy R. Davis, R.Ph., Angela L. Richey, R.Ph.

11:30 a.m.
96 Risk of Postpartum Depression in Women with
Pregravid Major Depression Disorder
Ruta M. Nonacs, M.D., Lee S. Cohen, M.D., Suzanne M.
Bouffard, B.A., Lauren Wise, M.S.C., Bernard L. Harlow, Ph.D.

12 noon
97 The Rising Prevalence of Antidepressant Treatment for
U.S. Youth
Julie M. Zito, Ph.D., Susan Dosreis, Ph.D., Karen S. Soeken, Ph.D.,
Daniel J. Safer, M.D., Myde Boles, Ph.D., James Gardner, S.M.,
Frances Lynch, Ph.D.

THIS SESSION WILL BE AUDIOTAPE.

WORKSHOPS

COMPONENTS 39-45

COMPONENT WORKSHOP 39 11:00 a.m.-12:30 p.m.
Rooms 333/334, Level 3, Convention Center

CAREER CHOICES IN PSYCHIATRY
APA Assembly Committee of Area Member-in-Training Representatives

Co-Chps.: Mary Ann Schaepper, M.D., Cathryn A. Galanter, M.D.
Participants: Barry W. Wall, M.D., Patrice A. Harris, M.D.,
Blaine S. Greenwald, M.D., Petros Levounis, M.D.

COMPONENT WORKSHOP 40 11:00 a.m.-12:30 p.m.
Rooms 335/335, Level 3, Convention Center

NEW REGULATORY REQUIREMENTS FOR
SECLUSION AND RESTRAINTS
APA Committee on Standards and Survey Procedures

Chp.: Charles E. Riordan, M.D.
Participants: Robert A. Wise, M.D., D. Jean Miller, Nicholas
Meyers, J.D.
COMPONENT WORKSHOP 41 11:00 a.m.-12:30 p.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

HOW TO ENHANCE MOTIVATION IN PATIENTS
WITH SUBSTANCE ABUSE PROBLEMS
APA Committee on Training and Education in Addiction Psychiatry
and American Academy of Addiction Psychiatry

Co-Chps.: Jonathan I. Ritvo, M.D., Richard S. Schottenfeld, M.D.
Participants: William M. Greenberg, M.D., Joyce A. Tinsley, M.D.,
David R. McDuff, M.D.

COMPONENT WORKSHOP 42 11:30 a.m.-12:30 p.m.
Grand Salon Sections 19 & 22, Street Level, Hilton

A COLLABORATIVE EFFORT TO DEFINE AND
MEASURE PSYCHIATRIC COMPETENCIES
APA Council on Medical Education and Career Development

Chp.: Nyapati R. Rao, M.D.
Participants: Sherwyn M. Woods, M.D., Sheldon I. Miller, M.D.,
James H. Scully, Jr., M.D., Ronald O. Reider, M.D., Marjina B.
Tamburini, M.D.

COMPONENT WORKSHOP 43 11:00 a.m.-12:30 p.m.
Melrose Room, Third Floor, Hilton

HISPANICS AND ALTERNATIVE MEDICINE
APA Committee of Hispanic Psychiatrists

Chp.: Oscar E. Perez, M.D.
Participants: Alberto G. Lopez, M.D., Ricardo P. Mendoza, M.D.,
Roberto Lewis-Fernandez, M.D., Pedro Ruiz, M.D.

COMPONENT WORKSHOP 44 11:30 a.m.-12:30 p.m.
Oak Alley Room, Third Floor, Hilton

SUCCESSFUL MODELS OF PSYCHIATRIC CARE IN
THE NURSING HOME
APA Committee on Long-Term Care and Treatment for the Elderly
and APA Committee on Access and Effectiveness of Psychiatric Services for
the Elderly

Chp.: Deborah A. Banazak, D.O.
Participants: Judith H. W. Crossett, M.D., Colleen J. Northcutt, M.D.,
Sharon S. Levine, M.D., Jacobo E. Mintzer, M.D.

COMPONENT WORKSHOP 45 11:00 a.m.-12:30 p.m.
Elmwood Room, Third Floor, Hilton

THE ADMINISTRATIVE PSYCHIATRY
CREDENTIAL
APA Committee on Psychiatric Administration and Management

Co-Chps.: William H. Reid, M.D., W. Walter Menninger, M.D.
Participants: Paul Rodenhauser, M.D., Dave M. Davis, M.D.,
Stuart B. Silver, M.D.
WEDNESDAY

ISSUE WORKSHOP 93 11:00 a.m.-12:30 p.m.
Grand Salon Section 4, Street Level, Hilton

FOUNDATION OF THE WORLD FEDERATION OF
PSYCHIATRIC TRAINEES
Co-Chps.: Victor J.A. Buwalda, M.D., Michelle Riba, M.D.

ISSUE WORKSHOP 94 11:00 a.m.-12:30 p.m.
Prince of Wales Suite, Second Floor, Hilton

EIGHT-DAY TREATMENT OF PANIC WITH
MODERATE TO SEVERE AGORAPHOBIA
Chp.: David A. Spiegel, M.D.

ISSUE WORKSHOP 95 11:00 a.m.-12:30 p.m.
Marlborough Suite A/B, Second Floor, Hilton

MIND MEETS BRAIN IN FAMILY THERAPY:
BRIDGES FOR HEALING
Chp.: Roy O. Resnikoff, M.D.

ISSUE WORKSHOP 96 11:00 a.m.-12:30 p.m.
Belle Chasse Room, Third Floor, Hilton

CONFIDENTIALITY AND SEXUAL HISTORY ISSUES
IN SEXUAL HARASSMENT CASES
Chp.: Rita R. Newman, M.D.
Participants: Liza H. Gold, M.D., Annette J. Hollander, M.D.,
Louise F. Fitzgerald, Ph.D., Naomi J. Weinshenker, M.D.

12 noon Sessions

FORUM 9
12 noon-1:30 p.m.
Grand Salon Sections 13 & 16, Street Level, Hilton

THE PHARMACEUTICAL INDUSTRY AND THE APA:
CONTROVERSIES AND APPROACHES
APA Committee on Commercial Support
Chp.: Stephen M. Goldfinger, M.D.
Participants: Ian E. Alger, M.D., Harvey Bluestone, M.D.,
Jacqueline M. Feldman, M.D., Charles R. Goldman, M.D.,
Philip R. Muskin, M.D., James W. Thompson, M.D., David S.
Wahl, M.D.

NEW RESEARCH POSTER SESSION 8
12 noon-2:00 p.m.
Exhibition Center, Second Floor, Hilton

PSYCHOPHARMACOLOGY, COMBINED PHARMACO-
THERAPY AND PSYCHOTHERAPY, OTHER SOMATIC
THERAPIES, AIDS AND HIV-RELATED DISORDERS,
AND PSYCHIATRIC EDUCATION
For further information on New Research Sessions, please refer
to the New Research Program and Abstracts Book included in your
registration packet.

12:30 p.m. Session

MEDIA SESSION 23
12:30 p.m.-2:00 p.m.
Versailles Ballroom, Third Floor, Hilton

LOSS AND GRIEF: THREE PERSPECTIVES
Chp.: Jacquelyn B. Chang, M.D.

39 Fighting Grandpa
(21 minutes)
Distributor: Filmmakers Library
For V39 &: Attn: Linda Gottesman
V40 124 East 40th Street
New York, NY 10016

Korean-American filmmaker Grek Pak creates a touching
meditation on the human heart. He tells the story of his
immigrant grandmother’s 70-year struggle with her husband.
Forced to give up her dreams of becoming a nurse, left with four
children for ten years alone in Korea while her husband studied
in America, and finally brought to Hawaii to endure new
hardships created in part by her husband’s parsimonious ways,
Grandma had every right to be bitter. But, as the filmmaker
discovers, questions of love have no simple answers. When
Grandma dies, Grandma’s stoicism gives way to a piercing grief,
which surprises and confounds her family. Clearly, the love that
bound together their immigrant forebears, shaped by a history of
hardship, could only be dimly understood by the young of today.

40 Men Like My Father, Families Like My Own
(27 minutes)
This is a sensitive portrait of men who had each lost a dearly
loved wife at an early age, through illness or sudden act of fate.
We learn how they fare bringing up their children, housekeeping,
dealing with their emotions, and sometimes finding new love.
The filmmaker’s mother had died when he was young, and his
father had never been able to speak of their loss. It was this
silence that ultimately propelled him to make the film and
explore the effect of loss on young families. During the course
of filming, father and son grew closer and the filmmaker is given
his parents’ precious wedding album. This is an impressive film
on male psychology as well as grief studies.

41 What Do I Tell My Children?
(30 minutes)
Distributor: Aquarius Healthcare Videos
5 Powderhouse Lane, P.O. Box 1159
Sherborn, MA 01770

What Do I Tell My Children? is a classic film internationally
recognized as the most outstanding video available for families
and professionals who are dealing with children and grief issues.
In this surprising video, children and parents share their stories
and feelings about the loss of a loved one, while leading
professionals in the field offer advice about coping and grief.
1:00 p.m. Sessions

COURSES 91-94
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 91
1:00 p.m.-5:00 p.m.
La Galerie 2, Second Floor, Marriott
MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS
Director: Alfred J. Lewy, M.D.

COURSE 92
1:00 p.m.-5:00 p.m.
La Galerie 3, Second Floor, Marriott
SUICIDAL PATIENTS IN THE MANAGED CARE ERA: ASSESSMENT AND RISK MANAGEMENT
Co-Directors: Mohammad Saeed, M.D., Thomas F. Brozovich, D.O.

COURSE 93
1:00 p.m.-5:00 p.m.
La Galerie 5, Second Floor, Marriott
UNDERSTANDING AND TREATING BIPOLAR DISORDER TODAY: AN UPDATE OF GOODWIN AND JAMISON'S MANIC-DEPRESSIVE ILLNESS
Co-Directors: Frederick K. Goodwin, M.D., Kay R. Jamison, Ph.D.

COURSE 94
1:00 p.m.-5:00 p.m.
Bonaparte Room, Fourth Floor, Marriott
CONTEMPORARY MALPRACTICE LIABILITY
Co-Directors: Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.
Faculty: Richard G. Hersh, M.D., Jacqueline Melonas, J.D.

2:00 p.m. Sessions

LECTURES 20-21

LECTURE 20
2:00 p.m.-3:30 p.m.
Rooms 252-254, Level 2, Convention Center
Leo Rangell, M.D.
The Science of Psychotherapy: Legacy of Psychoanalysis
Chp.: Marian L. Butterfield, M.D.

The influence of psychoanalysis on psychiatry in the 20th century was as profound as any scientific development affecting the theoretical armamentarium of the healing professions. Recent neuroscientific findings can be integrated with psychoanalytic perspectives to further a rational and comprehensive application of basic research across the spectrum of disciplines embracing behavior and mental functioning. Leo Rangell, M.D., examines the scientific base of psychoanalytic psychotherapy, the main enduring legacy of the science of psychoanalysis, and discusses its wide applicability throughout the healing professions. Dr. Rangell is Clinical Professor of Psychiatry at the University of California, Los Angeles, and Clinical Professor of Psychiatry (Psychoanalysis) at the University of California, San Francisco. A Past-President of the International Psychoanalytic Association and the American Psychoanalytic Association, Dr. Rangell has been a Fellow at the Center for Advanced Study in the Behavioral Sciences in Stanford, California. He is the author of more than 400 scientific articles in the fields of psychoanalysis, psychiatry, and neurology. A graduate of the Pritzker School of Medicine of the University of Chicago, Dr. Rangell completed psychiatry residencies at Grasslands Hospital in Valhalla, New York, and at the New York State Psychiatric Institute and received his psychoanalytic training at the Los Angeles Psychoanalytic Institute.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.
a Fellow of the APA, the New York Academy of Medicine, and the American College of Psychiatrists. Dr. Kornfeld received his medical degree from Yale University School of Medicine, completed his psychiatry residency at the New York State Psychiatric Institute, and received his psychoanalytic training at Columbia University Psychoanalytic Institute.

Distinguished Psychiatrist Lecture Series
THiS SESSION WILL BE AUDIOTAPEd.

MEDIA SESSIONS 24-25

MEDIA SESSION 24  2:00 p.m.-5:00 p.m.
Napoleon Ballroom, Third Floor, Hilton

YOUTH AND VIOLENCE
Chp.: Jacquelyn B. Chang, M.D.

42 Generations of Violence
(55 minutes)
Distributor: Filmmakers Library
For V42 &: Attn: Linda Gottesman
V43  124 East 40th Street
    New York, NY 10016

This documentary is a compelling portrait of the legacy of family violence that is passed on from one generation to another. It shows that children who experience abuse grow up to become abusive parents. It also shows that there are solutions for breaking this chain of destructiveness. We meet both the victims and the perpetrators of violent behavior, and hear their personal experiences. One young boy tells how his mother’s live-in boyfriend sexually abused him, and a mother reveals how she severely mistreated her son as a youth.

43 Colors Straight Up
(60 minutes)
In the ghetto of South Central, Los Angeles, where Latino and African-American kids struggle against a myriad of destructive influences, there is an option for a better life. Troubled teens discover their talents and self-dignity through “Colors United,” a performing arts group created for inner-city youth. This uplifting and emotional documentary offers powerful insights into the thoughts and feelings of these “at risk” children.

MEDIA SESSION 25  2:00 p.m.-5:00 p.m.
Versailles Ballroom, Third Floor, Hilton

WHEN DEVELOPMENT GOES AWRY
Chp.: Lesly T. Mega, M.D.

44 Come Back Jack
(55 minutes)

Distributor: Aquarius Healthcare Videos
5 Powderhouse Lane, P.O. Box 1159
Sherborn, MA 01770

Persistent ear infections, misguided medical treatments, and other mysterious physiological factors sent Jack’s mind spinning. His brilliant blue eyes grew glassy. He became a captive in his own world. By the time Jack reached the age of two, his intellectual and emotional development had come to a screeching halt. Terrified by the prospect of losing their youngest son, Jack’s parents began searching for answers. Initially, the medical “experts” labeled their handsome little boy as moderately to severely autistic. Come Back Jack chronicles the ups and downs of the Parish’s therapeutic journey, which led them to the Language and Cognitive Development Center in Lynnfield, Massachusetts. There, with the guidance of a team of special educators, Jack Parish began to emerge from his internal chaos, embracing life and the people who love him.

45 Autism: A World Apart
(29 minutes)
Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

Autism’s cause is unknown. There is no cure, and it strikes each victim differently. In Autism: A World Apart, three families show us what the textbooks cannot and what it’s like to live with autism. The video will show how to love and raise children who may be withdrawn, violent, and unable to connect with their families.

46 A Dyslexic Family Diary
(53 minutes)
Distributor: Filmmakers Library
Attn: Linda Gottesman
124 East 40th Street
New York, NY 10016

This film chronicles a mother’s 18-year struggle with the politics of teaching reading in order to get an education for her bright, dyslexic son. Dorothy Tod, the filmmaker/mother’s approach with the school is challenged by the very different perspective of her husband, a lawyer and former school board member. In a surprising twist, Dorothy discovers that she too has dyslexia, although it had not been diagnosed during her own school days. Dorothy’s son, Ben, was on the verge of suicide by the end of the sixth grade. This documentary explores the gift as well as the difficulties that come with dyslexia; how it plays out in education systems, legal and health systems, work, family, marriage, and daily life.

REVIEW OF PSYCHIATRY: SECTION 5
2:00 p.m.-5:30 p.m.
Rooms 343-345, Level 3, Convention Center

PSYCHIATRY UPDATE: SOMATOFORM AND FACTITIOUS DISORDERS
WEDNESDAY

Chp.: Katharine A. Phillips, M.D.

21 BDD
Katharine A. Phillips, M.D.

22 A Critical Analysis of Factitious Disorder
Marc D. Feldman, M.D.

23 Somatization Disorder
Vicenzio Holder-Perkins, M.D.

24 Conversion Disorder
Jose R. Maldonado, M.D.

25 Hypochondriasis
Brian A. Fallon, M.D.

SYMPOSIUM 65 2:00 p.m.-5:00 p.m.
Room 264, Level 2, Convention Center

UPDATE ON DEFICIT SCHIZOPHRENIA
Chp.: Silvana Galderisi, M.D.
Co-Chp.: Brian Kirkpatrick, M.D.

A The Italian Multicenter Study of Deficit Schizophrenia
Silvana Galderisi, M.D., Giovanni B. Cassano, M.D., Maria Del Zompo, M.D., Giordano Invernizzi, M.D., Alessandro Rossi, M.D., Antonio Vita, M.D., Mario Maj, M.D.

B The Treatment of Negative Symptoms
Donald C. Goff, M.D.

C Family Studies of Eye Tracking and the Heterogeneity of Schizophrenia
Dolores Malaspina, M.D.

D Course of Illness in Deficit Schizophrenia
Cenk Tek, M.D., Robert W. Buchanan, M.D., Brian Kirkpatrick, M.D.

E A Separate Disease Within the Syndrome of Schizophrenia
Brian Kirkpatrick, M.D., Robert W. Buchanan, M.D., David Ross, M.D., William T. Carpenter, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 66 2:00 p.m.-5:00 p.m.
Rooms 265/266, Level 2, Convention Center

WOMEN'S RESILIENCY TO ADVERSITY
Chp.: Susanne I. Steinberg, M.D.

A A Prospective Study of Depression in Pregnant Women: Risk Factors Related to Postpartum Relapse
Shaila Misri, M.D., Xanthoula Kostaras, B.S.C.

B Stalking: An Overview of the Problem
Gail E. Robinson, M.D., Karen M. Abrams, M.D.

C Attachment, Abuse, and Psychopathology Risk: Human Papillomavirus
Susanne I. Steinberg, M.D., Angela Lambrinos, M.S.C., Harriet Richardson, M.S.C., Eduardo L. Franco, M.D.

D Attributions of Cause and Recurrence in Long-Term Breast Cancer Survivors
Donna E. Stewart, M.D., A. Cheung, M.D., S. Duff, Felicia Wong, M. McQuestion, T. Cheng, Laura Purdy

E Challenges for Women in Academic Medicine
Katherine L. Wisner, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 67 2:00 p.m.-5:00 p.m.
Rooms 267-268, Level 2, Convention Center

CLINICAL ISSUES AND ETHICAL CONCERNS REGARDING ATTEMPTS TO CHANGE SEXUAL ORIENTATION: AN UPDATE
Association of Gay and Lesbian Psychiatrists and APA Committee on Gay, Lesbian, and Bisexual Issues

Chp.: Philip A. Bialer, M.D.
A Overview of the Research Problems and Ethics of Therapy to Change Sexual Orientation
Marshall Forstein, M.D.
B Subjects Who Claim to Have Benefited from Sexual Reorientation Therapy
Robert L. Spitzer, M.D., Jerome Wakefield, M.D.
C Clinical and Religious Attempts to Change Homosexual Orientations: An Empirical Study
Ariel Shicllo, Ph.D., Michael Schroeder, Psy.D.
D Ethical Issues in Efforts to Ban Reorientation Therapies
Mark Yarhouse, Psy.D., Warren Throckmorton, Ph.D.
E Ethical Concerns Raised When Patients Seek to Change Same-Sex Attractions
Jack Drescher, M.D.

Discussant: Paul S. Appelbaum, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 68 2:00 p.m.-5:00 p.m.
Room 269, Level 2, Convention Center

STATE VERSUS TRAIT DISTURBANCES FOUND IN EATING DISORDERS: RECENT FINDINGS
Chp.: Evelyn Attia, M.D.
A 5HT Function in Women with Anorexia Nervosa
Evelyn Attia, M.D., Sara Wolk, M.A., Thomas Cooper, M.A., Wahida Karmaly, Lauren Escott
B Resting Energy Metabolism in Anorexia Nervosa
Laurel Mayer, M.D., B. Timothy Walsh, M.D., Michael Rosenbaum, M.D., Rudolph Leibel, M.D., Richard Pierson, Jr., M.D., Erin Killory
C Psychobiological Studies of Women with Bulimia Nervosa
B. Timothy Walsh, M.D., Robyn J. Sysko, B.A., Ellen Zimmerli, Ph.D., Michael J. Devlin, M.D., Janet Guss, B.A., Harry Kissileff
D Eating Behavior in Binge Eating Disorder: Implications for Treatment
Michael J. Devlin, M.D., Claudia Kamenzet

Discussant: Walter H. Kaye, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 69 2:00 p.m.-5:00 p.m.
Room 270, Level 2, Convention Center

MODEL RESIDENCY PROGRAMS ON RELIGION AND SPIRITUALITY
Chp.: Francis G. Lu, M.D.
A Psychiatric Residency Training on Religion/Spirituality: An Overview
Francis G. Lu, M.D., Christina M. Puchalski, M.D.
B The Emory Spirituality, Religion, and Culture in Child and Adolescent Psychiatry Curriculum
Sandra Sexson, M.D., Shamina J. Henkel, M.D.
C The University of Alabama Curriculum on Religion, Spirituality, and Psychiatry
Nathan B. Smith, M.D.

D Expectable and Surprising Consequences of Templeton Award: A Three-Year Follow-Up at Baylor
James W. Lomax II, M.D., Linda B. Andrews, M.D., Arif M. Shoaiib, M.D.

Discussant: David B. Larson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 70 2:00 p.m.-5:00 p.m.
Room 271, Level 2, Convention Center

PSYCHOPATHOLOGICAL PATHWAYS FOLLOWING TRAUMATIC LIFE EXPERIENCE
Chp.: Bessel A. Van Der Kolk, M.D.
Co-Chp.: Julian Ford, Ph.D.
A Multiple Comorbidities or Trauma-Spectrum Disorders in the U.S. National Comorbidity Survey
Joseph F. Spinazzola, Ph.D., Cassandra Kisiel, Ph.D., Allison Tracy, Ph.D., Bessel A. Van Der Kolk, M.D.
B Traumatic Stress as an Antecedent to Psychotic Disorder
Alexander McFarlane, M.D., Gavin Andrews, Lorna Peters, Ph.D.
C Simple and Complex PTSD Among the Dually Diagnosed
Walter E. Penk, Ph.D., Jill Rieck, Ph.D., Marylee Losardo, M.S., Tatjana Mesheda, M.S., Charles Dreibing, Ph.D.
D Trauma, PTSD, and Disorders of Extreme Stress in Women with Severe Mental Illness
Julian Ford, Ph.D., Debra Fournier, B.A., Katherine Moffett, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 71  2:00 p.m.-5:00 p.m.
Rooms 335/336, Level 3, Convention Center

THE WORLD PSYCHIATRIC ASSOCIATION GLOBAL PROGRAM TO REDUCE THE STIGMA OF SCHIZOPHRENIA
_The World Psychiatric Association_

Chp.: Norman Sartorius, M.D.
Co-Chp.: Richard Warner, M.B.

A The German Program
Wolfgang Gaebel, M.D.

B World Psychiatric Association Antistigma Project: The Campaign in Canada
Julio E. Arboleda-Florez, M.D., Heather Stuart, Ph.D.

C The Campaign in Spain
Juan J. Lopez-Ibor, Jr., M.D.

D The Campaign in Egypt: Development, Activities, and Achievements
Mohamed H. El-Defrawi, Ismail Yosef, Magda Fahmy, Wafaa Hagag, Ashraf Tantany, Fatheia Nusseir, Moheb Salem

E The Campaign in India
Srinivasa Murthy, M.D.

Discussants: Bruce Link, Ph.D., Everett Rogers, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 72  2:00 p.m.-5:00 p.m.
Room 342, Level 3, Convention Center

EUROPEAN PERSPECTIVES ON THE BIOLOGY OF PERSONALITY DISORDERS
_The International Society for the Study of Personality Disorders_

Chp.: Kenneth R. Silk, M.D.
Co-Chp.: Jose L. Carrasco, M.D.

A Childhood Abuse and the HPA Axis in Adult Female Patients
Thomas Rinne, M.D., Wim Brink-Vanden, Ph.D., Jaap G. Geokoop, Ph.D., Roel Rijkode, Ph.D., E. Ronald Kloet, Ph.D.

B Dimensional Psychobiological Studies in BPD
Jose L. Carrasco, M.D., Marina Diaz-Marsa, M.D.

C Studies on Temperament Markers on Eating Disorders
Marina Diaz-Marsa, M.D., Jose L. Carrasco, M.D.

D Schizotypy: A Genetic, Epidemiological and Developmental Perspective
Marco Battaglia, M.D., Svend Torgersen, Ph.D., Andrea Fossati, M.D., Cesare Maffei, M.D.

E Serotonergic and Cognitive Impairment in Personality-Disordered Offenders
Mairead Dolan, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 73  2:00 p.m.-5:00 p.m.
Rooms 346/347, Level 3, Convention Center

AN EIGHT-WEEK RANDOMIZED TRIAL OF FLUVOXAMINE FOR PEDIATRIC ANXIETY DISORDER

Chp.: Laurence L. Greenhill, M.D.

A Background and Significance of the Research Units of Pediatric Psychopharmacology (RUPP) Pediatric Anxiety Disorder Trial of Fluvoxamine
Laurence L. Greenhill, M.D.

B Moderators and Mediators of Treatment Effect in the RUPP Pediatric Anxiety Disorder Trial of Fluvoxamine
Benedetto Vititello, M.D.

C Data from the Intent-to-Treat Data Analysis: RUPP Pediatric Anxiety Disorder Trial of Fluvoxamine
Daniel S. Fine, M.D.

D Use of the Pediatric Anxiety Rating Scale in the RUPP Pediatric Anxiety Disorder Trial of Fluvoxamine
John T. Walkup, M.D., Mark A. Riddle, M.D.

Discussant: Mark A. Riddle, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 74  2:00 p.m.-5:00 p.m.
Room 352, Level 3, Convention Center

PSYCHIATRIC MANAGEMENT IN NEUROLOGICAL DISEASE

Chp.: Edward C. Lauterbach, M.D.

A Psychiatric Aspects of Parkinson's Disease
Matthew A. Menza, M.D.

B Psychiatric Management in Huntington's Disease
Neal G. Ranen, M.D.

C Psychiatric Management in Wilson's Disease
Edward C. Lauterbach, M.D.

D Psychiatric Management of Stroke
Robert G. Robinson, M.D.

E Psychiatric Management in Multiple Sclerosis
Randolph B. Schiffer, M.D.

F Neuropsychiatric Aspects of AIDS
Francisco Fernandez, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 75  2:00 p.m.-5:00 p.m.
Room 356, Level 3, Convention Center

CRITICAL ISSUES IN EARLY INTERVENTION OF THE PSYCHOSIS PRODROME

Chp.: Tandy J. Miller, Ph.D.
Co-Chp.: Thomas H. McGlashan, M.D.

(Continued on next page)

85
A Early Detection by Screening Relatives of Schizophrenic Patients
Scott W. Woods, M.D., Tandy J. Miller, Ph.D., Lawrence Davidson, Ph.D., Keith A. Hawkins, Psy.D., Michael J. Sernyak, M.D.

B Diagnosing and Rating the Psychosis Prodrome
Tandy J. Miller, Ph.D., Thomas H. McGlashan, M.D., Joanna Rosen, Ph.D., Scott W. Woods, M.D.

C Psychosis Prodrome, Conversion, and Neuropsychological Course

D Medication Prescribed by Community Providers for Patients in Schizophrenic Prodromal States
Adrian Preda, M.D., Tandy J. Miller, Ph.D., Scott W. Woods, M.D., Joanna Rosen, Ph.D., Lubnee Somjee, Ph.D., Thomas H. McGlashan, M.D.

E Short-Term Outcome of Prodromal Patients Treated at Conversion to Psychosis
Joanna Rosen, Ph.D., Thomas H. McGlashan, M.D., Tandy J. Miller, Ph.D., Lubnee Somjee, Ph.D., Scott W. Woods, M.D.

F Ethical Issues in the Pre-Onset Treatment of Schizophrenia
Thomas H. McGlashan, M.D., Tandy J. Miller, Ph.D., Scott W. Woods, M.D., Joanna Rosen, Ph.D., Lawrence Davidson, Ph.D., Adrian Preda, M.D., Philip Markovich, B.S.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 76 2:00 p.m.-5:00 p.m.
Room 357, Level 3, Convention Center

MIND/brains, REDUCTION, AND SCHIZOPHRENIA
Chp.: John Z. Sadler, M.D.
Co-Chp.: Gerrit Glas, M.D.

A Understanding Anxiety: Conceptual, Clinical, and Neuroscientific Considerations
Gerrit Glas, M.D.

B Mind and Brain in Schizophrenia: Two Sides of the Same Coin?
Aaron L. Mishara, Ph.D.

C Ontological Reduction and Integration in Psychiatric Genetics Research
John Z. Sadler, M.D.

D The Cognitive Neuropsychiatry of Disorders of Will and Volition
Sean A. Spence, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 79 2:00 p.m.-5:00 p.m.
Grand Salon Sections 9 & 12, Street Level, Hilton

PSYCHOBIOLOGY AND PHARMACOTHERAPY OF BPD
Chp.: John M. Oldham, M.D.
Co-Chp.: Andrew E. Skodol II, M.D.

A Biological Correlates of BPD
Emil F. Coccaro, M.D.

B Psychobiology of Human Personality
C. Robert Cloninger, M.D.

C Longitudinal Patterns of Medication Utilization in BPD
John M. Oldham, M.D., Andrew E. Skodol II, M.D.,
Donna S. Bender, Ph.D., Regina T. Dolan, Ph.D., John G.
Gunderson, M.D.

D Pharmacotherapy of BPD
Paul H. Soloff, M.D.

E Clinical Management of Suicidality in BPD
Maria A. Oquendo, M.D., J. John Mann, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 80 2:00 p.m.-5:00 p.m.
Grand Salon Sections 19 & 22, Street Level, Hilton

SPECIAL TOPICS IN WOMEN'S MENTAL HEALTH
Chp.: Rajesh M. Parikh, M.D.
Co-Chp.: Shamsah B. Sonawalla, M.D.

A Alcoholism and Drug Abuse in Women
Monica L. Zilberman, Ph.D., Hermano Tavares, Ph.D.

B Pathological Gambling in Women
Hermano Tavares, Ph.D., Monica L. Zilberman, Ph.D.,
Fabio J. Beites, M.D., Valentim Gentil, M.D.

C The Role of Estrogen in Perimenopausal Depression
Claudio N. Soares, M.D., Lee S. Cohen, M.D.

D Comorbid Depression and Anxiety Disorders in Couples Presenting for In Vitro Fertilization
Rajesh M. Parikh, M.D., Shamsah B. Sonawalla, M.D.,
Firuza R. Parikh, M.D.

Discussant: David Mischoulon, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 81 2:00 p.m.-5:00 p.m.
Grand Salon Sections 21 & 24, Street Level, Hilton

THE ROLE OF RELIGION IN THE LIVES OF OUR PATIENTS: CLINICAL APPROACHES
Chp.: Irving S. Wiesner, M.D.

A Religion as a Framework in Understanding and Responding to Mental Illness
Irving S. Wiesner, M.D.

B The Role of Religion in the Lives of Our Patients: A Hindu Approach
Nalini V. Juthani, M.D.

C The Special Needs of the Orthodox Jewish Patient
Abba E. Borowich, M.D.

D Personhood and the Pursuit of Happiness: A Catholic Perspective
Judith A. Hughes, M.D.

E Clinical Challenges with Protestant Patients: Sin, Guilt, and Forgiveness
Mark E. Servis, M.D.

Discussant: Mohammad Shafii, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 82 2:00 p.m.-5:00 p.m.
Marlborough Suite A/B, Second Floor, Hilton

UPDATE ON TREATMENT OF STIMULANT ABUSE
Chp.: David A. Gorelick, M.D.

A Recovery-Oriented Psychosocial Treatments
Douglas M. Ziedonis, M.D., Jonathan Krejci, Ph.D., Marc Steinberg, M.A., Sylvia Atidja, Carolyn Eick, M.A., David A. Smelson, Psy.D.

B Psychotherapy and Counseling Approaches for Cocaine Abuse Treatment
David R. Gastfriend, M.D.

C Pharmacological Treatment of Stimulant Abuse
David A. Gorelick, M.D.

D Psychiatric Comorbidity in Stimulant Abusers
Richard N. Rosenthal, M.D.

E Methamphetamine Abuse: Update 2001
Steven L. Batki, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 83 2:00 p.m.-5:00 p.m.
Melrose Room, Third Floor, Hilton

POLITICS OF ADMINISTRATIVE RELATIONSHIPS IN PSYCHIATRY
Chp.: Wesley E. Sowers, M.D.

A Defining Administrative Roles: Divide and Cooperate
Clifton R. Tennison, Jr., M.D.

B Developing Relationships and Enhancing Roles in a Managed Care Organization
William G. Wood, M.D.

(Continued on next page)
C Psychiatrist/Administrator Alliances in Public Psychiatry
  Thomas A. Simpatico, M.D., Christopher G. Fichtner, M.D.

D Navigating in Rough Water: When It Doesn't Work
  Gordon H. Clark, Jr., M.D.

E The Value of Medical Leadership: More Than a Dream?
  Kathleen A. Daly, M.D.

Discussants: Anthony Arce, M.D., Jacqueline M. Feldman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 84  2:00 p.m.-5:00 p.m.
Rosedown Room, Third Floor, Hilton

OUTREACH TO BUSINESS: THE AMERICAN PSYCHIATRIC ASSOCIATION BUSINESS INITIATIVE
APA Committee on APA/Business Relationships

Chp.: Norman A. Clemens, M.D.
Co-Chp.: Jeffrey P. Kahn, M.D.

A Quality Mental Health Care and the Corporate Bottom Line
  Norman A. Clemens, M.D.

B Organizations and Their Impact on Productivity and Health
  Leonard T. Sperry, M.D.

C Helping Business to Understand Psychiatric Skills
  Marcia K. Goin, M.D.

D Patients' Workplace Lives: Career, Performance, and Development
  Jeffrey P. Kahn, M.D.

E Special Concerns of Business Conflict Management, Disability, Violence, and Employee Turnover
  Stephen H. Heidel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 85  2:00 p.m.-5:00 p.m.
Magnolia Room, Third Floor, Hilton

QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA: RESEARCH IN EUROPE AND THE AMERICAS

Chp.: Jacques Fortineau, M.D.
Co-Chp.: John A. Talbott, M.D.

A Quality of Life: History and Development in the U.S.
  Anthony F. Lehman, M.D.

B The Definition and Evaluation of Quality of Life
  Pierre Lalonde, M.D.

C Schizophrenia and Quality of Life Across Europe
  Viviane Kovess, M.D., Jose M. Caldas de Almeida, M.D.,
  Mauro G. Carta, M.D., Jacques M. Dubuis, M.D., Jacques Pellet, M.D., Jean-Luc Koellandt, M.D., Hans Salize, Ph.D.

D Quality of Life for Patients with Schizophrenia Treated in Day Hospitals
  Francois C. Petitjean, M.D., Corinne Launay, M.D., Franck Salone, Jean-Claude Demant, M.D.

E Quality of Life in Schizophrenia: A Two-Year Follow-Up Study of 145 Outpatients
  Oliver J. Caneill, M.D., Marcos Sampaio-Meireles, M.D.,
  Marie-Chantal Bourdel, Jean-Pierre Olie, M.D., Marie F. Poirier-Litbre, M.D.

F Quality-Adjusted Life Year (QALY) Measurement in Persons with Schizophrenia
  Jeffrey M. Pyne, M.D., Greer Sullivan, M.D., D. Keith Williams, Ph.D.

Discussants: Alexandra MacLean, M.D., F. Regis Cousin, M.D.,
  Gerald J. Sarwer-Foner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 86  2:00 p.m.-5:00 p.m.
Jasperwood Room, Third Floor, Hilton

CATATONIA AND NMS: PAST, PRESENT, AND FUTURE

Chp.: Brendan T. Carroll, M.D.
Co-Chp.: Harold W. Goforth, M.D.

A Development of the Concept of Catatonia: A Historical Overview
  Stephanie Kruger, M.D., Peter Braunig, M.D.

B The Nosology of Catatonia
  Gabor S. Ungvari, M.D.

C Laboratory Findings in Catatonia
  Joseph W. Lee, M.D.

D Catatonia in the Context of Medical Illness
  Brendan T. Carroll, M.D., Harold W. Goforth, M.D.

E NMS and Other Drug-Induced Catatonias
  Andrew J. Francis, M.D.

Discussants: Georg Northoff, M.D., Denise A.C. White, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 87  2:00 p.m.-5:00 p.m.
Oak Alley Room, Third Floor, Hilton

ADVANCE DIRECTIVES IN PSYCHIATRY: TREATMENT RESEARCH AND END OF LIFE

Chp.: Mary E. Foti, M.D.
Co-Chp.: Philip J. Candilis, M.D.
A Psychiatric Advance Directives: An Emerging Form of Psychosocial Intervention?
Patricia Backlar, Ph.D.

B Research Advance Directives in Psychiatry
Donald L. Rosenstein, M.D.

C End-of-Life Care and Mental Illness: A Model for All Disciplines
Philip J. Candilis, M.D., Mary E. Foti, M.D.

D Cognitive Variables in the Informed-Consent Assessment Process
Jacob C. Hofer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 88 2:00 p.m.-5:00 p.m.
Elmwood Room, Third Floor, Hilton

PSYCHOCUTANEOUS MEDICINE
Chp.: Donald J. Kushon, Jr., M.D.

A Introduction: Overview and Classification System for Psychocutaneous Disease
Donald J. Kushon, Jr., M.D.

B Stress and Cutaneous Biology
Francisco Tausk, M.D.

C Pruritus: Psychogenic and Central Factors
Iona Ginsberg, M.D.

D Treatment of Self-Mutilation
Sylvia G. Garnis-Jones, M.D.

E Integration of Psychotherapy and Psychoanalysis Into Dermatology Practice
Caroline S. Koblenzer, M.D.

F Psychopharmacology
Donald J. Kushon, Jr., M.D.

G Nonpharmacologic Management of Psychocutaneous Problems
Richard G. Fried, M.D.

Discussants: Francisco Tausk, M.D., Iona Ginsberg, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 89 2:00 p.m.-5:00 p.m.
Belle Chasse Room, Third Floor, Hilton

THE USE OF FORCE IN PSYCHIATRY: WHEN IS IT HELPFUL AND WHEN IS IT NOT? PART II
American Association of Community Psychiatrists
Chp.: David A. Pollack, M.D.

A Seclusion and Restraint in Child and Adolescent Facilities
Wanda Mohr, Ph.D.

B Excessive Use of Force: The Family Perspective
Andrea Eberle, M.D.

C Seclusion, Restraint, and Holding of Children and Adolescents: A Clinical Community Perspective
Charles W. Huffine, Jr., M.D.

D Use of Seclusion, Restraint, and Force in Juvenile Justice Settings
Debbie R. Carter, M.D.

E Managing and Treating Behavioral Dyscontrol in People with Developmental Disabilities
Ruth M. Ryan, M.D.

F Pharmacological Approaches: When Are They Indicated?
Andres J. Pumariega, M.D.

THIS SESSION WILL BE AUDIOTAPED.

TELECOMMUNICATIONS SESSION 4
2:00 p.m.-5:00 p.m.
Rooms 260/261, Level 2, Convention Center

DIGITAL DANGERS: SEX, SUICIDE, AND ADDICTIONS ON THE WEB
Chp.: Jonathan M. Metzl, M.D.

12 Caught in the Web: Sex, Suicide, and Addictions on the Internet
Keith Cheng, M.D., Kyle P. Johnson, M.D., Joshua F. Boverman, M.D., Laura Proud, B.A.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 9
3:00 p.m.-5:00 p.m.
Exhibition Center, Second Floor, Hilton

ANXIETY, ALCOHOL AND DRUG, SEX AND GENDER, AND SOMATOFORM DISORDERS; ADDICTION PSYCHIATRY; HEALTH SERVICES RESEARCH; PSYCHOIMMUNOLOGY; STRESS; AND VIOLENCE

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 44-48

INDUSTRY-SUPPORTED SYMPOSIUM 44
7:00 p.m.-10:00 p.m.
Hall G, Lobby Level, Convention Center

PLASTICITY AS EFFICACY? NEUROTROPHIC EFFECTS OF MOOD STABILIZERS
Supported by Abbott Laboratories

(Continued on next page)
A Neurotrophic and Neuroprotective Effects of Mood Stabilizers
Husseini K. Manji, M.D.

B Clinical and Neuroimaging Evidence of Illness Progression in Bipolar Disorder
Terence A. Ketter, M.D.

C Implications for the Treatment of Alzheimer’s Disease
Pierre N. Tariot, M.D.

D PTSD, Substance Use Disorders, and Personality Disorders: Commonalities in Mechanisms and Treatment
Hugh Myrick, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 45
7:00 p.m.-10:00 p.m.
La Nouvelle Ballroom, Level 2, Convention Center

BIPOLAR SPECTRUM DISORDERS: U.S. AND EUROPEAN PERSPECTIVES
Supported by the International Academy for Biomedical and Drug Research

Chp.: Lewis L. Judd, M.D.
Co-Chp.: Giorgio Racagni, Ph.D.

A Longitudinal Studies of Bipolar Disorders: Is There a Spectrum?
Lewis L. Judd, M.D.

B Bipolar Spectrum: Clinical and Familial Validation
Hagop S. Akiskal, M.D.

C Molecular Genetic Evidence for the Bipolar Spectrum
Julien Mendlewicz, M.D.

D Treatment Advances in Bipolar Spectrum Disorders: Mood Stabilizers
Susan L. McElroy, M.D.

E Treatment Advances in Bipolar Spectrum Disorders: Atypical Antipsychotics
Guy M. Goodwin, M.D.

Discussants: Julien Mendlewicz, M.D., Giorgio Racagni, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 46
7:00 p.m.-10:00 p.m.
Grand Ballroom A/B, Street Level, Hilton

ADVANCES IN ADHD: NAVIGATING COMORBIDITY
Supported by Alza Corporation

Chp.: Timothy E. Willens, M.D.
Co-Chp.: Joseph Biederman, M.D.

A Overview of Comorbid Conditions in ADHD
Joseph Biederman, M.D.

B Patterns of Comorbidity in ADHD: Artifact or Reality?
Stephen V. Faraone, Ph.D.

C Depressive Disorders and ADHD
Thomas J. Spencer, M.D.

D Bipolar Disorder and ADHD: An Overlooked Comorbidity
Janet Wozniak, M.D.

E ADHD and the Substance Use Disorders
Timothy E. Willens, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 47
7:00 p.m.-10:00 p.m.
Grand Ballroom C/D, Street Level, Hilton

EXCESSIVE DAYTIME SLEEPINESS: EVALUATION AND MANAGEMENT IN PSYCHIATRY
Supported by Cephalon Inc.

Chp.: John W. Winkelman, M.D.

A Neural Substrates of Arousal and Sleep: New Vistas
Robert W. McCarley, M.D.

B Evaluation and Measurement of Daytime Sleepiness
Mary A. Carskadon, Ph.D.

C Disorders of Excessive Daytime Somnolence: Diagnosis and Management
Karl Doghramji, M.D.

D Excessive Daytime Sleepiness in the Psychiatric Patient
John W. Winkelman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 48
7:00 p.m.-10:00 p.m.
Grand Ballroom A-C, Fifth Floor, Sheraton

AN EVIDENCE-BASED MEDICINE APPROACH TO PEDIATRIC PSYCHIATRY
Supported by Ortho-McNeil Pharmaceutical

Chp.: Robert L. Findling, M.D.

A Effects of Risperidone on the Behavior of Children with Subaverage IQs and Conduct Disorder or Oppositional Defiant Disorder
Michael G. Aman, Ph.D., Robert L. Findling, M.D., Albert T. Derivan, M.D., Ursula Merriman, M.S.

B Long-Term Efficacy in Conduct Disorder: Evidence from Maintenance Trials
Robert L. Findling, M.D.
A Placebo-Controlled Trial of Risperidone in Tourette’s Disorder: Preliminary Results
Lawrence D. Scahill, Ph.D.

Comparative Use of Olanzapine and Risperidone in Psychotic Youth
Linmarie Sikich, M.D., Joseph P. Horrigan, M.D., Jeffrey A. Lieberman, M.D., L. Jarrett Barnhill, Jr., M.D., Brian B. Sheitman, M.D., Helen E. Courvoisie, M.D.

Discussant: Judith H.L. Rapoport, M.D.

MEDIA SESSIONS 26-27

MEDIA SESSION 26
Napoleon Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES
Chp.: David A. Halperin, M.D.

47 The Talented Mr. Ripley
(139 minutes)
Distributor: Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

To be young and carefree amid the blue waters and idyllic landscape of sun-drenched Italy in the late 1950s is the life that Tom Ripley, played by Matt Damon, craved and the life that Dickie Greenleaf, played by Jude Law, led. When Dickie’s father, a wealthy ship builder, asks Tom to bring his errant playboy son back home to America, Dickie and his beautiful expatriate girlfriend, Marge Sherwood, played by Gwyneth Paltrow, never suspect the dangerous extremes to which Ripley will go to make their lifestyle his own. After all, it’s better to be a fake somebody than a real nobody. Paramount Pictures and Miramax Films present The Talented Mr. Ripley directed by Academy Award winner Anthony Minghella.

PSYCHIATRY GOES TO THE MOVIES
Chp.: Richard E. D’Alli, M.D.

48 2001: A Space Odyssey
(148 minutes)
Distributor: Swank Motion Pictures, Inc.
350 Vanderbilt Motor Parkway
Hauppauge, NY 11787

Ushering in a new era of cinematic special effects, Stanley Kubrick’s grand space fantasy unfolds almost like an avant-garde film, telling its largely nonverbal story through balletic, hypnotic imagery. 2001: A Space Odyssey provides the metaphor of a mysterious monolith that advances human development in various eras. Kubrick’s breathtakingly evolutionary leaps of logic and almost abstract visual expression convey his meditations on the godlike potential within the ape-like human species. Emotionally remote, with characters seeming less human than the computer onboard the spacecraft, 2001 brought about a quantum jump in the aspirations of the sci-fi genre.
American Psychiatric Association

Audiotapes
Recorded Live!

High Quality Continues for the 2001 Annual Meeting ...

Live recordings will be available for most of the following:

- Lectures • Advances in Research
- Presidential Symposium • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Research Advances in Medicine

Tapes may be purchased on site at Mobiltape’s booth in the Convention Center, Lobby Level.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 • (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com
THURSDAY, MAY 10, 2001

154TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 40-43

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 40, PART 2
7:00 a.m.-8:30 a.m.
Hall G, Lobby Level, Convention Center

CLINICAL CHALLENGES IN ANXIETY
Supported by Pfizer Inc.

Chp.: Mark H. Pollack, M.D.
Co-Chp.: James W. Jefferson, M.D.

A Clinical Challenges: Anxiety and Substance Abuse
Kathleen T. Brady, M.D.

B PTSD: Phenomenology and Treatment Approaches
Naomi M. Simon, M.D.

C Integrated Psychosocial Strategies with Pharmacotherapy
Michael W. Otto, Ph.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 41, PART 2
7:00 a.m.-8:30 a.m.
La Nouvelle Ballroom, Level 2, Convention Center

A NEW ERA FOR MANAGING PSYCHOSIS:
REBUILDING LIVES FOR PATIENTS AND FAMILIES
Supported by Janssen Pharmaceutica

Chp.: Ira D. Glick, M.D.
Co-Chp.: Stephen R. Marder, M.D.

A Consumer Organizations Improve Medication Compliance
Ira D. Glick, M.D.

B Enhancing Outcomes with Atypical Antipsychotics:
Weight, Akathisia, Affect, and Insight
S. Nassir Ghaemi, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 2
7:00 a.m.-8:30 a.m.
Grand Ballroom A/B, Street Level, Hilton

DEPRESSION: GENDER, AGE, AND SPECIAL POPULATIONS
Supported by Eli Lilly and Company

Chp.: David L. Dunner, M.D.

A Depression and the Treatment-Resistant Patient
Richard C. Shelton, M.D.

B The Depressed Patient with Comorbid Illness
Wayne J. Katon, M.D.

8:00 a.m. Sessions

COURSES 95-99
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 95 8:00 a.m.-12 noon
La Galerie 1, Second Floor, Marriott
HOW TO COMBAT THE STIGMA OF MENTAL ILLNESS
The World Psychiatric Association
Director: Richard Warner, M.B.
Faculty: Corinne L. Shaffer-Rogers, Ph.D., Barbara Hocking, B.S.C., Otto F. Wahl, Ph.D., Fay Herrick

COURSE 96 8:00 a.m.-12 noon
La Galerie 4, Second Floor, Marriott
INCREASING THE RELIABILITY OF OUTCOME MEASURES IN PSYCHIATRIC CLINICAL TRIALS
Director: Nina Engelhardt, Ph.D.
Faculty: Pierre V. Tran, M.D.

COURSE 97 - CANCELLED
THURSDAY

COURSE 98  8:00 a.m.-12 noon
Bacchus Room, Fourth Floor, Marriott

HOW TO BE MORE EFFECTIVE WITH MANAGED CARE "DOC-TO-DOC" REVIEWS

Director: Gabriel Kaplan, M.D.
Faculty: Elizabeth J. Rody, M.D., Matthew M. Keats, M.D.,
Neal R. Satten, M.D.

COURSE 99  8:00 a.m.-12 noon
Balcony K, Fourth Floor, Marriott

LIMIT SETTING WITH PSYCHIATRIC PATIENTS

Director: Donald A. Misch, M.D.
Faculty: Lydia E. Weisser, D.O., David W. Heilman, M.D.

9:00 a.m. Sessions

COURSES 100-102
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 100  9:00 a.m.-4:00 p.m.
La Galerie 2, Second Floor, Marriott

MODEL COMPLIANCE PLAN FOR SMALL PSYCHIATRIC PRACTICES

Co-Directors: Michael D. Murphy, M.D., Anne M. DeFelippo, J.D.

COURSE 101  9:00 a.m.-4:00 p.m.
Balcony J, Fourth Floor, Marriott

MULTIMODAL TREATMENT OF EATING DISORDERS

Co-Directors: Kathryn J. Zerbe, M.D., Mae S. Sokol, M.D.

COURSE 102  9:00 a.m.-4:00 p.m.
Balcony L, Fourth Floor, Marriott

HOW TO PRACTICE EVIDENCE-BASED PSYCHIATRY

Director: David R.S. Haslam, M.D.
Faculty: John Geddes, M.R.C., Elliot M. Goldner, M.D.,
David M. Gardner, Pharm.D.

DISCUSSION GROUPS 22-23

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

22 Silvia Hafliger, M.D., on Hepatitis C: What Every Psychiatrist Needs to Know
Chequers Suite, Second Floor, Hilton

23 Linda L.M. Worley, M.D., on Life Balance as a Psychiatrist… Easier Said Than Done!
Trafalgar Suite, Third Floor, Hilton
The expansion of computing power, the increase in the human life span, and the growth in technologies for communication, brain and genome scanning, and miniaturization of machines are likely to continue and accelerate in the 21st century. Ray Kurzweil explores how these developments may profoundly alter our experience in the century ahead. Over the past 30 years, Mr. Kurzweil has been at the forefront in the development of several products based on artificial intelligence and pattern recognition technologies, including print-to-speech reading machines for the blind, optical character recognition systems, the flat-bed scanner, text-to-speech and music synthesizers, and speech recognition systems. He is the author of three books, including *The Age of Intelligent Machines*, named the Most Outstanding Computer Science Book of 1990 by the Association of American Publishers, and *The Age of Spiritual Machines: When Computers Exceed Human Intelligence*. His national and international awards include the Dickson Prize (Carnegie Mellon University's top science prize), Engineer of the Year from *Design News*, Inventor of the Year from the Massachusetts Institute of Technology, the Grace Murray Hopper Award from the Association for Computing Machinery, and the National Medal of Technology. He is a graduate of the Massachusetts Institute of Technology in Cambridge.

**THESE SESSIONS WILL BE AUDIOTAPED.**

**MASTER EDUCATOR**

**CLINICAL CONSULTATIONS 18-20**

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

18 Howard J. Osofsky, M.D., on BPD: Considerations of the Cultural Context in Evaluation and Treatment
Room 337, Level 3, Convention Center

19 Don R. Lipsitt, M.D., on Patients Who Somatize
Room 340, Level 3, Convention Center

20 Nyapati R. Rao, M.D., on Crucial Issues in Training of International Medical Graduates as Psychiatrists
Room 341, Level 3, Convention Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

**MEDIA SESSION 28**

9:00 a.m.-11:00 a.m.
Versailles Ballroom, Third Floor, Hilton

**THE SECRETS OF LONGEVITY**

Chp.: Cheryl A. Kennedy, M.D.

49 *How to Live to Be 100*  
(52 minutes)

**Distributor:** Filmakers Library  
Attn: Linda Gottesman  
124 East 40th Street  
New York, NY 10016

People are living longer and healthier lives and centenarians are no longer a rarity. This film presents us with the latest research on the elderly in the U.S., China, and Denmark. James Vopel of the Max Planck Institute in Germany, and a senior scientist at Duke University leads a team of scientists seeking to unravel the secrets of longevity. It has been observed that every decade the number of centenarians double. Once people reach 80, the mortality rate seems to reach a plateau. Why do some people survive past 80? Through studying factors such as lifestyles, heredity, and nutrition, the film provides insights into the elusive secrets of long life. At the same time it challenges stereotypes about the extreme elderly.

**WORKSHOPS**

**COMPONENTS 46-52**

**COMPONENT WORKSHOP 46**  
9:00 a.m.-10:30 a.m.  
Room 264, Level 2, Convention Center

**RESPONSES TO THE SURGEON GENERAL’S REPORT ON MENTAL HEALTH**

APA Council on Psychiatric Services, American Association for Social Psychiatry, American Association of Community Psychiatrists, and American Orthopsychiatric Association

Co-Chps.: Zebulon C. Taintor, M.D., Kenneth S. Thompson, M.D.  
Participants: Howard H. Goldman, M.D., Altha J. Stewart, M.D., Joel S. Feiner, M.D.

**COMPONENT WORKSHOP 47**  
9:00 a.m.-10:30 a.m.  
Rooms 265/266, Level 2, Convention Center

**FINDING COMMON GROUND: GAYS AND LESBIANS TOGETHER**

APA New York County Branch’s Committee on Gay and Lesbian Issues

Co-Chps.: Steven T. Wozniak, M.D., Julie K. Schulman, M.D.  
Participants: Mary E. Barber, M.D., Serena Y. Volpp, M.D., Lisa R. Fortuna, M.D.

**COMPONENT WORKSHOP 48 - CANCELLED**
THURSDAY

COMPONENT WORKSHOP 49 9:00 a.m.-10:30 a.m.
Room 342, Level 3, Convention Center

THE USE OF ANABOLIC AND ANDROGENIC STEROIDS IN HIV DISEASE
APA Commission on AIDS
Chp.: Marshall Forstein, M.D.
Participant: Stephen J. Ferrando, M.D.

COMPONENT WORKSHOP 50 9:00 a.m.-10:30 a.m.
Rooms 346/347, Level 3, Convention Center

TREATMENT OF CHILD AND ADOLESCENT VICTIMS OF CRIME: NEW GUIDELINES FROM CALIFORNIA
APA Committee on Family Violence and Sexual Abuse
Co-Chps.: Graeme Hanson, M.D., Michele Winterstein, Ph.D.
Participant: Bradley D. Stein, M.D.

COMPONENT WORKSHOP 51 9:00 a.m.-10:30 a.m.
Grand Salon Section 4, Street Level, Hilton

PRACTICE GUIDELINES, STANDARDS, AND QUALITY INDICATORS: APA INITIATIVES
APA Council on Quality Improvement
Chp.: Sara C. Charles, M.D.
Participants: John M. Oldham, M.D., Charles E. Riordan, M.D., John S. McIntyre, M.D., Rhonda J.R. Beale, M.D., James C. MacIntyre, M.D.

COMPONENT WORKSHOP 52 9:00 a.m.-10:30 a.m.
Prince of Wales Suite, Second Floor, Hilton

PSYCHIATRIC DISCHARGE IN THE CRIMINAL JUSTICE SYSTEM
APA Consortium on Special Delivery Settings
Chp.: Cassandra F. Newkirk, M.D.
Participants: Ludwik S. Szymanski, M.D., Heather Barr, J.D., Erik J. Roskes, M.D., Hunter L. McQuistion, M.D.

ISSUE WORKSHOP 99 9:00 a.m.-10:30 a.m.
Room 270, Level 2, Convention Center

MENTAL HEALTH IN A JAIL
Chp.: Ole J. Thienhaus, M.D.
Participants: Joan Williamson, R.N., Melissa P. Piasecki, M.D.

ISSUE WORKSHOP 100 9:00 a.m.-10:30 a.m.
Room 271, Level 2, Convention Center

PROSPERING: MARKET DYNAMICS IN THE NEW POLITICAL CRUCIBLE
Chp.: Stuart B. Silver, M.D.
Participants: Dave M. Davis, M.D., Gary E. Miller, M.D., W. Walter Menninger, M.D., Philip E. Veenhuis, M.D.

ISSUE WORKSHOP 101 9:00 a.m.-10:30 a.m.
Room 272, Level 2, Convention Center

TEACHING PSYCHOPHARMACOLOGY TO RESIDENTS USING EVIDENCE-BASED ALGORITHMS
Chp.: David N. Osser, M.D.
Participants: Dan O. Ioanitescu, M.D., Jessica R. Oesterhedi, M.D., James J. Levitt, M.D.

ISSUE WORKSHOP 102 9:00 a.m.-10:30 a.m.
Room 273, Level 2, Convention Center

IF THERAPY IS NEEDED BUT NOT AVAILABLE, WHAT SHOULD WE DO?
Chp.: Theodor Bonstedt, M.D.
Participants: Janet W. Eustis, M.S.W., Raymond A. Johnson, M.D., Debra M. Patterson, M.A.

ISSUE WORKSHOP 103 9:00 a.m.-10:30 a.m.
Rooms 333/334, Level 3, Convention Center

IMPLEMENTING OUTPATIENT COMMITMENT IN NEW YORK CITY: A FORENSIC PERSPECTIVE
Co-Chps.: A. Sasha Bardey, M.D., Deborah S. Rose, Psy.D.
Participant: Gary R. Collins, M.D.

ISSUE WORKSHOP 104 9:00 a.m.-10:30 a.m.
Rooms 335/336, Level 3, Convention Center

MEMORY SCREENING PROGRAM FOR COMMUNITY-DWELLING ELDERS: A PRACTICAL APPROACH
Co-Chps.: Janet M. Lawrence, M.D., Donald A. Davidoff, Ph.D.
Participant: Debra Katt-Lloyd, B.S.
ISSUE WORKSHOP 105 9:00 a.m.-10:30 a.m.
Rooms 348/349, Level 3, Convention Center

ADMINISTRATIVE PSYCHIATRY: HOW TO PREPARE TO MEET THE CHALLENGE
Chp.: Paul Rodenhauser, M.D.

ISSUE WORKSHOP 106 9:00 a.m.-10:30 a.m.
Rooms 350/351, Level 3, Convention Center

COGNITIVE-BEHAVIORAL THERAPY TRAINING FOR RESIDENTS: HOW TO TEACH, MEASURE, AND ATTAIN RESIDENT COMPETENCY
Chp.: Donna M. Sudak, M.D.
Participants: Judith S. Beck, Ph.D., Hinda F. Dubin, M.D., Jesse H. Wright, M.D.

ISSUE WORKSHOP 107 9:00 a.m.-10:30 a.m.
Room 352, Level 3, Convention Center

HOW TO GIVE A MORE EFFECTIVE LECTURE: PITH, PUNCH, AND POLISH
Chp.: Phillip J. Resnick, M.D.

ISSUE WORKSHOP 108 9:00 a.m.-10:30 a.m.
Room 357, Level 3, Convention Center

BIOBEHAVIORAL INTEGRATION OF ADDICTION TREATMENT
Chp.: Richard J. Frances, M.D.
Participants: Sheldon I. Miller, M.D., Robert B. Millman, M.D., Sheila B. Blume, M.D., Marc Galanter, M.D., Lionel P. Solursh, M.D., Frances R. Levin, M.D.

ISSUE WORKSHOP 109 9:00 a.m.-10:30 a.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

ACHIEVING COMPREHENSIVE CARE FOR CHRONICALLY SUICIDAL INDIVIDUALS
Chp.: Ian C. Dawe, M.D.
Participants: Paul S. Links, M.D., Yvonne Bergmans, M.S.W.

ISSUE WORKSHOP 110 9:00 a.m.-10:30 a.m.
Grand Salon Sections 9 & 12, Street Level, Hilton

TEACHING THE CLINICAL ESSENTIALS: THE ROLE OF THE PSYCHIATRIST
Chp.: David C. Lindy, M.D.
Participants: Neil Pessin, Ph.D., Howard W. Telson, M.D., Christina Fragola, C.S.W., Annette Cutrino, C.S.W., Stephanie Moeller, M.A.

ISSUE WORKSHOP 111 9:00 a.m.-10:30 a.m.
Grand Salon Sections 13 & 16, Street Level, Hilton

THE IMPORTANCE OF PSYCHIATRIC MANAGEMENT FOR INPATIENT CARE AND TREATMENT
Chp.: Roger Peele, M.D.
Participants: Barbara Rosenblum, M.D., Joseph M. Jeral, M.D.

ISSUE WORKSHOP 112 9:00 a.m.-10:30 a.m.
Grand Salon Sections 15 & 18, Street Level, Hilton

GROUP PSYCHOTHERAPY WITH SUBSTANCE ABUSERS
American Group Psychotherapy Association
Co-Chps.: David W. Brook, M.D., Henry I. Spitz, M.D.
Participant: Philip J. Flores, Ph.D.

ISSUE WORKSHOP 113 9:00 a.m.-10:30 a.m.
Grand Salon Sections 19 & 22, Street Level, Hilton

ASPERGER'S DISORDER: FROM QUANDARY TO QUAGMIRE
Chp.: Donna L. Londino, M.D.
Participants: Robert Kaltenbach, Ph.D., Elizabeth Sirota, M.D.

ISSUE WORKSHOP 114 9:00 a.m.-10:30 a.m.
Grand Salon Sections 21 & 24, Street Level, Hilton

PSYCHIATRIC DISABILITY: THE ROLE OF PSYCHIATRIC ASSESSMENT
Chp.: Edward A. Volkman, M.D.
Participants: Janice Volkman, J.D., Deborah Bailey, V.E.

ISSUE WORKSHOP 115 9:00 a.m.-10:30 a.m.
Melrose Room, Third Floor, Hilton

PERSONAL AND INTERPERSONAL DIFFICULTIES IN ORGANIZATIONAL SETTINGS
Chp.: Stewart Gabel, M.D.

ISSUE WORKSHOP 116 9:00 a.m.-10:30 a.m.
Rosedown Room, Third Floor, Hilton

STRESS DISABILITY ASSESSMENT AND COMPENSATION SEEKING: ELUSIVE TRUTH
Chp.: Landy F. Sparr, M.D.
Participants: Neil A. Matteucci, M.D., Michael Maxwell, M.S., Nina P. Sparr
THURSDAY

ISSUE WORKSHOP 117  9:00 a.m.-10:30 a.m.
Magnolia Room, Third Floor, Hilton

STRATEGIES FOR PROMOTING COLLABORATIVE RESEARCH IN DEVELOPING COUNTRIES

Co-Chps.: Victoria E. Wells, M.D., Lawson R. Wulsin, M.D.
Participants: Pius A. Kigamwa, M.D., Athanase Hagengimana, M.D.

ISSUE WORKSHOP 118  9:00 a.m.-10:30 a.m.
Jasperwood Room, Third Floor, Hilton

OXYMORON: FINE UNIVERSITY AND SO-SO PUBLIC CARE

Co-Chps.: Karl S. Burgoyne, M.D., Milton H. Miller, M.D.
Participants: Peter C. Whybrow, M.D., Marvin Southard, D.S.W.,
Norman Sartorius, M.D., James Allen, M.B.A.

ISSUE WORKSHOP 119  9:00 a.m.-10:30 a.m.
Oak Alley Room, Third Floor, Hilton

MULTISYSTEMIC THERAPY: INTEGRATING PSYCHIATRY

Co-Chps.: Debbie R. Carter, M.D., Erica Viggiano, M.S.W.
Participant: Lori Gorshow, M.S.W.

ISSUE WORKSHOP 120  9:00 a.m.-10:30 a.m.
Belle Chasse Room, Third Floor, Hilton

COMMUNITY REINTEGRATION FOR SEVERELY MENTALLY ILL PATIENTS LEAVING JAIL

Co-Chps.: Thomas A. Klotz, M.D., Brock H. Summers, M.D.
Participants: Linda Richardson, Ph.D., Debbie Innes Gomberg, Ph.D., Michael Maloney, Ph.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 24-25
11:00 a.m.-12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

24 Laura W. Roberts, M.D., on Evidence-Based Ethics Issues in Psychiatry
Chequers Suite, Second Floor, Hilton

25 Ann E. Norwood, M.D., on My Experiences as a Military Psychiatrist (For Residents Only)
Trafalgar Suite, Third Floor, Hilton

MASTER EDUCATOR CLINICAL CONSULTATION
11:00 a.m.-12:30 p.m.
21 CANCELLED

MEDIA SESSION 29
11:00 a.m.-12:30 p.m.
Versailles Ballroom, Third Floor, Hilton

LIVING AND DYING

Chp.: Sudha Prathikanti, M.D.

50 The Andre Show
(43 minutes)

Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

When filmmaker Beverly Peterson was invited into the lives of Andre, an HIV-positive child and his mother, Vilma, it was the beginning of an extraordinary friendship, which eventually reshaped the lives of everyone around them. As she became friends with the family, Peterson and her husband Farrell became more and more involved, inviting Andre to stay with them while Vilma was in the hospital or in drug rehabilitation programs. When Vilma realized that she did not have long to live, she asked the Petersons to adopt Andre and, after considerable struggle, they agreed. The Andre Show is a poignant documentary where viewers will accompany the Petersons on their journey of adoption as they move from ambivalence and conflict to increasing mutual trust and resolution.

51 At Death's Door
(30 minutes)

Distributor: Aquarius Healthcare Videos
5 Powderhouse Lane, P.O. Box 1159
Sherborn, MA 01770

A young mother is told the devastating news, her three-year-old daughter has leukemia; a young husband receives a shocking phone call, his 53-year-old father has stomach cancer; and a 68-year-old woman's gnawing fears are confirmed, her husband has Lou Gehrig's disease. Through these experiences and others, At Death's Door will help you acknowledge your emotions about the terminal illness to someone you love, and will guide you in living fully with your loved one through the last months, weeks, or days of your time together.
THURSDAY

MEDICAL UPDATE 4
11:00 a.m.-12:30 p.m.
Grand Salon Sections 3 & 6, Street Level, Hilton

BRINGING THE SPACE STATION TO THE CLINICAL BEDSIDE: NEXT GENERATION BIO-PRODUCTS AND DRUG TESTING MODALITIES DEVELOPED USING STUDIES IN SPACE

Chp.: Patricia I. Ordorica, M.D.
Presenter: Timothy G. Hammond, M.B.
THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH
11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

3 Anita L.H. Clayton, M.D., on Sexual Dysfunction
Cambridge Suite, Second Floor, Hilton

SCIENTIFIC AND CLINICAL REPORT SESSIONS 33-40

SCIENTIFIC AND CLINICAL REPORT SESSION 33
11:00 a.m.-12:30 p.m.
Room 264, Level 2, Convention Center

PROMOTION OF MENTAL HEALTH

Chp.: Mary H. Davis, M.D.
Co-Chp.: Harvey L. Ruben, M.D.

11:00 a.m.
98 Popular Health Advice: A Historical Survey
Laura D. Hirshbein, M.D.

11:30 a.m.
99 A Systematic Review of Screening for Depression in Primary Care
Bradley N. Gaynes, M.D., Michael P. Pignone, M.D.,
C. Tracy Orleans, Ph.D., Jerry L. Rushton, M.D., Cynthia D. Mulrow, M.D., Catherine Mills, M.A., Kathleen N. Lohr, Ph.D.

12 noon
100 Medical Students' Mental and Physical Health Promotion: A North American School Survey
S. Evelyn Stewart, M.D., Paul K. Dagg, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 34
11:00 a.m.-12:30 p.m.
Room 270, Level 2, Convention Center

PSYCHIC AND SOMATIC ISSUES IN PSYCHIATRY

Chp.: Daniel K. Winstead, M.D.
Co-Chp.: Angelica J. Long-Harrell, M.D.

11:00 a.m.
101 Overweight Status of Parents: A Longitudinal Study of Offspring Adiposity
Debra L. Safer, M.D., W. Stewart Agras, M.D., Sue Bryson, M.S.,
Lawrence Hammer, M.D.

11:30 a.m.
102 Integrating Psychoanalysis and Neurobiology in the Treatment of Migraines
Scott M. Davis, M.D.

12 noon
103 Unremitting Depression: Cingulate Dysfunction and the Cleft-Self on Trial
Leo I. Jacobs, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 35
11:00 a.m.-12:30 p.m.
Rooms 335/336, Level 3, Convention Center

ISSUES IN PSYCHOPHARMACOLOGY

Chp.: Alan C. Swann, M.D.
Co-Chp.: Frederick G. Moeller, M.D.

11:00 a.m.
104 Prolactin Levels in Patients Taking Risperidone and Ziprasodone
Jambur V. Ananth, M.D., Karl S. Burgoyne, M.D.,
Michael W. Smith, M.D., Rangaesh Gadasalli, M.D., Monica Walia, B.S., Aswin Suri, M.H.A., Andrew P. Ho, M.D.

105 CANCELLED
11:45 a.m.
106 Use of Intravenous Lorazepam in Patients with Catatonia-Like Syndromes
Ramaswamy Viswanathan, M.D., Olivera J. Bogunovic, M.D.,
Allan L. Tusher, M.D., Marek D. Karpinski, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 36
11:00 a.m.-12:30 p.m.
Rooms 348/349, Level 3, Convention Center

FORENSICS

Chp.: Rahn K. Bailey, M.D.
Co-Chp.: Michael R. Harris, M.D.

(Continued on next page)
THURSDAY

11:00 a.m.
Michael M. Welner, M.D.

11:30 a.m.
108 Behavioral Treatment of the Aggressive Mentally Ill Inmate
Robert L. Trestman, M.D., Kathy Coleman, M.S., Clyde McDonald, B.S., Tod Bogdanoff, Psy.D., Giovanny Gomez, Aquil Hashim, M.S.W.

12 noon
109 Disability Evaluations in the U.S. Air Force
David M. Walker, M.D., Matthew D. Faubion, M.D., Joseph P. Chozinski, M.D., James A. Bourgeois, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 37
11:00 a.m.-12:30 p.m.
Grand Salon Sections 15 & 18, Street Level, Hilton

MOOD DISORDERS AND REPRODUCTIVE ISSUES

Chp.: Marian I. Butterfield, M.D.
Co-Chp.: Vladimir Coric, M.D.

11:00 a.m.
110 A Simple Screen to Identify Postpartum Major Depression
Kathleen S. Peindl, Ph.D., Katherine L. Wisner, M.D., Barbara Hanusa, Ph.D.

11:30 a.m.
111 Interpersonal Psychotherapy for Antepartum Depression: A Controlled Trial
Margaret G. Spinelli, M.D.

12 noon
112 Diminished Prolactin Secretion and Response to Fluoxetine Treatment

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 38
11:00 a.m.-12:30 p.m.
Rosedown Room, Third Floor, Hilton

SUICIDE AND THE LIFE CYCLE

Chp.: Edward F. Foulks, M.D.
Co-Chp.: Marcia K. Goin, M.D.

11:00 a.m.
113 Childhood Sexual Abuse and Suicidal Behavior in BPD
Paul H. Soloff, M.D., Kevin G. Lynch, Ph.D., Thomas M. Kelly, Ph.D.

11:30 a.m.
114 Multiplicity of Suicide Attempts in Bipolar Disorder
Joseph F. Goldberg, M.D., Tara M. Singer, M.A., Jessica L. Gorno, B.S., Mallay Charters, A.B., Miki Hertz, B.S.

12 noon
115 Suicidal Youth with First Emergency Room Presentations: Six-Month Outcome Predictions
Ian G. Manion, Ph.D., S. Evelyn Stewart, M.D., Simon Davidson, M.B., Paula F. Cloutier, M.A.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 39
11:00 a.m.-12:30 p.m.
Magnolia Room, Third Floor, Hilton

PATIENT AND PHYSICIAN AUTONOMY

Chp.: Carol L. Alter, M.D.
Co-Chp.: Mercedes M. Rodriguez, M.D.

11:00 a.m.
116 Managed Care and Malpractice Liability Today
Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.

11:30 a.m.
117 Parity Disparity: Mental Health Insurance Coverage Decision Making

12 noon
118 The Doctor-Patient Relationship: Autonomy, Gender, and Preferred Physician Style
Kalman J. Kaplan, Ph.D., Mark E. Schneiderman, Ph.D., Martin Harrow, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 40
11:00 a.m.-12:30 p.m.
Jasperwood Room, Third Floor, Hilton

WOMEN’S HEALTH ISSUES

Chp.: Valerie Raskin, M.D.
Co-Chp.: Nada L. Scotland, M.D.

11:00 a.m.
119 Mood and Anxiety Disorders and Health of Multi-Ethnic Midlife Women
Joyce T. Bromberger, Ph.D., Howard M. Kravitz, M.P.H., Adriana Cordal, M.D., Linda Jansen-McWilliams, M.S., Karen S. Matthews, Ph.D.

11:30 a.m.
120 Topiramate in PMDD
Mohammad Z. Hussain, M.D., Zubaida Chaudhry, M.D., Seema Hussain, M.D.
THURSDAY

12 noon

121 Verapamil Effectiveness in Women with Bipolar Disorder
Katherine L. Wisner, M.D., James M. Perel, Ph.D.,
Kathleen S. Peinlil, Ph.D., Catherine M. Piomtek, M.D.,
Susan W. Baab, M.S.N.
THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 53-54

COMPONENT WORKSHOP 53  11:00 a.m.-12:30 p.m.
Room 269, Level 2, Convention Center

COPING WITH MEDICAL ILLNESS
APA Committee on Consultation-Liaison Psychiatry and Primary Care Education

Chp.: Francisco Fernandez, M.D.
Participants: James L. Griffith, M.D., Karl Goodkin, M.D.

COMPONENT WORKSHOP 54  11:00 a.m.-12:30 p.m.
Room 273, Level 2, Convention Center

MORE ALIVE THAN DEAD: CHANGING STRATEGIES IN HIV PSYCHOTHERAPY
APA New York County District Branch's AIDS Committee

Co-Chps.: Kristina Jones, M.D., Kenneth B. Ashley, M.D.
Participants: David B. Goldenberg, M.D., Kyle S. Kato, M.D.

ISSUES 121-131

ISSUE WORKSHOP 121  11:00 a.m.-12:30 p.m.
Rooms 265/266, Level 2, Convention Center

SHOULD SUBSTANCE ABUSE TREATMENT BE COERCED?
Chp.: Mitchell S. Rosenthal, M.D.
Participants: Sally L. Satel, M.D., James R. McDonough

ISSUE WORKSHOP 122  11:00 a.m.-12:30 p.m.
Rooms 267-268, Level 2, Convention Center

MIND MEETS BRAIN IN PRACTICE: THE MCLEAN MULTIDISCIPLINARY NEUROPSYCHIATRIC CONSULTATION SERVICE
Chp.: Bruce Price, M.D.
Participants: Miles Cunningham, M.D., Alonso Montoya-Pulido, M.D., Julie Brudy, D.P., JoAnne Savoie, Ph.D., Jennifer Woehr, Psy.D., Martin A. Goldstein, M.D.

ISSUE WORKSHOP 123  11:00 a.m.-12:30 p.m.
Rooms 333/334, Level 3, Convention Center

COMMUNITY MEETINGS ON AN INPATIENT PSYCHIATRIC UNIT
Co-Chps.: Christopher L. Lange, M.D., John C. Bradley, M.D.

ISSUE WORKSHOP 124  11:00 a.m.-12:30 p.m.
Room 342, Level 3, Convention Center

INTEGRATING BEHAVIORAL HEALTH WITH PRIMARY CARE THROUGH DISEASE MANAGEMENT
Co-Chps.: Arthur L. Lazarus, M.D., David S. Brody, M.D.

ISSUE WORKSHOP 125  11:00 a.m.-12:30 p.m.
Rooms 350/351, Level 3, Convention Center

CAREER ADVANCEMENT FOR WOMEN PSYCHIATRISTS: THE ROLE OF MENTORSHIP
Co-Chps.: Ana A. Matorin, M.D., Sandra Sesson, M.D.
Participants: Cynthia W. Santos, M.D., Donna M. Mancuso, M.D., Pedro Ruiz, M.D.

ISSUE WORKSHOP 126  11:00 a.m.-12:30 p.m.
Grand Salon Section 4, Street Level, Hilton

SUBJECTIVITY: CRUCIAL KEY TO THE THERAPEUTIC ALLIANCE
Chp.: Vincenzo R. Sanguineti, M.D.

ISSUE WORKSHOP 127  11:00 a.m.-12:30 p.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

LEADERSHIP IN ORGANIZATIONAL TRANSITIONS
Chp.: Stewart Gabel, M.D.

ISSUE WORKSHOP 128  11:00 a.m.-12:30 p.m.
Grand Salon Sections 19 & 22, Street Level, Hilton

MIND AND BRAIN DO NOT NEED TO BE INTEGRATED IF WE DON'T SEGREGATE THEM IN THE FIRST PLACE
Chp.: Michael A. Schwartz, M.D.
Participant: Elena B. Bezzebova, M.D.

ISSUE WORKSHOP 129  11:00 a.m.-12:30 p.m.
Prince of Wales Suite, Second Floor, Hilton

HALLUCINOGENS: ILLICIT USE, RELIGIOUS USE, AND CURRENT PSYCHIATRIC RESEARCH
Co-Chps.: Charles S. Grob, M.D., John H. Halpern, M.D.
THURSDAY

ISSUE WORKSHOP 130 11:00 a.m.-12:30 p.m.
Marlborough Suite A/B, Second Floor, Hilton

REHABILITATION EDUCATION: INTERNATIONAL COMPARISONS
Chp.: Zebulon C. Taintor, M.D.
Participants: Michael Stark, M.D., Ida Kosza, M.D., Jacques M. Dubuis, M.D., Robert Cancro, M.D.

ISSUE WORKSHOP 131 11:00 a.m.-12:30 p.m.
Elmwood Room, Third Floor, Hilton

CRIMES OF INFAMY: PERSONAL INSIGHTS
Chp.: Phillip J. Resnick, M.D.

12 noon Sessions

FORUMS 10-11
FORUM 10 12 noon-1:30 p.m.
Room 263, Level 2, Convention Center

MENTAL ILLNESS: SURGEON GENERAL'S REPORT ON CULTURE, RACE, AND ETHNICITY
Chp.: Carl C. Bell, M.D.
Participants: James W. Thompson, M.D., Francis G. Lu, M.D., Pablo D. Hernandez, M.D.

FORUM 11 12 noon-1:30 p.m.
Room 252, Level 3, Convention Center

VIRTUAL PSYCHIATRY: FROM HUMANOID TO CYBERSPACE, THE FUTURE OF PSYCHIATRY AND VIRTUAL REALITY
Chp.: David M. McDowell, M.D.
Participants: Norman E. Alessi, M.D., Randall D. Marshall, M.D., Doug Wright, Milton Huang, M.D.

NEW RESEARCH POSTER SESSION 10
12 noon-2:00 p.m.
Exhibition Center, Second Floor, Hilton

BIOLOGICAL PSYCHIATRY, CHILD AND ADOLESCENT PSYCHIATRY, GERIATRICS, WOMEN'S HEALTH, COGNITIVE DISORDERS, MENTAL RETARDATION, EPIDEMIOLOGY, ETHICS, AND CROSS-CULTURAL AND MINORITY ISSUES

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

2:00 p.m. Sessions

SYMPOSIA 90-106

SYMPOSIUM 90 2:00 p.m.-5:00 p.m.
Room 262, Level 2, Convention Center

MANAGEMENT OF SCHIZOPHRENIA WITH COMORBID DISORDERS
Chp.: Michael Y. Hwang, M.D.
Co-Chp.: Javier I. Escobar, M.D.
A Management of Schizophrenia with Depression
Samuel G. Siris, M.D.
B Management of Schizophrenia with Anxiety Disorders
Michael Y. Hwang, M.D., Miklos F. Losonczy, M.D.
C Schizophrenia and Substance Abuse
Douglas M. Ziedonis, M.D.

52 Looking for Common Ground
(30 minutes)

Distributor: Filmmakers Library
For V52 & Attn: Linda Gottesman
V53 124 East 40th Street
New York, NY 10016

When Massachusetts enacted an antidiscrimination law establishing the rights of gay and lesbian high school students, the citizens of Westhampton were embroiled in controversy. Parents, students, school committee members, and local citizens were polarized. Looking for Common Ground gives voice to the gay and lesbian students who talk about their struggle or acceptance. It also allows us to hear articulate and passionate testimony from all sides to the controversy, both in interviews and community meetings. Among the issues raised are parents versus government in determining the education of minors; community values versus the rights of the individual; and nature versus nurture in determining sexual orientation.

53 Summer in My Veins
(41 minutes)

It would be wrong to classify this remarkable film as simply a “coming out” film; it is also a look at family dynamics, at the nuances of another culture, and a most unusual “road” movie. Harvard graduate Nish Saran, a gay Indian filmmaker, travels across America with his family who is visiting from India. He was recently tested for HIV after an unsafe encounter with an HIV-positive man. As he will not know the outcome for several weeks, the threat of terminal illness shadows the trip. In addition, Nish is planning to reveal his gayness to his mother during this journey, but finds it difficult to say the words. The unsuspecting mother and her sisters are enjoying the vacation. When Nish finally comes out to his mom, her reaction is powerful and moving.

12:30 p.m. Session

MEDIA SESSION 30
12:30 p.m.-2:00 p.m.
Versailles Ballroom, Third Floor, Hilton

COMING OUT: A STRUGGLE FOR ACCEPTANCE
Chp.: Dan H. Karasic, M.D.
D Clinical Management of Persistent Aggressive Behavior in Schizophrenia
Leslie L. Citrome, M.D., Jan Volavka, M.D.

E Long-Term Outcome: Influence of Comorbid Conditions
Nina R. Schooler, Ph.D.

Discussants: Lewis A. Opler, M.D., Javier I. Escobar, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 91 2:00 p.m.-5:00 p.m.
Room 264, Level 2, Convention Center

WHEN A SUBSTANCE ABUSER PRESENTS IN YOUR OFFICE: WHAT DO YOU DO?
Chp.: Marc Galanter, M.D.
Co-Chp.: Jonathan I. Ritvo, M.D.

A Inpatient Versus Outpatient Treatment for Abuse: A Reexamination
Laura F. McNicholas, M.D., James R. McKay, Ph.D., A. Thomas McLellan, Ph.D.

B The Dually Diagnosed Patient
Richard N. Rosenthal, M.D.

C Evaluation and Treatment of the Cocaine-Dependent Patient
Roger D. Weiss, M.D.

D The Initial Evaluation of Substance Use in Adolescents
Joyce A. Tinsley, M.D.

E Family and Social Support: Network Therapy
Marc Galanter, M.D.

Discussants: Jonathan I. Ritvo, M.D., Kathleen T. Brady, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 92 2:00 p.m.-5:00 p.m.
Room 269, Level 2, Convention Center

TREATMENTS REDUCING PERSONALITY DYSFUNCTION
Association for Research in Personality Disorders
Chp.: James H. Reich, M.D.

A Drug Treatment of Personality Disorder Traits
James H. Reich, M.D.

B The Interrupted Career Group
Elsa F. Ronningstam, Ph.D., David Anik, M.D.

C Treating Emotional Dysregulation
John Livesley, M.D.

D Treatment of a Personality Disorder Associated with Trauma
David F. Bernstein, Ph.D.

E An Independent, Randomized, Controlled Trial of Dialectical Behavior
Clive J. Robins, Ph.D., Cedar Koons, M.S.W.

Discussant: Giovanni de Girolamo, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 93 2:00 p.m.-5:00 p.m.
Room 271, Level 2, Convention Center

SOCIAL ANXIETY IN SCHIZOPHRENIA ASSESSMENT AND TREATMENT
Chp.: Robert G. Stern, M.D.
Co-Chp.: William E. Narrow, M.D.

A A Comparison of Social Anxiety Symptom Patterns in Schizophrenia and Social Anxiety Disorder
Robert G. Stern, M.D., Jane Luterek, Ph.D., Richard G. Heimberg, Ph.D.

B Schizophrenia with Comorbid Social Phobia: Epidemiology and Service Use
William E. Narrow, M.D., Donald S. Rae, M.A., Robert G. Stern, M.D.

C Treating Social Anxiety in Schizophrenia: A Group-Based Cognitive-Behavior Therapy Approach
David Castle, M.D., Paula Nathan, Patrick Kingsley, Steven Halperin, Peter Drummond, Ledley Jeffreys

D Social Anxiety and Premorbid Personality in Schizophrenic Patients Treated with Clozapine
Stefano Pallanti, M.D., Leonardo Quercioli, M.D., Adolfo Passaglia, Ph.D.

E Interpersonal Sensitivity, Social Anxiety Disorder, and Insight into Illness in Psychotic Patients
Stefano Pini, M.D., Liliana Dell'osso, M.D., Marco Saettoni, M.D., Alessandra Papaassogli, M.D., Xavier Amador, Ph.D., Paola Ruoci, D.Stat., Giovanni B. Cassano, M.D.

Discussant: John M. Davis, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 94 2:00 p.m.-5:00 p.m.
Room 272, Level 2, Convention Center

CLINICAL APPLICATIONS OF CULTURAL PSYCHIATRY
Chp.: Wen-Shing Tseng, M.D.
Co-Chp.: Jon M. Streltzer, M.D.

A Cultural Issues in Consultation-Liaison Psychiatry
Jon M. Streltzer, M.D.

(Continued on next page)
B Culture and Addiction
Joseph J. Westermeyer, M.D.

C Cultural Aspects of Geriatric Psychiatry
Iqbal Ahmed, M.D.

D Cultural Psychiatry on Inpatient Units: The Ethnic/Minority Programs at the University of California at San Francisco/San Francisco General Hospital
Francis G. Lu, M.D., Kenneth K. Gee, M.D., Jo Ellen Brain-Rowe-Diaz, M.D., J. Charles Ndilela, M.D., Alastair Donald, M.D., Mark Leary, M.D., Robert L. Okin, M.D.

E Ethnic/Cultural Considerations for Psychopharmacotherapy
Keh-Ming Lin, M.D.

F Culture and Practice of Psychotherapy
Wen-Shing Tseng, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 95 2:00 p.m.-5:00 p.m.
Rooms 335/336, Level 3, Convention Center

THE DIFFICULT-TO-TREAT PSYCHIATRIC PATIENT

Chp.: Mantosh J. Dewan, M.D.

A The Difficult-to-Treat Patient with Eating Disorders
Katherine A. Halmi, M.D., Wendy A. Harris, M.D., Claire Wiseman, Ph.D.

B The Difficult-to-Treat Patient with PTSD
Randall D. Marshall, M.D., Elizabeth A. Hembree, Ph.D., Lee A. Fitzgibbons, Ph.D., Edna B. Foa, Ph.D.

C The Difficult-to-Treat Patient with Bipolar Disorder
Frederick K. Goodwin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 96 2:00 p.m.-5:00 p.m.
Rooms 346/347, Level 3, Convention Center

BIPOLAR DEPRESSION

Chp.: Russell T. Joffe, M.D.
Co-Chp.: L. Trevor Young, M.D.

A Bipolar Depression: Phenomenology and Diagnosis
Hagop S. Akiskal, M.D.

B The Neurobiology of Bipolar Disorder
L. Trevor Young, M.D.

C Pharmacological Treatment of Bipolar Depression
Russell T. Joffe, M.D., L. Trevor Young, M.D., Glenda M. MacQueen, M.D.

D ECT in Bipolar Disorders
Charles H. Kellner, M.D.

Discussant: Robert M. Post, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 97 2:00 p.m.-5:00 p.m.
Rooms 348/349, Level 3, Convention Center

PSYCHIATRIC PRACTICE IN PRISON

Chp.: Lee H. Rome, M.D.
Co-Chp.: James E. Dillon, M.D.

A Psychiatrists Inside Prison: The Lay of the Land
Lee H. Rome, M.D.

B Do Mentally Ill Criminals Belong in Prison?
James E. Dillon, M.D.

C Existential and Spiritual Issues for People in Prison
Fleet W. Maull, M.A.

D Correctional Health Care Standards: A Historical Review and Recent Developments
Jeffrey L. Metzner, M.D.

E Treatment, Training, and Clinical Studies in a Prison-Based Mental Health Unit
Richard S. Jackson, M.D.

Discussant: Henry C. Weinstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 98 2:00 p.m.-5:00 p.m.
Room 352, Level 3, Convention Center

REDUCING DURATION OF UNTREATED FIRST PSYCHOSIS: THE TREATMENT AND INTERVENTION IN PSYCHOSIS STUDY (TIPS)

Chp.: Thomas H. McGlashan, M.D.

A Early Detection and Intervention: Rationale
Thomas H. McGlashan, M.D., Per Vaglum, M.D., Svein Friis, M.D., Erik Simonsen, M.D., Jan O. Johannessen, M.D., Ingrid Melle, M.D., Tor K. Larsen, M.D.

B Does Duration of Untreated Psychosis Bias Schizophrenia Study Samples?
Per Vaglum, M.D., Svein Friis, M.D., Ingrid Melle, M.D., Stein Opjordsmoen, M.D., Tor K. Larsen, M.D., Erik Simonsen, M.D., Thomas H. McGlashan, M.D.

C Reducing Duration of Untreated Psychosis: The TIPS Historical Control Study
Tor K. Larsen, M.D., Jan O. Johannessen, M.D., Erik Simonsen, M.D., Ingrid Melle, M.D., Svein Friis, M.D., Per Vaglum, M.D., Thomas H. McGlashan, M.D.
D TIPS Study: Duration of Untreated Psychosis and Baseline Clinical Severity in First-Episode Psychosis
Ingrid Melle, M.D., Stein Opjordsmoen, M.D., Tor K. Larsen, M.D., Svein Friis, M.D., Thomas H. McGlashan, M.D., Ulrik Haahr, M.D., Per Vaglum, M.D.

E TIPS: Stability of Cognitive Functioning in Patients with First-Episode Psychosis
Stein Opjordsmoen, M.D., Bjorn Rund, Ph.D., Ingrid Melle, M.D., Svein Friis, M.D., Per Vaglum, M.D., Tor K. Larsen, M.D., Thomas H. McGlashan, M.D.

F TIPS: First-Episode Psychosis Diagnostic Stability Over One Year
Ulrik Haahr, M.D., Erik Simonsen, M.D., Ingrid Melle, M.D., Svein Friis, M.D., Per Vaglum, M.D., Tor K. Larsen, M.D., Thomas H. McGlashan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 99 2:00 p.m.-5:00 p.m.
Room 356, Level 3, Convention Center

TOWARD A NEUROBIOLOGY OF DISSOCIATION
Chp.: Daphne Simeon, M.D.

A Dissociation and Child Development
Frank W. Putnam, Jr., M.D., Jennie Noll, Ph.D., Lisa Horowitz, Ph.D., Penelope Tricket, Ph.D., George Bonnand, Ph.D.

B Dissociation, Childhood Abuse, and Heart Rate in Delinquent Youths
Cheryl Koopman, Ph.D., Victor G. Carrio, M.D., Shiv Sudhaker, B.A., Hans Steiner, M.D.

C Depersonalization: HPA Axis Dysregulation and Association Cortex Dysfunction
Daphne Simeon, M.D., Orna Guralnik, Psy.D., Erin A. Hazlett, Ph.D., Eric Hollander, M.D., Monte S. Buchsbaum, M.D.

D Neural Responses to Emotional Expressions in Depersonalization
Mary L. Phillips, M.D., Anthony S. David, M.D., Kate Pietura, M.D., Kathryl Abel, M.D., Nicholas Medford, M.D., Matt Allen, M.D., Mauricio Sierra, M.D.

E Psychopharmacologic Insights into Dissociation
John H. Krystal, M.D., Steven M. Southwick, M.D., Dennis S. Charney, M.D., Amik Anand, M.D., D. Cyril D'Souza, J. Douglas Bremner, M.D.

Discussant: Rachel Yehuda, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 100 2:00 p.m.-5:00 p.m.
Room 357, Level 3, Convention Center

STABILITY VERSUS CHANGE IN PERSONALITY TRAITS AND DISORDERS: A DEVELOPMENTAL VIEW
Chp.: Andrew E. Skodol II, M.D.
Co-Chp.: Jeffrey G. Johnson, Ph.D.

A Linking Childhood Personality with Maladaptation Across Time
Rebecca L. Shiner, Ph.D.

B Change in Personality Disorder Symptoms Between Adolescence and Adulthood
Jeffrey G. Johnson, Ph.D., Patricia R. Cohen, Ph.D., Andrew E. Skodol II, M.D.

C The Longitudinal Study of Personality Disorders: Predictors of Change, Hints About Mechanism
Mark F. Lenzenweger, Ph.D.

D Two-Year Stability of Personality Disorder Criteria
M. Tracie Shea, Ph.D., Robert L. Stout, Ph.D., Shirley Yen, Ph.D., Andrew E. Skodol II, M.D., Leslie C. Morey, Ph.D., Mary C. Zanarini, Ed.D., Charles A. Sanislow, Ph.D.

E Personality Stability/Change and the Natural Course of Axis II Personality Disorders
Paul T. Costa, Ph.D.

Discussant: John C. Perry, M.D.

SYMPOSIUM 101 2:00 p.m.-5:00 p.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

BULIMIA NERVOSA: RECENT RESEARCH FINDINGS IN BIOLOGY AND TREATMENT
Chp.: Allan S. Kaplan, M.D.
Co-Chp.: David C. Jimerson, M.D.

A Binge Eating, Mood Regulation, and 5HT Function in Bulimia Nervosa
David C. Jimerson, M.D., Barbara E. Wolfe, Ph.D., Erand Metzger, M.D.

B Eating Disorders: Genes or Jeans?
Walter H. Kaye, M.D., Guido Frank, M.D.

C Psychobiology of Satiety in Bulimia Nervosa
B. Timothy Walsh, M.D.

D Cognitive-Behavior Therapy and Pharmacotherapy in the Treatment of Bulimia Nervosa
Allan S. Kaplan, M.D.

E New Treatment Approaches for Bulimia Nervosa
James E. Mitchell, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 102 2:00 p.m.-5:00 p.m.
Grand Salon Sections 9 & 12, Street Level, Hilton

BPD: INTEGRATING MIND AND BODY
Chp.: Marcia K. Goin, M.D.

A Heterogeneity Within BPD
John M. Oldham, M.D., Andrew E. Skodol II, M.D., Donna S. Bender, Ph.D.

(Continued on next page)
B Emotion, Motivation, and the Borderline Personality: A Neurobiology Perspective
Regina Pally, M.D.

C Psychoanalytic Perspectives on BPD
John F. Clarkin, Ph.D.

D Cultural Perspectives on the Borderline Personality
Leslie A. Horton, M.D.

Discussants: Sherwyn M. Woods, M.D., C. Robert Cloninger, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 103 2:00 p.m.-5:00 p.m.
Grand Salon Sections 13 & 16, Street Level, Hilton

INTEGRATING CLINICAL RESEARCH WITH CLINICAL PRACTICE: NATIONAL INSTITUTE OF MENTAL HEALTH EFFECTIVENESS TRIALS
Chp.: Gary S. Sachs, M.D.
Co-Chp.: Michael E. Thase, M.D.

A National Institute of Mental Health Approaches to Intervention Trials
Barry D. Lebowitz, Ph.D.

B The Systematic Treatment Enhancement Program for Bipolar Disorder
Gary S. Sachs, M.D., Michael E. Thase, M.D., Leslie F. Leahy, Ph.D., Jennifer Conley, M.A., Andrew A. Nierenberg, M.D., Phillip Lavori, Ph.D., Michael H. Allen, M.D.

C Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
A. John Rush, M.D.

D Effectiveness Trials of Antipsychotic Drugs
Jeffrey A. Lieberman, M.D., Lon S. Schneider, M.D., Joseph McEvoy, M.D., Pierre Pariot, M.D., Scott Stroup, M.D., John Adlai, M.D., Barry D. Lebowitz, Ph.D.

Discussants: Barry D. Lebowitz, Ph.D., Kenneth Z. Altshuler, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 104 2:00 p.m.-5:00 p.m.
Grand Salon Sections 19 & 22, Street Level, Hilton

NEW ANTIDEPRESSANTS: LIGHT AT THE END OF THE TUNNEL?
Chp.: Mark A. Demitrack, M.D.
Co-Chp.: John F. Greden, M.D.

A Unmet Need: What Justifies the Search for a New Antidepressant?
John F. Greden, M.D.

B Methodological Challenges in the Study of New Antidepressants
John H. Greist, M.D.

C Is There Room to Improve Monoamine-Based Therapies?
Mark A. Demitrack, M.D.

D Beyond Monoamine-Based Therapies: Clues to New Approaches
Phil Skolnick, Ph.D.

Discussant: David J. Kupfer, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 105 2:00 p.m.-5:00 p.m.
Elmwood Room, Third Floor, Hilton

CHANGING PERSPECTIVES FOR PSYCHIATRIC DIAGNOSIS: IMPLICATIONS FOR THERAPEUTIC INNOVATION
Chp.: Eric D. Caine, M.D.

A Alzheimer Disease Subsyndromes
Peter V. Rabins, M.D.

B Psychiatric Syndromes in Alzheimer's Disease: Cause or Effect?
Brian Lalor, M.D.

C FDA Perspective: Psychiatric Syndromes in Alzheimer's Disease
Thomas P. Laughren, M.D.

D Development of Psychiatric Treatments: Industry Challenges and Opportunities
Alan F. Breier, M.D., Jamie S. Street, M.D.

Rick A. Martinez, M.D.

F Shifting Paradigms: Promoting Research
Jason T. Olin, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 106 2:00 p.m.-5:00 p.m.
Belle Chasse Room, Third Floor, Hilton

HOW PSYCHIATRY DEFINES EVIL
Chp.: Michael M. Welner, M.D.

A Psychiatry's Efforts to Define and Understand Evil
Michael M. Welner, M.D.

B Personality and Evil: Psychiatric Understanding
Michael H. Stone, M.D.
C Psychological Testing and Evil  
  Bruce Ebert, Ph.D.

D The Depravity Scale: Development and Potential in Assessment  
  Michael M. Welner, M.D.

E Determining Evil: Psychiatry, Theology, or Both?  
  Reverend James LeBar

Discussants: Laurence R. Tancredi, M.D., Ralph Slovenko, L.L.B.

THIS SESSION WILL BE AUDIOTAPED.
## 2001 ANNUAL MEETING
### TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

#### DISORDERS

<table>
<thead>
<tr>
<th>Number</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>AIDS and HIV-Related Disorders</td>
</tr>
<tr>
<td>2.</td>
<td>Alcohol and Drug-Related Disorders</td>
</tr>
<tr>
<td>3.</td>
<td>Anxiety Disorders</td>
</tr>
<tr>
<td>4.</td>
<td>Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)</td>
</tr>
<tr>
<td>5.</td>
<td>Dissociative Disorders</td>
</tr>
<tr>
<td>6.</td>
<td>Eating Disorders</td>
</tr>
<tr>
<td>7.</td>
<td>Mental Retardation (Child/Adolescent/Adult)</td>
</tr>
<tr>
<td>8.</td>
<td>Mood Disorders</td>
</tr>
<tr>
<td>9.</td>
<td>Personality Disorders</td>
</tr>
<tr>
<td>10.</td>
<td>Schizophrenia and Other Psychotic Disorders</td>
</tr>
<tr>
<td>11.</td>
<td>Sexual and Gender Identity Disorders</td>
</tr>
<tr>
<td>12.</td>
<td>Sleep Disorders</td>
</tr>
<tr>
<td>13.</td>
<td>Somatoform Disorders</td>
</tr>
<tr>
<td>14.</td>
<td>Other Disorders Not Listed Above</td>
</tr>
</tbody>
</table>

#### PRACTICE AREAS/SETTINGS

<table>
<thead>
<tr>
<th>Number</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.</td>
<td>Psychiatric Administration and Services: Public, Private, and University</td>
</tr>
<tr>
<td>16.</td>
<td>Other</td>
</tr>
</tbody>
</table>

#### SUBSPECIALTY AREAS OR SPECIAL INTERESTS

<table>
<thead>
<tr>
<th>Number</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.</td>
<td>Addiction Psychiatry</td>
</tr>
<tr>
<td>18.</td>
<td>Biological Psychiatry and Neuroscience</td>
</tr>
<tr>
<td>19.</td>
<td>Brain Imaging</td>
</tr>
<tr>
<td>20.</td>
<td>Child and Adolescent Psychiatry and Disorders</td>
</tr>
<tr>
<td>21.</td>
<td>Consultation-Liaison and Emergency Psychiatry</td>
</tr>
<tr>
<td>22.</td>
<td>Cross-Cultural and Minority Psychiatry</td>
</tr>
<tr>
<td>23.</td>
<td>Diagnostic Issues</td>
</tr>
<tr>
<td>24.</td>
<td>Epidemiology</td>
</tr>
<tr>
<td>25.</td>
<td>Ethics and Human Rights</td>
</tr>
<tr>
<td>26.</td>
<td>Forensic Psychiatry</td>
</tr>
<tr>
<td>27.</td>
<td>Genetics</td>
</tr>
<tr>
<td>28.</td>
<td>Geriatric Psychiatry</td>
</tr>
<tr>
<td>29.</td>
<td>Neuropsychiatry</td>
</tr>
<tr>
<td>30.</td>
<td>Psychiatric Education</td>
</tr>
<tr>
<td>31.</td>
<td>Psychiatric Rehabilitation</td>
</tr>
</tbody>
</table>

#### TREATMENTS

<table>
<thead>
<tr>
<th>Number</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>32.</td>
<td>Psychoanalysis</td>
</tr>
<tr>
<td>33.</td>
<td>Psychoimmunology</td>
</tr>
<tr>
<td>34.</td>
<td>Research Issues</td>
</tr>
<tr>
<td>35.</td>
<td>Social and Community Psychiatry</td>
</tr>
<tr>
<td>36.</td>
<td>Stress</td>
</tr>
<tr>
<td>37.</td>
<td>Suicide</td>
</tr>
<tr>
<td>38.</td>
<td>Violence, Trauma, and Victimization</td>
</tr>
</tbody>
</table>

#### OTHER ISSUES

<table>
<thead>
<tr>
<th>Number</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>39.</td>
<td>Behavior and Cognitive Therapies</td>
</tr>
<tr>
<td>40.</td>
<td>Combined Pharmacotherapy and Psychotherapy</td>
</tr>
<tr>
<td>41.</td>
<td>Couple and Family Therapies</td>
</tr>
<tr>
<td>42.</td>
<td>Group Therapy</td>
</tr>
<tr>
<td>43.</td>
<td>Individual Psychotherapies</td>
</tr>
<tr>
<td>44.</td>
<td>Psychopharmacology</td>
</tr>
<tr>
<td>45.</td>
<td>Other Somatic Therapies</td>
</tr>
<tr>
<td>46.</td>
<td>Treatment Techniques and Outcome Studies</td>
</tr>
</tbody>
</table>

---

**GUIDE TO USING THE TOPIC INDEX**

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this Program Book to obtain further details about the session.
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DISORDERS</strong></td>
</tr>
<tr>
<td><strong>TOPIC 1: AIDS AND HIV-RELATED DISORDERS</strong></td>
</tr>
<tr>
<td>MEDIA PROGRAM</td>
</tr>
<tr>
<td>50 The Andre Show</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORT</td>
</tr>
<tr>
<td>51 Seriously Mentally Ill Persons Who Are HIV Positive</td>
</tr>
<tr>
<td>SYMPOSIA</td>
</tr>
<tr>
<td>10 Treating the Psychiatically Ill HIV Patient</td>
</tr>
<tr>
<td>52 Psychotherapeutic Aspects of HIV</td>
</tr>
<tr>
<td>WORKSHOPS - COMPONENTS</td>
</tr>
<tr>
<td>49 The Use of Anabolic and Androgenic Steroids in HIV Disease</td>
</tr>
<tr>
<td>54 More Alive than Dead: Changing Strategies in HIV Psychotherapy</td>
</tr>
<tr>
<td><strong>TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS</strong></td>
</tr>
<tr>
<td>CLINICAL CASE CONFERENCE</td>
</tr>
<tr>
<td>4 Assessment of Prognostic Factors in the Alcoholic Patient</td>
</tr>
<tr>
<td>COURSES</td>
</tr>
<tr>
<td>24 Office-Based Treatment of Opiate Dependent Patients</td>
</tr>
<tr>
<td>28 Dual Diagnosis: Basic Principles of Successful Intervention</td>
</tr>
<tr>
<td>62 Dealing with Resistance in Addiction Patients</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIUM</td>
</tr>
<tr>
<td>14 Alcoholism and Bipolar Disorder: Treatment Options Circa 2001</td>
</tr>
<tr>
<td>LECTURE</td>
</tr>
<tr>
<td>12 Imaging Brain Dysfunction in Substance Abuse</td>
</tr>
<tr>
<td>MEDIA PROGRAMS</td>
</tr>
<tr>
<td>16 Methamphetamine: From the Streets of San Diego</td>
</tr>
<tr>
<td>17 Drinking Apart: Families Under the Influence</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
</tr>
<tr>
<td>23 Longitudinal Predictors of Adolescent Alcohol Disorder Onset</td>
</tr>
<tr>
<td>24 Delirium Tremens: Diagnosis, Misdiagnosis, and Terminology</td>
</tr>
<tr>
<td>SYMPOSIA</td>
</tr>
<tr>
<td>82 Update on Treatment of Stimulant Abuse</td>
</tr>
<tr>
<td>91 When a Substance Abuser Presents in Your Office: What Do You Do?</td>
</tr>
<tr>
<td>WORKSHOP - COMPONENT</td>
</tr>
<tr>
<td>41 How to Enhance Motivation in Patients with Substance Abuse Problems</td>
</tr>
<tr>
<td>WORKSHOPS - ISSUES</td>
</tr>
<tr>
<td>9 Sleep Problems in Dual-Diagnosis Patients: Physiology and Management</td>
</tr>
<tr>
<td>23 Alcoholism Pharmacotherapy: A Case-Based Review for Clinicians</td>
</tr>
<tr>
<td>43 Ecstasy and the Rave Scene: A Canadian Perspective</td>
</tr>
<tr>
<td>50 Psychiatric Adverse Events During Rebatron Treatment of Hepatitis-C</td>
</tr>
<tr>
<td>121 Should Substance Abuse Treatment Be Coerced?</td>
</tr>
<tr>
<td><strong>TOPIC 3: ANXIETY DISORDERS</strong></td>
</tr>
<tr>
<td>COURSE</td>
</tr>
<tr>
<td>31 Shame and Social Anxiety Disorder</td>
</tr>
<tr>
<td>FORUM</td>
</tr>
<tr>
<td>7 Trauma, PTSD, and Personality Disorders: Understanding the Connections</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIUM</td>
</tr>
<tr>
<td>7 PTSD: Clinical Characteristics and Treatment Options</td>
</tr>
<tr>
<td>21 Critical Questions in Anxiety Disorders</td>
</tr>
<tr>
<td>22 Management of Anxiety: An International Perspective</td>
</tr>
<tr>
<td>37 Images of Anxiety: A New Look at GAD and PTSD</td>
</tr>
<tr>
<td>40 Clinical Challenges in Anxiety, Part 1</td>
</tr>
<tr>
<td>40 Clinical Challenges in Anxiety, Part 2</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
</tr>
<tr>
<td>17 PTSD Versus Panic Disorder: Differences in HPA Axis/Noradrenergic Functioning</td>
</tr>
<tr>
<td>18 Beyond One-Year Imipramine Maintenance in Panic Disorder with Agoraphobia</td>
</tr>
<tr>
<td>19 Social Phobia Treatment Survey</td>
</tr>
<tr>
<td>25 Cigarette Smoking and Risk for Anxiety Disorders</td>
</tr>
<tr>
<td>SYMPOSIA</td>
</tr>
<tr>
<td>4 PTSD: A Biopsychosocial Approach</td>
</tr>
<tr>
<td>63 The Psychiatric Consequences of Stress</td>
</tr>
<tr>
<td><strong>TOPIC 4: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)</strong></td>
</tr>
<tr>
<td>COURSES</td>
</tr>
<tr>
<td>47 Dementia: Advanced Diagnosis and Treatment</td>
</tr>
<tr>
<td>80 Psychiatric Aspects of Epilepsy</td>
</tr>
<tr>
<td>MEDIA PROGRAMS</td>
</tr>
<tr>
<td>34 Grace</td>
</tr>
<tr>
<td>36 Something Should Be Done About Grandma Ruthie</td>
</tr>
<tr>
<td><strong>TOPIC 5: DISSOCIATIVE DISORDERS</strong></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>99 Toward a Neurobiology of Dissociation</td>
</tr>
<tr>
<td><strong>TOPIC 6: EATING DISORDERS</strong></td>
</tr>
<tr>
<td>COURSES</td>
</tr>
<tr>
<td>21 Therapeutic Interventions in Eating Disorders</td>
</tr>
<tr>
<td>101 Multimodal Treatment of Eating Disorders</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>8 Eating Disorders: New Features and New Treatments</td>
</tr>
<tr>
<td>32 Physiology and Behavior: The Connection in Eating Disorders</td>
</tr>
<tr>
<td>45 Feeding, Eating, and Eating Disorders: The Development of Disordered Eating</td>
</tr>
<tr>
<td>68 State Versus Trait Disturbances Found in Eating Disorders: Recent Findings</td>
</tr>
<tr>
<td>101 Bulimia Nervosa: Recent Research Findings in Biology and Treatment</td>
</tr>
</tbody>
</table>
### TOPIC INDEX

#### TOPIC 7: MENTAL RETARDATION (CHILD/adolescent/adult)

<table>
<thead>
<tr>
<th>COURSE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>88 Assessment and Treatment of Patients with Mental Retardation</td>
<td>68</td>
</tr>
</tbody>
</table>

#### WORKSHOP - ISSUE

| 8 Towards a Rational, Integrated Treatment Approach to Mentally Retarded and Developmentally Disabled Patients | 19 |

#### TOPIC 8: MOOD DISORDERS

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 Evidence-Based Treatment of SAD: Focus on Light Therapy</td>
<td>8</td>
</tr>
<tr>
<td>42 Using Humanities to Understand Mood Disorders</td>
<td>14</td>
</tr>
<tr>
<td>54 Anticonvulsants in Bipolar Disorder</td>
<td>27</td>
</tr>
<tr>
<td>93 Understanding and Treating Bipolar Disorder Today: An Update of Goodwin and Jamison’s Manic-Depressive Illness</td>
<td>81</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DISCUSSION GROUPS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 Screening and Treating Depression in Primary Care: Let’s Be Realistic!</td>
<td>41</td>
</tr>
<tr>
<td>14 Bipolar Disorder in Children and Adults: Clinical and Research Issues</td>
<td>69</td>
</tr>
</tbody>
</table>

#### INDUSTRY-SUPPORTED SYMPOSIA

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Sildenafil Citrate Effectively Treats Erectile Dysfunction in Men Who Have Been Successfully Treated for Depression</td>
<td>22</td>
</tr>
<tr>
<td>7 Dreaming Contributes to Adaptation in the Depressed: A Review</td>
<td>22</td>
</tr>
<tr>
<td>9 Training Primary Care Physicians in the Diagnosis and Treatment of Depression</td>
<td>22</td>
</tr>
<tr>
<td>26 Does Medical Comorbidity Impact the Severity of Depression and Its Treatment?</td>
<td>23</td>
</tr>
<tr>
<td>27 Treatment-Resistant Depression and Axis I Comorbidity</td>
<td>24</td>
</tr>
<tr>
<td>28 The Complex Comorbidity Between Bipolar Illness and OCD: Clinical Implications and Treatment Outcome</td>
<td>24</td>
</tr>
<tr>
<td>59 Perceptions and Impact of Bipolar Disorder: How Far Have We Really Come?</td>
<td>50</td>
</tr>
<tr>
<td>60 Unipolar Compared with Bipolar Depression: Similar Depressive Subtypes</td>
<td>50</td>
</tr>
<tr>
<td>61 Cognitive Function in Euthymic Bipolar Patients, Schizophrenics, and Controls</td>
<td>50</td>
</tr>
<tr>
<td>69 Illness Beliefs of Depressed Chinese Americans in Primary Care</td>
<td>76</td>
</tr>
<tr>
<td>70 Depression in College Students in Bombay</td>
<td>76</td>
</tr>
<tr>
<td>86 The Response of Psychotic-Like Symptoms to Fluoxetine in Nonpsychotic MDD</td>
<td>77</td>
</tr>
<tr>
<td>87 Predictors of Stable Personality Disorders in Remitted Depressed Outpatients</td>
<td>77</td>
</tr>
<tr>
<td>88 Personality Disorders in Psychotic Major Depression</td>
<td>78</td>
</tr>
<tr>
<td>110 A Simple Screen to Identify Postpartum Major Depression</td>
<td>100</td>
</tr>
<tr>
<td>111 Interpersonal Psychotherapy for Antidepressant Depression: A Controlled Trial</td>
<td>100</td>
</tr>
<tr>
<td>112 Diminished Prolactin Secretion and Response to Fluoxetine Treatment</td>
<td>100</td>
</tr>
</tbody>
</table>

#### SYMPOSIA

<table>
<thead>
<tr>
<th>SYMPOSIAS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>23 Results from the Texas Medication Algorithm Project (TMAP)</td>
<td>34</td>
</tr>
<tr>
<td>31 The Role of Antidepressants in the Treatment of Bipolar Disorder: Pro and Con</td>
<td>55</td>
</tr>
<tr>
<td>34 Clinical Issues in Bipolar Disorder: The Stanley Foundation Bipolar Network</td>
<td>55</td>
</tr>
<tr>
<td>41 Bipolar Disorder: Current Guidelines, Practices, and Effectiveness Research</td>
<td>57</td>
</tr>
<tr>
<td>47 Treatment Pathways (Algorithms) in Managing Depression</td>
<td>59</td>
</tr>
</tbody>
</table>

#### WORKSHOP - ISSUE

| 15 A University Depression-Management Program | 19 |

#### TOPIC 9: PERSONALITY DISORDERS

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 Disorders of the Self: Differential Diagnosis and Treatment</td>
<td>1</td>
</tr>
<tr>
<td>50 Personality Disorders in the Workplace</td>
<td>1</td>
</tr>
<tr>
<td>83 Dialectical Behavior Therapy and Partial Hospital in the Difficult-to-Treat Patient</td>
<td>27</td>
</tr>
<tr>
<td>87 Partial Hospitalization for Patients with BPD</td>
<td>68</td>
</tr>
<tr>
<td>89 Psychotherapy of Borderline Personality</td>
<td>69</td>
</tr>
</tbody>
</table>

#### MASTER EDUCATOR CLINICAL CONSULTATION

<table>
<thead>
<tr>
<th>MASTER EDUCATOR CLINICAL CONSULTATIONS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 Adult Patients with Comorbid Mood and Personality Disorders</td>
<td>42</td>
</tr>
<tr>
<td>14 Depression, Antidepressants, and Sexual Dysfunction: Differential Diagnosis, Avoiding, Treating</td>
<td>70</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RESEARCH CONSULTATION</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Mood Disorders</td>
<td>48</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REVIEW OF PSYCHIATRY: SECTION 1</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of Recurrent Depression: A Call to Arms</td>
<td>29</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEDIA PROGRAMS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 Girl, Interrupted: The Film and the Book</td>
<td>28</td>
</tr>
<tr>
<td>38 Between the Lines</td>
<td>76</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 Psychiatric Treatment of Borderline Patients Followed for Four Years</td>
<td>23</td>
</tr>
<tr>
<td>21 Predictors of Outcome in a 27-Year Follow-Up of BPD</td>
<td>23</td>
</tr>
<tr>
<td>22 Confirmatory Factor Analysis of DSM-IV Schizotypal Personality Disorder Criteria</td>
<td>23</td>
</tr>
</tbody>
</table>
### TOPIC INDEX

#### SYMPOSIA
- 24 Field Testing Dimensional Models for DSM-V Axis II
- 64 Findings from Multisite Collaborative Longitudinal Study of Personality
- 72 European Perspectives on the Biology of Personality Disorders
- 79 Psychobiology and Pharmacotherapy of BPD
- 92 Treatments Reducing Personality Dysfunction
- 96 Bipolar Depression
- 100 Stability Versus Change in Personality Traits and Disorders: A Developmental View
- 102 BPD: Integrating Mind and Body

#### WORKSHOPS - ISSUES
- 36 Cognitive Therapy for Personality Disorders
- 79 International Problems with Personality Disorders in the Workplace
- 92 Update on the Practice Guideline on BPD

#### TOPIC 10: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS

##### INDUSTRY-SUPPORTED SYMPOSIAS
- 9 Critical Decisions in the Lifetime Treatment of Schizophrenia
- 11 Meeting the Challenge of Schizophrenia and Co-Occurring Addictions
- 15 Treating Psychotic Disorders: What Is the State of the Art?
- 26 Moving Towards a More Comprehensive Management of Patients with Schizophrenia
- 36 Men, Women, and Schizophrenia: Does Anatomy Determine Destiny?
- 41 A New Era for Managing Psychosis: Rebuilding Lives for Patients and Families, Part 1
- 41 A New Era for Managing Psychosis: Rebuilding Lives for Patients and Families, Part 2

##### MEDIA PROGRAMS
- 4 Out of My Mind
- 6 Means of Grace
- 37 Through Madness
- 47 The Talented Mr. Ripley

##### RESEARCH ADVANCES IN MEDICINE
- Schizophrenia and the Thalamus: A New Paradigm

##### SCIENTIFIC AND CLINICAL REPORTS
- 35 What Predicts Functioning Across 10 Years of Schizophrenic Illness?
- 36 Perinatal Brain Damages and Slower Development Interact as Risks for Psychosis
- 37 Social Sequels of Mental Disorders in the 1966 North Finland Birth Cohort
- 53 Placebo-Controlled Trial of Omega-3 Fatty Acid in Schizophrenia
- 54 Atypical Antipsychotics and Hostility in Schizophrenia: A Double-Blind Study
- 55 Factors Associated with Medication Adherence in Persons with Schizophrenia

##### SYMPOSIAS
- 2 Risk Factors for Schizophrenia and Prevention
- 3 New Approaches to Improve Long-Term Treatment Adherence in Schizophrenia
- 65 Update on Deficit Schizophrenia
- 85 Quality of Life in Patients with Schizophrenia: Research In Europe and the Americas
- 90 Management of Schizophrenia with Comorbid Disorders
- 93 Social Anxiety in Schizophrenia Assessment and Treatment
- 98 Reducing Duration of Untreated First Psychosis: The Treatment and Intervention in Psychosis Study (TIPS)

#### WORKSHOP - ISSUE
- 12 Clozapine Augmentation in Refractory Schizophrenia

#### TOPIC 11: SEXUAL AND GENDER IDENTITY DISORDERS

##### COURSE
- 90 The Assessment and Treatment of Child Molesters

##### DISCUSSION GROUP
- 10 Treating Sexual Dysfunction in the 21st Century

##### MEDIA PROGRAM
- 14 The Remarkable Story of John/Joan

##### RESEARCH CONSULTATION
- 3 Sexual Dysfunction

##### SCIENTIFIC AND CLINICAL REPORTS
- 2 Correlation Between Patient Self-Assessment of Erectile Function and the International Index of Erectile Function (IIEF-5)
- 4 Psychotropic-Induced Sexual Dysfunction Among Outpatients

##### SYMPOSIUM
- 33 Evidence-Based Management of SSRI Antidepressant-Associated Sexual Dysfunction

#### WORKSHOP - ISSUE
- 20 Recent Advances in Female Sexual Medicine

#### TOPIC 12: SLEEP DISORDERS

##### COURSE
- 13 Irresistible Sleep: Narcolepsy Update

##### INDUSTRY-SUPPORTED SYMPOSIAS
- 1 Sleep: A Window on Mind and Brain
- 39 Current and Future Management of Insomnia and Psychiatric Illnesses
- 47 Excessive Daytime Sleepiness: Evaluation and Management in Psychiatry

#### TOPIC 13: SOMATOFORM DISORDERS

##### COURSE
- 76 The Evaluation and Management of Pain

##### MASTER EDUCATOR CLINICAL CONSULTATION
- 19 Patients Who Somatize

##### REVIEW OF PSYCHIATRY: SECTION 5
- 83 Psychiatric Update: Somatoform and Factitious Disorders

##### SYMPOSIUM
- 88 Psychocutaneous Medicine

#### TOPIC 14: OTHER DISORDERS NOT LISTED ABOVE

##### COURSES
- 53 ADD in Adults
- 63 Advanced Assessment and Treatment of ADD

(Continued on next page)
### TOPIC 18: BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Behavioral Neuroanatomy: An Introduction</td>
<td>1</td>
</tr>
<tr>
<td>82 Behavioral Neuroanatomy: An Introduction</td>
<td>68</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIUM</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>5 The New Biology of Depression and Antidepressant Treatment</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LECTURES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Genes, Synapses, and Long-Term Memory</td>
<td>16</td>
</tr>
<tr>
<td>6 Bipolar Disorder: Using Affective Neuroscience to Bridge the Gap</td>
<td>27</td>
</tr>
<tr>
<td>9 Gene Therapy and Its Potential Applications to Psychiatry</td>
<td>41</td>
</tr>
<tr>
<td>15 How Matter Becomes Imagination: From Brain Dynamics to Consciousness</td>
<td>69</td>
</tr>
<tr>
<td>22 Gut Sensation: Serotonin and Brain-Bowel Crosstalk</td>
<td>94</td>
</tr>
</tbody>
</table>

### MEDICAL UPDATE

<table>
<thead>
<tr>
<th>1 Can Stem Cells from Bone Marrow Serve As a Fountain of Youth for the Brain?</th>
<th>22</th>
</tr>
</thead>
<tbody>
<tr>
<td>RESEARCH ADVANCES IN MEDICINE</td>
<td></td>
</tr>
<tr>
<td>Neurorteroids in Psychiatry</td>
<td>43</td>
</tr>
<tr>
<td>The Expanding Role of CNS Electrical Stimulation</td>
<td>43</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>48 Cerebral Hemodynamics and Depression in the Elderly</td>
<td>49</td>
</tr>
<tr>
<td>106 Use of Intravenous Lorazepam in Patients with Catatonia-Like Syndromes</td>
<td>99</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIUM</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>5 Perimenopause, Mood, and Cognition: The Role of Reproductive Hormones</td>
<td>30</td>
</tr>
</tbody>
</table>

### TOPIC 19: BRAIN IMAGING

<table>
<thead>
<tr>
<th>RESEARCH ADVANCES IN MEDICINE</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>New Direction in In vivo Brain Imaging</td>
<td>43</td>
</tr>
<tr>
<td>REVIEW OF PSYCHIATRY: SECTION 4</td>
<td></td>
</tr>
<tr>
<td>Brain Imaging in the New Millennium</td>
<td>71</td>
</tr>
<tr>
<td>WORKSHOP - ISSUE</td>
<td></td>
</tr>
<tr>
<td>84 Neuroimaging: Integrating Bioethics with Clinical and Basic Sciences</td>
<td>74</td>
</tr>
</tbody>
</table>

### TOPIC 20: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS

<table>
<thead>
<tr>
<th>COURSES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>20 ADD in Children and Adolescents</td>
<td>7</td>
</tr>
<tr>
<td>59 Fundamental Knowledge Needed for Clinical Work with Infants and Toddlers</td>
<td>40</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DISCUSSION GROUP</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4 Risk Factors for Adolescent Psychotic Disorders</td>
<td>20</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIA</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>46 Advances in ADHD: Navigating Comorbidity</td>
<td>90</td>
</tr>
<tr>
<td>48 An Evidence-Based Medicine Approach to Pediatric Psychiatry</td>
<td>90</td>
</tr>
</tbody>
</table>

### MEDIA PROGRAMS

<table>
<thead>
<tr>
<th>MEDIA PROGRAMS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 No Fear... No Tears: Thirteen Years Later</td>
<td>70</td>
</tr>
<tr>
<td>32 In Grandma's Hands</td>
<td>70</td>
</tr>
<tr>
<td>44 Come Back Jack</td>
<td>82</td>
</tr>
<tr>
<td>45 Autism: A World Apart</td>
<td>82</td>
</tr>
<tr>
<td>46 A Dyslexic Family Diary</td>
<td>82</td>
</tr>
</tbody>
</table>

### REVIEW OF PSYCHIATRY: SECTION 2

<table>
<thead>
<tr>
<th>PTSD in Children and Adolescents</th>
<th>43</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>14 Some Long-Term Consequences of Orphanage Care</td>
<td>23</td>
</tr>
<tr>
<td>16 Self-Comforting Strategies Used by Adolescent Males and Females</td>
<td>23</td>
</tr>
<tr>
<td>41 Diagnostic Efficiency of BPD Criteria in Hospitalized Adolescents</td>
<td>48</td>
</tr>
<tr>
<td>42 Overlap Between Child Depressive Inventory and Projectives in Uncovering a Child's Depression</td>
<td>48</td>
</tr>
<tr>
<td>43 Comorbidity in Conduct Disorder: Gender and Age Differences</td>
<td>48</td>
</tr>
<tr>
<td>83 Adderall and Methylphenidate in ADHD</td>
<td>77</td>
</tr>
<tr>
<td>84 Comparison of Duration of Effect of OROS MPH with MPH TID in ADHD Children</td>
<td>77</td>
</tr>
<tr>
<td>85 Once-Daily-Dosed SLI381 for Pediatric ADHD</td>
<td>77</td>
</tr>
<tr>
<td>115 Suicidal Youth with First Emergency Room Presentations: Six-Month Outcome Predictions</td>
<td>100</td>
</tr>
</tbody>
</table>

### SYMPOSIAS

| 7 Arab Perspective on Child and Adolescent Psychiatry                    | 30    |
| 22 Frontiers of Depression in Children and Adolescents                   | 34    |
| 77 Childhood-Onset Depression: A Multigenerational Multidisciplinary Study | 86    |

### WORKSHOPS - COMPONENTS

| 10 Students and Schools at Risk: Where Is the Violence?                  | 18    |
| 12 A Model Infant Psychiatry Program for Abuse and Neglect Cases         | 24    |
| 16 Mission Impossible: Treating the Undiagnosable Child                  | 25    |
| 50 Treatment of Child and Adolescent Victims of Crime: New Guidelines from California | 96    |

### WORKSHOPS - ISSUES

| 14 From Play Therapy to Pills and Back Again: Child Treatment in the Decade of the Mind | 19    |
| 49 The Emperor's New Clothes: Polypharmacy and Kids                      | 46    |
| 64 Nature and Nurture: Developing Comprehensive Services for Young Children | 72    |
| 81 Does Johnny Need Methylphenidate?                                      | 73    |

### TOPIC 21: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY

<table>
<thead>
<tr>
<th>COURSES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>38 Families and Medical Illness: An Integrative Treatment Approach</td>
<td>14</td>
</tr>
<tr>
<td>41 Medical and Psychiatric Implications of Cytochrome P450: An Update</td>
<td>14</td>
</tr>
<tr>
<td>46 Delirium and Other Acute Confusional States: Diagnosis and Management</td>
<td>15</td>
</tr>
<tr>
<td>79 Innovative Therapeutics in Consultation-Liaison Psychiatry</td>
<td>67</td>
</tr>
</tbody>
</table>

### DISCUSSION GROUPS

| 6 Why Hospitalized?                                                      | 41   |
| 12 Psychiatry in Primary Care: What Do We Want to Accomplish?           | 46   |
| 17 Psychiatric Drugs in the Medically Ill                               | 69   |
| 20 Psychiatry at the Medical Interface: Opportunities in the New Millennium | 74   |
| 22 Hepatitis C: What Every Psychiatrist Needs to Know                    | 94   |

(Continued on next page)
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LECTURE</strong></td>
</tr>
<tr>
<td>21 Psychiatry for the Medically Ill: What Is It? What Was It? What Has It Done?</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATION</strong></td>
</tr>
<tr>
<td>3 Psychiatric Problems in Medical/Surgical Patients</td>
</tr>
<tr>
<td>11 Optimizing Your Relationship with Primary Care Physicians: Ways to Maximize Your Referral Network and Satisfaction</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td>8 A Systematic Review of Depression as a Risk Factor for Coronary Disease</td>
</tr>
<tr>
<td>10 Screening for Depression in Head and Neck Cancer Patients</td>
</tr>
<tr>
<td>31 A Case of Ketamine Psychosis</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
</tr>
<tr>
<td>75 Critical Issues in Early Intervention of the Psychosis Prodrome</td>
</tr>
<tr>
<td><strong>WORKSHOPS - COMPONENTS</strong></td>
</tr>
<tr>
<td>27 Studies on Integration of Mental Health and Primary Care in the Veterans Administration</td>
</tr>
<tr>
<td>53 Coping with Medical Illness</td>
</tr>
<tr>
<td><strong>WORKSHOP - ISSUE</strong></td>
</tr>
<tr>
<td>122 Mind Meets Brain in Practice: The McLean Multidisciplinary Neuropsychiatric Consultation Service</td>
</tr>
<tr>
<td><strong>TOPIC 22: CROSS-CULTURAL AND MINORITY PSYCHIATRY</strong></td>
</tr>
<tr>
<td><strong>COURSE</strong></td>
</tr>
<tr>
<td>74 DSM-IV Cultural Formulations: Diagnosis and Therapy</td>
</tr>
<tr>
<td><strong>FORUM</strong></td>
</tr>
<tr>
<td>10 Mental Illness: Surgeon General's Report on Culture, Race, and Ethnicity</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATIONS</strong></td>
</tr>
<tr>
<td>17 Cultural Issues in Clinical Case Formulation</td>
</tr>
<tr>
<td>20 Crucial Issues in Training of International Medical Graduates As Psychiatrists</td>
</tr>
<tr>
<td><strong>MEDIA PROGRAMS</strong></td>
</tr>
<tr>
<td>1 The Joy Luck Club</td>
</tr>
<tr>
<td>22 The Mirror Lied</td>
</tr>
<tr>
<td>23 Struggle for Identity</td>
</tr>
<tr>
<td>26 The Italian Gardens of South Brooklyn</td>
</tr>
<tr>
<td>27 Delta Jews</td>
</tr>
<tr>
<td>28 A Wok in Progress</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td>38 Body Dissatisfaction and BMI Across Ethnic Groups</td>
</tr>
<tr>
<td>40 Hypersexuality in Handic-Jewish Inpatients</td>
</tr>
<tr>
<td>68 Depression in Chinese Primary Care Patients</td>
</tr>
<tr>
<td><strong>SYMPOSIAS</strong></td>
</tr>
<tr>
<td>28 Cultural Identity and Quality of Life</td>
</tr>
<tr>
<td>44 Cultural Influences on the Psychiatric Treatment of Women</td>
</tr>
<tr>
<td>94 Clinical Applications of Cultural Psychiatry</td>
</tr>
<tr>
<td><strong>WORKSHOPS - COMPONENTS</strong></td>
</tr>
<tr>
<td>17 Narcissism Below Sea Level: A Dutch View of Future Gay Developments</td>
</tr>
<tr>
<td>47 Clinical Paths Across Cultural and Racial Barriers: How to Do It</td>
</tr>
<tr>
<td>54 Folktales and Movies: Using the Media to Learn About Culture</td>
</tr>
<tr>
<td>66 Treating Haredi (Very Orthodox) Jews in the United States and Israel</td>
</tr>
<tr>
<td><strong>TOPIC 23: DIAGNOSTIC ISSUES</strong></td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
</tr>
<tr>
<td>17 Psychiatric Diagnosis: Are We Prepared for a New Millennium?</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
</tr>
<tr>
<td>81 Post-Traumatic Spectrum Disorders: A Radical Revision of PTSD</td>
</tr>
<tr>
<td><strong>SYMPOSIAS</strong></td>
</tr>
<tr>
<td>35 Substance Use and Psychosis: Tackling the Chicken-and-Egg Problem</td>
</tr>
<tr>
<td>105 Changing Perspectives for Psychiatric Diagnosis: Implications for Therapeutic Innovation</td>
</tr>
<tr>
<td><strong>WORKSHOP - ISSUE</strong></td>
</tr>
<tr>
<td>85 Implementing Multidisciplinary Diagnosis and Management of Pseudoseizures</td>
</tr>
<tr>
<td><strong>TOPIC 24: EPIDEMIOLOGY</strong></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
</tr>
<tr>
<td>89 Lifetime and 12-Month Prevalence of Mental Illness in Chile</td>
</tr>
<tr>
<td><strong>TOPIC 25: ETHICS AND HUMAN RIGHTS</strong></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
</tr>
<tr>
<td>26 Medical Ethics</td>
</tr>
<tr>
<td>72 Psychiatrists as Teachers of Boundaries to Physicians</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUPS</strong></td>
</tr>
<tr>
<td>2 Psychiatric Aspects of End-of-Life Care</td>
</tr>
<tr>
<td>5 The Professional Ethic and Current Psychiatric Practice</td>
</tr>
<tr>
<td>13 Ethical Issues in Psychiatric Practice</td>
</tr>
<tr>
<td>24 Evidence-Based Ethics Issues in Psychiatry</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td>77 Willingness and Competence of Depressed Inpatients to Consent to Research</td>
</tr>
<tr>
<td>90 Race and Psychiatry in Post-Apartheid South Africa</td>
</tr>
<tr>
<td><strong>SYMPOSIAS</strong></td>
</tr>
<tr>
<td>42 Teaching Ethics to Psychiatric Residents</td>
</tr>
<tr>
<td>46 National Bioethics Advisory Commission (NBAC) Revisited: Implementation of Independent Capacity Assessment</td>
</tr>
<tr>
<td><strong>WORKSHOP - COMPONENT</strong></td>
</tr>
<tr>
<td>19 The Individual Versus the State: Patients' Privacy and Abuses of Psychiatry</td>
</tr>
<tr>
<td><strong>WORKSHOPS - ISSUES</strong></td>
</tr>
<tr>
<td>10 Nonsexual Boundary Violations</td>
</tr>
<tr>
<td>37 Balancing Power in the Psychiatrist-Patient Alliance for Therapeutic Success</td>
</tr>
<tr>
<td>96 Confidentiality and Sexual History Issues in Sexual Harassment Cases</td>
</tr>
</tbody>
</table>
TOPIC 26: FORENSIC PSYCHIATRY

COURSES
18 The Psychiatrist as Expert Witness
56 Sexual Harassment: Psychological and Legal Aspects
57 The Detection of Malingered Mental Illness
60 Introduction to Correctional Psychiatry
81 The Forensic Assessment of Competency to Make a Decision (In Spanish)
85 Insanity Defense Evaluations
94 Contemporary Malpractice Liability

SCIENTIFIC AND CLINICAL REPORTS
65 Can Psychologists Help Psychiatrists in Assessing Sex Offenders?
66 Heterogeneity of Psychopathology Among Juvenile Sexual Offenders
67 Dangerous Offender Statutes: The Canadian Perspective
79 False Confessions: The Bane of Criminal Justice
108 Behavioral Treatment of the Aggressive Mentally Ill Inmate

WORKSHOPS - COMPONENT
20 Legal, Ethical, and Practice Implications of Dot-Com Psychiatry

TOPIC 27: GENETICS

SCIENTIFIC AND CLINICAL REPORTS
56 Schizophrenia and Bipolar Disorder: Specific and Common Susceptibility Loci
57 Comorbid Panic Disorder as a Marker of Genetic Heterogeneity in Bipolar Disorder

SYMPOSIUM
39 Personality and Psychopathology: A Behavior-Genetic Perspective

TOPIC 28: GERIATRIC PSYCHIATRY

INDUSTRY-SUPPORTED SYMPOSIA
18 Advances in the Treatment of Geriatric Depression
33 Recognition and Treatment of Alzheimer's Disease: Practical Lessons from New Research

TOPIC 30: PSYCHIATRIC EDUCATION

LECTURE
4 Beyond DSM IV: From Appearances to Essences

(Continued on next page)
### TOPIC INDEX

#### MASTER EDUCATOR CLINICAL CONSULTATION
- **Page #**
  - 4 Using Cinema to Enhance the Teaching of Psychiatry and Behavioral Sciences (ADMSEP Council on Education Master Teacher) 21

#### SCIENTIFIC AND CLINICAL REPORT
- **Page #**
  - 62 Using the “Moral Accounting” Metaphor to Teach Psychodynamic Formulations 50

#### SYMPOSIUM
- **Page #**
  - 61 Reform, Resident Training, Contemporary Practice, and the Public’s Health 62

#### WORKSHOPS - COMPONENTS
- **Page #**
  - 8 Make the Media Work for You: Television Interview Tips and Techniques 18
  - 28 Putting Your Best Foot Forward: The Art of Self-Presentation 50
  - 29 Career Development in Academic Psychiatry for Asian Psychiatrists 50
  - 42 A Collaborative Effort to Define and Measure Psychiatric Competencies 79

#### WORKSHOPS - ISSUES
- **Page #**
  - 19 How to Develop a Lecture 20
  - 22 Teaching Behavioral Sciences to Family Doctors 20
  - 28 Mental Health Education for the Primary Care Physician 25
  - 42 The Use of the Mock Trial in Psychiatric Staff Education 45
  - 48 Beyond the Lecture Hall: Integrating Educational Concepts 45
  - 53 The Consumer Perspective in Psychiatric Education 51
  - 93 Foundation of the World Federation of Psychiatric Trainees 80
  - 107 How to Give a More Effective Lecture: Pith, Punch, and Polish 97
  - 110 Teaching the Clinical Essentials: The Role of the Psychiatrist 97
  - 130 Rehabilitation Education: International Comparisons 102

#### TOPIC 31: PSYCHIATRIC REHABILITATION

- **WORKSHOP - ISSUE**
  - 114 Psychiatric Disability: The Role of Psychiatric Assessment 97

#### TOPIC 32: PSYCHOANALYSIS

- **LECTURE**
  - 20 The Science of Psychotherapy: Legacy of Psychoanalysis 81

#### MEDIA PROGRAMS
- **Page #**
  - 2 The Conformist 12
  - 24 Fat Chance 52
  - 25 Mr. Death 54
  - 30 Sankofa 65

#### SCIENTIFIC AND CLINICAL REPORT
- **Page #**
  - 102 Integrating Psychoanalysis and Neurobiology in the Treatment of Migraines 99

- **TOPIC 33: PSYCHOIMMUNOLOGY**
- **Page #**
  - 58 Antibodies to Prothrombin and Thrombin in First Psychotic Episode of Schizophrenia 49

- **TOPIC 34: RESEARCH ISSUES**
- **Page #**
  - 20 Advances in Research
    - From Clinical Trials to Clinical Practice: Can You Get There From Here?
  - 40 Courses
    - 64 Doing Research on a Shoestring Budget
    - 96 Increasing the Reliability of Outcome Measures in Psychiatric Clinical Trials
  - 52 Forum
    - 8 Diagnostic and Statistical Manual (DSM) Research Planning Process
  - 53 Lecture
    - 14 An Example of Neuropsychoanalytic Research: The Right Hemisphere Syndrome
  - 99 Medical Update
    - 4 Bringing the Space Station to the Clinical Bedside: Next Generation Bioproducts and Drug Testing Modalities Developed Using Studies in Space

- **TOPIC 35: SOCIAL AND COMMUNITY PSYCHIATRY**
- **COURSE**
  - 78 Individual and Community Interventions in Disaster 53

- **TOPIC 35: SOCIAL AND COMMUNITY PSYCHIATRY**
- **SCIENTIFIC AND CLINICAL REPORTS**
- **Page #**
  - 92 Mental Health and Stress in Highly Educated Employees 78
  - 93 The Next Step Group: Multimodal Strategies in Group Therapy for Serious Illness 78

- **SYMPOSIUM**
  - 37 The Biopsychosocial Model: Social Perspectives 56

- **TOPIC 35: SOCIAL AND COMMUNITY PSYCHIATRY**
- **WORKSHOPS - COMPONENTS**
- **Page #**
  - 6 Psychiatrists in the Schools: Reducing the Impact of Trauma 18
  - 37 Mind, Brain, and Environment: How Can Clinicians Address Social Ills? 72

- **TOPIC 35: SOCIAL AND COMMUNITY PSYCHIATRY**
- **WORKSHOPS - ISSUES**
- **Page #**
  - 56 Community Psychiatry: How to Avoid Being a Psychotech Slave Chained to the Pill Box 51
  - 99 Mental Health in a Jail 96

- **Page #**
  - 116
TOPIC 36: STRESS

MEDIA PROGRAMS
39 Fighting Grandpa 80
40 Men Like My Father, Families Like My Own 80
41 What Do I Tell My Children? 80
51 At Death's Door 98

SCIENTIFIC AND CLINICAL REPORT
94 Psychiatric Issues in Space: Implications from the Space Shuttle/MIR Program 78

SYMPOSIUM
48 The Trauma of Bereavement: A New Paradigm 59

WORKSHOPS - ISSUES
1 Psychiatric Illness and the Workplace 18
116 Stress Disability Assessment and Compensation Seeking: Elusive Truth 97

TOPIC 37: SUICIDE

COURSE
92 Suicidal Patients in the Managed Care Era: Assessment and Risk Management 81

INDUSTRY-SUPPORTED SYMPOSIUM
3 Suicide Risk and Bipolar Disorder: Neurobiology and Treatment 2

MEDIA PROGRAM
5 A Journey Back: Coping with a Parent's Suicide 17

RESEARCH CONSULTATION
2 Youth Suicide Research 76

SCIENTIFIC AND CLINICAL REPORTS
74 Suicide Mortality in the Ukraine in 1999 77
75 Decreasing Suicide Mortality in Hungary: What Are the Main Causes? 77
76 Suicide Risk Factors Among Treated Patients with BPD 77
78 Childhood Sexual Abuse and Suicidal Behavior in BPD 100
114 Multiplicity of Suicide Attempts in Bipolar Disorder 100

SYMPOSIAS
19 How Can Psychiatrists Impact the Problem of Suicide at the Community Level? 33
21 Achieving Comprehensive Care for the Suicidal Individual 34

WORKSHOPS - ISSUES
18 The Impact of Suicide on Clinicians 20
109 Achieving Comprehensive Care for Chronically Suicidal Individuals 97

TOPIC 38: VIOLENCE, TRAUMA, AND VICTIMIZATION

COURSES
35 Risk Assessment for Violence 14
39 Assessment and Treatment of Traumatic Grief 14

INDUSTRY-SUPPORTED SYMPOSIAS
32 The Impulsive Aggressive Spectrum: Challenging Populations, Part 1 14
32 The Impulsive Aggressive Spectrum: Challenging Populations, Part 2 39

LECTURE
1 Stalkers and Their Victims 10

MEDIA PROGRAMS
7 Stolen Lives 21
15 Invisible Revolution 42
42 Generations of Violence 82
43 Colors Straight Up 82

SCIENTIFIC AND CLINICAL REPORTS
39 Creativity as a Resource for Moving from Trauma Toward Connection 48
52 HIV, Health Care, and Mental Health Outcomes of Childhood Disruption 49
80 Violence and Clinical Symptoms in Different Diagnoses 77

SYMPOSIAS
12 PTSD in Women: Integrating Mind and Brain in Treatment 32
14 Trauma and the Life Cycle: Multidisciplinary Perspectives 32
16 Childhood Sexual Abuse: Perpetrators and Victims 33
70 Psychopathological Pathways Following Traumatic Life Experience 84

WORKSHOPS - COMPONENTS
18 Prediction of Dangerousness in Patients 43
22 The Cost of PTSD: A Crisis We Can Prevent 44

WORKSHOPS - ISSUES
16 Disaster Psychiatry: LAPA Flight 3142 19
27 Understanding the Dynamics of Abusive Relationships 25
29 Intergenerational Aspects of Trauma and Aggressive Behavior 25
67 A Review of Patient Assaults on Staff 72
98 Domestic Violence in the Psychiatric Emergency Department 96

TREATMENTS

TOPIC 39: BEHAVIOR AND COGNITIVE THERAPIES

CONTINUOUS CLINICAL CASE CONFERENCES
1 Cognitive-Behavioral Therapy: A Case of Comorbid Major Depression, Personality Disorder, and Episodic Alcohol Abuse 15
2 Cognitive-Behavioral Therapy: A Case of Comorbid Major Depression, Personality Disorder, and Episodic Alcohol Abuse 40

COURSES
9 Cognitive-Behavioral Therapy: An Overview 1
37 Cognitive Therapy for Severe Mental Disorders 14
71 Cognitive Therapy: The Basics 52

WORKSHOPS - ISSUES
41 Graphotechnology: How to Save Time and Reveal Clues in Handwriting Analysis 45
52 Cognitive-Behavioral Treatment: Prolonged Exposure for Treatment of Trauma Victims 51
106 Cognitive-Behavioral Therapy Training for Residents: How to Teach, Measure, and Attain Resident Competency 97

TOPIC 40: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

DISCUSSION GROUP
21 Integrating Pharmacotherapy and Psychotherapy in PTSD 74

(Continued on next page)
## TOPIC INDEX

### SCIENTIFIC AND CLINICAL REPORT

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>71</td>
<td>A 45-Year Experience with OCD Patients Who Fear Harm (Symposium)</td>
</tr>
<tr>
<td>72</td>
<td>Solving the Riddle of Working Through in Psychotherapy (Presentation)</td>
</tr>
<tr>
<td>76</td>
<td>Psychotherapy Viewed from a Basic Science Social Brain Perspective (Presentation)</td>
</tr>
</tbody>
</table>

### SYMPOSIUM

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>53</td>
<td>A Most Common Challenge: The Dual-Diagnosed Patient (Presentation)</td>
</tr>
<tr>
<td>60</td>
<td>What Ever Happened to Psychotherapy? (Presentation)</td>
</tr>
</tbody>
</table>

### WORKSHOP - ISSUE

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>63</td>
<td>Psychodynamics in Treatment-Refractory Depression (Presentation)</td>
</tr>
<tr>
<td>72</td>
<td>If Therapy Is Needed But Not Available, What Should We Do? (Presentation)</td>
</tr>
</tbody>
</table>

### TOPIC 41: COUPLE AND FAMILY THERAPIES

<table>
<thead>
<tr>
<th>Course</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>44</td>
<td>The Multiple Perspectives of Couples Therapy: Skills and Techniques (Presentation)</td>
</tr>
</tbody>
</table>

### WORKSHOP - ISSUE

<table>
<thead>
<tr>
<th>Issue</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>119</td>
<td>Multisystemic Therapy: Integrating Psychiatry (Presentation)</td>
</tr>
</tbody>
</table>

### TOPIC 42: GROUP THERAPY

<table>
<thead>
<tr>
<th>Course</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>Outpatient Group Therapy for the Seriously Mentally Ill (Presentation)</td>
</tr>
</tbody>
</table>

### TOPIC 43: INDIVIDUAL PSYCHOTHERAPIES

<table>
<thead>
<tr>
<th>Case Conference</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>A Neuroscience Perspective on Transference in Psychotherapy (Presentation)</td>
</tr>
</tbody>
</table>

### CLINICAL CASE CONFERENCES

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
</tr>
</tbody>
</table>

### COURSES

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
</tr>
<tr>
<td>1</td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Issue</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Working-Through in Psychotherapy (Presentation)</td>
</tr>
<tr>
<td>45</td>
<td>Dynamic Therapy with Self-Destructive BPD (Presentation)</td>
</tr>
</tbody>
</table>

### TOPIC 44: PSYCHOPHARMACOLOGY

### ADVANCES IN RESEARCH

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
</tr>
</tbody>
</table>

### COURSES

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
</tr>
</tbody>
</table>

### INDUSTRY-SUPPORTED SYMPOSIA

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
</tr>
</tbody>
</table>

### TOPIC 45: PSYCHOPHARMACOLOGY

### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
</tr>
<tr>
<td>24</td>
</tr>
</tbody>
</table>

### FORUM

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>51</td>
</tr>
</tbody>
</table>

### LECTURE

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
</tr>
</tbody>
</table>

### MASTER EDUCATOR CLINICAL CONSULTATIONS

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>47</td>
</tr>
<tr>
<td>70</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORT

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>77</td>
</tr>
</tbody>
</table>
### TOPIC INDEX

#### TOPIC 45: OTHER SOMATIC THERAPIES

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECT Practice Update</td>
<td>14</td>
</tr>
<tr>
<td>A Practical Approach to Herbs and Nutrients in Psychiatry</td>
<td>41</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOPS - ISSUES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Homeopathic Medicine and Psychiatry</td>
<td>72</td>
</tr>
<tr>
<td>Educating Patients and Families About ECT</td>
<td>73</td>
</tr>
</tbody>
</table>

#### TOPIC 46: TREATMENT TECHNIQUES AND OUTCOME STUDIES

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Hypnosis: Principles and Applications</td>
<td>2</td>
</tr>
<tr>
<td>Dream Translation: One Empirically-Based Approach</td>
<td>8</td>
</tr>
<tr>
<td>Advanced Hypnosis: Applications in Psychiatry</td>
<td>41</td>
</tr>
<tr>
<td>The Psychosocial Management of Bipolar Disorder</td>
<td>68</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MASTER EDUCATOR CLINICAL CONSULTATIONS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication and Psychodynamic Therapies: Can Treatments in Conflict Be Integrated?</td>
<td>21</td>
</tr>
<tr>
<td>Treatments Based on the Perspectives of Psychiatry</td>
<td>70</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEDICAL UPDATE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Will Medicalizing Obesity Treatment Improve Outcomes?</td>
<td>76</td>
</tr>
</tbody>
</table>

#### TOPIC 47: COMPUTERS

<table>
<thead>
<tr>
<th>COURSE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Only Computer Course You Will Ever Need</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOPS - ISSUES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>E-Supporting Clinical Practice: Guidelines and the Psychiatric Research Network</td>
<td>19</td>
</tr>
<tr>
<td>Computer Odyssey 2001: Updates for New Computer Purchasers</td>
<td>25</td>
</tr>
<tr>
<td>Mobile Computing in Psychiatry with Personal Digital Assistants</td>
<td>96</td>
</tr>
</tbody>
</table>

#### TOPIC 48: CREATIVITY AND THE ARTS

<table>
<thead>
<tr>
<th>LECTURES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Trip to the Moon and Beyond</td>
<td>37</td>
</tr>
<tr>
<td>Quills: The Marquis on the Marquee</td>
<td>75</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEDIA PROGRAMS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Century of Satchmo</td>
<td>26</td>
</tr>
<tr>
<td>The Art of Being Human</td>
<td>26</td>
</tr>
<tr>
<td>Faces of the Hand</td>
<td>26</td>
</tr>
<tr>
<td>The Matrix</td>
<td>64</td>
</tr>
<tr>
<td>2001: A Space Odyssey</td>
<td>91</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORT</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Familial Background and Literary Creativity</td>
<td>23</td>
</tr>
</tbody>
</table>

#### TOPIC 49: ELECTRONIC MEDICAL RECORDS

<table>
<thead>
<tr>
<th>COURSE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Using Open Infrastructure for Outcome: A Customizable Web-Based Clinical and Research Record System</td>
<td>8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TELECOMMUNICATIONS PRESENTATIONS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic Medical Record: Psychiatric Survival Tool for the Decade</td>
<td>62</td>
</tr>
<tr>
<td>The CAPER System: Patient Assessment and Treatment Planning Software</td>
<td>62</td>
</tr>
<tr>
<td>Booting Up Your Practice: Computerized Record Keeping in Psychiatry</td>
<td>63</td>
</tr>
<tr>
<td>The Impact of Electronic Psychiatric Records on Patients and the Doctor-Patient Relationship</td>
<td>71</td>
</tr>
</tbody>
</table>

#### TOPIC 50: GENDER ISSUES

<table>
<thead>
<tr>
<th>LECTURE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>What Do Women Really Want?</td>
<td>53</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MASTER EDUCATOR CLINICAL CONSULTATION</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unique Gender Issues in All of Psychiatric Assessment and Treatment</td>
<td>16</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Comparison of Evaluations of Male and Female Psychiatry Supervisors</td>
<td>50</td>
</tr>
<tr>
<td>The Doctor-Patient Relationship: Autonomy, Gender, and Preferred Physician Style</td>
<td>100</td>
</tr>
</tbody>
</table>

(Continued on next page)
### TOPIC INDEX

**SYMPOSIUM**
- Women's Resiliency to Adversity 66
  Page # 83

**WORKSHOPS - ISSUES**
- Balancing Career and Family 24
  Page # 25
- Career Advancement for Women Psychiatrists: The Role of Mentorship 125
  Page # 101

**TOPIC 51: HEALTH SERVICES RESEARCH**

**SCIENTIFIC AND CLINICAL REPORTS**
- The World Psychiatric Association: An International Survey of Urban Mental Health 91
  Page # 78
- A Systematic Review of Screening for Depression in Primary Care 99
  Page # 99

**SYMPOSIAS**
- New Findings on Psychiatric Practice: Access and Patterns of Care 11
  Page # 31
- Closing the Efficacy/Effectiveness Gap in Psychopharmacology 56
  Page # 61

**TOPIC 52: INFORMATION TECHNOLOGY**

**TELECOMMUNICATIONS PRESENTATIONS**
- Use of a CD-ROM Multimedia Interactive System to Teach Interviewing Skills 2
  Page # 43
- Interfaced Information Systems: Networked Office 7
  Page # 63

**WORKSHOPS - ISSUES**
- Distance-Learning Options 73
  Page # 73
- Making the Media Work for You 89
  Page # 79

**TOPIC 53: INTERNET**

**COURSES**
- An Introduction to Using the World Wide Web 3
  Page # 1
- Making a Home on the World Wide Web 19
  Page # 7

**TELECOMMUNICATIONS PRESENTATIONS**
- Evaluation of a Web-Based Intervention for Depression in Pregnant Women 1
  Page # 43
- Internet Algorithms for the Pharmacotherapy of Depression: Java Version 11
  Page # 71
- Caught in the Web: Sex, Suicide, and Addictions on the Internet 12
  Page # 89

**TOPIC 54: LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES**

**MEDIA SESSIONS**
- Boys Don't Cry 3
  Page # 17
- Looking for Common Ground 52
  Page # 102
- Summer in My Veins 53
  Page # 102

**WORKSHOPS - COMPONENTS**
- Psychiatric Views on Talking About Homosexuality to Kids 7
  Page # 18
- Transgender Issues: Female to Male 34
  Page # 71
- Finding Common Ground: Gays and Lesbians Together 47
  Page # 95

**WORKSHOP - ISSUE**
- Hospital-Based Program for Lesbian, Gay, Bisexual, and Transgender Patients 5
  Page # 19

**TOPIC 55: MANAGED CARE AND HEALTH CARE FUNDING**

**COURSE**
- How to Be More Effective with Managed Care "Doc-to-Doc" Reviews 98
  Page # 94

**SCIENTIFIC AND CLINICAL REPORTS**
- Managed Care and Malpractice Liability Today 116
  Page # 100
- Parity Disparity: Mental Health Insurance Coverage Decision Making 117
  Page # 100

**SYMPOSIUM**
- Outreach to Business: The American Psychiatric Association Business Initiative 84
  Page # 88

**WORKSHOP - COMPONENT**
- Medicare and Medicaid: Problems and Progress 3
  Page # 18

**TOPIC 56: MEN'S HEALTH ISSUES**

**INDUSTRY-SUPPORTED SYMPOSIUM**
- Men Over 50: An Endangered Species 12
  Page # 6

**SYMPOSIUM**
- Body Image Disorders in Men 59
  Page # 61

**TOPIC 57: POLITICAL QUESTIONS**

**COURSE**
- Personality and Political Behavior 8
  Page # 1

**SYMPOSIUM**
- Clinical Issues and Ethical Concerns Regarding Attempts to Change Sexual Orientation: An Update 67
  Page # 84

**WORKSHOP - COMPONENT**
- Responses to the Surgeon General's Report on Mental Health 46
  Page # 95

**TOPIC 58: PROFESSIONAL AND PERSONAL ISSUES**

**COURSES**
- Treating Medical Students and Physicians 11
  Page # 2
- Money Matters: Using Theory in Clinical Practice 22
  Page # 7
- Model Compliance Plan for Small Psychiatric Practices 100
  Page # 94

**DISCUSSION GROUP**
- Life Balance as a Psychiatrist... Easier Said Than Done! 23
  Page # 94

**LECTURES**
- Authentic Representation, Belonging, and the Narrative of Self-Identification 10
  Page # 42
- International Cooperation in Mental Health in the Americas: An Agenda for the New Millennium 11
  Page # 46

**SCIENTIFIC AND CLINICAL REPORTS**
- Arthur Kronfeld: Professional and Personal Tragedy of a Great Psychiatrist 78
  Page # 77
- Popular Health Advice: A Historical Survey 98
  Page # 99

**SYMPOSIUM**
- Professional Boundaries and Training in Psychiatry: A Comprehensive View 30
  Page # 54

**WORKSHOPS - COMPONENTS**
- Physician Disability: Treatment, Insurance, and Conflicts 3
  Page # 17
- To Retire or Not to Retire, That Is the Question 9
  Page # 18
- Defining Boundaries in Medical Education: Ethics Applied by Role Playing 17
  Page # 43
- Legal Issues in Psychiatric Private Practice 32
  Page # 51
- Career Change for Psychiatrists and Patients Young and Old 38
  Page # 72
### WORKSHOPS - ISSUES
- **35 Women's Leadership and Career Development** Page 45
- **39 Children of Psychiatrists** Page 45
- **57 Early Career Psychiatrist: Role of Mentorship** Page 51
- **62 Treating Physicians: Cutting-Edge Issues** Page 72
- **70 Working with Small Businesses** Page 73
- **72 Do I Need an MBA to Transform My Career?** Page 73
- **76 Mid-Career Psychiatry: Staying Fresh and Creative** Page 73

### TOPIC INDEX

#### WORKSHOPS - ISSUES
- **TOPIC 59: RELIGION, SPIRITUALITY AND PSYCHIATRY**
  - **COURSES**
    - **50 Issues in Transpersonal Psychiatry** Page 15
    - **66 Transpersonal Psychiatry: Clinical Applications** Page 41
  - **LECTURE**
    - **3 Existential Psychotherapy and Religious Consolation: Convergence and Divergence** Page 16
  - **SCIENTIFIC AND CLINICAL REPORT**
    - **34 Spirituality in the Detoxification Phase of Substance Abuse Treatment** Page 24
  - **SYMPOSIA**
    - **58 Beyond Mind and Brain: Considering the Patient's World View** Page 61
    - **69 Model Residency Programs on Religion and Spirituality** Page 84
    - **81 The Role of Religion in the Lives of Our Patients: Clinical Approaches** Page 87
  - **WORKSHOP - COMPONENT**
    - **13 The Interface Between Religion and Existential Psychotherapy** Page 25
  - **WORKSHOPS - ISSUES**
    - **60 Spiritual/Religious Assessment in Clinical Work** Page 72
    - **68 Spiritual Struggles: The New Priority in Treatment** Page 73

#### TOPIC 59: RELIGION, SPIRITUALITY AND PSYCHIATRY

- **COURSES**
  - **50 Issues in Transpersonal Psychiatry** Page 15
  - **66 Transpersonal Psychiatry: Clinical Applications** Page 41

- **LECTURE**
  - **3 Existential Psychotherapy and Religious Consolation: Convergence and Divergence** Page 16

- **SCIENTIFIC AND CLINICAL REPORT**
  - **34 Spirituality in the Detoxification Phase of Substance Abuse Treatment** Page 24

- **SYMPOSIA**
  - **58 Beyond Mind and Brain: Considering the Patient's World View** Page 61
  - **69 Model Residency Programs on Religion and Spirituality** Page 84
  - **81 The Role of Religion in the Lives of Our Patients: Clinical Approaches** Page 87

- **WORKSHOP - COMPONENT**
  - **13 The Interface Between Religion and Existential Psychotherapy** Page 25

- **WORKSHOPS - ISSUES**
  - **60 Spiritual/Religious Assessment in Clinical Work** Page 72
  - **68 Spiritual Struggles: The New Priority in Treatment** Page 73

#### TOPIC 60: RESIDENT AND MEDICAL STUDENT CONCERNS

- **DISCUSSION GROUPS**
  - **7 Consultation-Liaison Psychiatry: Career and Subspecialization Opportunities at the Medicine-Psychiatry Interface (For Residents Only)** Page 41
  - **15 Career Opportunities in Women's Mental Health (For Residents Only)** Page 69
  - **25 My Experiences as a Military Psychiatrist (For Residents Only)** Page 98

- **MASTER EDUCATOR CLINICAL CONSULTATIONS**
  - **8 The Journey: Exploring Learning with Our Students (AAP Council on Education Master Teacher)** Page 42
  - **15 Teaching Psychopathology to Medical Students (AADPRT Council on Education Master Teacher)** Page 75

- **RESIDENT'S SESSION**
  - **Meet the Experts: Sunny Side-Up** Page 14

### WORKSHOPS - COMPONENTS
- **WORKSHOPS - ISSUES**
  - **4 The Great Beyond: Making Career Decisions at the End of Residency Training** Page 18
  - **5 The Interpretation of Dreams: Fantasy and Reality in Residency Training** Page 18
  - **24 Stalking: The Psychiatric Trainee at Risk** Page 44
  - **35 Using Practice Guidelines in Residency Training** Page 72
  - **36 Psychiatry in the Neuroscience Curriculum: Promise and Peril** Page 72
  - **39 Career Choices in Psychiatry** Page 78

- **TOPIC 59: RELIGION, SPIRITUALITY AND PSYCHIATRY**
  - **COURSES**
    - **50 Issues in Transpersonal Psychiatry** Page 15
    - **66 Transpersonal Psychiatry: Clinical Applications** Page 41
  - **LECTURE**
    - **3 Existential Psychotherapy and Religious Consolation: Convergence and Divergence** Page 16
  - **SCIENTIFIC AND CLINICAL REPORT**
    - **34 Spirituality in the Detoxification Phase of Substance Abuse Treatment** Page 24
  - **SYMPOSIA**
    - **58 Beyond Mind and Brain: Considering the Patient's World View** Page 61
    - **69 Model Residency Programs on Religion and Spirituality** Page 84
    - **81 The Role of Religion in the Lives of Our Patients: Clinical Approaches** Page 87
  - **WORKSHOP - COMPONENT**
    - **13 The Interface Between Religion and Existential Psychotherapy** Page 25
  - **WORKSHOPS - ISSUES**
    - **60 Spiritual/Religious Assessment in Clinical Work** Page 72
    - **68 Spiritual Struggles: The New Priority in Treatment** Page 73

- **TOPIC 60: RESIDENT AND MEDICAL STUDENT CONCERNS**
  - **DISCUSSION GROUPS**
    - **7 Consultation-Liaison Psychiatry: Career and Subspecialization Opportunities at the Medicine-Psychiatry Interface (For Residents Only)** Page 41
    - **15 Career Opportunities in Women's Mental Health (For Residents Only)** Page 69
    - **25 My Experiences as a Military Psychiatrist (For Residents Only)** Page 98
  - **MASTER EDUCATOR CLINICAL CONSULTATIONS**
    - **8 The Journey: Exploring Learning with Our Students (AAP Council on Education Master Teacher)** Page 42
    - **15 Teaching Psychopathology to Medical Students (AADPRT Council on Education Master Teacher)** Page 75
  - **RESIDENT'S SESSION**
    - **Meet the Experts: Sunny Side-Up** Page 14

### SCIENTIFIC AND CLINICAL REPORTS
- **5 Self, Object, and Neurobiology** Page 22
- **6 Conceptual Integration of Mind and Brain in Philosophy and Psychiatry** Page 22
- **103 Unremitting Depression: Cingulate Dysfunction and the Cleft-Self on Trial** Page 99

### SYMPOSIA
- **18 Mind and Brain: The Concepts of Psychiatry** Page 33
- **20 Thinking About Mind and Brain: Psychoanalysts and Neuroscientists Converse: Part I** Page 34
- **26 Exercise, Athletic Participation, and Mental Health: When It Works and When It Doesn’t** Page 35
- **51 Thinking About Mind and Brain: Psychoanalysts and Neuroscientists Converse: Part II** Page 59
- **55 Psychoanalysis and Psychotherapy Long-Term Outcome** Page 60
- **76 Mind/Brain, Reduction, and Schizophrenia** Page 86

### WORKSHOPS - ISSUES
- **32 Does the Mind Meet the Brain in Residency? And What About the Body?** Page 44
- **51 How the Theory of Evolution Is Fundamental to Our Biopsychosocial Model** Page 51
- **82 Treating PTSD Complicated by Medical Problems: Mind and Brain Meet Body** Page 74
- **86 Beyond Reductionism: Clinical Implications** Page 74
- **95 Mind Meets Brain in Family Therapy: Bridges for Healing** Page 80
- **126 Subjectivity: Crucial Key to the Therapeutic Alliance** Page 101
- **128 Mind and Brain Do Not Need to Be Integrated If We Don’t Segregate Them in the First Place** Page 101

### TOPIC 62: STIGMA/ADVOCACY

- **COURSE**
  - **95 How to Combat the Stigma of Mental Illness** Page 93

- **DISCUSSION GROUP**
  - **3 Psychiatrists in Mental Health Advocacy Groups** Page 20
### TOPIC INDEX

<table>
<thead>
<tr>
<th>MEDIA PROGRAMS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 King Gimp</td>
<td>28</td>
</tr>
<tr>
<td>13 Soop on Wheels</td>
<td>28</td>
</tr>
<tr>
<td>33 Twitch and Shout</td>
<td>71</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIUM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>71 The World Psychiatric Association Global Program to Reduce the Stigma of Schizophrenia</td>
<td>85</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOP - ISSUE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>87 Psychiatric Illness in Psychiatrists: Overcoming Stigma</td>
<td>79</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TOPIC 63: TELEPSYCHIATRY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>TELECOMMUNICATIONS PRESENTATION</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Prison Telepsychiatry: Realities and Prospects</td>
<td>43</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TOPIC 64: VIRTUAL REALITY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>LECTURE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>23 Why We Will Spend Most of Our Time in Virtual Reality in the 21st Century</td>
<td>94</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TELECOMMUNICATIONS PRESENTATIONS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 Digital Phenomenology of Depression</td>
<td>71</td>
</tr>
<tr>
<td>10 Using Virtual Reality to Treat Acrophobia</td>
<td>71</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TOPIC 65: WOMEN'S HEALTH ISSUES</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIA</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>28 Women's Mental Health: Antidepressant Therapy During the Childbearing Years, Part 1</td>
<td>13</td>
</tr>
<tr>
<td>28 Women's Mental Health: Antidepressant Therapy During the Childbearing Years, Part 2</td>
<td>39</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MASTER EDUCATOR CLINICAL CONSULTATIONS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 The Psychiatric Aspects of Breast Cancer</td>
<td>16</td>
</tr>
<tr>
<td>6 Use of Psychotropic Drugs in Pregnancy and Lactation</td>
<td>21</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEDICAL UPDATE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Breast Cancer Prevention: An Example of Translational Research</td>
<td>48</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>96 Risk of Postpartum Depression in Women with Pregravid Major Depression Disorder</td>
<td>78</td>
</tr>
<tr>
<td>119 Mood and Anxiety Disorders and Health of Multi-Ethnic Midlife Women</td>
<td>100</td>
</tr>
<tr>
<td>120 Topiramate in PMDD</td>
<td>100</td>
</tr>
<tr>
<td>121 Verapamil Effectiveness in Women with Bipolar Disorder</td>
<td>101</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIAS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 Women's Mental Health: A Current Perspective</td>
<td>35</td>
</tr>
<tr>
<td>80 Special Topics in Women's Mental Health</td>
<td>87</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOPS - ISSUES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 Women and Suicide: Hormones and Genes</td>
<td>45</td>
</tr>
<tr>
<td>44 Integrated Treatment Programs for Pregnant, Mothering Women and Their Children</td>
<td>45</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Psychiatric Disorders in Pregnancy and Postpartum</td>
<td>8</td>
</tr>
<tr>
<td>84 Treatment Issues for Women in Minority Groups</td>
<td>68</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DISCUSSION GROUPS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Treating Women Patients: What Clinicians Need to Know</td>
<td>15</td>
</tr>
<tr>
<td>19 Medicine, Marriage, and Motherhood</td>
<td>74</td>
</tr>
</tbody>
</table>

**122**
PARTICIPANT INDEX

APA 154TH ANNUAL MEETING
Del Zombo, Maria .......................................................... 83
Demann, C. ................................................................. 103
Demrick, Mark A .......................................................... 106
Denicoff, Kirk D ............................................................ 55, 56
Derivan, Albert T .......................................................... 90
Deutschman, David A ..................................................... 1, 7, 12
Devanand, D.... ............................................................. 63
Devins, Gerald M .......................................................... 22
Devlin, Bernard .............................................................. 86
Devlin, Michael J ............................................................ 84
Dewan, Manto J ............................................................. 40, 104
Dewan, Nakeesh ............................................................. 1
Diamond, Robert ............................................................ 50
Diaz-Marsa, Marina ........................................................ 85
Dickerson, Faith ............................................................. 49
Dickson, Amy ................................................................. 30
Dickstein, Daniel P ........................................................ 26
Dickson, Amy ................................................................. 30
Diamond, Robert ............................................................ 50
Dewan, Naakeesh .......................................................... 40
Devins, Gerald M .......................................................... 22
Doolan, Rega ................................................................. 35, 83, 87
Dominguez, Roberto ....................................................... 24
Donovan, Alastair .......................................................... 104
Doo, Rachel S ................................................................. 69
Dorsawany, P. Marali ...................................................... 6
Dording, Christina M ...................................................... 77, 78
Doss, Susan ................................................................. 78, 79
Douglass, Robert ........................................................... 57
Downey, Jennifer I ........................................................ 31
Downs, Sarah R .............................................................. 68
Dreay, Brian B ............................................................... 27
Dracan, Sarah ................................................................. 76
Drake, Robert E .............................................................. 5
Dralle, Penelope ............................................................. 30
Dreising, Charles ............................................................ 84
Drew, Marian J ............................................................... 39, 40
Drescher, Jack ............................................................... 18, 84
Drevets, Wayne C ......................................................... 71
Drummond, Peter .......................................................... 103
Druss, Benjamin G ........................................................ 44
Dryden-Edwards, Roxanne ............................................. 25
D'Souza, D. Cyril ............................................................ 105
Ducat, Sarah ................................................................. 63
Duckworth, Kenneth S ................................................... 51
Duffy, Parthosh ............................................................. 31
Duman, Ronald S .......................................................... 63
Dunn, Laura D ............................................................... 18
Dunner, David L ............................................................ 67, 93
Dupignan, Joanna .......................................................... 19, 72
Dupont, Randolph T ...................................................... 57
Dvorak, Nemanja .......................................................... 27
Dwyer, Donard S ........................................................... 3
Dyk, Ingrid R ................................................................. 35, 83
Eisendrath, Stuart J ........................................................ 19
Eisele, Lisa ................................................................. 73
El-Deray, Mohamed H ................................................... 31, 85
El-Sayed, Hesham .......................................................... 31
Elson, Hal ................................................................. 62, 71
Elman, Ido ................................................................. 74
Elshagga, Tamer ............................................................ 33
Engelhardt, Jenna .......................................................... 5
England, Mary Jane ........................................................ 62
Ersdal, Brandon Z .......................................................... 72
Erskine, Chris .............................................................. 13
Erman, Milton K ........................................................... 2
Erie, Spencer ............................................................... 43
Erwin, Mark S .............................................................. 52
Evans, Dwight L ............................................................ 39
Eynman-Harvey, Rael .................................................... 60
Faber, Raymond A ........................................................ 26, 40
Fabiny, Magda .............................................................. 85
Faber, Roseanne ........................................................... 25, 33
Faison, Waracha ............................................................ 50
Fallon, Brian A .............................................................. 83
Farabaugh, Amy H ......................................................... 83
Fasone, Stephen V ........................................................ 27, 79, 90
Farvolden, Peter ........................................................... 23
Faulkner, Matt .............................................................. 100
Faulkner, Larry R ........................................................... 19
Fava, Maurizio ............................................................. 51
Fawcett, Jan A ............................................................... 14, 59
Fazio, Lydia O ............................................................... 24, 44
Feder, Adriana .............................................................. 34
Fein, John P ................................................................. 24
Feigen, Paul ................................................................. 25
Fein, Sidney ................................................................. 48
Fein, Joel S ................................................................. 56, 95
Feinstein, Carl B ........................................................... 25
Feldman, Jacqueline M .................................................. 80, 88
Feldman, Marc D ........................................................... 83
Felder, Bradford L .......................................................... 44
Feng, Wenzu .............................................................. 49
Fenton, Wayne S ........................................................... 49
Ferguson, Yvonne B ....................................................... 53
Fernandez, Francisco ..................................................... 31, 67, 85, 101
Ferrando, Stephen J ....................................................... 31, 96
Festa, Donna ............................................................... 19
Fichter, Manfred M ........................................................ 55
Fichter, Matthias G ......................................................... 88
Fleider, Donald C .......................................................... 42
Fleissig, John .............................................................. 7
Finazzo, Michelle .......................................................... 7
Finlay, Robert L ............................................................ 90
Fink, Margit ............................................................... 74
Fink, Paul J ................................................................. 33, 43
Fiorello, Michelle .......................................................... 74
Finn, Michael I ............................................................ 14, 35, 52, 56
Fischer, Alan ............................................................... 77
Fischman, Mariah .......................................................... 32
Fink, Diana J ............................................................... 31
Fitzgerald, Louise F ........................................................ 80
Fitzgibbons, Lee A ........................................................ 104
Flicker, Joseph A ........................................................... 62
Fowler, J. Christopher ................................................... 61
Duncan, Brenda ............................................................. 50
Dunn, Lisa ................................................................. 35, 83
Dwyer, Donard S ........................................................... 3
Dyk, Ingrid R ................................................................. 35, 83
Eberle, Andrea ............................................................. 89
Ebert, Bruce ................................................................. 19
Ebert, Michael H ........................................................... 19
Eddy, Ramsay T ............................................................ 31
Edell, William S ............................................................ 48
Edeleman, Randle .......................................................... 69
Edman, Jeanne ............................................................. 48
Edwards, Kimberly B ..................................................... 86
Eck, Carolyn ................................................................. 87
Eisendrath, Stuart J ........................................................ 19
Eisele, Lisa ................................................................. 73
El-Deray, Mohamed H ................................................... 31, 85
El-Sayed, Hesham .......................................................... 31
Elson, Hal ................................................................. 62, 71
Elman, Ido ................................................................. 74
Elshagga, Tamer ............................................................ 33
Engelhardt, Jenna .......................................................... 5
England, Mary Jane ........................................................ 62
Ersdal, Brandon Z .......................................................... 72
Erskine, Chris .............................................................. 13
Erman, Milton K ........................................................... 2
Erie, Spencer ............................................................... 43
Erwin, Mark S .............................................................. 52
Evans, Dwight L ............................................................ 39
Eynman-Harvey, Rael .................................................... 60
Faber, Raymond A ........................................................ 26, 40
Fabiny, Magda .............................................................. 85
Faber, Roseanne ........................................................... 25, 33
Faison, Waracha ............................................................ 50
Fallon, Brian A .............................................................. 83
Farabaugh, Amy H ......................................................... 83
Fasone, Stephen V ........................................................ 27, 79, 90
Farvolden, Peter ........................................................... 23
Faulkner, Matt .............................................................. 100
Faulkner, Larry R ........................................................... 19
Fava, Maurizio ............................................................. 51
Fawcett, Jan A ............................................................... 14, 59
Fazio, Lydia O ............................................................... 24, 44
Feder, Adriana .............................................................. 34
Fein, John P ................................................................. 24
Feigen, Paul ................................................................. 25
Fein, Sidney ................................................................. 48
Fein, Joel S ................................................................. 56, 95
Feinstein, Carl B ........................................................... 25
Feldman, Jacqueline M .................................................. 80, 88
Feldman, Marc D ........................................................... 83
Felder, Bradford L .......................................................... 44
Feng, Wenzu .............................................................. 49
Fenton, Wayne S ........................................................... 49
Ferguson, Yvonne B ....................................................... 53
Fernandez, Francisco ..................................................... 31, 67, 85, 101
Ferrando, Stephen J ....................................................... 31, 96
Festa, Donna ............................................................... 19
Fichter, Manfred M ........................................................ 55
Fichter, Matthias G ......................................................... 88
Fleider, Donald C .......................................................... 42
Fleissig, John .............................................................. 7
Finazzo, Michelle .......................................................... 7
Finlay, Robert L ............................................................ 90
Fink, Margit ............................................................... 74
Fink, Paul J ................................................................. 33, 43
Fiorello, Michelle .......................................................... 74
Finn, Michael I ............................................................ 14, 35, 52, 56
Fischer, Alan ............................................................... 77
Fischman, Mariah .......................................................... 32
Fink, Diana J ............................................................... 31
Fitzgerald, Louise F ........................................................ 80
Fitzgibbons, Lee A ........................................................ 104
Flicker, Joseph A ........................................................... 62
Flaherty, Lois T ............................................................. 18
PARTICIPANT INDEX

Garno, Jessica L ........................................... 89
Gartno, Jessica L ........................................... 100
Gask, Linda ................................................ 25
Gass, Charlie A ............................................ 24
Gass, David R ............................................. 73
Gatti, Marino ............................................... 36
Gavioli, F. Moises ........................................ 46, 86
Gaynes, Bradley N ........................................ 99
Geedes, John ............................................... 94
Gee, Kenneth K ............................................ 104
Gelberg, Alan J ............................................ 48, 55
Gendel, Michael H ........................................ 17
Gendel, Valentin .......................................... 87
Genus, Jose A ............................................. 45
Geilloop, Jaap G .......................................... 85
George, Mark S ........................................... 15
Gerber, Patricia L ......................................... 41
Gerstein, Hertzel C ....................................... 3
Gerber, Robert P ......................................... 15, 16
Gerber, Annette .......................................... 29
Grassi, Luigi ............................................... 36
Gray, Ernestine S ......................................... 30
Gray, Kevin F ............................................ 26, 63
Gray, Sheils H ............................................ 72
Greder, John F ........................................... 16, 29, 106
Greder, John F ........................................... 5
Green, Alan I ............................................... 71
Green, Jamison ........................................... 12
Green, Michael F ......................................... 12
Green, Ronald L .......................................... 62
Greenberg, David ........................................ 72
Greenberg, Harvey R .................................... 12, 54, 64
Greenberg, Leslie S ...................................... 41
Greenberg, William E ................................... 44
Greenberg, William M ................................... 79
Greenberg, David J ...................................... 64
Greenfield, Shelly F ...................................... 44
Greenhal, Laurence L .................................... 77, 85
Greenleaf, Wayne ........................................ 30
Greenwald, Blaine S ..................................... 78
Greiner, Carl B ........................................... 72
Green, John H ............................................. 106
Grinsham, Jr., Robert L ................................ 76, 78
Griffith, Ezra E.H ........................................ 35, 42
Griffith, James L .......................................... 15, 51, 67, 101
Greal, Carlos M ........................................... 23, 48, 83
Greene, W. S. ............................................ 61
Grob, Charles S ........................................... 101
Grosch, William N ....................................... 25
Grossman, Linda S ........................................ 50
Gross, Hansu J ........................................... 77
Gros, Mark S ............................................... 18
Gruhnen, Peter B ......................................... 57
Grud, Ellen M ............................................. 78
Gruf, Iden D .............................................. 73
Guggenheim, Frederick G .............................. 44
Guille, Constance ........................................ 50
Gunngson, John G ....................................... 83, 87
Gur, Raquel E ............................................. 30
Guralik, Orna ............................................. 105
Guachan, Marianne T ................................... 20, 44
Grahan, V ................................................... 78
Guss, Jane .................................................. 84
Gutman, David A ......................................... 77
Gyurokoe, Kevin L ....................................... 50

H

Haahr, Ulrik ............................................... 105
Hadamom, I ............................................... 49
Hadeley, Sally J ......................................... 11
Hafliger, Silvio .......................................... 94
Hage, Wafa ............................................... 85
Haghen, Ahmed .......................................... 98
Hajak, Goran ............................................. 64
Halbreich, Ursel ......................................... 49
Hales, Robert E .......................................... 13, 39
Hall, Sharon ............................................. 19
Haller, Ellen ............................................... 19, 68
Ham, Katherine A ....................................... 7, 31, 55, 104
Halperin, David A ....................................... 91
Halperin, Steven ........................................ 103
Halpen, Abraham L ...................................... 44, 73
Halpen, John H .......................................... 44, 101
Hambrug, Paul .......................................... 58
Hammer, Lawrence ...................................... 99
Hammond, Timothy G ................................... 99
Han, Xuesong ............................................ 57
Hanin, Edward .......................................... 73
Hankins, Melissa M ..................................... 73
Hansen, Mark R .......................................... 2
Hansen, Thomas E ...................................... 8
Harr, Graeme ............................................ 96
Harms, Barbara .......................................... 100
Higashin, David ......................................... 48
Harbin, Henry T .......................................... 17
Harden, Cynzia L ........................................ 74
Harding, Richard K ..................................... 10, 14, 36, 32
Harding, George T ...................................... 25
Harlow, Bernard L ....................................... 30, 78
Harris, Michael R ........................................ 99
Harris, Pamie A .......................................... 42, 78
Harris, Wendy A .......................................... 104
Harrison, Wilma M ...................................... 48
Harrow, Martin .......................................... 24, 100
Hartman, David E ....................................... 73
Hartmann, Lawrence .................................... 28, 56
Harvey, Sharon C ....................................... 33
Haskin, Aqui ............................................. 100
Haus, Deborah S .......................................... 56
Hatterson, James R ...................................... 94
Hassan, Fatma ........................................... 31
Hatterman, Charles ...................................... 22
Hautor, Misko ............................................ 29
Hawkns, Keith A .......................................... 86
Hedlas, Erinn A .......................................... 105
Head, Journ .............................................. 60
Held, Stephen H .......................................... 72, 88
Helgeodt, John H ........................................ 35
Hedman, David W ........................................ 94
Heinberg, Richard G ..................................... 103
Helrne, Ricardo .......................................... 33
Heltensoon, David J ..................................... 48
Hembree, Elizabeth A ................................... 104
Henderson, David C ...................................... 3
Hendin, Herbert .......................................... 50
Hendren, Robert L ........................................ 25
Hendrick, Victoria ....................................... 9, 39
Henke, Shamina .......................................... 84
Hennein, John ............................................ 3, 23
Hensley, Paula L .......................................... 48, 55
Herbeck, Diane M ........................................ 31, 32
Herbener, Ellen S ........................................ 24
Hernandez, Pablo D ...................................... 102
Hernandez-Serrano, Ruben J ......................... 33
Herrick, Fay ............................................... 93
Herron, Stephen M ....................................... 36
Hers, Richaer G ........................................... 81
Hirtz, Miki .................................................. 100
Hiro, Alison M ............................................ 43
Hirtz, David B ............................................ 31, 58
Hester, Thomas W ........................................ 15
Hettinga, Nicolaas F.J ................................... 25
Hett, John F ............................................... 15, 41
Hedel, Stephen H ........................................ 72
Hickey, Grace ............................................ 19, 72
Hicks, Brian M ............................................ 57
Hicks, Daniel W .......................................... 18
Hild, Fred C ............................................... 7
Hill, Kevin P .............................................. 24
Hirsch, Alan R ............................................ 73
Hirschfield, Roberts M.A ................................ 13, 39, 57
Hodstein, Laura D ........................................ 99
Hof, Andrew P ............................................ 8, 52, 99
Hocking, Barbara ........................................ 93
Holten, Ralph E ........................................... 86
Holman, Albert .......................................... 46
Hoge, Michael ............................................ 62
Holder-Persico, Vicenzio ................................ 83
Hollos, Jimm C ........................................... 46
Holland, Annette J ....................................... 40
Hollander, Eric ........................................... 11, 14, 39, 105
Holman, Julie ............................................ 23
Holst, Jacob C ............................................ 89
Honberg, Ron ............................................ 25
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lambrinos, Angela</td>
<td>83</td>
</tr>
<tr>
<td>Lambert, Timothy</td>
<td>1</td>
</tr>
<tr>
<td>Lam, Raymond W</td>
<td>8</td>
</tr>
<tr>
<td>Lambert, Trotsky</td>
<td>51</td>
</tr>
<tr>
<td>Laminou, Angela</td>
<td>83</td>
</tr>
<tr>
<td>Lane, Deforia L</td>
<td>73</td>
</tr>
<tr>
<td>Lane, Richard D</td>
<td>41</td>
</tr>
<tr>
<td>Lang, Joan A</td>
<td>51</td>
</tr>
<tr>
<td>Lange, Christopher L</td>
<td>101</td>
</tr>
<tr>
<td>Langer, Alan</td>
<td>70</td>
</tr>
<tr>
<td>Langley, Donald G</td>
<td>57, 77</td>
</tr>
<tr>
<td>Lapp, Kathleen G</td>
<td>43</td>
</tr>
<tr>
<td>Laren, Julie A</td>
<td>24</td>
</tr>
<tr>
<td>Larsen, Tor K</td>
<td>104, 105</td>
</tr>
<tr>
<td>Larson, David B</td>
<td>72, 84</td>
</tr>
<tr>
<td>Las, Maricene</td>
<td>36</td>
</tr>
<tr>
<td>Laughter, Thomas P</td>
<td>106</td>
</tr>
<tr>
<td>Launay, Corinne</td>
<td>88</td>
</tr>
<tr>
<td>Lauriello, John</td>
<td>48</td>
</tr>
<tr>
<td>Lauterbach, Edward C</td>
<td>1, 8, 68, 85</td>
</tr>
<tr>
<td>Lavis, Maria</td>
<td>31</td>
</tr>
<tr>
<td>Lavon, Phillip</td>
<td>106</td>
</tr>
<tr>
<td>Lawrence, James M</td>
<td>76</td>
</tr>
<tr>
<td>Lawson, William R</td>
<td>45, 62</td>
</tr>
<tr>
<td>Lazarus, Arthur L</td>
<td>24, 49, 73, 101</td>
</tr>
<tr>
<td>Leach, Leslie F</td>
<td>57, 106</td>
</tr>
<tr>
<td>Leacy, Mark</td>
<td>88</td>
</tr>
<tr>
<td>Lebar, Reverend James</td>
<td>107</td>
</tr>
<tr>
<td>Lebovitz, Harold E</td>
<td>3</td>
</tr>
<tr>
<td>Lebowitz, Barry D</td>
<td>106</td>
</tr>
<tr>
<td>Lee, Joshua</td>
<td>8</td>
</tr>
<tr>
<td>Lefer, Gary L</td>
<td>56</td>
</tr>
<tr>
<td>Lehman, Anthony F</td>
<td>52, 88</td>
</tr>
<tr>
<td>Lehmann, Laurence S</td>
<td>44</td>
</tr>
<tr>
<td>Leibl, Rudolph</td>
<td>84</td>
</tr>
<tr>
<td>Leibenluft, Ellen</td>
<td>27, 69</td>
</tr>
<tr>
<td>Lench, Sharyn A</td>
<td>27</td>
</tr>
<tr>
<td>Lenox, Robert H</td>
<td>30</td>
</tr>
<tr>
<td>Lessenreger, Mark F</td>
<td>105</td>
</tr>
<tr>
<td>Leon-Andrade, Carlos</td>
<td>33</td>
</tr>
<tr>
<td>Lerner, Mark</td>
<td>77</td>
</tr>
<tr>
<td>Levav, Irzhak</td>
<td>22</td>
</tr>
<tr>
<td>Levensholtz, Philip G</td>
<td>1</td>
</tr>
<tr>
<td>Levenson, James L</td>
<td>69</td>
</tr>
<tr>
<td>Leverich, Gabriele S</td>
<td>55</td>
</tr>
<tr>
<td>Levin, Frances R</td>
<td>13, 77</td>
</tr>
<tr>
<td>Levine, Rush E</td>
<td>21</td>
</tr>
<tr>
<td>Levine, Sharon S</td>
<td>79</td>
</tr>
<tr>
<td>Levine, Stewart</td>
<td>45</td>
</tr>
<tr>
<td>Levtz, Anthony J</td>
<td>18</td>
</tr>
<tr>
<td>Levit, James J</td>
<td>96</td>
</tr>
<tr>
<td>Levounis, Petros</td>
<td>78</td>
</tr>
<tr>
<td>Lewis, Lydia J</td>
<td>59, 50, 59</td>
</tr>
<tr>
<td>Lewis-Fernandez, Roberto</td>
<td>32, 52, 79</td>
</tr>
<tr>
<td>Ley, Alfred J</td>
<td>81</td>
</tr>
<tr>
<td>Li, Chiou-Ping</td>
<td>45</td>
</tr>
<tr>
<td>Liang, Warren M</td>
<td>60</td>
</tr>
<tr>
<td>Liberto, Joseph G</td>
<td>17</td>
</tr>
<tr>
<td>Lichmecker, Jonathan E</td>
<td>19</td>
</tr>
<tr>
<td>Lieberman, Jeffrey A</td>
<td>5, 8, 49, 91, 106</td>
</tr>
<tr>
<td>Libowicz, Michael R</td>
<td>11, 23</td>
</tr>
<tr>
<td>Lieff, Susan</td>
<td>75</td>
</tr>
<tr>
<td>Lienar, Walter K</td>
<td>100</td>
</tr>
<tr>
<td>Liu, Yehsukel</td>
<td>22</td>
</tr>
<tr>
<td>Lins, Russell H</td>
<td>52</td>
</tr>
<tr>
<td>Linsinger, Richard F</td>
<td>17</td>
</tr>
<tr>
<td>Lin, Keh-Ming</td>
<td>45, 104</td>
</tr>
<tr>
<td>Lin, Margaret T</td>
<td>72</td>
</tr>
<tr>
<td>Lindauer, Lauren A</td>
<td>64</td>
</tr>
<tr>
<td>Linden, Michael</td>
<td>59</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lindenmayer, Jean-Pierre</td>
<td>19, 49</td>
</tr>
<tr>
<td>Lindy, David C</td>
<td>1, 97</td>
</tr>
<tr>
<td>Link, Bruce</td>
<td>85</td>
</tr>
<tr>
<td>Link, Paul S</td>
<td>60, 97</td>
</tr>
<tr>
<td>Lipshitz, Alan</td>
<td>50</td>
</tr>
<tr>
<td>Lipshutz, Don R</td>
<td>32, 95</td>
</tr>
<tr>
<td>Lipstein, Steven H</td>
<td>18, 77</td>
</tr>
<tr>
<td>Lipka, Barbara K</td>
<td>9</td>
</tr>
<tr>
<td>Lit, Wilson M</td>
<td>45</td>
</tr>
<tr>
<td>Liveley, John</td>
<td>1, 35, 57, 103</td>
</tr>
<tr>
<td>Lobboerhida, Sheila M</td>
<td>73</td>
</tr>
<tr>
<td>Logdohn, Linda</td>
<td>17</td>
</tr>
<tr>
<td>Loh, Kathleen N</td>
<td>99</td>
</tr>
<tr>
<td>Lohr, Naomi</td>
<td>60</td>
</tr>
<tr>
<td>Lomax II, James W</td>
<td>73, 84</td>
</tr>
<tr>
<td>Londono, Donna L</td>
<td>77</td>
</tr>
<tr>
<td>Londono, Erich H</td>
<td>46</td>
</tr>
<tr>
<td>Long-Harrell, Angelia J</td>
<td>44, 99</td>
</tr>
<tr>
<td>Longo, Lance P</td>
<td>25</td>
</tr>
<tr>
<td>Lopes, Alberto G</td>
<td>79</td>
</tr>
<tr>
<td>Lopes, Frank</td>
<td>77</td>
</tr>
<tr>
<td>Lopes, Juan F</td>
<td>3</td>
</tr>
<tr>
<td>Lopes-Ibor, Maria J</td>
<td>43</td>
</tr>
<tr>
<td>Lopes-Kor, Jr, Juan F</td>
<td>63, 85</td>
</tr>
<tr>
<td>Losekoot, Marylee</td>
<td>84</td>
</tr>
<tr>
<td>Loschen, Earl L</td>
<td>23</td>
</tr>
<tr>
<td>Losconzy, Miklos P</td>
<td>102</td>
</tr>
<tr>
<td>Lousier, Ben</td>
<td>10</td>
</tr>
<tr>
<td>Love, Anthony</td>
<td>36</td>
</tr>
<tr>
<td>Lowenkopf, Eugene L</td>
<td>81, 100</td>
</tr>
<tr>
<td>Lowenthal, David A</td>
<td>50</td>
</tr>
<tr>
<td>Lowe, Walter F S</td>
<td>2</td>
</tr>
<tr>
<td>Lu, Francis G</td>
<td>12, 15, 45, 50, 52, 72, 75, 84, 102, 104</td>
</tr>
<tr>
<td>Luber, M. Philip</td>
<td>72</td>
</tr>
<tr>
<td>Luborsky, Lester</td>
<td>60</td>
</tr>
<tr>
<td>Lucke, Sylvia</td>
<td>49</td>
</tr>
<tr>
<td>Luhmann, Tanya M</td>
<td>56</td>
</tr>
<tr>
<td>Luther, Jesse H</td>
<td>64</td>
</tr>
<tr>
<td>Luo, John</td>
<td>1, 96</td>
</tr>
<tr>
<td>Luterek, Jane</td>
<td>103</td>
</tr>
<tr>
<td>Lyktens, Constatine G</td>
<td>11, 15, 20, 56, 57</td>
</tr>
<tr>
<td>Lynch, Frances</td>
<td>78</td>
</tr>
<tr>
<td>Lynch, Kevin M</td>
<td>100</td>
</tr>
<tr>
<td>Lynch, Robert A</td>
<td>78</td>
</tr>
<tr>
<td>Matorin, Anu A</td>
<td>51, 74, 101</td>
</tr>
<tr>
<td>Matteucci, Neil A</td>
<td>97</td>
</tr>
<tr>
<td>Matthews, John D</td>
<td>77, 78</td>
</tr>
<tr>
<td>Matthews, Karen S</td>
<td>100</td>
</tr>
<tr>
<td>Maull, Fleet W</td>
<td>104</td>
</tr>
<tr>
<td>Matiasikiam, Murtag H</td>
<td>23</td>
</tr>
<tr>
<td>Maxwell, Michael</td>
<td>97</td>
</tr>
<tr>
<td>Mayberg, Helen S</td>
<td>3</td>
</tr>
<tr>
<td>Mayer, Laurel</td>
<td>58, 84</td>
</tr>
<tr>
<td>Mazzie, Michael</td>
<td>49</td>
</tr>
<tr>
<td>Mazzaret, Chiara</td>
<td>49</td>
</tr>
<tr>
<td>McCall, W. Vaughn</td>
<td>14</td>
</tr>
<tr>
<td>McCamant, Lynn E</td>
<td>100</td>
</tr>
<tr>
<td>McCarley, Robert W</td>
<td>90</td>
</tr>
<tr>
<td>McCarley, Richard H</td>
<td>19, 44</td>
</tr>
<tr>
<td>McCartney, Cheryl F</td>
<td>48</td>
</tr>
<tr>
<td>McCarley, Teresa A</td>
<td>23</td>
</tr>
<tr>
<td>McDermott, Stephen P</td>
<td>15, 40</td>
</tr>
<tr>
<td>McDonald, Clyde</td>
<td>130</td>
</tr>
<tr>
<td>McDonald, Colin</td>
<td>29</td>
</tr>
<tr>
<td>McDonough, James R</td>
<td>101</td>
</tr>
<tr>
<td>McDowell, David M</td>
<td>32, 33, 75, 102</td>
</tr>
<tr>
<td>McDuff, David R</td>
<td>79</td>
</tr>
<tr>
<td>McElroy, Susan L</td>
<td>11, 56, 90</td>
</tr>
<tr>
<td>McElroy, Joseph P</td>
<td>106</td>
</tr>
<tr>
<td>McEvoy, Joseph P</td>
<td>49</td>
</tr>
<tr>
<td>McFadden, Benjamin H</td>
<td>20</td>
</tr>
<tr>
<td>McFarlane, Alexander</td>
<td>84</td>
</tr>
<tr>
<td>McCarney, Elizabeth L</td>
<td>49, 50, 77</td>
</tr>
<tr>
<td>McGlashan, Thomas H</td>
<td>23, 33, 48, 83, 85, 86, 104, 105</td>
</tr>
<tr>
<td>McGregor, Jacqueline C</td>
<td>48</td>
</tr>
<tr>
<td>McGregor, Victor</td>
<td>78</td>
</tr>
<tr>
<td>McGue, Matt</td>
<td>57</td>
</tr>
<tr>
<td>McGugh, Paul R</td>
<td>20, 70</td>
</tr>
<tr>
<td>McInnes, L. Alison</td>
<td>19</td>
</tr>
<tr>
<td>McIntyre, John S</td>
<td>31, 58, 72, 79, 96</td>
</tr>
<tr>
<td>McKay, James R</td>
<td>103</td>
</tr>
<tr>
<td>McKenzie, Dean P</td>
<td>36</td>
</tr>
<tr>
<td>McElen, A. Thomas</td>
<td>101</td>
</tr>
<tr>
<td>McEskin, Hayne D</td>
<td>63</td>
</tr>
<tr>
<td>McNicholas, Laura F</td>
<td>7, 103</td>
</tr>
<tr>
<td>McQueation, M.</td>
<td>83</td>
</tr>
<tr>
<td>McQuiney, Hunter L</td>
<td>72, 78, 96</td>
</tr>
<tr>
<td>Medford, Nicholas</td>
<td>105</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>A</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td></td>
</tr>
<tr>
<td>E</td>
<td></td>
</tr>
<tr>
<td>F</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td></td>
</tr>
<tr>
<td>J</td>
<td></td>
</tr>
<tr>
<td>K</td>
<td></td>
</tr>
<tr>
<td>L</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>O</td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Q</td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
</tr>
<tr>
<td>S</td>
<td></td>
</tr>
<tr>
<td>T</td>
<td></td>
</tr>
<tr>
<td>U</td>
<td></td>
</tr>
<tr>
<td>V</td>
<td></td>
</tr>
<tr>
<td>W</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Z</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Pearlstein, Teri B</td>
<td>2</td>
</tr>
<tr>
<td>Pedelec, Roger</td>
<td>60, 97</td>
</tr>
<tr>
<td>Peindl, Kathleen S</td>
<td>100, 101</td>
</tr>
<tr>
<td>Pellet, Jacques</td>
<td>88</td>
</tr>
<tr>
<td>Peck, Walter E</td>
<td>84</td>
</tr>
<tr>
<td>Penner, Norma R</td>
<td>100</td>
</tr>
<tr>
<td>Perl, James M</td>
<td>23, 101</td>
</tr>
<tr>
<td>Peretz, Oscar E</td>
<td>46, 79</td>
</tr>
<tr>
<td>Perkins, Diana O</td>
<td>26, 63, 64</td>
</tr>
<tr>
<td>Perlis, Roy H.</td>
<td>100</td>
</tr>
<tr>
<td>Perry, Dana M</td>
<td>61</td>
</tr>
<tr>
<td>Perry, John C.</td>
<td>23, 60, 61, 105</td>
</tr>
<tr>
<td>Perugia, Girolamo</td>
<td>24</td>
</tr>
<tr>
<td>Pest, Linda F</td>
<td>45, 72</td>
</tr>
<tr>
<td>Pestin, Neil</td>
<td>7</td>
</tr>
<tr>
<td>Peters, John R.</td>
<td>61</td>
</tr>
<tr>
<td>Peters, Lorna M</td>
<td>84</td>
</tr>
<tr>
<td>Petersen, Timothy J</td>
<td>24, 100</td>
</tr>
<tr>
<td>Peterson, Herbert W</td>
<td>26</td>
</tr>
<tr>
<td>Petri, Alain Q.</td>
<td>19, 71</td>
</tr>
<tr>
<td>Rae, Donald S.</td>
<td>103</td>
</tr>
<tr>
<td>Raeburn, Bruce B.</td>
<td>73, 106</td>
</tr>
<tr>
<td>Ragozzino, Francesco J</td>
<td>50, 57</td>
</tr>
<tr>
<td>Raine, Michael C.</td>
<td>100</td>
</tr>
<tr>
<td>Ram, Nyati E.</td>
<td>95</td>
</tr>
<tr>
<td>Rapaport, Mark H.</td>
<td>5</td>
</tr>
<tr>
<td>Rapoport, Judith H.</td>
<td>8, 91</td>
</tr>
<tr>
<td>Raskin, Valerie Davis</td>
<td>100</td>
</tr>
<tr>
<td>Rasmussen, Karen S.</td>
<td>68</td>
</tr>
<tr>
<td>Rassenti, Aretta E.</td>
<td>22</td>
</tr>
<tr>
<td>Ratliff, Brenda</td>
<td>15</td>
</tr>
<tr>
<td>Ray, Scott L.</td>
<td>31</td>
</tr>
<tr>
<td>Rea, Christine E.</td>
<td>43</td>
</tr>
<tr>
<td>Reznik, Michael C.</td>
<td>22</td>
</tr>
<tr>
<td>Reich, James H.</td>
<td>27, 73, 103</td>
</tr>
<tr>
<td>Reichman, William E.</td>
<td>15, 57</td>
</tr>
<tr>
<td>Reid, William H.</td>
<td>69, 79</td>
</tr>
<tr>
<td>Reider, Ronald O.</td>
<td>79</td>
</tr>
<tr>
<td>Reifler, Burton V.</td>
<td>19</td>
</tr>
<tr>
<td>Reiner, William G.</td>
<td>28</td>
</tr>
<tr>
<td>Remington, Gary J.</td>
<td>9</td>
</tr>
<tr>
<td>Rempasly, Phillip</td>
<td>19, 72</td>
</tr>
<tr>
<td>Rennick, Phillip J.</td>
<td>6, 14, 40, 68, 97, 102</td>
</tr>
<tr>
<td>Renikoff, Roy O.</td>
<td>80</td>
</tr>
<tr>
<td>Renz, Lynda</td>
<td>24</td>
</tr>
<tr>
<td>Rhodes, Anne E.</td>
<td>34</td>
</tr>
<tr>
<td>Riba, Michelle</td>
<td>7, 21, 45, 54, 80</td>
</tr>
<tr>
<td>Richards, Lawrence K.</td>
<td>25</td>
</tr>
<tr>
<td>Richardson, Harriet</td>
<td>83</td>
</tr>
<tr>
<td>Richardson, Jarrett W.</td>
<td>2</td>
</tr>
<tr>
<td>Richardson, Linda R.</td>
<td>98</td>
</tr>
<tr>
<td>Rice, Angela L.</td>
<td>78</td>
</tr>
<tr>
<td>Riddle, Mark A.</td>
<td>85</td>
</tr>
<tr>
<td>Rieder, Ronald O.</td>
<td>75</td>
</tr>
<tr>
<td>Rierand, Jill</td>
<td>84</td>
</tr>
<tr>
<td>Rihm, Zoran</td>
<td>77</td>
</tr>
<tr>
<td>Riecke, Roel</td>
<td>85</td>
</tr>
<tr>
<td>Rinaldi, Osvaldo</td>
<td>50</td>
</tr>
<tr>
<td>Rinne, Thomas</td>
<td>85</td>
</tr>
<tr>
<td>Rios, Charles E.</td>
<td>78, 96</td>
</tr>
<tr>
<td>Risso, Pedro</td>
<td>78</td>
</tr>
<tr>
<td>Ritter, Richard C.</td>
<td>78</td>
</tr>
<tr>
<td>Rivato, Jonathan I.</td>
<td>44, 79, 103</td>
</tr>
<tr>
<td>Roane, David M.</td>
<td>44</td>
</tr>
<tr>
<td>Roberts, Jessica G.</td>
<td>44</td>
</tr>
<tr>
<td>Roberts, Laura W.</td>
<td>78</td>
</tr>
<tr>
<td>Robinson, Michael D.</td>
<td>41, 68</td>
</tr>
<tr>
<td>Robinson, Carolyn B.</td>
<td>27, 45, 73</td>
</tr>
<tr>
<td>Robbins, Olivia J.</td>
<td>103</td>
</tr>
<tr>
<td>Robinson, Gail E.</td>
<td>27, 55, 83</td>
</tr>
<tr>
<td>Robinson, Robert G.</td>
<td>85</td>
</tr>
<tr>
<td>Robinson III, Charles T.</td>
<td>49</td>
</tr>
<tr>
<td>Rocca, Catherine A.</td>
<td>58, 93</td>
</tr>
<tr>
<td>Rockwell, Enid</td>
<td>64</td>
</tr>
<tr>
<td>Rodenhauser, Paul</td>
<td>27, 79, 97</td>
</tr>
<tr>
<td>Rodriguez, Mercedes M.</td>
<td>22, 100</td>
</tr>
<tr>
<td>Rodriguez-Villa, Fernando</td>
<td>51</td>
</tr>
<tr>
<td>Roedel, Elizabeth J.</td>
<td>84</td>
</tr>
<tr>
<td>Roeland, Jean Luc</td>
<td>88</td>
</tr>
<tr>
<td>Rogers, Everett</td>
<td>85</td>
</tr>
<tr>
<td>Roldan, Ismaila</td>
<td>51</td>
</tr>
<tr>
<td>Rolf, John O. S.</td>
<td>74</td>
</tr>
<tr>
<td>Roman, Jasmin S.</td>
<td>74</td>
</tr>
<tr>
<td>Rome, Lee H.</td>
<td>40, 61, 104</td>
</tr>
<tr>
<td>Ronningen, Elsa F.</td>
<td>77</td>
</tr>
<tr>
<td>Roose, Steven P.</td>
<td>6, 11, 21</td>
</tr>
<tr>
<td>Roscoo, Clare</td>
<td>45</td>
</tr>
<tr>
<td>Rose, J.</td>
<td>36</td>
</tr>
<tr>
<td>Rosen, Deborah S.</td>
<td>56</td>
</tr>
<tr>
<td>Rosen, Arnold M.</td>
<td>62</td>
</tr>
<tr>
<td>Rosen, Joanna</td>
<td>86</td>
</tr>
<tr>
<td>Rosen, Karen J.</td>
<td>68</td>
</tr>
<tr>
<td>Roben, Harvey C.</td>
<td>6, 29</td>
</tr>
<tr>
<td>Rosenthal, Leonard A.</td>
<td>32</td>
</tr>
<tr>
<td>Rosenthal, Michael</td>
<td>84</td>
</tr>
<tr>
<td>Rosenthal, Milton</td>
<td>23</td>
</tr>
<tr>
<td>Rosenbeuk, Doug</td>
<td>45</td>
</tr>
<tr>
<td>Rosenberg, James E.</td>
<td>43</td>
</tr>
<tr>
<td>Rosenberg, Kenneth P.</td>
<td>22, 43</td>
</tr>
<tr>
<td>Rosenberger, John W.</td>
<td>19</td>
</tr>
<tr>
<td>Rosenblum, Barbara</td>
<td>97</td>
</tr>
<tr>
<td>Rosenstein, Donald L.</td>
<td>58, 89</td>
</tr>
<tr>
<td>Rosenthal, Michael S.</td>
<td>101</td>
</tr>
<tr>
<td>Rosen, Richard N.</td>
<td>103</td>
</tr>
<tr>
<td>Roslos, Erik J.</td>
<td>96</td>
</tr>
<tr>
<td>Ross, David</td>
<td>83</td>
</tr>
<tr>
<td>Ross, Alessandro</td>
<td>33</td>
</tr>
<tr>
<td>Rossignol, Michel</td>
<td>23</td>
</tr>
<tr>
<td>Rothbaum, Barbara O.</td>
<td>3</td>
</tr>
<tr>
<td>Rothenberg, Albert</td>
<td>23</td>
</tr>
<tr>
<td>Rotondo, Alessandro</td>
<td>103</td>
</tr>
<tr>
<td>Rounsville, Bruce J.</td>
<td>52</td>
</tr>
<tr>
<td>Rovars, Michael</td>
<td>10</td>
</tr>
<tr>
<td>Roy, Alec</td>
<td>50</td>
</tr>
<tr>
<td>Roy, Carmella</td>
<td>60</td>
</tr>
<tr>
<td>Roy, Marc-Andre</td>
<td>49</td>
</tr>
<tr>
<td>Rozenberg, Marina</td>
<td>20</td>
</tr>
<tr>
<td>Ruben, Harvey L.</td>
<td>18</td>
</tr>
<tr>
<td>Rubin, Howard C.</td>
<td>18</td>
</tr>
<tr>
<td>Rubinow, David R.</td>
<td>30, 38</td>
</tr>
<tr>
<td>Rucci, Paolo</td>
<td>103</td>
</tr>
<tr>
<td>Rudhush, John R.</td>
<td>27</td>
</tr>
<tr>
<td>Rues, David S.</td>
<td>26</td>
</tr>
<tr>
<td>Rueter, Martha A.</td>
<td>23</td>
</tr>
<tr>
<td>Ruiz, Maria A.</td>
<td>36</td>
</tr>
<tr>
<td>Ruiz, Edmundo J.</td>
<td>73</td>
</tr>
<tr>
<td>Ruiz, Pedro</td>
<td>19, 25, 33, 45, 51, 56, 74, 79, 101</td>
</tr>
<tr>
<td>Rund, Bjorn</td>
<td>99</td>
</tr>
<tr>
<td>Rush, A. John</td>
<td>5, 13, 34, 59, 106</td>
</tr>
<tr>
<td>Ruiton, Jerry L.</td>
<td>99</td>
</tr>
<tr>
<td>Ryall, Jo-Ellen M.</td>
<td>7</td>
</tr>
<tr>
<td>Ryan, Dierdre M.</td>
<td>8</td>
</tr>
<tr>
<td>Ryan, Donna H.</td>
<td>76</td>
</tr>
<tr>
<td>Ryan, Neal D.</td>
<td>34</td>
</tr>
<tr>
<td>Ryan, Roth M.</td>
<td>68, 89</td>
</tr>
<tr>
<td>Rychlic, Abbe M.</td>
<td>81, 100</td>
</tr>
<tr>
<td>Ryansear, Edward R.</td>
<td>14, 26, 59</td>
</tr>
<tr>
<td>Sabat, Silvana</td>
<td>36</td>
</tr>
<tr>
<td>Sachem, Harold A.</td>
<td>73</td>
</tr>
<tr>
<td>Sachs, Gary S.</td>
<td>13, 39, 50, 57, 106</td>
</tr>
<tr>
<td>Sack, Lawrence C.</td>
<td>44</td>
</tr>
<tr>
<td>Sackew, Harold A.</td>
<td>11, 71</td>
</tr>
<tr>
<td>Sadler, John Z.</td>
<td>33, 86</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Segal, Gerald</td>
<td>19</td>
</tr>
<tr>
<td>Segal, Stuart N</td>
<td>6, 22</td>
</tr>
<tr>
<td>Seligman, Rooolyn</td>
<td>23, 76</td>
</tr>
<tr>
<td>Seminyah, Michael J</td>
<td>86</td>
</tr>
<tr>
<td>Servis, Mark E</td>
<td>87</td>
</tr>
<tr>
<td>Sexson, Sandra</td>
<td>51, 84</td>
</tr>
<tr>
<td>Shaffer, David</td>
<td>3, 76</td>
</tr>
<tr>
<td>Shafii, Mohammad</td>
<td>34, 87</td>
</tr>
<tr>
<td>Shah, Manoj R</td>
<td>77</td>
</tr>
<tr>
<td>Shalev, Arieh Y</td>
<td>32</td>
</tr>
<tr>
<td>Shapiro, Edward R</td>
<td>20, 45, 72</td>
</tr>
<tr>
<td>Shafrochin, Steven S</td>
<td>17, 25, 56</td>
</tr>
<tr>
<td>Shafir, Zafar</td>
<td>19</td>
</tr>
<tr>
<td>Sharma, Rajiv P</td>
<td>1</td>
</tr>
<tr>
<td>Sharma, Toomoy</td>
<td>29</td>
</tr>
<tr>
<td>Shaw, Daniel</td>
<td>86</td>
</tr>
<tr>
<td>She, M. Tracie</td>
<td>105</td>
</tr>
<tr>
<td>Shea, Shawn C</td>
<td>7</td>
</tr>
<tr>
<td>Sheer, M. Katharine</td>
<td>59</td>
</tr>
<tr>
<td>Sheldr, Jonathon</td>
<td>24</td>
</tr>
<tr>
<td>Shernhan, David V</td>
<td>10, 31, 64</td>
</tr>
<tr>
<td>Shenfer-Rogers, Corinne L</td>
<td>93</td>
</tr>
<tr>
<td>Sheitman, Brian B</td>
<td>49, 91</td>
</tr>
<tr>
<td>Shelton, Richard C</td>
<td>93</td>
</tr>
<tr>
<td>Sherman, Bonnie J</td>
<td>31</td>
</tr>
<tr>
<td>Sherrill, Joel T</td>
<td>34, 86</td>
</tr>
<tr>
<td>Shew, Steven P</td>
<td>34, 86</td>
</tr>
<tr>
<td>Shilo, Arial</td>
<td>84</td>
</tr>
<tr>
<td>Shiner, Rebecca L</td>
<td>105</td>
</tr>
<tr>
<td>Shoaab, Arif M</td>
<td>84</td>
</tr>
<tr>
<td>Shin, Michael Joseph F</td>
<td>34</td>
</tr>
<tr>
<td>Shore, Miles F</td>
<td>17</td>
</tr>
<tr>
<td>Shrier, Diane K</td>
<td>35</td>
</tr>
<tr>
<td>Siro, Patrick</td>
<td>56</td>
</tr>
<tr>
<td>Shucrher, Stephen R</td>
<td>24</td>
</tr>
<tr>
<td>Sickinger, Andrea H</td>
<td>77</td>
</tr>
<tr>
<td>Siegel, Alan P</td>
<td>67</td>
</tr>
<tr>
<td>Siegel, Edward A</td>
<td>24</td>
</tr>
<tr>
<td>Siegel, Richard L</td>
<td>22, 48</td>
</tr>
<tr>
<td>Siegel, Steven J</td>
<td>29, 30</td>
</tr>
<tr>
<td>Sierra, Davidson</td>
<td>105</td>
</tr>
<tr>
<td>Sigeal, John K</td>
<td>23</td>
</tr>
<tr>
<td>Silbree, Lawrence</td>
<td>5, 91</td>
</tr>
<tr>
<td>Silverberg, Joel M</td>
<td>23</td>
</tr>
<tr>
<td>Silberman, Edward R</td>
<td>40</td>
</tr>
<tr>
<td>Sik, Kenneth B</td>
<td>52, 80, 85</td>
</tr>
<tr>
<td>Silver, Ann-Louise S</td>
<td>34, 59</td>
</tr>
<tr>
<td>Michael A.</td>
<td>78</td>
</tr>
<tr>
<td>Silver, Stuart B</td>
<td>79, 96</td>
</tr>
<tr>
<td>Silverman, Steven M</td>
<td>44</td>
</tr>
<tr>
<td>Silverstein, Steven M</td>
<td>44</td>
</tr>
<tr>
<td>Simeon, Daphne</td>
<td>11, 105</td>
</tr>
<tr>
<td>Simon, Ashley B</td>
<td>51</td>
</tr>
<tr>
<td>Simon, Nanci R</td>
<td>93</td>
</tr>
<tr>
<td>Simonsen, Erik</td>
<td>104, 105</td>
</tr>
<tr>
<td>Simpson, Thomas A</td>
<td>88</td>
</tr>
<tr>
<td>Simpson, Elizabeth B</td>
<td>68</td>
</tr>
<tr>
<td>Singal, Thomas J</td>
<td>22</td>
</tr>
<tr>
<td>Singer, Tara M</td>
<td>100</td>
</tr>
<tr>
<td>Siro, Samuel G</td>
<td>102</td>
</tr>
<tr>
<td>Siota, Elizabeth</td>
<td>97</td>
</tr>
<tr>
<td>Siota, Pincshas</td>
<td>49</td>
</tr>
<tr>
<td>Sivertz, Kristin S</td>
<td>8</td>
</tr>
<tr>
<td>Sklarow, Bruce H</td>
<td>12</td>
</tr>
<tr>
<td>Skolodil, Andrew B</td>
<td>35, 83, 87, 105</td>
</tr>
<tr>
<td>Skolnick, Phil</td>
<td>106</td>
</tr>
<tr>
<td>Sled, Aleksander</td>
<td>78</td>
</tr>
<tr>
<td>Sipp, Samuel</td>
<td>60</td>
</tr>
<tr>
<td>Slavenskii, Karel</td>
<td>107</td>
</tr>
<tr>
<td>Slok, Iviis G</td>
<td>15</td>
</tr>
<tr>
<td>Smal, Elizabeth C</td>
<td>68</td>
</tr>
<tr>
<td>Smith, E. L.</td>
<td>35</td>
</tr>
<tr>
<td>Smith, Graeme C</td>
<td>36</td>
</tr>
<tr>
<td>Smith, Megan M</td>
<td>23, 107</td>
</tr>
<tr>
<td>Smith, Michael W</td>
<td>52, 99</td>
</tr>
<tr>
<td>Smith, Nathan B</td>
<td>84</td>
</tr>
<tr>
<td>Smith, Wendy T</td>
<td>77</td>
</tr>
<tr>
<td>Smidt, G. Richard</td>
<td>19</td>
</tr>
<tr>
<td>Smolka, Michael L</td>
<td>59</td>
</tr>
<tr>
<td>Smoller, Jordan W</td>
<td>50</td>
</tr>
<tr>
<td>Smouara, Joseph M</td>
<td>18</td>
</tr>
<tr>
<td>Smaye, Anna T</td>
<td>24</td>
</tr>
<tr>
<td>Soares, Claudia N</td>
<td>30, 87</td>
</tr>
<tr>
<td>Soeken, Karen</td>
<td>78</td>
</tr>
<tr>
<td>Sokol, M. A</td>
<td>94</td>
</tr>
<tr>
<td>Solikshik, Ramon</td>
<td>25</td>
</tr>
<tr>
<td>Solms, Mark L</td>
<td>29, 53</td>
</tr>
<tr>
<td>Soloff, Paul H</td>
<td>77, 79, 87, 100</td>
</tr>
<tr>
<td>Soltys, Stephen M</td>
<td>15, 73</td>
</tr>
<tr>
<td>Solurah, Lionel P</td>
<td>97</td>
</tr>
<tr>
<td>Sojin, Luheh</td>
<td>24</td>
</tr>
<tr>
<td>Somawall, Shamsah B</td>
<td>49, 76, 87, 100</td>
</tr>
<tr>
<td>Southard, Marvin</td>
<td>56, 98</td>
</tr>
<tr>
<td>Southwick, Steven M</td>
<td>3, 33, 105</td>
</tr>
<tr>
<td>Sowers, Wesley E</td>
<td>87</td>
</tr>
<tr>
<td>Spar, Landon F</td>
<td>97</td>
</tr>
<tr>
<td>Spero, Nina P</td>
<td>27</td>
</tr>
<tr>
<td>Speanberg, Stephanie</td>
<td>61</td>
</tr>
<tr>
<td>Spence, Sean A</td>
<td>86</td>
</tr>
<tr>
<td>Spence, Neil R</td>
<td>35, 90</td>
</tr>
<tr>
<td>Sperry, Leonard T</td>
<td>22, 88</td>
</tr>
<tr>
<td>Spiegel, David</td>
<td>2, 36, 41, 79</td>
</tr>
<tr>
<td>Spiegel, David A</td>
<td>80</td>
</tr>
<tr>
<td>Spinnazrola, Joseph F</td>
<td>84</td>
</tr>
<tr>
<td>Spindella, Margretta G</td>
<td>100</td>
</tr>
<tr>
<td>Spitz, Deborah</td>
<td>41</td>
</tr>
<tr>
<td>Spitz, Henry L</td>
<td>97</td>
</tr>
<tr>
<td>Spitzer, Robert L</td>
<td>35, 84</td>
</tr>
<tr>
<td>Spivak, Baruch</td>
<td>24</td>
</tr>
<tr>
<td>Sabinisky, Harvey</td>
<td>19, 24</td>
</tr>
<tr>
<td>Sabinisky, Susan</td>
<td>19, 22</td>
</tr>
<tr>
<td>Stango, Susan J</td>
<td>46</td>
</tr>
<tr>
<td>Stahl, Stephanie A</td>
<td>20</td>
</tr>
<tr>
<td>Stahl, Lawrence H</td>
<td>33</td>
</tr>
<tr>
<td>Stampler, Ronald S</td>
<td>44, 71, 94</td>
</tr>
<tr>
<td>Stanley, Jonathan A</td>
<td>30</td>
</tr>
<tr>
<td>Stark, Michael</td>
<td>102</td>
</tr>
<tr>
<td>Starko, Robert S</td>
<td>60</td>
</tr>
<tr>
<td>Steinbuhler, Ellen</td>
<td>68</td>
</tr>
<tr>
<td>Stein, Bradley D</td>
<td>96</td>
</tr>
<tr>
<td>Stein, Dan J</td>
<td>32</td>
</tr>
<tr>
<td>Stein, Kira D</td>
<td>44</td>
</tr>
<tr>
<td>Steffen, Hilary L</td>
<td>11, 57</td>
</tr>
<tr>
<td>Steffen, Seth P</td>
<td>18</td>
</tr>
<tr>
<td>Steinberg, Joel L</td>
<td>49</td>
</tr>
<tr>
<td>Steinberg, Mark</td>
<td>87</td>
</tr>
<tr>
<td>Ster, Robert K</td>
<td>85</td>
</tr>
<tr>
<td>Steinberg, Suzanne I</td>
<td>83</td>
</tr>
<tr>
<td>Steiner, Hans</td>
<td>39, 105</td>
</tr>
<tr>
<td>Stephans, Edward M</td>
<td>18</td>
</tr>
<tr>
<td>Ster, Joseph D</td>
<td>84</td>
</tr>
<tr>
<td>Stern, Robert G</td>
<td>103</td>
</tr>
<tr>
<td>Stevens, Marydale</td>
<td>68</td>
</tr>
<tr>
<td>Stevenson, Ellen M</td>
<td>56</td>
</tr>
<tr>
<td>Stewart, Ahla J</td>
<td>95</td>
</tr>
<tr>
<td>Stewart, Donna E</td>
<td>21, 50, 53, 83</td>
</tr>
<tr>
<td>Stewart, Jonathan W</td>
<td>11</td>
</tr>
<tr>
<td>Stewart, S. Evelyn</td>
<td>99, 100</td>
</tr>
<tr>
<td>Stewart, Jr., Dudley M</td>
<td>36</td>
</tr>
<tr>
<td>Stone, Alan A</td>
<td>28, 79</td>
</tr>
<tr>
<td>Stone, Clint</td>
<td>73</td>
</tr>
<tr>
<td>Stone, Jr., James H</td>
<td>73</td>
</tr>
<tr>
<td>Stone, Michael H</td>
<td>31, 60, 106</td>
</tr>
<tr>
<td>Stone, Walter N</td>
<td>14</td>
</tr>
<tr>
<td>Stonish-Riggs, Gail</td>
<td>36</td>
</tr>
<tr>
<td>Stone, Mr. Judda L</td>
<td>7, 15, 26, 45, 72, 79, 100</td>
</tr>
<tr>
<td>Stout, Robert L</td>
<td>83, 105</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Whybrow, Peter C.</td>
<td>98</td>
</tr>
<tr>
<td>Wickerma, K. A. S.</td>
<td>23</td>
</tr>
<tr>
<td>Widiger, Thomas A.</td>
<td>35, 57</td>
</tr>
<tr>
<td>Wienjes, Hans</td>
<td>62</td>
</tr>
<tr>
<td>Wiener, Irving S.</td>
<td>16, 61, 87</td>
</tr>
<tr>
<td>Wigal, Sharon</td>
<td>77</td>
</tr>
<tr>
<td>Wigg, Karen</td>
<td>86</td>
</tr>
<tr>
<td>Wiers, Timothy E.</td>
<td>35, 90</td>
</tr>
<tr>
<td>Williams, D. Keith</td>
<td>88</td>
</tr>
<tr>
<td>Williams, Mark D.</td>
<td>71</td>
</tr>
<tr>
<td>Williams, Richard</td>
<td>1</td>
</tr>
<tr>
<td>Williams, Veronica L.</td>
<td>18, 44</td>
</tr>
<tr>
<td>Williams, Joan</td>
<td>96</td>
</tr>
<tr>
<td>Willick, Daniel H.</td>
<td>51</td>
</tr>
<tr>
<td>Wilson, Daniel</td>
<td>59</td>
</tr>
<tr>
<td>Wilson, G. Terrence</td>
<td>31</td>
</tr>
<tr>
<td>Wilson, Rodgers M.</td>
<td>73</td>
</tr>
<tr>
<td>Winey, Karen</td>
<td>30</td>
</tr>
<tr>
<td>Winkelstein, John W.</td>
<td>90</td>
</tr>
<tr>
<td>Winstead, Daniel K.</td>
<td>19, 20, 99</td>
</tr>
<tr>
<td>Winstead, Michele</td>
<td>96</td>
</tr>
<tr>
<td>Winstead, Will C.</td>
<td>30</td>
</tr>
<tr>
<td>Wissel, Claire</td>
<td>104</td>
</tr>
<tr>
<td>Wissel, Katherine L.</td>
<td>62, 83, 100, 101</td>
</tr>
<tr>
<td>Wissel, Steve</td>
<td>57</td>
</tr>
<tr>
<td>Woehr, Jennifer</td>
<td>101</td>
</tr>
<tr>
<td>Wolf, Charles J.</td>
<td>73</td>
</tr>
<tr>
<td>Wolfe, Barbara E.</td>
<td>105</td>
</tr>
<tr>
<td>Wolfson, Lee K.</td>
<td>68</td>
</tr>
<tr>
<td>Wolk, Sara</td>
<td>84</td>
</tr>
<tr>
<td>Wolkoff, David A.</td>
<td>73</td>
</tr>
<tr>
<td>Wong, Felicia</td>
<td>83</td>
</tr>
<tr>
<td>Wood, William G.</td>
<td>87</td>
</tr>
<tr>
<td>Woods, Scott W.</td>
<td>86</td>
</tr>
<tr>
<td>Woods, Sherwyn M.</td>
<td>79, 106</td>
</tr>
<tr>
<td>Woody, George E.</td>
<td>60</td>
</tr>
<tr>
<td>Worley, Linda L.M.</td>
<td>45, 94</td>
</tr>
<tr>
<td>Worthington III, John J.</td>
<td>23</td>
</tr>
<tr>
<td>Wonisch, Janet</td>
<td>11, 90</td>
</tr>
<tr>
<td>Wossnig, Steven T.</td>
<td>95</td>
</tr>
<tr>
<td>Wright, Doug</td>
<td>75, 102</td>
</tr>
<tr>
<td>Wright, Harry H.</td>
<td>40</td>
</tr>
<tr>
<td>Wright, Jesse H.</td>
<td>14, 97</td>
</tr>
<tr>
<td>Wulfin, Lawson R.</td>
<td>22, 98</td>
</tr>
<tr>
<td>Wynn, John D.</td>
<td>72</td>
</tr>
<tr>
<td>Yager, Joel</td>
<td>7, 19, 31, 58, 73</td>
</tr>
<tr>
<td>Yalom, Irvin D.</td>
<td>16, 25</td>
</tr>
<tr>
<td>Yarhouse, Mark</td>
<td>84</td>
</tr>
<tr>
<td>Yates, A.</td>
<td>48</td>
</tr>
<tr>
<td>Yates, William R.</td>
<td>61</td>
</tr>
<tr>
<td>Yehuda, Rachel</td>
<td>25, 32, 43, 64, 105</td>
</tr>
<tr>
<td>Yen, Shirley</td>
<td>105</td>
</tr>
<tr>
<td>Yeomans, Frank E.</td>
<td>69</td>
</tr>
<tr>
<td>Yeung, Albert</td>
<td>76, 77</td>
</tr>
<tr>
<td>Yonkers, Kimberly A.</td>
<td>62, 67</td>
</tr>
<tr>
<td>York, Douglas L.</td>
<td>19</td>
</tr>
<tr>
<td>Yosef, Ismail</td>
<td>85</td>
</tr>
<tr>
<td>Young, Alexander S.</td>
<td>61</td>
</tr>
<tr>
<td>Young, Allan</td>
<td>30</td>
</tr>
<tr>
<td>Young, Keith W.</td>
<td>18, 44, 51, 59</td>
</tr>
<tr>
<td>Young, L. Trevor</td>
<td>104</td>
</tr>
<tr>
<td>Yudofsky, Stuart C.</td>
<td>13, 39, 44, 47</td>
</tr>
<tr>
<td>Zajec, John M.</td>
<td>63</td>
</tr>
<tr>
<td>Zanarini, Mary C.</td>
<td>23, 35, 60, 83, 105</td>
</tr>
<tr>
<td>Zarate, Jr., Carlos A.</td>
<td>64</td>
</tr>
<tr>
<td>Zaratey, Ari E.</td>
<td>51</td>
</tr>
<tr>
<td>Zarin, Deborah A.</td>
<td>31, 57</td>
</tr>
<tr>
<td>Zavodnick, Jacquelynn M.</td>
<td>46</td>
</tr>
<tr>
<td>Zazensh, Charles H.</td>
<td>24, 40</td>
</tr>
<tr>
<td>Zeebo, Kathryn J.</td>
<td>32, 70, 94</td>
</tr>
<tr>
<td>Zhang, Wendy</td>
<td>30</td>
</tr>
<tr>
<td>Zherednick, Barbara</td>
<td>61</td>
</tr>
<tr>
<td>Zordan, Douglas M.</td>
<td>5, 54, 87, 102</td>
</tr>
<tr>
<td>Zilberman, Monica L.</td>
<td>87</td>
</tr>
<tr>
<td>Zimmerli, Ellen</td>
<td>84</td>
</tr>
<tr>
<td>Zipsuski, Robert B.</td>
<td>9</td>
</tr>
<tr>
<td>Zook, Sidney</td>
<td>8, 59</td>
</tr>
<tr>
<td>Ziman, Francis G.</td>
<td>61, 62</td>
</tr>
<tr>
<td>Zito, Julie M.</td>
<td>78</td>
</tr>
<tr>
<td>Zolkind, Neil A.</td>
<td>19</td>
</tr>
<tr>
<td>Zong, Higuera</td>
<td>73</td>
</tr>
<tr>
<td>Zung, Franck, Halbre</td>
<td>23</td>
</tr>
</tbody>
</table>

133
Grow professionally and increase your knowledge of psychiatric practices through the APPI Bookstore. Our extensive selection of topics and titles allows you to pick up the titles you’ve always wanted or find a title to complete series collections and annual reviews. We look forward to seeing you!

**Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR™)**

American Psychiatric Association

Since DSM-IV™ was published in 1994, we've seen many advances in our knowledge of psychiatric illness. This Text Revision incorporates information culled from a comprehensive literature review of research about mental disorders published since DSM-IV™ was completed in 1994. Updated information is included about the associated features, culture, age, and gender issues, prevalence, course, and familial pattern of mental disorders.

2000 • 1000 pages • ISBN 0-89042-024-6 • hardcover • $71.95 • Item #2024

2000 • 1000 pages • ISBN 0-89042-025-4 • paperback • $54.95 • Item #2025

---

**Desk Reference to the Diagnostic Criteria From DSM-IV-TR™**

American Psychiatric Association

Includes all the diagnostic criteria from DSM-IV-TR™ in an easy-to-use, spiralbound format. With a useful pull-out chart of the DSM-IV-TR™ Classification.

2000 • 496 pages • ISBN 0-89042-027-0 • spiralbound • $32.50 • Item #2027

---

**Quick Reference to the Diagnostic Criteria From DSM-IV-TR™**

American Psychiatric Association

Includes all the diagnostic criteria from DSM-IV-TR™ in a small paperback format.

2000 • 496 pages • ISBN 0-89042-026-2 • paperback • $29.00 • Item #2026

---

**Borderline Personality Disorder: A Clinical Guide**

John G. Gunderson, M.D.

"This book is a masterpiece of clinical wisdom. Gunderson is one of the world’s experts in understanding and treating patients with borderline personality disorder, and he brings that expertise to these pages with a highly personal authentic style. . . . This is an optimistic book, presenting how much we do now know about how to successfully help those who suffer with this condition."—John M. Oldham, M.D., Professor and Acting Chairman, Department of Psychiatry, Columbia University College of Physicians and Surgeons, Director, New York State Psychiatric Institute

March 2001 • 360 pages • ISBN 1-58562-016-5 • hardcover • $57.00 • Item #2016
Visit us at the 2001 APA Annual Meeting

NEW in 2001

JANUARY

American Psychiatric Association Practice Guideline for the Treatment of Patients With HIV/AIDS
American Psychiatric Association
2001 • 128 pages • ISBN 0-88048-318-0 paperback • $28.50 • Item #2318

(A Task Force Report of the American Psychiatric Association)
American Psychiatric Association
2001 • 400 pages • ISBN 0-88048-206-0 hardcover • $52.00 • Item #2206

F.M. Baker, M.D., M.P.H.
2001 • 192 pages • ISBN 0-88048-697-X paperback • $29.50 • Item #6679

Treating Mental Illness and Behavior Disorders in Children and Adults With Mental Retardation
2001 • 304 pages • ISBN 0-88048-800-X hardcover • $64.00 • Item #8800

Treatments of Obsessive-Compulsive Disorder, Second Edition
Edited by Michele Tortora Pato, M.D., and Joseph Zohar, M.D.
2001 • 336 pages • ISBN 0-88048-773-9 hardcover - 2 volumes • $279.00 hardcover • $49.95 • Item #8779

Concise Guide to Cross-Cultural Psychiatry
Edited by Chen-Sheng Yang, M.D.
2001 • 240 pages • ISBN 0-88048-828-X paperback • $39.00 • Item #6628

SCHIZOPHRENIA AND COMORBID CONDITIONS: Diagnosis and Treatment
Edited by Michael Y. Huang, M.D., and Paul C. Bernasconi, M.D.
2001 • 256 pages • ISBN 0-88048-771-2 hardcover • $46.00 • Item #6671

Culture and Psychotherapy: A Guide to Clinical Practice
Edited by Wan-Sheng Tung, M.D., and Jon Strain, M.D.
2001 • 320 pages • ISBN 0-88048-965-3 paperback • $44.00 • Item #6665

Psychological Aspects of Women’s Health Care: The Interface Between Psychiatry and Obsterics and Gynecology, Second Edition
Edited by Nadia L. Stotland, M.D., M.P.H., and Donna E. Stewart, M.D., D.Psych., F.R.C.P.C.
2001 • 488 pages • ISBN 0-88048-831-X paperback • $85.00 • Item #6831

MAY

Concise Guide to the Cytochrome P450: Drug Interaction Principles for Medical Practice
Kelly L. Cozza, M.D., and Scott C. Armstrong, M.D.
2001 • 272 pages • ISBN 1-58562-000-9 paperback • $29.95 • Item #66200

Psychiatric Neuromaging Research: Bridging the 21st Century
Edited by Myrna M. Weissman, Ph.D.
2001 • 400 pages • ISBN 0-88048-397-0 hardcover • $64.00 • Item #6697

FEBRUARY

Ethics Primer of the American Psychiatric Association
American Psychiatric Association
2001 • 128 pages • ISBN 0-88048-217-2 paperback • $24.00 • Item #6217

School Violence: Assessment, Management, Prevention
Edited by Mohammad Shafi, M.D., and Sharon Lee Shafi, R.N., B.S.N.
2001 • 352 pages • ISBN 1-58662-009-2 paperback • $49.95 • Item #6209

SCHIZOPHRENIA AND COMORBID CONDITIONS: Diagnosis and Treatment
Edited by Michael Y. Huang, M.D., and Paul C. Bernasconi, M.D.
2001 • 256 pages • ISBN 0-88048-771-2 hardcover • $46.00 • Item #6671

MARCH

Self-Injurious Behaviors: Assessment and Treatment
Edited by Daphne Simeone, M.D., and Eric Hollander, M.D.
2001 • 240 pages • ISBN 0-88048-808-5 paperback • $34.00 • Item #6808

Edited by John A. Talbott, M.D., and Robert E. Hayes, M.D., M.B.A.
2001 • 480 pages • ISBN 0-88048-745-3 hardcover • $74.00 • Item #6674

APRIL

Concise Guide to Women’s Mental Health, Second Edition
Edited by Helen K. Burt, M.D., Ph.D., and Victoria C. Hendrick, M.D.
2001 • 180 pages • ISBN 0-88048-020-0 paperback • $27.95 • Item #62030

Edited by Albert C. Daw, M.D.
2001 • 224 pages • ISBN 0-88048-907-3 paperback • $27.95 • Item #6907

JUNE

Concise Guide to Cross-Cultural Psychiatry
Edited by Chen-Sheng Yang, M.D.
2001 • 240 pages • ISBN 0-88048-828-X paperback • $39.00 • Item #6628

Concise Guide to Psychiatry for Law and Clinicians, Third Edition
Robert J. Simon, M.D.
2001 • 280 pages • ISBN 1-58562-017-3 paperback • $75.00 • Item #66217

Clinical Study Guide for the Oral Boards in Psychiatry
Nathan R. Strahl, M.D., Ph.D.
2001 • 320 pages • ISBN 0-88048-830-1 paperback • $29.95 • Item #66830
INDUSTRY-SUPPORTED SYMPOSIUM 1
Saturday, May 5, 7:00 PM-10:00 PM
Grand Ballroom A/B, Street Level, Hilton

The Pathogenesis of Narcolepsy and Hypersomnia
Emmanuel Mignot, MD
Stanford University

Influences of Light on Sleep and Mood
Barbara L. Parry, MD
University of California

Violent Behaviors Arising from the Sleep Period
Mark W. Malow, MD
Hennepin County Medical Center

Sleep Apnea: Why Treat It?
Meir H. Kryger, MD
University of Minnesota

New Options in the Treatment of Insomnia
Milton K. Erman, MD
University of California

There will be 45 minutes for Questions and Answers
at the end of the symposium.

Objectives:
Better understand molecular and genetic influences on sleep, recognize the role that light plays in regulation of sleep and mood, understand how violent behaviors may occur in sleep, diagnose and treat sleep apnea, and use new and more effective treatments for insomnia.

Registration:
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-557-7921 (within the U.S. or Canada) or 202/362-0000.

Sponsored by the American Psychiatric Association.
Supported by an unrestricted educational grant from Vichy Avene Cosmetics.

American Psychiatric Association
Supported by an unrestricted educational grant from Vichy Avene Cosmetics.

INDUSTRY-SUPPORTED SYMPOSIUM 2
Saturday, May 5, 7:00 PM-10:00 PM
Grand Ballroom C/D, Street Level, Hilton

BUFFET DINNER: 6:30 PM - SYMPOSIUM: 7:00 TO 10:00 PM

Title: Sleep: a Window on Mind and Brain
Chair: Milton K. Erman, MD

Program Description
While healthy restful sleep is essential in order to maintain overall well-being, it turns out that the brain is very active during sleep. This scientific presentation will focus on the role of sleep in mental health, including the relationship between sleep and mood disorders, anxiety, and depression. The presentation will highlight recent advances in our understanding of the mechanisms underlying sleep disorders and introduce new therapeutic strategies for these conditions. The symposium will provide an opportunity for attendees to engage in interactive discussions with experts in the field.

Program Objectives:
1. To increase awareness about the importance of sleep in mental health.
2. To understand the mechanisms underlying sleep disorders and their impact on mental well-being.
3. To explore the therapeutic potential of sleep interventions in the treatment of mood and anxiety disorders.
4. To discuss the role of sleep in cognitive function and its relationship with psychiatric illnesses.
5. To foster collaboration and knowledge exchange among professionals in the field of sleep and mental health.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Vichy Avene Cosmetics.

American Psychiatric Association
Supported by an unrestricted educational grant from Vichy Avene Cosmetics.
**INDUSTRY-SUPPORTED SYMPOSIUM 3**  
Saturday, May 5, 7:00 PM-10:00 PM  
Napoleon Ballroom, Third Floor, Hilton Hotel  

**APA 2001 ANNUAL MEETING**  

**Suicide Risk and Bipolar Disorder: Neurobiology and Treatment**  
Saturday, May 5, 2001 • Napoleon Ballroom, Third Floor, Hilton Hotel • New Orleans, Louisiana  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 PM – 7:00 PM</td>
<td>Dinner</td>
</tr>
<tr>
<td>7:00 PM – 10:00 PM</td>
<td>Symposium</td>
</tr>
</tbody>
</table>
| 7:00 PM – 7:10 PM | Welcome and Introduction  
JJ. John Mann, MD-Chairperson-College of Physicians and Surgeons of Columbia University |
| 7:10 PM – 7:35 PM | Clinical Factors Affecting Suicide Risk in Bipolar Disorder  
Kay R. Jamison, PhD-Johns Hopkins University School of Medicine |
| 7:35 PM – 8:00 PM | Neurobiology of Suicide and Bipolar Disorder  
J. John Mann, MD |
| 8:00 PM – 8:25 PM | Efficacy of Mood Stabilizers in Suicide Prevention  
Ross J. Baldessarini, MD-Harvard Medical School |
| 8:25 PM – 8:50 PM | Clinical Management of the Suicidal Bipolar Patient  
Frederick K. Goodwin, MD-George Washington University School of Medicine and Health Sciences |
| 8:50 PM – 9:15 PM | Management of Bipolar Disorder in Youth  
David Shaffer, MD-College of Physicians and Surgeons of Columbia University |
| 9:15 PM – 10:00 PM | Question-and-answer session                                                      |

**Educational Objectives**  
At the conclusion of this presentation, the participants will be better able to:  
- Make a better selection of the most appropriate medication and nonmedication interventions to reduce the risk of suicide attempts in bipolar adults and youth  
- Increase their knowledge of the neurobiological underpinnings of mood disorders and suicide risk  

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at (888) 357-7924 (within the United States or Canada) or (202) 682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in Category 1 credit toward the Physician's Recognition Award of the American Medical Association and for the continuing medical education requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This symposium is sponsored by the American Psychiatric Association. Supported by an unrestricted educational grant from Solvay Pharmaceuticals, Inc., and the American Foundation for Suicide Prevention.

---

**INDUSTRY-SUPPORTED SYMPOSIUM 4**  
Saturday, May 5, 7:00 PM-10:00 PM  
Acadia Ballroom, Third Floor, Marriott  

**To Switch or Augment: Contemporary Approaches to Resistant Depression**  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 PM</td>
<td>Dinner Reception</td>
</tr>
</tbody>
</table>
| 7:00 PM - 7:10 PM | Introduction  
Andrew A. Nierenberg, MD |
| 7:10 PM         | Neurobiological Mechanisms of Endogenous and Exogenous Stress  
Joan E. Lever, MD, University of California Medical School |
| 7:35 PM         | The Neural Basis of Antidepressant Resistance and Nonresponsiveness  
Wayne C. Drevets, MD, National Institute of Mental Health |
| 8:00 PM         | The Use of Switching in Depression Treatment  
Charles D. Blumenthal, MD, Stanford University School of Medicine |
| 8:25 PM         | When to Augment Antidepressants  
Andrew A. Nierenberg, MD, Harvard Medical School |
| 9:00 PM         | The Role of Nonpharmacologic Interventions for Treatment-Resistant Depression  
Ludvig H. Hirschfeld, MD, M.D., College of Medicine |

**Pharmacia**
INDUSTRY-SUPPORTED SYMPOSIUM 5
Saturday, May 5, 7:00 PM-10:00 PM
Carondelet Ballroom, Third Floor, Marriott

The New Biology of Depression and Antidepressant Treatment

APA 2001 Annual Meeting
Saturday, May 5, 2001
6:30 PM - 7:00 PM Dinner
7:00 PM - 10:00 PM Scientific Program
Marriott, Carondelet Ballroom
Third Floor
New Orleans, Louisiana

INDUSTRY-SUPPORTED SYMPOSIUM 6
Saturday, May 5, 7:00 PM-10:00 PM
Mardi Gras Ballroom, Third Floor, Marriott

Glucose Control and Diabetes Mellitus During Antipsychotic Treatment

Symposium to be held during the Year 2001 APA Annual Meeting
Saturday, May 5, 2001
6:30 - 7:00 PM, Dinner; 7:00 - 10:00 PM, Symposium
New Orleans Marriott, Third Floor, Mardi Gras Ballroom
Chair: John W. Newman, MD

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Janssen

Educational Objectives: On completion of this activity, participants shall be able to:
1. Recognize the clinical and laboratory signs of diabetes mellitus.
2. Identify antipsychotic medications that can increase the risk of hyperglycemia.
3. Review options for monitoring and initial management of plasma glucose.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3.0 hours in category 1 credit toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Audience must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.
INDUSTRY-SUPPORTED SYMPOSIUM 7
Saturday, May 5, 7:00 PM-10:00 PM
Grand Ballroom A-C, Fifth Floor, Sheraton

AGENDA
9:30 AM 
Dinner
Sitting and Introduction
Kenneth L. Travis, M.D., Ph.D.
Professor of Psychiatry
Department of Psychiatry
Medical University of South Carolina
Charleston, South Carolina
9:45 AM
Posttraumatic Stress Disorder: Diagnostic Issues and Co-Morbidity
Kathleen T. Brady, M.D., Ph.D.
Professor of Psychiatry
New York University School of Medicine
New York, New York
10:00 AM
Sustained Nerve Stimulation in Posttraumatic Stress Disorder
David J. Duman, M.D.
Professor of Psychiatry
Yale University School of Medicine
New Haven, Connecticut
10:15 AM
Advances in the Pharmacotherapy of Posttraumatic Stress Disorder
Charles R. Murdock, M.D.
Professor and Vice Chair
Department of Psychiatry
University of California, San Francisco, California

OBJECTIVES
At the conclusion of this symposium, participants should be able to:
• Review current findings concerning the neurobiology of posttraumatic stress disorder (PTSD).
• Discuss how comorbidities can impact the presentation and course of PTSD.
• Describe psychotherapeutic approaches for managing PTSD.
• Identify new developments in the pharmacotherapeutic treatment of PTSD.

139

INDUSTRY-SUPPORTED SYMPOSIUM 8
Sunday, May 6, 8:00 AM-11:00 AM
Grand Ballroom A/B, Street Level, Hilton

APN 2001 Annual Meeting
Symptomatic and Functional Recovery: Attainable Goals in Treating Depression?

Buffet Breakfast: 7:30 a.m. / Symposium: 8:00 - 11:00 a.m.
Chair: A. John Rush, M.D.

Topics and Faculty
What is Remission? Why is it Important and When Does it Occur?
Lauren B. Marangell, M.D.
Baylor College of Medicine
Michael E. Thase, M.D.
University of Pittsburgh
Jack M. Gorman, M.D.
Columbia University
A. John Rush, M.D.
University of Texas/Southwestern Medical Center

Are All Antidepressant Medications Equivalent in Attaining Remission?
Lauren B. Marangell, M.D.
Baylor College of Medicine
Michael E. Thase, M.D.
University of Pittsburgh
Jack M. Gorman, M.D.
Columbia University
A. John Rush, M.D.
University of Texas/Southwestern Medical Center

Does Combining Medications or Medication Sequences Lead to Remission?
Lauren B. Marangell, M.D.
Baylor College of Medicine
Michael E. Thase, M.D.
University of Pittsburgh
Jack M. Gorman, M.D.
Columbia University
A. John Rush, M.D.
University of Texas/Southwestern Medical Center

What is the Role of Psychotherapy in Attaining Remission?
Lauren B. Marangell, M.D.
Baylor College of Medicine
Michael E. Thase, M.D.
University of Pittsburgh
Jack M. Gorman, M.D.
Columbia University
A. John Rush, M.D.
University of Texas/Southwestern Medical Center

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Wyeth-Ayerst Pharmaceuticals.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7524 (within the U.S. or Canada) or 202-363-6000.

There will be 45 minutes of questions and answers at the end of the symposium.
INDUSTRY-SUPPORTED SYMPOSIUM 9
Sunday, May 6, 8:00 AM-11:00 AM
Grand Ballroom C/D, Street Level, Hilton

Sunday, May 6, 2001
7:30 AM Breakfast
8:00 AM-11:00 AM Educational Program
Hilton New Orleans Riverside • Grand Ballroom C/D,
Street Level • New Orleans, Louisiana
American Psychiatric Association
2001 Annual Meeting

Program Objectives
After attending this continuing education program, the psychiatrist
should be able to:

a. Describe measures of quality of life that can be used to assess the
impact of depression and anxiety disorders and the treatment of
these disorders.

b. Outline management approaches that can improve the quality of life
in patients with bipolar disorder.

c. Review the poor quality of life that occurs in patients with anxiety
disorders and the benefits that can result from appropriate treatment.

d. Identify the impact that depression has on quality of life and measure
improvements that can occur following effective treatment.

T* Work & Live: Focus on QUALITY OF LIFE in
Mood and Anxiety Disorders
A BREAKFAST SYMPOSIUM HELD AT
THE AMERICAN PSYCHIATRIC ASSOCIA-
TION 154TH ANNUAL MEETING (SUNDAY,
MAY 6, 2001) 8:00 AM – 11:00 AM • Hilton
New Orleans Riverside • Napoleon Ballroom,
Third Floor
Sponsored by an unrestricted educational
grant from Janssen-Cilag

Agenda
7:30 AM Breakfast
8:00 AM Welcome and Introduction
Mark H. Rapoport, MD
Symposium CoChair
University of California San Diego
Mark H. Pollack, MD
Symposium CoChair
Harvard Medical School
8:10 AM Measures of Quality of Life
Jean Endicott, MD
Columbia University
8:40 AM Improving Quality of Life for Patients
With Bipolar Disorder
Holly A. Swartz, MD
University of Pittsburgh
9:10 AM Quality of Life in the Anxiety Disorders
Mark H. Pollack, MD
9:40 AM The Impact of Depression and Its
Treatment
Mark H. Rapoport, MD
10:10 AM Panel Discussion With Questions
and Answers
10:55 AM Closing Remarks

Sponsored by the American Psychiatric Association.
The American Psychiatric Association (APA) is accredited by the
Accreditation Council for Continuing Medical Education to
provide continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the APA
Physician Recognition Program for the CME requirement of the APA. Each participant must claim only
those hours of credit that he/she actually spent in the educational activity.
Participants must be registered for the APA Annual Meeting to attend this symposium. Funding is limited and will
be based on first-in, first-served. For more information about the meeting, please visit the APA website at
www.psych.org or contact the APA toll-free at 1-888-651-7564 within the US or Canada or 1-202-682-6000.
INDUSTRY-SUPPORTED SYMPOSIUM 11
Sunday, May 6, 8:00 AM-11:00 AM
Acadia Ballroom, Third Floor, Marriott

AGENDA
8:00 SCHIZOPHRENIA AND CO-OCCLUDING DISORDERS: THE SCOPE OF THE PROBLEM AND IMPACT ON OUTCOMES
- Lisa B. Dyer, MD
8:30 THE NEUROBIOLOGY OF ADDICTION AND SCHIZOPHRENIA IN RELATION TO THE ACTION OF ANTIPSYCHOTIC DRUGS
- Herbert Y. Meltzer, MD
9:00 PHARMACOTHERAPY OF COMORBID SUBSTANCE USE DISORDERS
- Allan I. Green, MD
9:30 INTEGRATING PHARMACOTHERAPY AND DUAL RECOVERY THERAPY
- Doug M. Ziedonis, MD
10:00 BEST SYSTEMS AND PRACTICES FOR DUAL DIAGNOSIS
- Robert E. Drake, MD
10:30 DISCUSSION
- William M. Glazer, MD
10:45 AUDIENCE PANEL DISCUSSION

THE SYMPOSIUM WILL END AT 11:00 AM.

INDUSTRY-SUPPORTED SYMPOSIUM 12
Sunday, May 6, 8:00 AM-11:00 AM
Carondelet Ballroom, Third Floor, Marriott

Men Over 50: An Endangered Species

APA 2001 Annual Meeting
8:00 AM Introduction
Steven P. Roose, MD, Chairman
8:10 AM Testosterone Decline in Aging Men: Does "Andropause" Exist? Stuart M. Seidman, MD Columbia University
8:40 AM Sexual Functioning Past 50* Raymond C. Rosen, MD Robert Wood Johnson University Hospital
9:10 AM Vascular Disease and Depression* Range R. Khatri, MD Duke University Medical Center
9:40 AM Depression and Dementia in Older Men* Gary W. Small, MD University of California, Los Angeles
10:10 AM Suicide in Men Over 50: An Epidemic* Steven P. Roose, MD Columbia University
10:40 AM Question and Answer Session
* Each presentation will be followed by a 5 minute question and answer session.

Sunday, May 6, 2001
7:30 AM - 8:00 AM Breakfast
8:00 AM - 11:00 AM Scientific Program
Marriott, Carondelet Ballroom, Third Floor
New Orleans, Louisiana

Men over 50 enter a period in life in which they must face the increasing prevalence of life-threatening illness and other conditions that can markedly impair quality of life. Most mortality in men results from vascular disease, either stroke or myocardial infarction, and from suicide, which has become a virtual epidemic in older men. Other disorders that markedly impair quality of life in men are the increasing prevalence of sexual dysfunction, particularly erectile failure, and cognitive deterioration. These conditions may be associated with the age-associated decline in testosterone. Perhaps most striking is the vascular disease, erectile dysfunction, cognitive decline, and decreased testosterone are all strongly associated with depression. This symposium will review the conditions that contribute to morbidity and mortality in men over 50, the significance of depression as a comorbid illness, and the reciprocal benefits of treating depression as well as the medical disorders.

Supported by an unrestricted educational grant from Forest Pharmaceuticals, Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 13
Sunday, May 6, 8:00 AM-11:00 AM
Mardi Gras Ballroom, Third Floor, Marriott

Sunday, May 6th
7:30 AM Breakfast ~ 8:00 – 11:00 AM Clinical Program
New Orleans Marriott – Mardi Gras Ballroom, 3rd Floor

Issues in the Long-Term Treatment of Depression

Anita H. Clayton, MD
Symposium Chair

Maurizio Fava, MD
Symposium Co-Chair

The Role of Psychotherapy in Long-Term Treatment
Gabor L. Kelemen, MD
Director of the Mind-Body Program
Western Psychiatric Institute and Clinic

Weight Changes During Long-Term Antidepressant Treatment
Maurizio Fava, MD
Assistant Chief of Psychiatry
Western Psychiatric Institute and Clinic

Antidepressant-Induced Sexual Dysfunction
Anita H. Clayton, MD
Associate Professor of Psychiatry
University of Virginia

INDUSTRY-SUPPORTED SYMPOSIUM 14
Sunday, May 6, 8:00 AM-11:00 AM
Grand Ballroom A-C, Fifth Floor, Sheraton

Alcoholism and Bipolar Disorders: Treatment Options circa 2001

Symposium Objectives
Upon completion of this CME activity, the practicing clinician should be better able to:
- Assess and treat primary alcoholism and alcoholism withdrawal
- Evaluate how alcohol use affects suicidality, long-term course of bipolar illness, and mood stabilization response
- Discuss current treatment options for substance abuse withdrawal
- Explain the rationale for use of antiepileptic drugs in treating alcoholism.

Scientific Program
(Each presentation is approximately 5 minutes in duration)
7:30 am – 8:00 am
Welcome and Introduction
Mark A. Faye, MD • University of California, Los Angeles

8:00 am – 8:45 am
New Pharmacotherapies for Alcohol Dependence
Barbara J. Mason, PhD • University of Miami

8:45 am – 9:10 am
Suicidality, Impulsivity, and Alcoholism
Joseph P. Goldberg, MD • Cornell University School of Medicine

9:10 am – 9:45 am
Antiepileptic Drugs in Alcohol Withdrawal and Relapse
Hugh March, MD • Medical University of South Carolina

9:45 am – 10:15 am
Bipolar Disorder and Comorbid Alcoholism:
Course of Illness and Treatment Implications
Mark A. Faye, MD

10:15 am – 10:45 am
Antiepileptic Drugs and Lithium in the Treatment of Bipolar Stress and Alcohol Use Disorders
Patrick Stengel, MD, PhD • The University of Texas Southwestern Medical Center

10:45 am – 11:00 am
Q & A, Discussion and Close
Mark A. Faye, MD

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit toward the APA Psychiatry Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit he/she actually spent in the educational activity.

Registration
Accreditation is limited for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-787-7034 (within the US or Canada) or 202-463-6000.
A Dinner Symposium...
Treating Psychotic Disorders: What Is the State-of-the-Art?

Sunday, May 6, 2001
1:30 PM-4:30 PM
Grand Ballrooms A & B Street Level
Hilton New Orleans, Louisiana

OBJECTIVES
Upon completion of this symposium, attendees should be able to:
1. Discuss the pharmacological and clinical differences among conventional, atypical, and atypical antipsychotics.
2. List treatment options for psychotic depression.
3. Review evidence that atypical antipsychotics may offer additional benefits for treatment-resistant patients.
4. Review evidence that atypical antipsychotics may offer additional benefits for treatment-resistant patients.

AGENDA
11:00 AM    Lunch/Reception
1:30 PM    Introduction
Jeffrey A. Lieberman, MD, Chairperson
Issues in Managing Psychosis in Geriatric Patients
Dale V. Jeste, MD
University of California Medical School at San Diego
Treatment of Depression with Psychosis
Robert N. Goldman, MD
University of North Carolina School of Medicine
Emerging Treatments in Bipolar Disorder
Terrence A. Ketter, MD
Stanford University School of Medicine
Treatment of Schizophrenia
Jeffrey A. Lieberman, MD
University of California Medical School at San Diego
Emerging Treatments in Bipolar Disorder
Terrence A. Ketter, MD
Stanford University School of Medicine
3:30 PM    Issues in Managing Psychosis in Geriatric Patients
Dale V. Jeste, MD
University of California Medical School at San Diego
4:00 PM    Adjournment

INDUSTRY-SUPPORTED SYMPOSIUM 16
Sunday, May 6, 1:30 PM-4:30 PM
Grand Ballroom C/D, Street Level, Hilton

Providing Complete Treatment for Patients With Bipolar Disorder

Sunday, May 6, 2001
1:30 PM-4:30 PM
Educational Program
Hilton New Orleans Riverside
Grand Ballroom C/D, Street Level
New Orleans, Louisiana

American Psychiatric Association 2001 Annual Meeting

Program Description
During this four-hour symposium, participants will earn 2.5 CME credits. The objective is to provide information about the treatment of patients with bipolar disorder.

Learning Objectives
1. Discuss the pharmacological and clinical differences among conventional, atypical, and atypical antipsychotics.
2. Discuss the pharmacological and clinical differences among conventional, atypical, and atypical antipsychotics.
3. Discuss the pharmacological and clinical differences among conventional, atypical, and atypical antipsychotics.
4. Discuss the pharmacological and clinical differences among conventional, atypical, and atypical antipsychotics.

Registration
Registration information is available at the APA Annual Meeting website.
INDUSTRY-SUPPORTED SYMPOSIUM 17
Sunday, May 6, 1:30 PM-4:30 PM
Acadia Ballroom, Third Floor, Marriott

MAO Is Revisited

OBJECTIVE
To update psychiatrists on diagnostic methods, new treatment options, and methods for managing difficult patients, including the use of MAOIs.

CONTINUING MEDICAL EDUCATION
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

APA 2001 ANNUAL MEETING
Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

INDUSTRY-SUPPORTED SYMPOSIUM 18
Sunday, May 6, 1:30 PM-4:30 PM
Carondelet Ballroom, Third Floor, Marriott

Advances in the Treatment of Geriatric Depression

APA 154th Annual Meeting
Sunday, May 6, 2001
1:30-4:30 PM LUNCHEON
3:30-6:30 PM SYMPOSIUM
Harriott New Orleans • Third Floor • Carondelet Ballroom

Program Chair: J. Craig Nelson, MD • Yale University School of Medicine
Co-Chair: G. M. Murphy, Jr, MD, PhD • Stanford University School of Medicine

1:45 PM Diagnosis and Treatment of Depression in the Elderly Patient
J. Craig Nelson, MD
The University School of Medicine

2:15 PM Benefits of Different Classes of Antidepressants for Geriatric Depression
Alan F. Schusberg, MD
Stanford University School of Medicine

4:15 PM DNA Microarray Technology and the Treatment of Depression
G. M. Murphy, Jr, MD, PhD
Stanford University School of Medicine

4:45 PM Pharmacology of Antidepressants Pertinent to Older Patients
Bruce G. Pollock, MD, PhD
University of Pittsburgh School of Medicine

4:55 PM Questions and Answers

Educational Objectives: At the conclusion of this symposium, participants should be able to discuss the diagnosis and detection of depression in the elderly, including interactions between depression and concurrent medical illnesses; summarize the general treatment of depression in the geriatric patient; outline the genetics of geriatric depression; discuss the pharmacology of antidepressants pertinent to elderly patients and the impact of possible drug interactions.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit actually spent in the educational activity.

Sponsored by the American Psychiatric Association
INDUSTRY-SUPPORTED SYMPOSIUM 19
Sunday, May 6, 1:30 PM-4:30 PM
Mardi Gras Ballroom, Third Floor, Marriott

INDUSTRY-SUPPORTED SYMPOSIUM 20
Sunday, May 6, 1:30 PM-4:30 PM
Grand Ballroom A-C, Fifth Floor, Sheraton
INDUSTRY-SUPPORTED SYMPOSIUM 21
Sunday, May 6, 7:00 PM - 10:00 PM
Grand Ballroom A/B, Street Level, Hilton

Objective
1. Better understand the cost burden in and barriers to effective treatment in anxiety disorders.
2. Effectively apply the new treatments available for social anxiety disorder and generalized anxiety disorder.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202/682-6000.

There will be 45 minutes of questions and answers at the end of the symposium.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Wyeth-Ayerst Pharmaceuticals.

APA 2001 ANNUAL MEETING
Sunday, May 6, 2001
6:30 PM - 7:00 PM Dinner
7:00 PM - 10:00 PM Symposium
Grand Ballroom C/D, Street Level, Hilton Hotel
New Orleans, Louisiana

Educational Objectives
At the conclusion of this symposium, participants will be better able to
- Define contributing factors for refractory anxiety disorders, obsessive compulsive disorder, and social anxiety disorder
- Integrate psychological and neurobiological approaches
- Discuss the role of anxiety in suicide

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in Category 1 credit towards the Physician's Recognition Award of the American Medical Association and for the continuing medical education requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This symposium is sponsored by the American Psychiatric Association.
Supported by an unrestricted educational grant from Solvay Pharmaceuticals, Inc.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or (202) 682-6000.
INDUSTRY-SUPPORTED SYMPOSIUM 23
Sunday, May 6, 7:00 PM-10:00 PM
Acadia Ballroom, Third Floor, Marriott

Upon completion of this symposium, attendees should be able to: Discuss clinical and therapeutic issues that emerge in the treatment of depressed patients who do not respond to standard treatments.

Treatment-Resistant Depression Across the Lifespan

Symposium to be held during the American Psychiatric Association 2001 Annual Meeting

6:30 PM Dinner Reception
7:00 PM Introduction
7:10 PM The Phenomenology and Course of Treatment-Resistant Depression
Patrick J. McGrath, MD, Columbia University College of Physicians and Surgeons
7:35 PM Pharmacological Treatment Options
Maurizio Pava, MD, Harvard Medical School
8:00 PM Management of Depression in the Medically Ill: Practical Approaches to Treatment
Prakash S. Masand, MD, SUNY Upstate Medical University
8:25 PM Juvenile Bipolar Disorder: An Overlooked Condition in Treatment-Resistant Depressed Children
Janet Wozniak, MD, Harvard Medical School
8:50 PM Treatment Advances in Geriatric Depression
George J. Alexopoulos, MD, Weill Medical College of Cornell University
9:15 PM Question-and-Answer Session
10:00 PM Adjourn

INDUSTRY-SUPPORTED SYMPOSIUM 24
Sunday, May 6, 7:00 PM-10:00 PM
Carondelet Ballroom, Third Floor, Marriott

Neurobiology, Depression, and the Specificity of Treatment Response

APA 134th Annual Meeting
Sunday, May 6, 2001
Marriott New Orleans + Third Floor + Carondelet Ballroom

6:30 - 7:00 PM Dinner
7:00 - 10:00 PM Symposium

OVERALL EDUCATIONAL OBJECTIVES

At the conclusion of this symposium, participants should understand the implications and limitations of neurotransmitter-based classifications of antidepressants. Further, it should be clear that, even though all antidepressants overlap in their actions, they have a distinct spectrum of activity that varies significantly by antidepressant class.

Questions and Answers

Sponsored by the American Psychiatric Association
INDUSTRY-SUPPORTED SYMPOSIUM 25
Sunday, May 6, 7:00 PM-10:00 PM
Mardi Gras Ballroom, Third Floor, Marriott

INDUSTRY-SUPPORTED SYMPOSIUM 26
Sunday, May 6, 7:00 PM-10:00 PM
Grand Ballroom A-C, Fifth Floor, Sheraton

Agenda

6:30 PM  Dinner
7:00  Welcome and Introduction
Daniel R. Carner, MD, Program Co-Chairperson
Chief, Psychiatric Research/Psychopharmacology
Portland VA Medical Center
Department of Mental Health
Portland, Oregon

7:00  Acute Psychiatric Agitation: Exploring New Options
Alan Z. Mandell, MD
Chief, Psychiatric Services
Maimonides Hospital
Department of Psychiatry
Brooklyn, New York

7:30  Beyond the Acute Phase: Issues in Stabilization
Robert J. Weinberg, MD
Director, Schizophrenia Research Program
Professor of Psychiatry
NYU Health Sciences Center at Brooklyn
Brooklyn, New York

8:00  Psychosocial Treatment for Schizophrenia: Strategies for the New Era
Nina R. Schifrin, PhD

9:25  Raising the Bar from Symptom Reduction to Disability Reduction
Michael F. Green, MD
Professor
UCSF Neuroscience Institute
Department of Psychiatry
Los Angeles, California

9:45  Enhancing the Overall Health of Patients with Schizophrenia
Daniel E. Carney, MD

9:15  Question and Answer Session
10:00  Adjourn

Objectives
At the conclusion of this symposium, participants should be able to:

- Recognize and list multiple disorders that can be treated with antipsychotic agents, describe and explain the various mechanisms of action of antipsychotic agents, and discuss the relative advantages and disadvantages of various antipsychotic agents.

- Summarize the current state of knowledge on the clinical management of patients with schizophrenia, including the use of antipsychotic agents, and discuss the potential for future treatment options.

- Identify the key components of a comprehensive management plan for patients with schizophrenia, including the role of ongoing treatment, monitoring, and support.

- Discuss the importance of cultural and contextual factors in the treatment of schizophrenia, and how these factors can impact the effectiveness of treatment.

- Discuss the role of family members and caregivers in the management of schizophrenia, and the importance of providing support and education for these individuals.
Women’s Mental Health: Antidepressant Therapy During the Childbearing Years

### APA 2001 Annual Meeting

**Monday, May 7, 2001**
- **Breakfast:** 6:30 a.m.
- **7:00 a.m.**
  - The Epidemiology of Depression Throughout the Female Life-Cycle
  - Vivien K. Burt, MD, PhD
  - University of California Los Angeles
  - 7:20 a.m.
  - Diagnosis and Treatment of Premenstrual Dysphoric Disorder
  - Elias Eriksson, PhD
  - Göteborg University, Sweden
  - 7:45 a.m.
  - Antidepressant Therapy During Pregnancy
  - Lori Althuler, MD
  - University of California Los Angeles
  - 8:05 a.m.
  - Questions & Answers

**Tuesday, May 8, 2001**
- **Breakfast:** 6:30 a.m.
- **7:00 a.m.**
  - The Treatment of Postpartum Depression: Risks and Benefits to Mother and Child
  - Victoria Hendrick, MD
  - University of California Los Angeles
  - 7:30 a.m.
  - Treatment Guidelines for Breast-Feeding Women
  - Zachary S. Stowe, MD
  - Emory University
  - 8:05 a.m.
  - Questions & Answers

### Learning Objectives:
- appreciate the importance of identifying and treating depression in women;
- recognize the symptoms and treatment options for PMDD;
- consider the risks and benefits of antidepressant therapy during pregnancy;
- consider the consequences of postpartum depression on both mother and child;
- understand the association between menopause and depression.

Epidemiological studies have shown that women are more susceptible to depression than men during their reproductive years, and it has been suggested this increased risk of depression may in part be related to hormonal changes. This symposium will review the presentations of depression throughout the childbearing years, addressing the safety and efficacy of antidepressant treatment of premenstrual dysphoric disorder and postpartum depression. Antidepressant safety in the setting of pregnancy and breast-feeding also will be discussed, and overall treatment guidelines will be presented.

This program is sponsored by the American Psychiatric Association. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA website at www.psych.org, or contact APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

This program is supported by an unrestricted educational grant from Forest Laboratories.
INDUSTRY-SUPPORTED SYMPOSIUM 29
Monday, May 7, and Tuesday, May 8, 7:00 AM-8:30 AM
Grand Ballroom C/D, Street Level, Hilton

INDUSTRY-SUPPORTED SYMPOSIUM 30
Monday, May 7, and Tuesday, May 8, 7:00 AM-8:30 AM
Acadia Ballroom, Third Floor, Marriott
INDUSTRY-SUPPORTED SYMPOSIUM 31
Monday, May 7, and Tuesday, May 8, 7:00 AM-8:30 AM
Carondelet Ballroom, Third Floor, Marriott

INDUSTRY-SUPPORTED SYMPOSIUM 32
Monday, May 7, and Tuesday, May 8, 7:00 AM-8:30 AM
Mardi Gras Ballroom, Third Floor, Marriott
INDUSTRY-SUPPORTED SYMPOSIUM 33
Tuesday, May 8, 7:00 PM-10:00 PM
Hall G, Lobby Level, Convention Center

Recognition and Treatment of Alzheimer’s Disease
Practical Lessons from New Research

Tuesday, May 8, 2001 • Hall G, Lobby Level, Convention Center • New Orleans, Louisiana

Agenda
6:15 pm Dinner
7:00 pm Welcome and Introduction
Gary W. Evans, MD, Chairperson
Director, UCLA Center on Aging
Ronald Reagan UCLA Medical Center
Los Angeles, California

7:15 pm Alzheimer’s Disease: Genetics and Brain Imaging
Jeffrey C. Cummings, MD
Director, NINCDS/NIH Alzheimer’s Disease Research Center
University of California at Los Angeles, Los Angeles, California

7:30 pm Alzheimer’s Disease: Integrated Treatment
S. Rosemary Newhouse, MD, MPH
Professor of Neurology and Biostatistics
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

7:45 pm Alzheimer’s Disease: The Interface of Depression and Dementia
Richard J. Buckman, MD
Professor of Psychiatry
University of California at San Diego, La Jolla, California

7:50 pm Alzheimer’s Disease: Long-Term Benefits of Early Pharmacological Treatment
Edward J. Becker, MD
Professor of Psychiatry
University of California at San Francisco, San Francisco, California

8:00 pm Alzheimer’s Disease: Reducing Emotional Vulnerability
Jennifer L. Wolf, MD
Professor of Psychiatry
University of California at San Francisco, San Francisco, California

8:15 pm Alzheimer’s Disease: Nonpharmacological Approaches to Behavior and Function
Michael P. Voss, MD
Professor of Psychiatry
University of California at San Francisco, San Francisco, California

8:30 pm Alzheimer’s Disease: Long-Term Benefits of Early Pharmacological Treatment
Edward J. Becker, MD
Professor of Psychiatry
University of California at San Francisco, San Francisco, California

8:45 pm Alzheimer’s Disease: Reducing Emotional Vulnerability
Jennifer L. Wolf, MD
Professor of Psychiatry
University of California at San Francisco, San Francisco, California

9:00 pm Alzheimer’s Disease: Nonpharmacological Approaches to Behavior and Function
Michael P. Voss, MD
Professor of Psychiatry
University of California at San Francisco, San Francisco, California

9:15 pm Alzheimer’s Disease: Long-Term Benefits of Early Pharmacological Treatment
Edward J. Becker, MD
Professor of Psychiatry
University of California at San Francisco, San Francisco, California

9:30 pm Alzheimer’s Disease: Reducing Emotional Vulnerability
Jennifer L. Wolf, MD
Professor of Psychiatry
University of California at San Francisco, San Francisco, California

9:45 pm Alzheimer’s Disease: Nonpharmacological Approaches to Behavior and Function
Michael P. Voss, MD
Professor of Psychiatry
University of California at San Francisco, San Francisco, California

10:00 pm Adjourn

Objectives
At the conclusion of the program, the participant will be able to:

• Understand the impact of pharmacological and nonpharmacological approaches to Alzheimer’s disease treatment;
• Describe emerging research;
• Use screening techniques in effective prevention and recognition of the disease early in its course.

INDUSTRY-SUPPORTED SYMPOSIUM 34
Tuesday, May 8, 7:00 PM-10:00 PM
La Nouvelle Ballroom, Level 2, Convention Center

A Dinner Symposium...
Everyday Challenges in Managing Patients on Psychotropic Medications

Tuesday, May 8, 2001
7:00 PM-10:00 PM
La Nouvelle Ballroom, Level 2
Convention Center
New Orleans, Louisiana

Objectives
Upon completion of this symposium, attendees should be able to:

• Define successful remission of psychiatric illnesses
• List potential factors leading to remission
• Outline the safety and tolerability profiles of medications used to treat psychiatric disorders
• Identify challenges in the diagnosis and treatment of psychoses in children, adolescent and geriatric populations

AGENDA
6:30 pm Dinner Reception
7:00 pm Introduction
Charles B. Nemeroff, MD, PhD
Program Chairperson
7:15 pm Approaches to Optimizing Therapies Across Psychiatric Diagnoses: Remission is the Goal
Charles B. Nemeroff, MD, PhD
Emory University School of Medicine
7:45 pm Optimizing Patient Outcomes Across Psychiatric Diagnoses: Focus on Safety and Tolerability
John M. Jazwa, MD
Rush Medical College
8:15 pm Special Challenges When Using Psychotropic Medications in Children and Adolescents
Karen D. Wiegand, MD, PhD
University of Texas Medical Branch at Galveston
8:45 pm Special Challenges When Using Psychotropic Medications in the Geriatric Population
A. Milan Kestenbaum, MD
Duke University Medical Center
9:15 pm Panel Discussion
All Faculty
10:00 pm Adjourn
INDUSTRY-SUPPORTED SYMPOSIUM 35
Tuesday, May 8, 7:00 PM-10:00 PM
Grand Ballroom A/B, Street Level, Hilton

APA 2001 ANNUAL MEETING
OFF-LABEL ON THE TABLE
Using New Pharmacologic Agents

OBJECTIVES

1. Understand the boundaries for use of psychotropic agents.

2. Weigh the importance of symptoms, diagnosis and diagnostic spectrum when selecting atypical antipsychotics, antidepressants, or mood stabilizers for individual patients.

EDUCATIONAL COUNCIL

- William M. Glazer, MD
- Harvard Medical School
- Boston, Massachusetts

- Jerrold Rosenbaum, MD
- Harvard Medical School
- Boston, Massachusetts

- Paul E. Keck, MD
- University of Cincinnati
- Cincinnati, Ohio

- Jonathan Alpert, MD
- Massachusetts General Hospital
- Boston, Massachusetts

- Alan Swann, MD
- University of Texas Medical School
- Houston, Texas

AGENDA

7:00 Dinner will be provided 30 minutes prior to the scheduled event.
There will be a 10 minute question and answer session following each presentation.

7:00 Introduction/Symptoms, Syndrome, or Spectrum: How Do We Select Medications? A Clinical Case Vignette
- William M. Glazer, MD – Jerrold F. Rosenbaum, MD

7:30 Atypical Antipsychotics in the Treatment of Aggressive Behaviors
- Paul E. Keck Jr., MD

8:00 The Role of Antidepressant Medications for Aggressive Behaviors
- Jonathan E. Alpert, MD – Maurizio Fava, MD

8:30 The Role of Mood Stabilizers for Aggressive Behavior
- Alan C. Swann, MD

9:00 Synthesis: Spectrum Versus Signal
- Jerrold F. Rosenbaum, MD – William M. Glazer, MD

9:30 Interactive Panel Discussion
The Symposium will end at 10:00 PM.

INDUSTRY-SUPPORTED SYMPOSIUM 36
Tuesday, May 8, 7:00 PM-10:00 PM
Grand Ballroom C/D, Street Level, Hilton

American Psychiatric Association 2001 Annual Meeting

MEN, WOMEN, AND SCHIZOPHRENIA
DOES ANATOMY DETERMINE DESTINY?

AGENDA

6:30 Welcome and Program Overview
- HENRY A. MASH, M.D. (CHAIRPERSON)
- University of Iowa School of Medicine and Public Health
- University of South Carolina at Charleston

7:15 Normal Sexual Brain Dimorphism: Impact of Schizophrenia in Men and Women
- JILL M. GOLDSTEIN, Ph.D

7:30 Outcome and Treatment Response in Schizophrenia: Influences of Gender
- PETER F. BUCKLEY, M.D.

8:00 Male-Female Differences in Schizophrenia: A Biopsychosocial Perspective
- Mary V. Seeman, M.D., M.P.H., F.R.C.P.C.

8:25 Neuropsychiatric Side Effects of Antipsychotic Treatment in Men and Women
- DIANA D. PERKINS, M.D., M.P.H.

8:50 Gender Differences in Late-Life Schizophrenia and Its Treatment
- DILIP V. JESTE, M.D.

9:15 Questions and Answers

10:00 Adjourn

LEARNING OBJECTIVES

After attending this symposium, participants will be able to:

- Recognize how schizophrenia is different in men and women and how these differences impact treatment response and neurodevelopmental outcomes.
- Understand how differences in treatment responses and neurodevelopmental outcomes in schizophrenia may be influenced by biological, psychological, and social factors.
- Identify differences in treatment responses and neurodevelopmental outcomes, and how these differences may impact treatment decisions.
- Discuss the implications of sex differences in mental illness and treatment response, and how these differences may impact treatment decisions.

- Explore the implications of sex differences in mental illness and treatment response, and how these differences may impact treatment decisions.
INDUSTRY-SUPPORTED SYMPOSIUM 37
Tuesday, May 8, 7:00 PM-10:00 PM
Acadia Ballroom, Third Floor, Marriott

Program Objectives
After attending this continuing education program, the psychiatrist should be able to:

- Review current knowledge of neuroimaging in posttraumatic stress disorder (PTSD) and generalized anxiety disorder (GAD) and the correlation with clinical presentation
- Understand the rates of comorbidity in GAD and PTSD and the implications for treatment and patient outcome
- Understand why some individuals develop PTSD following trauma whereas others do not
- Identify appropriate treatment strategies for trauma survivors depending on the nature of the traumatic response
- Gain a better understanding of the diagnostic criteria for GAD and the application of these criteria in clinical practice and research settings
- Identify treatments for GAD that are more effective than earlier treatments

Agenda
6:00 PM  Welcome and Introduction
Jack M. Gorman, MD
Symposium Chair
Columbia University
6:05 PM  Update on Neuroimaging
Jack M. Gorman, MD
Columbia University
7:00 PM  The Anxiety Brain: GAD and PTSD
Jeremy C. Caplan, MD
Columbia University
7:05 PM  The Comorbidity Factor in GAD and PTSD
James C. Ballenger, MD
Medical University of South Carolina
8:20 PM  An Update on PTSD
Rachel Wuhrer, PhD
Mount Sinai School of Medicine
9:15 PM  Current Concepts in the Diagnosis and Treatment of GAD
David V. Shewman, MD, MBA
University of South Florida
9:10 PM  Panel Discussion With Questions and Answers
9:55 PM  Closing Remarks

Sponsored by the American Psychiatric Association.

INDUSTRY-SUPPORTED SYMPOSIUM 38
Tuesday, May 8, 7:00 PM-10:00 PM
Carondelet Ballroom, Third Floor, Marriott

Please join us at the APA 2001 Annual Meeting - Sponsored by the American Psychiatric Association

Moderator
Joseph E. Calabrese, MD
Director, Mood Disorders Program
University Hospitals of Cleveland
Cleveland, Ohio
University School of Medicine - Case Western Reserve University
Cleveland, Ohio

Novel Aspects of Lithium Therapy in Bipolar Disorder
Guy M. Goodwin, MD
W.A. Hendry Professor of Psychiatry
University of Oxford
Oxford, United Kingdom

Melatonin: Mechanisms Underlying Mood Stabilization in Bipolar Disorder
Hassan K. Pardeshi, MD
Chief, Laboratory of Molecular Pathophysiology
National Institute of Mental Health
Bethesda, Maryland

Exploring Novel Treatment Strategies for Mood Disorders
Trais Suppes, MD, PhD
Clinical Assistant Professor of Psychiatry
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Illuminating the Pathway of Bipolar Disorder
Carole A. Zanarini, MD
Chief, Mood Disorders Research Unit
National Institute of Mental Health
Bethesda, Maryland
INDUSTRY-SUPPORTED SYMPOSIUM 39
Tuesday, May 8, 7:00 PM-10:00 PM
Mardi Gras Ballroom, Third Floor, Marriott

CURRENT AND FUTURE MANAGEMENT OF INSOMNIA AND PSYCHIATRIC ILLNESSES
TUESDAY, MAY 8, 2001 7:00 PM TO 10:00 PM
MARRIOTT HOTEL, MARDI GRAS BALLROOM
NEW ORLEANS, LOUISIANA

Upon completion of this symposium, attendees should be able to:
- Understand the relationship between insomnia and psychiatric illnesses and the importance of addressing sleep issues within the context of treating the psychiatric disorder.
- Identify normal and abnormal sleep patterns and discuss their relationship to psychiatric illnesses.
- Discuss the role of medications and psychological therapies in the treatment of insomnia from a complementary perspective.
- Describe the influence of psychiatric medications, with a focus on Bipolar Disorder, on drug interactions, and how this can impact the treatment of sleep disorders in patients with psychiatric conditions.

6:30 PM Dinner Reception
7:00 PM Introduction
Michael E. Thoma, MD, Chairperson
7:10 PM The Correlation Between Insomnia and Psychiatric Illnesses
Ruth M. Bense, MD, PhD, University of Wisconsin School of Medicine
7:35 PM The Neurobiology of Sleep in Health and Psychiatric Illnesses
Daniel J. Boyce, MD, University of Pittsburgh School of Medicine
8:00 PM Safety and Tolerance Issues in the Treatment of Insomnia
J. Mattiello, MD, University of Maryland School of Medicine
8:25 PM Converging Therapies for Insomnia and Psychiatric Illnesses
Kevin M. Jones, MD, University of Pittsburgh School of Medicine
9:10 PM Question-and-Answer Session
Michael E. Thoma, MD
9:45 PM Adjourn

INDUSTRY-SUPPORTED SYMPOSIUM 40
Wednesday, May 9, and Thursday, May 10, 7:00 AM-8:30 AM
Hall G, Lobby Level, Convention Center

Clinical Challenges in Anxiety
AGENDA
American Psychiatric Association 154th Annual Meeting
2-DAY BREAKFAST SYMPOSIUM
May 9 & 10, 2001 7:00 AM - 8:30 AM
Breakfast Available at 6:30 AM
Morial Convention Center
Hall G, Lobby Level • New Orleans, Louisiana

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this educational activity for up to 3.0 hours in category 1 credit towards the APA Physician's Recognition Award and for the CME component of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendance at the APA Annual Meeting is limited. The registration fee is $70.00 per person and includes all course-related materials. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA at 1-800-227-0222.

Sponsored by the American Psychiatric Association
Supporter of an educational grant from Pfizer Inc.

May 9, 2001
7:00 AM Opening Remarks
Mark R. Pollack, MD, Penn State University
Harvard Medical School
7:05 AM Anxiety Disorders: Moving From Better to Best
Mark R. Pollack, MD, Penn State University
7:20 AM Innovative Pharmacologic Approaches in Treatment-resistant Anxiety Disorders
James R. Jeffers, MD, Penn State University
Madison Institute of Medicine
University of Wisconsin Medical School
7:40 AM Novel Anxiolytics in Development and Abroad
Stuart A. Montgomery, MD, PhD
Imperial College London, England, UK
8:00 AM Panel Discussion/Questions and Answers
8:25 AM Closing Remarks
Mark R. Pollack, MD, Penn State University

May 10, 2001
7:00 AM Opening Remarks and Recap of Day 1
James R. Jeffers, MD, Penn State University
7:05 AM Clinical Challenges: Anxiety and Substance Abuse
Kathleen R. Brady, MD
Medical University of South Carolina
7:25 AM PTSD: Pharmacology and Treatment Approaches
Karen H. Simon, MD
Massachusetts General Hospital
7:40 AM Integrating Psychosocial Strategies with Pharmacotherapy
Michael M. Gotz, MD
Massachusetts General Hospital
Harvard Medical School
8:00 AM Panel Discussion/Questions and Answers
8:25 AM Closing Remarks
James R. Jeffers, MD, Penn State University

LEARNING OBJECTIVE
At the conclusion of this symposium, the participants should be able to:
- Identify and discuss the challenges associated with the treatment of anxiety disorders in clinical practice and potential strategies to improve outcomes.

155
INDUSTRY-SUPPORTED SYMPOSIUM 41
Wednesday, May 9, and Thursday, May 10, 7:00 AM-8:30 AM
La Nouvelle Ballroom, Level 2, Convention Center

A New Era for Managing Psychosis: Rebuilding Lives for Patients and Families
Symposium to be held during the 2001 APA Annual Meeting
Wednesday, May 9, 2001; Thursday, May 10, 2001
6:30 - 7:00 AM, Breakfast; 7:00 - 8:30 AM, Symposium
Convention Center, Level 2, La Nouvelle Ballroom
Chair: Ira D. Glick, MD • Co-Chair: Stephen R. Marder, MD

Wednesday Sessions
7:00 - 7:30 AM
Welcome and Introduction
Ira D. Glick, MD (Chair)
Stephen R. Marder, MD (Co-Chair)
7:30 - 7:45 AM
The Treatment of Juvenile-Onset Schizophrenia
Patrick S. McGorry, PhD
Department of Psychiatry
University of Melbourne
Parkville, Victoria, Australia
7:45 - 8:00 AM
The Older Patient and Family
Ego Boron, MD
Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle, Washington
8:00 - 8:30 AM
Question and Answer Session

Thursday Sessions
7:00 - 7:15 AM
Evaluating Outcomes With Atypical Antipsychotics:
Weight, Atrial Fibrillation, and Insight
N. Nathaniel Grebb, MD
Department of Psychiatry
Boston University School of Medicine
Boston, Massachusetts
7:15 - 7:30 AM
Consumer Organizations Improve Medication Compliance
Ira D. Glick, MD
Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Stanford, California
6:30 - 8:30 AM
Question and Answer Session

EDUCATIONAL OBJECTIVES: On completion of this activity, participants should be able to:
1. Review data from recent trials involving atypical antipsychotic agents and clozapine in elderly patients with psychiatric disorders.
2. Discuss the need for augmentation of pharmacotherapy with non-pharmacologic intervention to improve outcomes.
3. Evaluate the implications of the new pharmacogenetic models of antidepressant treatment in the elderly.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from
JANSSEN
PHARMACEUTICALS, INC.

INDUSTRY-SUPPORTED SYMPOSIUM 42
Wednesday, May 9, and Thursday, May 10, 7:00 AM-8:30 AM
Grand Ballroom A/B, Street Level, Hilton

Treatment of Depression in Women: From Acute Remission to Sustained Recovery
Breakfast: 6:30 AM—Symposium: 7:00 TO 8:30 AM
Chairs: LEE S. COHEN, MD and ADELE C. VIGUERA, MD

PART 1
Wednesday, May 9th
Sex-Based Differences in Mood and Anxiety Disorders
ADELE C. VIGUERA, MD
Harvard Medical School
Postpartum Depression: From Acute Treatment Response to Functional Recovery
LEE S. COHEN, MD
Harvard Medical School
PMDD: How it Affects Women's Lives
KIMBERLY A. YOUNKERS, MD
Yale University School of Medicine

PART 2
Thursday, May 10th
The Neuroendocrinology of Maternal Depression and Stress During Pregnancy
D. JEFFREY NEWPORT, MD
Emory University School of Medicine
Role of Hormonal Therapies for Depressed Perimenopausal Women
CATHERINE RODA, MD
Bethesda, MD
There will be 25 minutes for Questions and Answers at the end of each day.

Supported by an unrestricted educational grant from Wyeth-Ayerst Pharmaceuticals:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 1 Category 1 credit toward the AMA Physician's Recognition Award and the CME requirement for the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
INDUSTRY-SUPPORTED SYMPOSIUM 43
Wednesday, May 9, and Thursday, May 10, 7:00 AM-8:30 AM
Grand Ballroom C/D, Street Level, Hilton

INDUSTRY-SUPPORTED SYMPOSIUM 44
Wednesday, May 9, 7:00 PM-10:00 PM
Hall G, Lobby Level, Convention Center

Neuroprotective effects of Mood Stabilizers

Wednesday, May 9, 2001

Pierre N. Tariot, MD
Professor of Psychiatry, Department of Psychiatry, University of Rochester School of Medicine

6:30 PM - 7:00 PM Introduction

7:00 PM - 7:30 PM Neuroprotective and Mood Stabilizing Effects of Mood Stabilizers

Hussein K. Manji, MD
Chair, Laboratory of Molecular Psychopharmacology, National Institute of Mental Health

7:30 PM - 8:00 PM Clinical and Neuroimaging Evidence of Antidepressant Effect of Mood Stabilizers

Terence A. Ketter, MD
Professor of Psychiatry, Department of Psychiatry, University of Rochester School of Medicine

8:00 PM - 8:30 PM Implications for the Treatment of Alzheimer's Disease

Pierre N. Tariot, MD
Professor of Psychiatry, Department of Psychiatry, University of Rochester School of Medicine

8:45 PM - 9:15 PM Plasmonic Use of Mood Stabilizers and Personality Disorders: Comorbidities in Mechanisms and Treatment

Hugh Myrick, MD
Professor of Psychiatry, Medical University of South Carolina

9:15 PM - 10:00 PM Panel Discussion / Q & A

Program Objectives
- Understand new scientific techniques being applied to the study of major mood disorders and the effects of mood stabilizers on specific disorders
- Review current use of mood stabilizers in psychiatry and the treatment of mood disorders, such as major depressive disorder, bipolar disorder, and schizoaffective disorder

Credit Designation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is supported by an unrestricted educational grant from Abbott Laboratories.
Objectives:

At the conclusion of the program, participants will be able to:

• Enhance their diagnostic acumen by understanding the dynamic and fluctuating nature of the longitudinal structure of bipolar spectrum disorders

• Better understand the science supporting the bipolar spectrum concept and to apply this understanding in improving the diagnosis and management of bipolar spectrum disorders.

Agenda:

6:30 pm  Refreshments
7:00 pm  Welcome and Introductions
Lewis L. Judd, M.D.
University of CA, San Diego SOM
7:10 pm  Longitudinal Studies of Bipolar Disorders:
Is There a Spectrum?
Lewis L. Judd, M.D.
7:35 pm  Bipolar Spectrum: Clinical and Familial Validation
Hagop Akiskal, M.D.
University of CA, San Diego SOM
8:00 pm  Molecular Genetic Evidence for the Bipolar Spectrum
Julien Mendlewicz, M.D., Ph.D.
Erasme Hospital, Brussels, Belgium
8:25 pm  Treatment Advances in Bipolar Spectrum Disorders: Mood Stabilizers
Susan McElroy, M.D.
University of Cincinnati College of Medicine
8:50 pm  Treatment Advances in Bipolar Spectrum Disorders: Atypical Antipsychotics
Guy Goodwin, M.D.
University College Medical School, UK
Sponsored by the
American Psychiatric
Association.
9:15 pm  Question and Answer Session
Giorgio Racagni, Ph.D.
University of Milan, Italy
10:00 pm  Program Ends

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours of Category I credit towards the Physician's Recognition Award of the American Medical Association and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. Supported by an unrestricted educational grant from International Academy for Biomedical and Drug Research (IABDR).
INDUSTRY-SUPPORTED SYMPOSIUM 47
Wednesday, May 9, 7:00 PM-10:00 PM
Grand Ballroom C/D, Street Level, Hilton

Excessive Daytime Sleepiness
Evaluation and Management in Psychiatry

6:30 to 7:00 Dinner Reception
7:00 Welcome/Introduction
John W. Winkelman, MD, PhD
Chairman
7:15 Neural Substrates of Arousal and Sleep: New Vistas
Robert W. McCarley, MD
Harvard Medical School
VA Medical Center
Brockton, Massachusetts

7:45 Evaluation and Measurement of Daytime Sleepiness
Mary A. Carskadon, PhD
Brown University
Providence, Rhode Island

Learning objectives: 1. Identify the differential diagnoses of excessive daytime sleepiness in psychiatric patients. 2. Recognize the appropriate means of testing such hypotheses. 3. Understand the principal treatments available for excessive daytime sleepiness.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 9.5 hours toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (in the U.S. and Canada) or 202-882-6000.

Sponsored by the American Psychiatric Association

An Evidence-Based Medicine Approach to Pediatric Psychiatry

Symposium to be held during the Year 2001 APA Annual Meeting
Wednesday, May 9, 2001
6:30 - 7:00 PM, Dinner
7:00 - 10:00 PM, Symposium

New Orleans Sheraton, Fifth Floor, Grand Ballroom A-C
Chair: Robert L. Findling, MD

Educational Objectives: It is anticipated that participants will be able to: (1) Review results of recent, well-designed studies using specific antidepressants for pediatric psychiatric conditions, including conduct disorder, opposition, and Tourette syndrome. (2) Explain the clinical implications of these data with regard to treatment planning.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 9.5 hours toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (in the U.S. and Canada) or 202-882-6000.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from ORTHO-McNEIL

159
In short, visits to the APA Resource Center will provide much to see, hear, and take home with you. And speaking of home, you can even stay in touch with happenings on the homefront by checking your e-mail at the E-Mail Village, located within the APA Resource Center.

So stop by the APA Resource Center in the Exhibit Hall during the APA Annual Meeting. See how the APA works to advocate for patients, educate the public, and promote the profession, and how the APA can work for you.